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Alice: Would you tell me, please, which way I ought to go from here? 
The Cheshire Cat: That depends a good deal on where you want to get to. Lewis Carroll 
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Supervised Injectable Opiate Treatment (IOT) is a complex, intensive treatment modality that 
has been effective in treating long-term, chronic, previously treatment refractory heroin users. 
The mechanisms that make it an effective treatment modality are little explored, and never in 
a UK context. 
Aims 
In a UK supervised IOT context, this thesis set out to describe the long-term treatment 
trajectory of patients receiving IOT. Additional aims were to describe the experience of patients 
receiving IOT and ascertain the role of IOT in the patient’s overall journey of recovery. In so 
doing, the thesis contributes to the scientific understanding of IOT. 
Method 
Quantitative measures are employed to describe treatment process and the effect of treatment 
duration on outcome. Qualitative measures are utilised to describe the following: patients’ drug 
use and treatment histories; goals for, motivations, and expectations of IOT; experience with 
IOT; satisfaction with IOT; views on the impact of IOT; and views of, and goals for, patients’ 
recovery 
Results 
Quantitative findings illustrate that some participants remained in IOT long-term, whereas 
others discharged or moved back on to oral treatment modalities. When long-term IOT was 
undertaken, initial gains made were sustained. Qualitative findings illustrate that patients 
conceive effective IOT as flexible, psychosocial, person-centred, and encompasses 
autonomous ongoing support. Recovery is perceived as an ongoing, individualised journey, 
and the need for support following both IOT and abstinence are identified. 
Discussion 
Strengths and limitations of the research are discussed. IOT is best delivered as an 
individualised, time-limited, goal-driven, flexible treatment programme for those entrenched 
users with long-term, treatment refractory histories. Numerous findings have utility for policy 
and clinical practice and there is scope for examination of individually tailored treatment 
programmes through further research and, a systematic exploration of longitudinal outcomes.  
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Chapter 1: Introduction 
 
The aim of this thesis is to contribute to existing research and scientific evidence-
base regarding the delivery and effectiveness of supervised Injectable Opiate 
Treatment (IOT) in the UK through examination of the outcomes, experiences and 
perspectives of patients in the UK Randomised Injectable Opiate Treatment Trial 
(RIOTT). The thesis aims to contribute to the scientific understanding of both 
Supervised Injectable Heroin (SIH) and Recovery in the context of this treatment. 
This introduction chapter includes:  
Details regarding the prevalence of heroin use, dependence and injecting, and 
information about the numbers of patients receiving treatment for heroin 
dependence.  
The different types of treatment available, including an outline of the history of non-
supervised IOT in the UK and the introduction of the new European and Canadian 
supervised injecting clinics.  
The overall context in which supervised Injectable Opiate Treatment (IOT) is carried 
out.   
Relevant policy in this area is outlined along with details of the RIOTT trial and the 
current situation for IOT.  




The National Institute on Drug Abuse define addiction as a chronic, relapsing disease, 
characterised by compulsive drug seeking and use, and by neuro-chemical and 
molecular changes in the brain (National Institute on Drug Abuse, 2013). Substance 
dependence or addiction, as defined by (American Psychiatric Association and Task 
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Force on DSM-IV, 2000) the Diagnostic and Statistical Manual of Mental Disorders, 
Fourth Edition (DSM-IV) (American Psychiatric Association and Task Force on DSM-
IV, 2000), is a maladaptive pattern of substance use, leading to clinically significant 
impairment or distress, as indicated by the manifestation of three or more of the 
following: withdrawal symptoms; tolerance; continued use despite harm; loss of 
control; failed attempts to reduce or cease use despite desire to reduce or cease use; 
significant reduction in involvement in important activities, and preoccupation with 
thinking about or obtaining the drug (American Psychiatric Association and Task 
Force on DSM-IV 1994; McLellan, Lewis, O’Brien, & Kleber, 2000). 
The use of psychoactive substances has prevailed since the dawn of recorded history 
(Hill and Newlin, 2002) and opiates have a long history of both medicinal and 
recreational use, dating back to at least the Sumerian civilisation of 4000BC 
(Friedman, 1996). Psychoactive substances have assumed increasing public 
attention in most parts of the world, especially when broadly defined to include licit 
and illicit drugs, and to include pharmacological agents that have high dependence 
potential (Babor, 2010).  
 
1.2. Heroin: history and dependence 
1.2.2. Opioids 
 
The opioids are a class of drug that include the natural products of the opium poppy 
(‘Papaver somniferum’), and synthetic compounds derived from it (Darke, 2011). The 
term describes any of the narcotic alkaloids found as natural products in the opium 
poppy plant, as well as many semi-synthetic chemical derivatives (European 
Monitoring Centre for Drugs and Drug Addiction, 2010). This includes heroin, 
morphine, codeine, methadone, oxycodone and fentynl. The term ‘opiate’ relates to 
the natural alkaloids found in the resin of the opium poppy (Darke, 2011). Major 
production for both opium and heroin are South-West Asia - mainly Pakistan and 
Afghanistan - and south-east Asia - mainly Laos and Myanmar (United Nations and 






The word ‘heroin’ comes from the German word ‘heroisch’ - which translates as 
‘heroic’. The translation perhaps provides some insight into how positively the drug 
was interpreted by medical practitioners in its early days. Diacetylmorphine (more 
commonly known as diamorphine or heroin) was first synthesised and used as a 
medicinal product from the late nineteenth century to the early twentieth century 
(Strang, Groshkova, and Metrebian, 2012). Its production was developed on a 
commercial scale by the Bayer Company in 1898. Beginning with the Hague 
Convention in 1912, heroin was brought under international control; its use limited to 
‘legitimate’ medical and scientific purposes – however, the drug continued to be 
abused by a small number of people in Europe (Strang, Groshkova, and Metrebian, 
2012). Heroin was first controlled in the United Kingdom under the Dangerous Drugs 
Act of 1920 (Dangerous Drugs Act, 1923). Thereby the medical profession regulated 
the distribution of licit opioid supplies, and the provision of the Dangerous Drugs Acts 
of 1920 and 1923 controlled illicit supplies. 
Between the world wars the number of individuals dependent on heroin and morphine 
was relatively small and largely therapeutic - i.e., doctor induced - (Merry, 1975). From 
1954 there was a steady rate of increased addiction to heroin, particularly amongst 
younger people (Merry, 1975). In 1959 the number of known heroin addicts was 68; 
in 1960 it was 94; in 1962 it was 175; in 1964 it was 342; and in 1966 it was 749 
(Merry, 1975). In 1968 - when treatment centres had been established - the number 
registered in treatment was under 2000 (Merry, 1975). Until the 1950s, the majority 
of heroin dependent individuals in the United Kingdom were addicted in the course of 
medical treatment, and middle-aged or elderly (Bean, 1974).  
During the 1950s, the small increase in illegal drug use in Britain led to a process of 
rapid policy review and change, the impact of which is relevant to the present day 
(Bennett, 1988). Because of this change, a complicated process of legal and medical 
constraints, treatment methods, and information controls evolved (Bennett, 1988; 
Smart 1984). The Brain Committee 1965 (Stimson and Ogborne, 1970) 
recommended that special clinics be established in which greater control over the 
amount of drugs prescribed would be exercised, and that notification of heroin users 
to the Home Office should be made compulsory. 
By the 1960s, numbers of heroin users had started to steadily grow, and structured 
treatment services were set up by the end of the decade (Berridge, 1980). In the mid-
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1970s, use of the drug increased across Europe (Hartnoll et al., 1985), peaking during 
the 1980s and into the 1990s in western and southern European countries. A heroin 
epidemic emerged in the UK in the early 1980s, and by the 1990s drug-related deaths 
were a major cause of mortality among young adults (Edwards, 2004). Since 1980, 
notifications of new dependent heroin users rose by almost 40% per year (Hartnoll et 
al., 1985). In 1983, 85% of first notifications involved heroin as the principal drug of 
addiction (Hartnoll et al. 1985). There was a further peak in heroin use - in the 1990s 
to early 2000s; in eastern and central European countries (Hartnoll et al., 1985; 
Strang, Groshkova, and Metrebian, 2012).  
 
1.2.4. Dependence and consequences 
 
Today it is known that heroin use can produce profound degrees of tolerance and 
physical dependence, and these can become powerful motivating factors for 
compulsive use and abuse (National Institute on Drug Abuse, 2013). Now recognised 
as a chronic, relapsing condition, for many dependent users heroin dependence is a 
persistent, long-term affliction with severe consequences, particularly in terms of 
premature mortality and high morbidity. (Hser, 2007b). The risks of opioid 
dependence include fatal overdoses, infections (including endocarditis, human 
immunodeficiency virus infection, and hepatitis C virus infection), social 
disintegration, violence, and crime (Oviedo-Joekes et al., 2009). The associated costs 
to communities include medical, public health, and criminal justice costs as well as 
public disturbance and crimes against property (Oviedo-Joekes et al., 2009). This 
information further emphasises the pertinence and importance of effective treatment 
programmes for dependent heroin users. 
It is known that once dependent, users of heroin gradually spend more and more time 
and energy obtaining and using the drug, and eventually this may become the primary 
focus for existence (National Institute on Drug Abuse, 2013). Problematic drug use 
has a high social and economic cost to society (Mark et al., 2001) and once 
established, heroin addiction is a relapsing, unremitting condition with high rates of 
ill-health and mortality (Davoli et al., 1997). Heroin use is associated with serious 
health risks (Oviedo-Joekes et al., 2009) such as abscesses; blood born viruses such 
as HIV and hepatitis C; violence; overdose and serious social disadvantage, such as 
unemployment; homelessness; lack of support networks; engagement in crime and 
drugs subcultures (Bell et al., 1997; Darke, 2011) and an association with higher rates 
23 
 
of premature disengagement from education (Darke, 2011). The high prevalence of 
hepatitis C among injecting drug users, for example, means that there will be 
substantial mortality, morbidity and associated economic costs, as a result of higher 
incidence of liver disease in this group (Stockwell et al., 2005). The lives of injecting 
drug users are characterised by instability and chaos, with disadvantages for local 
communities, such as incidences of acquisitive crime, and for the larger community, 
through costs associated with treatment and medical care (Darke, 2011). Psychiatric 
comorbidity – particularly anxiety, but also affective, antisocial and other personality 
disorders – is common among opioid-dependent people (National Institute for Health 




Compared to other illicit drugs - for example cannabis, which has a worldwide usage 
prevalence of an estimated 186 million (United Nations Office on Drugs and Crime, 
2013) - the prevalence of opioid use is relatively low, with a prevalence rate of 0.3% 
amongst 16-59 year olds in England and Wales (in 2013), as compared to 6.4% for 
cannabis and 1.9% for cocaine (Office of National Statistics, 2011). However it is 
consumed by individuals in most countries across the world (Office of National 
Statistics, 2011). Injecting drug use has been reported to occur in more than 148 
countries worldwide and in 2013 the global injecting drug using population was 
estimated at around 16.5 million (United Nations Office on Drugs and Crime, 2013).  
 
During 2005 and 2006, of the estimated 150,000 injection drug users in the UK aged 
15 to 64 years (Mathers et al., 2008), 41% were in contact with drug treatment 
services (Hay et al. 2008). 2010 reports by Hay, Gannon, Casey and Millar (2010) 
estimate that there were approximately 264,000 opiate users across England, with an 
estimated 42,511 (16%) of these residing in London. There were an estimated 
103,185 Injecting Drug Users (IDUs) across England and approximately 13,056 
(13%) resided in London (Hay et al. 2010). Precise figures are difficult to establish, 
not least because of the stigma attached to illicit drug use, and particularly to injecting 
drug use. 
 
More recent statistics demonstrate that around 1 in 12 (8.2%) adults aged 16 to 59 
had consumed an illicit drug (excluding mephedrone) in the last year; a fall compared 
with 2011/12 of 8.9% (Lifestyles Statistics, Health and Social Care Information 
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Centre, 2013). This equates to around 2.7 million people (Lifestyles Statistics, Health 
and Social Care Information Centre, 2013). 2.6% of adults had taken a Class ‘A’ drug 
in the last year (almost 850,000 people; Lifestyles Statistics, Health and Social Care 
Information Centre, 2013). Cannabis was the most commonly used drug, with 6.4% 
of adults having used it in the last year (Lifestyles Statistics, Health and Social Care 
Information Centre, 2013).  
The next most commonly used drugs in the preceding year were powder cocaine 
(1.9%) and ecstasy (1.3%; Lifestyles Statistics, Health and Social Care Information 
Centre, 2013). Between 2011 and 2012 there were an estimated 256,163 individuals 
using opiates in England (Hay, Dos, and Worsley, 2012). Of these 87,302 were 
injecting drug users (Hay, Dos, and Worsley, 2012). Between 2013 and 2014, 
193,198 individuals in England were treated for drug dependence and most (79%; 
47% opiates only and 32% opiates and crack) patients in contact with treatment 
services were using opiates (Public Health England, 2013). The most common routes 
into treatment for patients beginning treatment in 2013-14 were self-referrals (44%) 
and referrals from the criminal justice system (27%). Onward referrals from other drug 
services together accounted for 11% (Public Health England, 2013).  
 
1.2.6. Mortality rates 
 
In terms of mortality rates there were 3,346 drug poisoning deaths registered in 
England and Wales in 2014, the highest since comparable records began in 1993 
(ONS, 2015). Of these, 2,248 (or 67%) were drug misuse deaths involving illegal 
drugs (ONS, 2015). The mortality rate from drug misuse was the highest ever 
recorded at 39.9 deaths per million population. Males were over 2.5 times more likely 
to die from drug misuse than females - 58 and 21.9 deaths per million population for 
males and females respectively (ONS, 2015). Deaths involving heroin and/or 
morphine increased by almost two-thirds between 2012 and 2014, from 579 to 952 
deaths (Office for National Statistics, 2015).  
Data in 2012-2013 (Lifestyles Statistics, Health and Social Care Information Centre, 
2013) on hospital admissions where the primary diagnosis is poisoning by illicit drugs 
are as follows. In the South East England Strategic Health Authority (SHA) there were 
n=818 admissions, with an n=111 in Brighton and Hove City Primary Care Trust 
(PCT). In the London SHA there were n=1029 admissions (Lambeth n=44; Southwark 
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n= 47). In North East England SHA there were n=976 admissions, with n=39 in 
Darlington. Overall these figures illustrate the extent of the problem and the 
pertinence of efficacious treatment programmes. It should be noted that these specific 
regions are of relevance to the samples included in the thesis. 
On an individual level, for treated users with over 20 years of addiction, the chances 
of becoming and remaining abstinent are roughly equal to chances of dying 
prematurely; about a third in each case (Hser 1993; Goldstein and Herrera, 1995). 
The remaining third move through a cycle of imprisonment, drug treatment, and active 




The term ‘Recovery’ is the commonly accepted goal for the treatment of disorders, 
including addiction (El-Guebaly, 2012). Despite the recognition of heroin as a chronic, 
relapsing condition, relatively little is known about long-term recovery processes 
among heroin users who attain and maintain long periods of abstinence (Hser, 
2007a). Hser (2007a) sought to identify predictors of long-term stable recovery from 
heroin dependence based on N=242 heroin users who were followed for more than 
33 years. Findings showed that recovery and non-recovery groups did not differ in 
deviant behaviours and familial or educational difficulties in their earlier lives (Hser, 
2007a).  
This is an interesting area and more detail about the pre-treatment lives of heroin 
using and heroin treatment samples might be useful for exploring potential patterns 
and themes amongst these groups. In Hser’s (2007a) research, both groups (defined 
as ‘recovered’ and ‘non-recovered’) had previously attempted formal treatment and 
self-directed recovery (“self-treatment”), and often repeatedly. The non-recovered 
heroin users were significantly more likely to: use substances to cope with stressful 
conditions; have spouses who also misused drugs, and lack non-drug-using social 
support. Stable recovery ten years later was predicted by: ethnicity, self-efficacy, and 
psychological distress.  
These findings suggest that in addition to early intervention to limit heroin addiction, 
increasing self-efficacy and addressing psychological difficulties are likely to enhance 
the odds of maintaining long-term stable recovery (Hser, 2007a). These findings 
demonstrate the necessity for individualised psychological interventions through 
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Opiate Substitution Treatment (OST). Hser (2007a) highlights the pertinence of 
obtaining a detailed pre-treatment history from treatment groups, encompassing how 
individuals came to become habitually dependent upon heron. This is more 
commonplace in therapeutic practice and may have use within research with these 
samples. This may perhaps provide relevant information for individual recovery and 
treatment journeys in research patient case examples. 
Few studies have investigated the process of stable recovery, yet a number of 
theories have been created in an attempt to explain how stable recovery evolves 
(Hser, 2007a). The ‘maturing out’ hypothesis states that users grow out of addiction 
as they mature with age. This hypothesis was proposed by Winick (1962; cited in 
Searby, Maude, and McGrath, 2015), who maintained that over two-thirds of narcotic 
users achieved and maintained abstinence as a result of the resolution of social and 
vocational pressures present during adolescence and early adulthood. Winick's 
maturing-out hypothesis was a dominant school of thought for some time in addiction 
treatment and research (Hser, 2007a). This was problematic in the sense that service 
provision at that time shifted to the targeting of younger users and thereby neglected 
those failing to ‘mature out’ (Anglin et al., 1986), arguably a significant proportion of 
drug users, in reality. The substitution hypothesis argues that one addiction is simply 
replaced by another (Vaillant, 1966). Other studies have further identified factors that 
may be related to relapse (Hser, 2007a). 
The Relapse Prevention (RP) model proposed by Marlatt and Gordon (1985) 
suggests that both immediate determinants (e.g., high-risk situations; coping skills; 
outcome expectancies; and the abstinence violation effect – self-blame, guilt, loss of 
perceived control – associated with relapse) and covert antecedents (e.g., lifestyle 
factors; urges; and cravings) can contribute to relapse (Marlatt and Gordon, 1985). 
The RP model incorporates numerous specific and global intervention strategies that 
allow therapist and client to address each step of the relapse process (Marlatt and 
Donovan, 2005). Specific interventions include: identifying specific high-risk situations 
for each client; enhancing the client’s skills for coping with these situations - thereby 
increasing the client’s self-efficacy - eliminating myths regarding the drug’s effects; 
managing lapses; and restructuring the client’s perceptions of the relapse process 
(Marlatt and Donovan, 2005). Global strategies comprise a process of ‘balancing’ the 
client’s lifestyle (and facilitating him or her to develop more positive addictions – i.e., 
a form of behavioural activation); employing stimulus control and urge-management 
techniques; and developing relapse road maps to facilitate awareness during the 
recovery journey. Based on a cognitive-behavioural framework, this approach is 
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widely employed in addiction treatment services and the focus of substantial research 
(Marlatt and Donovan, 2005). 
Edwards (1987 cited in Mitcheson et al., 2010) highlighted the importance of taking 
in to account the individual idiosyncrasies of the relapse trajectory - perhaps 
reinforcing that the recovery journey is personal and individual, and as such treatment 
must be person-centred. Of further relevance is treatment context: giving up a 
substance is clearly correlated with the environment the individual operates within 
(Allsop et al., 1997). Here the argument is that this is of greater pertinence than simply 
equipping an individual to cope in a debilitating environment (Allsop et al., 1997). Key 
predictors of recovery include active engagement in the community, and immersion 
in peer support groups and activities (Best and Lubman, 2012). Recovery requires a 
parallel process approach: enabling and supporting individual recovery journeys; 
while creating environmental conditions that enable and support a ‘social contagion’ 
of recovery (Best and Lubman, 2012). Here the concept of recovery is transmitted 
through dedicated, supportive social networks and recovery groups (Best and 
Lubman, 2012). 
Recovery from addiction is conceived as a process of change through which an 
individual achieves abstinence and improved health, wellness, and quality of life 
(Sheedy and Whitter, 2009). Sheedy and Whitter (2009) developed 12 guiding 
principles of recovery (as identified by the patients in their study) and are conceived 
as follows: there are many pathways to recovery; recovery is self-directed and 
empowering; recovery involves personal recognition of the need for change and 
transformation; recovery is holistic; recovery has cultural dimensions; recovery exists 
on a continuum of improved health and wellness; recovery emerges from hope and 
gratitude; recovery involves a process of healing and self-redefinition; recovery 
involves both addressing discrimination, and transcending shame and stigma; 
recovery is supported by peers and allies; recovery involves (re)joining and 
(re)building a life in the community; and recovery is a reality. A critical way to 
overcome the stigma of addiction is to convey the message that recovery is a reality 
– this can provide hope to both affected individuals and their families, and can inform 
the general public and provide realistic expectations for stakeholders (Laudet, 2007). 
Neale, Nettleton, and Pickering (2012) describe that although the term ‘recovery’ is 
sometimes used interchangeably with the term ‘abstinence’, it is generally accepted 
that recovery is not simply a matter of taking or not taking drugs. It is rather about 
drug users achieving benefits in a wide range of life areas, including their 
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relationships, housing, health, employment, and offending (Neale, Nettleton, and 
Pickering 2012). Recovery will manifest differently for each individual user, but should 
enable individuals to have aspirations, feel that they are part of society, and lead more 
fulfilling lives (Neale, Nettleton, and Pickering, 2012). Neale et al. (2012) argue that 
despite some useful attempts at defining recovery, unanswered questions about the 
concept remain – such as: What is the precise meaning of the concept; How should 
recovery be measured? Can individuals ever be ‘recovered’ or are they only ever ‘in’ 
recovery? When does recovery start and end? Who can define whether or not 
someone is in recovery? Does recovery require complete abstinence from all drugs, 
including prescribed drugs and tobacco? And must recovery be voluntary? (Neale, 
Nettleton, and Pickering, 2012).  
Neale et al. (2012) interviewed 40 heroin users in recovery and outlined a number of 
key themes derived from this work. Narratives focussed on various dimensions in the 
recovery journey – such as: the initial consideration of recovery, perhaps analogous 
with the contemplation stage of the Transtheoretical Model of health behaviour 
change (Prochaska and DiClemente, 1983); treatment experiences (of varying types; 
from abstinence, to Opiate Substitution Treatment (OST) and detox and rehabilitation, 
and included peer support); the coming off of drugs stage; the rebuilding of 
relationships; the experience of emotional changes; bodily adjustments; health and 
illness; self-care; housing and living arrangements (including financial arrangements); 
filling the void; and thinking about the future (including: hopes; goals; fears; wanting 
to be normal; change and growth). These narratives arose from interviews with four 
types of individual in recovery: those in OST; ‘ex-users’; residential detoxification 
patients; and those who had detoxed. Aside from demographics, and these four basic 
typology descriptors, more specific information about patients, their history or current 
situation is not elaborated upon.  
Best and Laudet (2011) outline the inspiring idea that recovery is contagious; that is, 
it has a positive impact on both families and communities, in addition to the impact 
felt by the individual undergoing the process. Best and Laudet (2011) usefully 
differentiate the concept of recovery in addictions, from that of recovery in the mental 
health field. Best and Laudet (2011) outline that in the mental health field the focus is 
mostly on the quality of life dimension. By contrast, Best and Laudet (2011) outline 
the definition of recovery in the addictions by the UK Drug Policy Commission (2008, 
p.6) as “voluntarily sustained control over substance use which maximises health and 
wellbeing and participation in the rights, roles and responsibilities of society." Whilst 
this definition encompasses wellbeing and quality of life, it also includes some degree 
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of community engagement or citizenship, and a measure of sobriety (Best and Laudet 
2011).  
Best and Laudet (2011) outline that recovery encompasses a sense of empowerment; 
and focus on central ideas of aspiration, choice, hope, and freedom, and notably, are 
experienced rather than diagnosed. Best and Laudet (2011) also distinguish that 
recovery occurs in real life settings rather than in the rarefied surroundings of clinical 
settings; and finally that recovery is a journey rather than an end state. 
This introduces the idea of recovery capital. Best and Laudet (2011) describe this as 
the resources the individual has available to him or her to facilitate this journey, or 
process. Best and Laudet (2011) describe the four elements of recovery capital. 
Firstly, the social; involving relationships and groups. This provides support but also 
entails commitments. The second is physical capital. This encompasses tangible 
assets, such as property, which may facilitate recovery options, such as moving away 
from drug using communities and dealers. The third is human capital. This is multi-
faceted and includes skills, positive health, aspiration, and hopes. High educational 
attainment and intelligence are valuable advantages for the problem-solving required 
during the journey of recovery. The final aspect is cultural capital; this includes beliefs, 
values and attitudes. It also links to the social conformity of prevailing social 
behaviours (Best and Laudet, 2011). Recovery capital gives rise to recovery 
champions, who are generally well-connected and charismatic figures within a 
recovery community. They are prominent figures of success and allow the spread of 
recovery capital, for example, through social learning (Best and Laudet, 2011). 
Laudet (2007) argues that recovery goes well beyond abstinence, and describes it as 
a bountiful “new life,” an ongoing process of growth, self-change, and a reclaiming of 
the self. That the concept is seen by this researcher as an ongoing, evolving process 
is interesting, implying that the individual remains in recovery through the life-course. 
To this end it is worthwhile exploring the conception of recovery with specific 
treatment samples and addiction types, to enable a person-centred modality of 
support.  
As outlined in The National Treatment Agency (2012) report: Medications in 
Recovery: Re-orientating Drug Dependence Treatment (National Treatment Agency 
2012) the question of how many people with heroin dependence recover remains 
difficult to answer, since few research studies have followed-up with patients into their 
fifth and sixth decade. NTA (2012) describe that the small pool of longitudinal 
research encompasses research conducted at different times, in different cultures 
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and using different methods. Methodologically these studies are prone to selection 
and differential bias and attrition at follow-up (NTA, 2012). NTA (2012) also outline 
that a single episode of treatment is very unlikely to achieve lasting abstinence. NTA 
(2012) outline that the norm is for an individual re-enter treatment a number of times 
before achieving remission. Anglin et al. (1997) and Hser et al. (1997) report that 
three to four treatment episodes are most likely. Positively, Moos (2003) proposes 
that a specific focus on recovery may improve treatment effectiveness, by virtue of 
the creation of therapeutic goals. Further, these goals must be specific and 
individualised (Moos, 2003). 
NTA (2012) outline various factors that encompass the concept of recovery. The first 
is recovery support and this encompasses the need for recovery capital (as outlined 
above), particularly for those with low levels of support, peer-role models, support 
from other services, and family support. Housing support is identified as a further area 
of importance, including working with local housing partnerships and planners. The 
encouragement of well-being is highlighted, such as making social connections, being 
active, and continuing to learn. Post-treatment support is also highlighted, and the 
level of intensity of this support is dependent on individual levels of recovery capital. 
NTA (2012) also makes specific recommendations with regard to components of 
effective OST. These encompass good leadership (Ball and Ross, 1991); motivated 
staff with belief in the treatment they are offering (Rogers, 1957); good retention to 
treatment (Zhang, Friedmann, and Gerstein, 2003); a good programme of 
psychosocial support (National Institute for Health and Care Excellence 2007b) and 
adequate dosage for Opiate Substitution Treatment programmes (NTA, 2012). What 
is unexplored is the relative contribution of each factor of importance in treatment 
engagement and outcome. 
 
1.3.1. Recovery: Policy and practice issues 
 
As also discussed below in section 1.5: Abstinence versus maintenance, one of the 
central debates concerning the definition of recovery stems from the abstinence-
orientated ethos versus the agonist-maintenance ethos within the addictions field 
and treatment system. This discussion has relevance to the debate on what 
constitutes recovery. Uchtenhagen (2013) outlines that recovery is used to describe 
a rehabilitation process, as well as a socialisation process to good citizenship. The 
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abstinence ethos is perceived as vital for health and social improvement 
(demonstrated through the term ‘abstinence-based therapy’), or as a final objective 
(‘abstinence-oriented therapy’) (Uchtenhagen, 2013). Maintenance therapy may be 
viewed as a temporary approach to engage those users who are hard to reach 
(‘maintenance to abstinence’) or as a treatment of a chronic condition (‘unlimited 
maintenance’) (Uchtenhagen, 2013). Uchtenhagen (2013) describes this opposition 
as crude, yet importantly encapsulates that it represents an age old question – ‘what 
are the goals of addiction treatment?’ (Uchtenhagen, 2013). Uchtenhagen (2013) 
illustrates that both approaches (e.g., drug-free residential approaches and agonist 
maintenance treatment programmes) have long-term positive outcomes when 
provided in regular services which adhere to routine practices in indication and 
delivery. Uchtenhagen (2013) concludes that in our epoch of individualised 
healthcare there is no argument against having multiple evidence-based treatment 
routes, which incorporate individual tailoring to the client’s needs and risks. 
Entering and remaining in treatment, finishing a course of opioid substitution 
treatment (OST), and exiting structured treatment services are all pertinent 
indicators of an individual’s progress in recovery, however, they are not in and of 
themselves definitions of recovery (NTA, 2012). In their report ‘A vision of recovery’ 
the UKDPC (2008) Recovery Consensus group (comprising leading experts in the 
field of addictions) outline that because there are individual perceptions amongst 
individuals in recovery about what recovery is, the consensus group’s focus was on 
recovery ‘process’, rather than a specific end point that attempted to capture the 
diversity of recovery experiences (UKDPC, 2008). For some individuals in recovery, 
recovery is seen as an ongoing process, and in this case the individual may always 
consider themselves in recovery, rather than recovered, whereas others may 
ultimately feel that they are no longer at risk to addiction or relapse. The diversity of 
experience amongst those in recovery themselves, is reflected, and perhaps lies 
behind, the ongoing debate amongst professionals in the drugs field (UKDPC, 
2008). 
The UKDPC (2008) aimed, however, to develop a vision of recovery that might 
provide a useful and helpful focus for service development, with recovery as 
conceived from the perspective of an ongoing process. The recovery consensus 
group outlined the following key features, which are borne out of their work with 
individuals in recovery. Recovery was viewed as a process by which the individual 
accumulates positive benefits, as opposed to simply eliminating or reducing harms 
caused by the use of substances. Related to this, the group viewed recovery as a 
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process of building hope and aspiration, for the individual user, but also their 
families, and those who support them through treatment and support services. The 
group emphasised that there are a number of different types of intervention and 
support, that there was no ‘one size fits all’ programme. Within this conception, it 
was emphasised that recovery can also occur without formal external agencies 
(UKDPC, 2008). 
The UKDPC (2008, p.5) consensus group specifically state that recovery is a 
process, as opposed to a single event. They emphasise that this process may take 
some time and effort to succeed, and that the length of time taken to do so will vary 
across individuals (UKDPC, 2008). Importantly, the group outline that in order for 
the recovery process to be lasting, it must be voluntarily sustained. It was 
recognised, however, that the process may be initiated or assisted by coercion and 
mandates as a function of criminal justice system interventions. 
The UKDPC (2008) vision states that recovery does require control over substance 
use, however, stipulate that this is not sufficient on its own. The definition given 
comprises a comfortable and sustained independence from the compulsion to use 
illicit substances. The group acknowledge that whilst this does not equate controlled 
use, controlled use may still be harmful. The point is that the individual is able to 
make a choice to use a substance in a way that is not problematic for themselves, 
families, and society (UKDPC, 2008). Importantly, the ethos of the ‘no one size fits 
all’ approach applies to the process of independence from a compulsion to use – 
that is, for some, this is abstinence from problematic, or indeed all, substances. 
Others may be abstinent from the problematic substance, and supported in this 
process through prescribed medication. Others still may be able to moderate use of 
some/other substances, such as an occasional alcoholic beverage (UKDPC, 2008). 
The UKDPC (2008) group outline that recovery maximises health and wellbeing, 
including both mental and physical health, to the fullest extent that it can be 
achieved for both an individual, and their social environment. High aspirations are 
reflected within this dimension, to ensure that individuals may move forward and 
achieve as fulfilling a life as may be possible. Finally, the group emphasise the 
importance of a meaningful and satisfying life. This may be individually defined, but 
should encompass societal roles, responsibilities and rights (UKDPC, 2008). The 
group recognise the stigma and discrimination that individuals in the process of 
recovery may face. Therefore, the UKDPC (2008) outline inclusion as part of the 
recovery process, in terms of (re)integration back into society and the resultant 
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improved self-identity – such as inclusion in family life or voluntary or paid 
employment. 
These tenets were drawn together by the UKDPC (2008) consensus group and 
culminated in their vision statement for recovery:  
‘The process of recovery from problematic substance use is characterised 
by voluntarily-sustained control over substance use which maximises health 
and wellbeing and participation in the rights, roles and responsibilities of 
society.’ (UKDPC, 2008, p. 6).  
The NTA (2012) ‘Medications in Recovery’ report continues the recovery debate, 
but with important reference to opiate substitution treatment (OST). Leaving OST 
and structured treatment prematurely can harm individuals, especially if it leads to 
relapse, which may also have negative consequences for communities and society 
(NTA, 2012). Recovery is seen as a broader and more complex journey that 
incorporates overcoming dependence, reducing risk-taking behaviour and offending, 
improving health, functioning as a productive member of society, and achieving 
personal fulfilment (NTA, 2012). Crucially, these recovery outcomes are often 
mutually reinforcing (NTA, 2012).  
The cultural and political context is deemed important. With reference to the UK 
context, the NTA (2012) ‘Medications in Recovery: Re-orienting Drug Dependence 
Treatment’ report outlines that previous government drug strategies focused on 
reducing both crime, and drug-related harm to public health. In this case, the benefit 
to society accrued from people being ‘retained’ in treatment programmes, as much 
as just the completion of them. However, it is argued that this reinforced a culture of 
commissioning and practice that gave insufficient primacy to an individual’s desire 
to overcome his or her drug or alcohol dependence (NTA, 2012). The NTA (2012) 
report usefully emphasises that this has been particularly apparent for heroin users 
receiving OST, whereby the protective benefits have often become an end in and of 
themselves, rather than providing a safe base from which heroin users might 
progress towards further recovery (NTA, 2012). 
More specifically, the NTA (2012) justly outline that well-delivered OST programmes 
provide a platform of safety and stability that protects individuals, and creates the 
time and space for them to progress in their individual recovery trajectories. 
Thereby, OST has an important and appropriate role within recovery-orientated 
systems of care. The drug strategies clearly demonstrate that medication-assisted 
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recovery can and do occur (NTA, 2012). However, the NTA (2012) report 
emphasises the really important need to ensure that OST is the greatest platform it 
can be, but with equal focus upon the quality, range and purposeful management of 
the broader care and support system it fits within (NTA, 2012). 
As with the UKDPC (2008 report, the NTA (2012) report also outlines the 
importance of acknowledging individual differences in levels of ‘recovery capital’ 
(Best and Laudet, 2011). Specifically, some heroin users in treatment may stabilise 
and leave treatment quickly, whereas many others have long-term problems and 
complex needs, meaning their recovery may take much longer, and that they 
require help to build their recovery capital (NTA, 2012). Treatment administered 
over such timescales must maintain their recovery orientation (NTA, 2012). 
Importantly, the NTA (2012) highlight that prematurely ceasing an individual’s OST 
against their will is an externally imposed action, thereby it has no meaning to the 
individual, and in this case, gains made in recovery may be lost or regressed (NTA, 
2012). The need instead for clear, ambitious, co-collaborated goals with agreed 
timescales are key components of effective individualised treatment (NTA, 2012). 
An aspect of relevance to the current thesis’s aims outlined by the NTA (2012) is the 
importance of an exit strategy from OST. NTA (2012) emphasise the need for visible 
exits from treatment, as soon as clients enter treatment. The importance of this is 
rationalised as giving patients enough information to understand the components of 
a treatment trajectory, and the visibility of other patients who have successfully 
exited treatment, through use of both recovery mentors and communities. An 
interesting further recommendation is the implementation of recovery check-ups for 
those who have left treatment, and the availability of a rapid re-entry process back 
into treatment, if necessary. NTA (2012) make the recommendation that clinicians 
and service leads should audit and consider changing the balance between the 
promotion of overcoming dependence and promotion of reduction of harm. Within 
this recommendation, the need for informed choice, with pertinence to individual 
situations, is emphasised. These recommendations are framed as recovery-oriented 
treatment systems and services (NTA, 2012) and align with the 2010 Drug Strategy 
(HM Government, 2010). NTA (2012) make the point that neither medication alone, 
nor abstinence alone, is likely to be sufficient to support an individual to achieve 
recovery. These facets of effective recovery are concomitant. 
In terms of implication for practice, the UKDPC (2008) make the important point that 
their overarching definition of recovery may assist substance misuse professionals 
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to maintain an overall vision of recovery, with an ethos of multi-service, multi-
disciplinary and collaborative working. Thereby, multi-service professionals and 
teams can contribute to the recovery vision, as opposed to seeing one primary area 
of intervention as the only way. The UKDPC (2008) outline that the separate tenets 
of their definition of recovery can be viewed as a continuum along which progress 
can be charted. They assert that their single definition may facilitate a system that 
works together as required, in order to support the recovery process for individuals 
(UKDPC, 2008).  
With reference to the abstinence versus maintenance debate, drug-free 
programmes may not be automatically recovery-orientated, simply because of their 
abstinence ethos, and correspondingly, maintenance programmes do not 
automatically negate a recovery orientation, simply because they are characterised 
by medication (UKDPC, 2008). The UKDPC (2008) call for an identification of what 
characteristics make a service and the wider system recovery-orientated, 
irrespective of specific modalities operated. The need for additional instruments that 
can measure recovery and improve service provision is also called for (UKDPC, 
2008) and Uchtenhagen (2013) outlines that structured assessment using 
appropriate brief wellbeing measures could facilitate discussions about broader life 
needs. If may be argued that if these measures are not prioritised by 
commissioners, and utilised by services, then progress in recovery will continually 
be perceived by services, policy makers and researchers as simplistically 








1.4. Opiate Substitution Treatment 
 
Opioid Substitution Treatment (OST) supplies illicit drug users with a replacement 
drug - a prescribed medicine such as methadone or buprenorphine - which is usually 
administered orally in a supervised clinical setting (Kermode et al., 2011). Substitution 
treatments for opioid dependence, mainly utilising methadone concentrations, have 
a reasonable level of availability and acceptance throughout Europe (EMCDDA 
2000). Methadone is a long-acting orally administered drug, for the shorter-acting 
heroin that is usually injected (Dole and Nyswander, 1965) and the effectiveness of 
this regimen has been consistently demonstrated (Daulouède et al., 2010; Mattick, 
Ali, and Lintzeris, 2009). Additionally, evidence of treatment efficacy has been 
assessed in multiple domains, including physical and mental health, associated risks, 
delinquency, compliance with therapy, use of illicit drugs, and quality of life (Farrell et 
al. 1994; EMCDDA 2000; Ward, Hall, and Mattick, 1999). Prior to the Dangerous 
Drugs Act (1967), methadone characterised prescribing and treatment practices with 
heroin users in Britain (Mccusker and Davies, 1996). Traditional opiate maintenance 
treatments (such as methadone and buprenorphine) are effective for a high proportion 
of patients by reducing or eliminating the need for illicit injecting, thereby reducing 
associated health and social problems and providing a greater chance for stability.  
 
1.4.1. The aim of Opiate Substitution Treatment 
 
Reduction or cessation of illicit injecting may reduce the user’s engagement with the 
drug subculture, thus the likelihood of committing crime, and resultant involvement in 
the criminal justice system. Through attendance at community treatment centres, the 
individual undergoes regular health checks and attends regular meetings with key-
workers or case-managers, where progress and concerns can be addressed. Other 
issues such as health and housing may be monitored, and referrals made to 
appropriate agencies. Treatment centres often offer psychosocial therapies to 





1.4.2. Opiate Substitution Treatment failures 
 
Whilst there is a good evidence base on the effectiveness of methadone, 
demonstrated by reduction in major risks associated with untreated opioid 
dependence (Farrell et al., 1994; Ward, Hall, and Mattick, 1999; Mattick et al., 2009), 
a proportion – 15-25% (Johnson et al., 2000); and at least 5-10% (Strang et al., 2010) 
- of entrenched heroin users fail to benefit in this way from oral methadone treatment 
(Oviedo-Joekes et al., 2009). Failure to benefit from treatment has typically been 
defined as treatment drop-out or continued use of illicit opioids through maintenance 
treatment (Strang et al., 2010; Oviedo-Joekes et al., 2009). Additionally, many 
patients demonstrate ambivalent attitudes towards methadone treatment (Dürsteler-
MacFarland et al., 2010). 
 
1.5. Abstinence versus maintenance treatment 
 
As in other European countries, the public health problem associated with heroin 
misuse has led to a change in treatment philosophy (Romo et al., 2009). The focus 
has moved away, somewhat, from pursuing abstinence as a priority, and towards 
harm minimisation as a more fundamental and overriding aim (Mccusker and Davies 
1996; Romoet al., 2009). That abstinence is no longer viewed as the ultimate priority 
attunes well with the discourse on the concept of recovery, such as the pertinence of 
reintegration and ‘filling the void’ with meaningful activities (Neale et al., 2012).  
It has been suggested that social and clinical considerations mediated this change 
(Wilks, 1989). These included the need to limit the growing illicit market in heroin, fed 
by surplus National Health Service (NHS) supplies (Mccusker and Davies, 1996). 
Additionally, Wilks (1989) suggested that the idea that the user who, having attained 
a heroin prescription, could continue to lead an otherwise conventional life, arose in 
the context of a middle-class and often professional heroin user of the past. The 
younger, recreational drug users who emerged through the 1960s tended to lead 
more chaotic and deviant lives irrespective of their drug use (Mccusker and Davies, 
1996). The need to illustrate the history and background of the user in the specific 
recovery context is pertinent. 
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Whilst Methadone Maintenance Treatment (MMT) is known to improve health and 
reduce illicit heroin use, infectious-disease transmission, and overdose death (Ward, 
Hall, and Mattick, 1999) its effectiveness is compromised if low maintenance doses 
of methadone (<60 mg) are administered and patients are pressured to become 
prematurely abstinent from methadone (Ward, Hall, and Mattick, 1999).  
Guidelines on prescribing have attempted to establish recommended practice, but in 
reality, there is much variation in clinical practice (Witton, Keaney, and Strang, 2005). 
For example, daily doses of methadone may vary from 5mgs to an extreme of more 
than 1000mgs daily (Witton, Keaney, and Strang, 2005). As an alternative to MMT, 
other oral opioid agents (e.g., naltrexone, buprenorphine) may increase patient 
choice and avoid some of the more unpleasant aspects of MMT (Ward, Hall, and 
Mattick, 1999). For the archetypal dependent heroin user, periods of daily heroin use 
are interrupted by episodes of detoxification drug treatment, and imprisonment for 
drug-related crimes (Ward, Hall, and Mattick, 1999). The proportion of people who 
achieve persistent abstinence from opioid drugs after any treatment is marginal, 
though it does gradually increase with age (Ward, Hall, and Mattick, 1999). The low 
rates of abstinence after treatment are unsurprising given that most dependent heroin 
users enter drug treatment under pressure from family and friends, or because they 
have been charged with a drug or property offence (Ward, Hall, and Mattick,1999). 
 
1.6. Injectable Opiate Treatment 
 
Mars (2003) outlines the approach that operated from the 1920s to the 1960s which 
came to be known as the ‘British System’ of opiate prescribing for heroin dependence. 
Specifically, the Government appointed Rolleston Committee (Rolleston, 1926) 
advised that it was valid medical practice to administer heroin to individuals for the 
maintenance of their addiction if such maintenance enabled them to lead "a normal, 
useful life." Within this system, medically prescribed maintenance doses of opioids in 
cases of intractable heroin dependence were legitimised where normal functioning 
was considered otherwise impossible (Berridge and Mars, 2004). Bennett (1988) 
asserts that the word "system" was perhaps too strong, connoting organisation, 
planning, and directives. It was said that, at that time, British drugs policy actually 
evolved out of practice rather than planning and tended to be directed only by loose 
guidelines (Smart, 1984; Bennett, 1988). 
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The practice began in the late 1950s and early 1960s when individual psychiatrists in 
the United Kingdom started to prescribe heroin to heroin users for maintenance 
purposes (Strang et al., 1994). The so called ‘British System’ operated for a small 
number of heroin users and involved detoxification or maintenance medication of 
morphine or heroin (Mars, 2003). Initially only available through private healthcare 
services these treatment approaches came to be available through NHS practitioners 
(Mars, 2003). As reported numbers of drug users increased, treatment was removed 
from primary care and became available through new specialist drug treatment 
centres (Mars, 2003). These clinics began by prescribing injectable heroin and 
methadone and eventually came to prescribe oral methadone, as advocated by a 
number of leading London psychiatrists (Mars 2003). Moreover, prescribers of heroin 
fell in the minority, and the practice was contested by the medical colleagues of those 
who continued to do so (Mars, 2003). 
The practice has been part of the British response to opiate dependence since its 
validation by the Rolleston Committee in 1926 (Rolleston, 1926). Until 1968 any 
doctor could prescribe diamorphine to opiate-dependent drug users for the treatment 
of opiate dependence and there was no specific system or legal dose limit (Metrebian, 
Carnwath, Stimson, & Storz, 2002). Before 1960 the extent of the opiate problem in 
the United Kingdom was very slight (Strang & Gossop, 1994), then in the 1960s there 
was an increase in the number of heroin users who used prescribed pharmaceutical 
diamorphine obtained from the illicit market (Metrebian et al., 2002). This came almost 
exclusively from the diversion of medical prescriptions to heroin dependent 
individuals (Stimson & Oppenheimer, 1982). The small increase in illegal drug use in 
Britain in the 1950s stimulated a process of rapid policy reconsideration and change 
which has persisted to the present day (Bennett, 1988). Because of this change, a 
complicated web of legal and medical constraints, treatment methods, and 
information controls has evolved (Bennett, 1988). Comments in the 1980s include 
that drugs policy became so complex that "the task of policy commentary is more 
complicated (now) than at any other period in the history of British drugs policies" 
(Bennett, 1988; Smart, 1984). 
At the height of diamorphine prescribing in the mid to late 1960s there were probably 
in the region of 1000 individuals receiving the drug (Thorley, Oppenheimer, & 
Stimson, 1977). At the same time new drug clinics were set up, mainly in London 
(Metrebian et al., 2002). After a few years of operation, there was a move away from 
prescribing diamorphine, towards prescribing injectable and oral methadone (Strang 
& Gossop, 1994). Historically diamorphine was dispensed for unsupervised 
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consumption at home; usually daily (71%), or a few times a week (60%) by a 
community pharmacist (94%) (Metrebian et al., 2002).  
Since 1968, prescription of heroin to users was legally restricted to physicians 
specially licensed by the Home Office for this purpose (Hartnoll et al., 1980). All such 
physicians were working within hospital clinics, mostly free under the National Health 
Service (NHS), but at least one private clinic included licensed physicians (Hartnoll, 
Mitcheson, and Battersby, 1980). The supply of methadone hydrochloride was not 
subject to the same stringent controls (Hartnoll et al., 1980). In practice, the 
maintenance treatment of addiction with heroin or methadone was carried out almost 
exclusively in the special clinics (Hartnoll et al., 1980). The majority of clinics were in 
London where it was said that most users were concentrated (Hartnoll et al., 1980). 
Whilst the practice was a distinct feature of the UK drug treatment system it operated 
on a small scale (Strang and Gossop, 1994; Mayet et al., 2010). That the practice has 
not been widespread has been largely due to the perceived incongruence of 
prescribing heroin for heroin addiction, perceived increased overdose risk, and 
increased costs associated with prescribing this treatment instead of methadone. For 
these reasons and concerns about diversion to the illicit market, opiate treatment is 
most safely administered in controlled, clinical settings by licenced doctors (Metrebian 
et al., 2002). Previously there was little in the way of prescribing policy for injectable 
diamorphine treatment and, of particular note, no eligibility recommendations for 
individuals who were to receive it (Metrebian et al., 2002).  
One striking feature of the British approach is that it allowed doctors, in their role as 
prescribers, such great autonomy. It was only in 1984 that the first prescribing 
guidelines, The Guidelines of Good Clinical Practice, were published by the 
Department of Health Medical Working Group on Drug Dependence (1984), and 
these were recently revised (Department of Health (England) and the devolved 
administrations, 2007). This more comprehensive document targets general 
practitioners (GPs) and emphasises the importance of good assessment, shared-
care of patients by general practitioners and specialist services, supervised ingestion 
(where available), and training (Witton, Keaney, and Strang, 2005). However, these 
guidelines have no defined legal position, are not themselves regulations, and the 





1.7. Supervised Injectable Heroin 
 
In Switzerland in the 1990s Professor Ambros Uchtenhagen and colleagues 
established a new practice of providing injectable heroin treatment under medical 
supervision with additional psychosocial services (now referred to as supervised 
injectable heroin; SIH). Clinics were open 364 days per year and patients had to 
attend once or twice per day for medically supervised injections. It is commonly 
agreed that the procedure of these clinics (which preceded the subsequent European 
and North American trials, and which are discussed in more detail in chapter 2) make 
this a unique treatment regimen. The first studies to mark the beginning of scientific 
interest in SIH treatment were conducted by Uchtenhagen et al (1999) in Switzerland 
between 1994 and 1996. Individuals participating in these studies formed a large 
cohort receiving heroin treatment, and which provided evidence for the potential 
effectiveness of this approach to treatment. Evidence was limited, however, by the 
lack of a control group. The Uchenthagen (1999) studies paved the way for scientific 
interest in this new approach, through developing SIH treatment and conducting the 
first evaluation of this unique treatment (Uchtenhagen et al., 1999).  
Heroin users may fail in oral substitution programmes because they still need the 
“high” produced by heroin injection or the ritual of preparing and injecting the drug 
(Perneger et al., 1998). Programmes which provide intravenous heroin – in 
structured, monitored settings - may be effective for such individuals (Perneger et al., 
1998) and thereby reduce the need for illicit injecting and associated health and social 
costs. Injectable opiate treatment by its very nature attracts attention and controversy, 
therefore a more complete picture of what we know about it is required (Strang, 
Groshkova, and Metrebian, 2012).  
Seven international trials (in Germany: Haasen et al., 2007; Spain: March et al., 2006; 
the Netherlands: Rehm et al., 2001; Switzerland: Perneger et al., 1998; Canada: 
Oviedo-Joekes et al., 2009; the UK: Strang et al., 2010; Belgium: Demaret et al., 
2015) followed this work and sought to investigate the effectiveness of SIH as a 
second line treatment for entrenched opiate users for whom oral methadone had 
repeatedly failed, using a Randomised Controlled Trial methodology. Demaret et al. 
(2015) then subsequently took place in Belgium. The details of these trials are 
outlined in detail in the literature review in chapter two. 
The five randomised trials (mentioned above) of more than 1000 patients (conducted 
prior to the UK RIOTT trial and before Demaret, 2015) illustrated that treatment with 
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heroin has substantial benefits over oral methadone for individuals who have not 
responded to previous or continuing methadone treatment (Strang et al., 2010). 
However, these five studies relied on self-reported primary outcomes and used 
various complex measures of benefit, leading to the report in a Cochrane review (Ferri 
et al., 2005) that outcomes were not comparable between the studies and, therefore, 
effectiveness remained uncertain (Strang et al., 2010; Ferri et al., 2005). Furthermore, 
only two studies had used a control group of optimised doses of oral methadone 
(Strang et al., 2010). 
Strang et al. (2010) also specifically outline that in the UK, use of injectable 
methadone needed assessment since, for several decades, this treatment was more 
common than injectable heroin for the treatment of addiction. These arguments and 
critique demonstrated the need for the UK RIOTT trial, which utilised: a control group 
of injectable methadone, optimised oral methadone dosing, urinalysis as primary 
outcome variable, and a battery of widely used measures of physical and mental 
wellbeing as secondary outcome variables. 
The five trials prior to the UK RIOTT trial used a fully supervised approach to heroin 
treatment, in which all heroin doses were administered under strict supervision in 
clinics that were open 365 days per year for the treatment of the most entrenched 
heroin users (Uchtenhagen et al., 1999). This model ensures community safety and 
protection against diversion of supplies to the illicit market (Strang et al., 2010). 
Similar supervised injecting clinics were established in England after publication of 
the UK Government’s Updated Drug Strategy, which stated that “The administration 
of prescribed heroin for those with a clinical need will take place in safe, medically-
supervised areas with clean needles. Strict and veriﬁable measures will be in place 
to ensure there is no risk of seepage into the wider community.” (Home Office, 
2002a). 
The 2003 NTA guidance recommends that injectable maintenance treatment is most 
appropriate for long-term dependent heroin users who have not responded to oral 
maintenance treatment (National Treatment Agency for Substance Misuse, 2003) 
(National Treatment Agency for Substance Misuse, 2003). Where injectable heroin 
and methadone maintenance prescriptions are provided as part of a comprehensive 
treatment programme, both may have beneficial effects on health, social functioning 
and crime reduction (National Treatment Agency for Substance Misuse, 2003). The 
National Treatment Agency (2003) publication makes the worthwhile point that since 
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the majority of evidence relates to patients who have “failed” oral programmes, there 
is a need to probe the cause and definition of “failure”.  
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1.8. The UK Randomised Injectable Opiate Treatment Trial 
 
The UK Randomised Opiate Treatment Trial (RIOTT) trial was funded by the 
Community Fund (Big Lottery) research section, through the charity Action on 
Addiction. Chronic heroin dependent patients (aged 18–65 years) receiving 
conventional oral maintenance treatment (for more than six months) were eligible for 
the study if they were continuing to inject street heroin regularly (for more than 50% 
of days in the preceding 3 months). Patients were enrolled from the local catchment 
areas of supervised injecting clinics in south London, Darlington, and Brighton. 
Patients were enrolled and screened for eligibility by the doctor or lead nurse at the 
study site, and patient eligibility was double-checked by a research worker. Patients 
provided written informed consent after they were screened for eligibility and prior to 
randomisation. Ethical approval was received from the London Multi-site Research 
Ethics Committee. The trial was overseen by a trial steering committee, and by a data 
monitoring and ethics committee, comprising a statistician and two consultant 
addiction psychiatrists (Strang et al., 2010). 
The UK RIOTT trial (Strang et al., 2010) assigned 127 heroin using patients to one of 
three randomised conditions for a six month period: injectable heroin treatment 
(N=43), injectable methadone treatment (N=42) and oral methadone treatment 
(N=42). Patients completed six months of assigned treatment and outcomes were 
documented at baseline, three months and six months. After this time, and in 
consultation with trial consultants, patients could choose to move to another treatment 
condition if they felt, or if it was indicated, that they would benefit from this change – 
e.g., if illicit use persisted. Primary outcome was use of illicit heroin (through self-
report and urinalysis). Secondary outcomes included use of crack (self-report), quality 
of life (measured through the EQ-5D and Short Form; SF36 questionnaires), social 
functioning (as measured through the drug use section of the Opiate Treatment Index; 
OTI), use of alcohol, use of benzodiazepines, and engagement in crime.  
Drug treatment and dose changes were also tracked. Following the six month RCT, 
outcome measures continued to be collected for a total of three years. Outcomes at 
6 months were published in a paper by the RIOTT research team in 2010 and two 
year outcome data has been prepared. Outcomes at six months showed that 80% 
(n=101) patients remained in assigned treatment: 81% (n=34) on injectable 
methadone, 88% (n=38) on injectable heroin, and 69% (n=29) on oral methadone. 
Patients on injectable heroin were significantly more likely to have achieved the 
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primary outcome, which was reduction in use of illicit heroin, than were those on oral 
methadone (66% [n=28] versus 19% [n=8], p<0·0001). The difference between 
injectable methadone (30% [n=14]) and oral methadone was not significant 
(p=0·249). A significant difference between injectable heroin and injectable 
methadone was recorded (p=0·002), however the study was not powered for this 
comparison; differences were evident within the first six weeks of treatment (Strang 
et al., 2010), p. 1885.1 
 
1.9. Current international prevalence and policy 
 
Strang et al. (2012) illustrated that the number of people receiving SIH treatment was 
changing, but that – at that time - there were approximately 1000 SIH patients in the 
European Union (EU) and a further 1400 in Switzerland. In the United Kingdom, the 
medical use of heroin has been used in clinical practice since it was first synthesised 
— both for the relief of terminal pain and for the treatment of opioid dependence - 
even though it has rarely been used in recent years for the treatment of addiction 
(Strang et al., 2012). In recent years, four other countries (Denmark, Germany, the 
Netherlands and Switzerland) have granted approval for diamorphine to be used as 
a medicinal product for the specific indication of treatment-refractory heroin users 
(Strang et al., 2012). In these countries, SIH clinics are now integrated into local 
addiction service networks and appear to successfully deliver important benefits to a 
small number of severely affected chronic heroin users (Strang et al., 2012). In Spain, 
one SIH clinic continues to provide treatment to patients enrolled in their trial, now 
operating under legal exemption, and Canada has approved diacetylmorphine for 
research trials only (Strang et al., 2012). 
  
                                                          
1 The following information is taken from the description of the RIOTT trial by Strang et al. (2010) 
and more detail will be described in chapter 2; literature review. 
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1.10. Government Drugs Policy 
  
From a policy perspective the thesis is topical; in May 2012 the Department of Health 
(2012) stated that as a result of the studies in the UK and overseas, IOT is now 
evidenced as a clinically effective second line treatment for a small group of people 
who have repeatedly failed to respond either to standard methadone treatment or to 
residential rehabilitation (Department of Health, 2012). In 2012, the Department of 
Health (2012) committed six million pounds into continuing IOT for relevant patients 
until 2015. In March 2015 all remaining IOT clinics closed down following the end of 
central funding and the reluctance of local funders to meet the treatment cost (John 
Strang, personal communication, January, 2016). The distinctive feature of this 
treatment is the complete supervision of all injectable doses, between one to three 
times daily, every day of the year. More generally, the 2010 Drug Strategy (the year 
of the publication of the RIOTT trial primary data) placed its predominant focus upon 
recovery and building recovery in communities. The strategy emphasises working 
with people who want to take the necessary steps to tackle their dependence on drugs 
and alcohol, and proposes a route out of dependence by putting the goal of recovery 
at the forefront (HM Government, 2010). The policy context, and IOT generally, is 
explored in more detail in chapter two. 
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1.11. Thesis Aims and Objectives 
 
1.11.1. Thesis aims 
 
Overall the thesis will contribute to the scientific understanding of injectable opiate 
treatment, and specifically, determine the role of IOT in the patient’s overall journey 
of recovery. 
The primary aim of the research is to determine the long-term treatment trajectory 
and to describe the experience of patients receiving injectable opiate treatment (IOT). 
Study one determines the long-term treatment trajectory of patients receiving IOT and 
study two describes the experience of patients receiving injectable opiate treatment.  
 
1.11.2. Study one aim 
 
To determine the long-term treatment trajectory of patients receiving IOT. 
 
1.11.3. Study one objectives 
 
1. To illustrate broad patient outcomes over 36 months for those receiving 
Injectable Opiate Treatment (IOT); 
2. To determine the length of time patients receive IOT and whether they move 
away from IOT to oral treatment routes or abstinence; 
3. To determine treatment outcome (including drug use status, health status, 
social functioning status, discharge status) of patients receiving IOT (SIH and 
SIM) long term; 
4. To describe IOT received (including mean dose, number of injections per day); 
5. To determine whether IOT treatment duration affects treatment outcome 





1.11.4. Study two aim 
 
To describe patients’ experiences of injectable opiate treatment. 
 
1.11.5. Study two objectives 
 
6. To formulate and describe patient typology (including treatment allocation and 
discharge status) for each patient interviewed; 
7. To describe patients’ drug use and treatment histories; 
8. To determine patients’ goals for, motivations, and expectations of IOT 
9. To explore patients’ experience with IOT 
10. To explore patients’ satisfaction with IOT; 
11. To explore patients’ views on impact of IOT; 
12. To explore patients’ views of, and goals for, their recovery. 
 
Objectives 7-12 will be achieved through qualitative interviews with IOT patients and 
analysed using thematic analysis. Objective 6 will be achieved through formulation, 
development and illustration of typology for each patient; a chapter in its own right 
(chapter 5), and referenced in qualitative analysis. The literature review aims to 
provide the historical context to IOT, including longitudinal research, and both 
quantitative and qualitative research describing patients’ perceptions and 
experiences. 
 
1.12. Thesis structure 
 
Chapter two includes a full literature review of the topic, which introduces OST, IOT, 
IOT worldwide, longitudinal IOT research, qualitative research in IOT, and patients’ 
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perspectives. Chapter three is the methodology chapter; and outlines methodologies 
for study one (longitudinal quantitative outcomes); and study two (qualitative patients’ 
experiences and perceptions). Chapter four describes the formation of patient 
typologies, which provide the context for the subsequent qualitative findings; and 
chapter five outlines the findings from study one; a description and mapping of 
longitudinal quantitative outcomes. The following six chapters are qualitative findings, 
encompassing patients’ experiences and perspectives on IOT and their recovery in 
this context: chapter six: heroin use history; chapter seven: referral to IOT; chapter 
eight: experience of IOT; chapter nine: impact of IOT; chapter ten: recovery; chapter 
eleven; current situation and goals for the future. Chapter twelve concludes the thesis, 
presenting a general discussion of the two main studies’ findings. The discussion 
takes into account the implication of the thesis’ findings for future research, clinical 
practice and drug policy. 
The patients’ medical and research notes were reviewed and assimilated as individual 
case-note reviews; these data are illustrated in the appendix. The full appendix 
(including 41 patient case-studies) follows chapter 11; appendix 5.  
In summary the thesis maps and describes patient trajectory and experience of 
longitudinal IOT, and synthesises patient accounts with a review of patient case-
notes. Patients’ experiences and perspectives are interpreted in the context of patient 
typologies, created specifically for this purpose. This allows interpretation of the 
results in the context of the trajectory through the RIOTT trial. In so doing, the thesis 
contributes to the overall debate on the role of injectable opiate treatment in the 
individual patient’s journey of recovery, and in the British treatment system. Overall 
the thesis provides a more complete picture of the role and scope of this unique 




Chapter 2 – Literature Review 
 
The literature review is a narrative literature review outlining and evaluating research 
conducted in the field of IOT to date which led to the development of the research 
projects and methodology within the thesis. The narrative review outlines the 
historical trajectory of this research area, including IOT conducted both prior to and 
as a consequence of the development of the specific supervised injectable heroin 
(SIH) trials in Europe and Canada. These studies and trials are outlined and 
discussed, along with secondary outcomes, longitudinal IOT research studies, 
research examining patients’ perspectives of IOT, and qualitative research conducted 
in this field to date. 
 
2. Injectable heroin treatment: A review of the context, history and evidence 
 
2.1. Rationale for choice of literature review 
 
A narrative literature review was chosen for several reasons. The primary reason 
being that there have already been several recent systematic reviews and meta-
analyses conducted to date – by Strang et al. (2015); Ferri, Davoli, and Perucci 
(2005); Ferri, Davoli, and Perucci (2011), and the results of these will be 
encompassed in the following review. The largest project within the thesis is a 
qualitative exploration of patient experience of IOT, including patients’ conception of 
recovery from heroin dependence in the context of an IOT trajectory. Given the less 
utilised – in this area - research method (qualitative interviewing) employed for the 
main study within the thesis, previous qualitative research in opiate substitution 
treatment will be outlined and discussed.  
It is important to note that there is a relatively wide qualitative research literature 
around the experiences of injecting heroin users’ experiences of conventional OST - 
such as methadone and buprenorphine – and that these could have formed the focus 
of the current literature review. This would be a useful literature review, and this 
literature was initially surveyed. However, it was decided that because the thesis 
comprises the patient’s complete treatment and recovery trajectory, beginning at 
treatment outset through to treatment discharge (with the quantitative work providing 
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the context for patient’s treatment and recovery journey), it was felt important to study 
and outline the research history of this treatment. Importantly, it was decided that 
because supervised injectable heroin treatment is such a unique regimen, with a 
relatively small number of research papers published on it worldwide, it was important 
to capture the specifics of this unique treatment by means of exploration of all the 
research that has been conducted to-date. By focussing on injectable treatment only, 
this provided a more concise focus to the literature review. Upon survey of the 
qualitative literature on users’ experiences of both drug use and conventional 
treatment, results yielded proved too diverse for a comprehensive yet succinct review. 
This research will be mentioned in this narrative literature review, however (on page 
94). The PhD candidate also felt that by comprehensively reviewing the literature on 
injectable opiate treatment, she would increase her knowledge of this research field 
– which was a primary research interest – and which would be beneficial for 
qualitative interviewing and analysis of the qualitative research sections. 
Due to the breadth and pace of development of addictions research and treatment, a 
truly comprehensive review is probably impossible, and certainly beyond the scope 
(and relevance) of this thesis. The following narrative review will focus primarily on 
injectable opiate treatment, and aims to synthesise a focussed detail of research 
conducted to date, including relevant discourse, what is missing from this research 
pool and how the research to date necessitates the conduct of the current thesis 
research. The review aims to outline the history of IOT prescribing to date, highlighting 
areas of deficit, and hence the need for the current research projects. 
 
2.2. Addiction and drug misuse 
 
Drug misuse is defined as the use of a substance for purposes not consistent with 
legal or medical guidelines (Hoare 2009). The Misuse of Drugs Act (1971) is the main 
piece of legislation that still applies today covering drugs and categorises drugs as 
Class A, B or C. Under the Act the main offences are to: unlawfully possess a 
controlled substance and/or have intent to supply it; supply a controlled drug; and to 
allow premises you occupy or manage to be used for the purpose of drug taking 
(Lifestyles Statistics, Health and Social Care Information Centre, 2013). 
The use of addictive substances might be viewed as just one of the contributory 
factors of health and social problems linked to the dependence syndrome. Addiction 
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is recognised as a complex interaction of multiple factors including substance, 
personality characteristics, environmental stressors and lack of alternative options for 
pleasurable experiences (Uchtenhagen, 2015). In fact addictive behaviour may be 
equally fostered by health and social problems, and environmental determinants have 
a major role in shaping health and social consequences of use (Rehm et al., 2004). 
Poverty, educational deﬁcits and migration (with disruption of social networks and 
support) are all factors correlated with substance use and dependence, and a range 
of mental health problems can contribute to self-medication through illicit substance 
use (Uchtenhagen, 2004). Blanken et al. (2010) illustrate that heroin dependent 
patients are comparable to other psychiatric patients and should be treated in a 
similar context, but that the complicating factor is that they take an illegal drug that is 
traded in a criminal environment. Blanken et al. (2010) highlight that this factor 
hampers the recognition and fulfilment of the medical needs of heroin users. 
 
2.3. Injectable Opiate Treatment 
 
As introduced in chapter one the British system involved detoxification or 
maintenance medication of morphine and heroin. This operated for a small number 
of heroin users. The following section outlines research examining the effectiveness 
of this approach.  
Mccusker and Davies (1996) conducted a quasi-experimental design using a case-
control methodology, whereby heroin treatment patients already in a treatment 
programme were matched to methadone treatment counterparts; by variables: age, 
gender, heroin use history duration, and treatment duration. The study comprised 
n=27 heroin treatment patients and n=39 methadone treatment patients. Between 
group comparisons of outcomes were made at one month and then five - six months 
later (the longitudinal component), with between group comparisons across the two 
time points. Prescribing doses were described as flexible; attempting to compensate 
for the extent of street dosing (Mccusker and Davies, 1996). At six months 35.9% had 
dropped out of methadone treatment, compared to 3.7% in heroin treatment.  
Heroin treatment patients met more regularly with their keyworker (regular meetings 
being a condition of treatment in the respective services). Here we are introduced to 
the idea that retention in treatment and engagement in programmes is improved 
through the process of heroin treatment. By the second research interview those in 
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the heroin treatment group were more likely to have negotiated an increase in heroin 
dosage and methadone treatment patients were more likely to have decreased their 
dosage. It could be hypothesised that respective dose reductions (methadone) and 
increases (heroin) contribute to drop-out and retention respectively. Yet why doses 
were altered is unknown. The study found that illicit drug use continued in both 
treatment groups; cocaine use was in fact higher in the heroin treatment group on 
both interview occasions. The same was found for illicit heroin, and in fact a 
prescription of heroin, even at high doses, did not completely eliminate use of illicit 
heroin (Mccusker and Davies, 1996). 
Interestingly although significantly fewer numbers of the heroin treatment group 
(compared to the methadone treatment group) had used illegal heroin in the previous 
thirty days at the time of the first interview - 22% compared to 69% respectively - 
these between group differences were not present at the time of the second interview 
- 35% compared to 40% (Mccusker and Davies, 1996). Money spent on heroin was 
significantly reduced in the heroin treatment group compared to the methadone 
treatment group (£67.1 and £42.9 in the methadone group and £16.9 and £16.6 in 
the heroin treatment group). It was interesting that the methadone group reduced the 
amount spent over time, whereas heroin group changes did not meaningfully alter 
over time. The strength of this study was that, whilst not as scientifically robust as an 
RCT, it offered findings in a more naturalistic setting, perhaps more reflective of the 
treatment experience in clinical practice at that time. Studies like this one also paved 
the way for the subsequent RCTs examining IOT’s effectiveness. That patients were 
required to meet more frequently with their keyworker if enrolled in heroin treatment 
is an important factor of consideration. It is reasonable to propose that an increase in 
intensity of therapeutic contact may have a role to play in the effectiveness of this 
treatment. It may be that patients are initially motivated by heroin administration, yet 
through the additional support required from this treatment, they are more likely to 
recover. 
Hartnoll, Mitcheson, Battersby, Brown, Ellis, Fleming and Hedley (1980) conducted 
the first randomised study examining IOT’s effectiveness. It should be noted, 
however, that this study is not classified as those that fall in to the supervised 
injectable heroin treatment umbrella conducted in Europe and Canada later – as 
these later studies employed use of a specially created supervised clinical injecting 
facility. Hartnoll et al. (1980) describe the set-up of heroin treatment prescribing at 
this time. Each clinic was led by a psychiatrist who was usually a full staff member of 
the hospital and likely devoted half his/her working week to this function. She/he was 
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assisted by other part-time clinical staff and various support staff, including nurses, 
social workers, and sometimes a clinical psychologist. Patients attended the clinic 
usually once every two weeks (sometimes weekly and sometimes less frequently). 
Health care and counselling was generally available, and in some cases more 
intensive psychotherapy. Patients did not collect prescriptions at the clinic but a 
prescription was mailed to a retail pharmacy, where a special arrangement was made 
for the drugs to be dispensed daily. Thereby, virtually all patients had take-home 
privileges, and only in exceptional circumstances were injections administered under 
medical supervision on the clinic premises (Hartnoll et al., 1980). This is a really useful 
historical picture and illustrates the stark difference between prescribing of the past 
and the new supervised approach; outlined in the next section. 
In Hartnoll et al. (1980) N=96 heroin dependent patients were randomly allocated to 
heroin treatment and methadone treatment with outcomes monitored over a 12-
month period. Patients in the study were those who had rejected methadone 
treatment between five and eight years prior to the study’s publication. Inclusion 
criteria included those dependent patients who were judged to continue illicit use of 
heroin, had injected daily for the three months prior to trial enrolment, and who had 
persistently requested heroin treatment. By 12-months 74% of heroin treatment 
patients were retained in treatment and 29% in methadone treatment. However, 
interestingly, of those who dropped out of methadone treatment by 12-months, 40% 
were no longer using illicit opiates regularly. Slightly more (64%) heroin treatment 
patients continued to use illicit heroin than the oral methadone group (59%) though 
the difference was not statistically significant. 12% of those in the heroin group were 
selling some of their prescription every day. In the heroin group there was a tendency 
to use smaller amounts of heroin regularly, whereas the methadone group were 
polarised by either not using illicitly at all, or using larger amounts (Hartnoll et al. 1980) 
illustrating the divide of those responding effectively to methadone treatment relative 
to those who did not. Across both groups mean daily amounts of illicit heroin reduced 
from 74mg to 21mg (heroin) and 37mg (methadone) per day. There were no 
differences across groups in use of other illicit drugs. There were no differences in 
employment status, health outcomes – and controlling for baseline crime levels – 
criminal activity, across the two groups (Hartnoll et al., 1980), although levels of crime 
did decrease over the year of the trial.  
It was interesting that aside from retention to treatment there were no significant 
differences across groups. The researchers in the Hartnoll et al. (1980) study report 
that they were aware that patients modified drug use prior to attending the clinic for 
55 
 
testing, or failed to attend to conceal illicit drug use. On this basis the researchers 
suggest caution over the reliability of urine drug screening as an indicator of illicit drug 
use (Hartnoll et al., 1980). Patients enrolled in specifically designed research trials 
may be more motivated to take the programme seriously and strive to reduce illicit 
use on this basis. Additionally, the intensity of the supervised requirement for later 
trials may be a key component of what supports patients in making long-term 
changes. This study - in the context of later open-label, supervised trials indicating 
superiority of heroin treatment over methadone treatment - indicates that it is not just 
the administration of heroin treatment that motivates positive change and wider 
recovery. Another subject of interest is dosage prescribed during the Hartnoll (1980) 
RCT – the study describes a relatively – as compared to previous British standards 
(Hartnoll et al., 1985) – conservative (45% were on 40-70mg of heroin treatment per 
day, with smaller percentages on lower or higher; 80mg+ amounts) dosage, as 
opposed to an unlimited supply of heroin on demand. Overall the study finds that the 
results do not indicate a clear overall superiority of either treatment approach. Both 
treatments have advantages in some areas, but at the expense of disadvantages in 
other areas. The approach favoured depends on the priorities assigned to the various 
outcome variables (Hartnoll et al., 1980). This links appropriately to the different ideas 
outlined in chapter one about what constitutes recovery. 
The Hartnoll et al (1980) study had an interesting methodology whereby those who 
received methadone were ‘refused’ heroin treatment and offered methadone instead. 
The psychological impact of this event is discussed in the context of the outcomes of 
the study. Those who were refused heroin were more likely to be totally or almost 
abstinent; whilst those who did continue injecting heroin regularly were obtaining 
larger quantities of illicit opiates than were those given a heroin prescription. In terms 
of social functioning, those who were refused heroin had either stopped associating 
with other users and ceased drug-related activities, or they were heavily involved in 
the drug scene.  
Hartnoll et al. (1980) suggest that refusal to prescribe heroin (and offering oral 
methadone instead) may be seen as a more actively confrontational policy that is 
associated with greater change. This directly contradicts the more contemporary 
notion of the importance of person-centred regimens for engagement and 
effectiveness, however. The need for specific RCTs assigning patients to clear 
treatment arms, with relative control groups is made very clear in the context of this 
research. Hartnoll et al. (1980) argue that the polarisation found in the OM group may 
be seen as divergent responses to frustrated hopes and, further, that the differences 
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between the two groups might have been different without those pre-existing 
expectations. This is of course a very different methodology to one whereby patients 
are explicitly assigned to a treatment, and told that they will be able to move on to 
heroin treatment following a six-month RCT. These contrasts illuminate the potential 
power of hope and expectation on retention and outcomes. These are concepts that 
could be usefully explored in qualitative research. 
Finally, Hartnoll et al. (1980) discuss access and perceptions. Hartnoll et al. (1980) 
argued that in England, users may often be reluctant to approach a clinic despite the 
possibility of obtaining heroin. Apart from suspicion of physicians and official 
agencies, anxiety about the consequences of becoming "registered," and a feeling 
that it would be "giving up," individuals may consider that there are too many 
restrictions and conditions attached to receiving a prescription. This is interesting and 
pre-treatment perceptions (and their potential role in subsequent engagement and 
experience) could be usefully explored qualitatively with patients. Hartnoll et al. (1980) 
contrast this idea with the much greater degree of control envisaged in most American 
proposals at that time: comprising on-the-premises administration; participation in 
counselling and training; and relatively quick transfer to oral medication or into drug-
free programs. Hartnoll et al. (1980) argue that these factors would almost certainly 
have deterred many of their sample from initially approaching the clinic. This is an 
assumption, and in light of the effectiveness of later RCTs – albeit in the concept of 
methadone maintenance being the contemporary mainstream prescribing option – 
may not be a correct one.  
Following Hartnoll et al. (1980) and after some debate in the field, many clinics 
refused to prescribe injectable drugs to new patients (Mitcheson, 1994; in Strang et 
al, 1994; Blanken et al., 2010). In 1994 only 1–2% of the estimated 75,000–150,000 
heroin users in the United Kingdom received a prescribed supply of any injectable 
drug, and only a small proportion of these received injectable heroin (Strang et al., 
1994; Blanken et al., 2010). 
In 1998 in West London (England), Metrebian et al. (1998) assessed the feasibility of 
prescribing injectable heroin and methadone to patients, examining associated health 
gains and harm reduction. This study followed a prospective observational 
methodology and type of injectable opiate treatment received was based on self-
selection (Metrebian et al., 1998). The setting was a large west London drug 
treatment clinic and the sample involved N=58 patients between 1995 and 1996.  
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Patients were long-term opiate dependent injecting drug users, who had previous 
failed attempts in oral methadone treatment defined by the following: regular 
continued use of illicit opiates while receiving oral methadone; continuing to inject 
regularly; receiving doses of oral methadone in excess of 80 mg per day; and 
problems relating to drug use in areas of health, social functioning or crime. 
(Metrebian et al.,1998). The highest dose of either drug was 200mg. In this study 
patients were not permitted to inject on-site and in order to reduce the risk of injectable 
opiates being diverted to other users, patients were required to return used ampoules 
(batch numbers were checked) before receiving subsequent ampoules. This arguably 
does not ensure that medication has been taken, and not diverted, since ampoules 
could be retrieved following diversion. If medication is not taken and diverted, validity 
of results is compromised. Of note was the fact that forty per cent of the original 
sample were ejected from the study for violation of the study protocol.  
Results showed that thirty-seven patients (64%) chose heroin treatment and 21 (36%) 
chose injectable methadone treatment. Fifty (86%) were retained in treatment after 
three months, 40 (69%) after six months and 33 (57 %) after 12 months. Among those 
in treatment at three months, there were significant reductions in illicit drug use, illicit 
drug-injecting risk behaviour, and criminal activity (Metrebian et al., 1998). There were 
also significant improvements in social functioning, health status and psychological 
adjustment. Generally, these gains were sustained between three, six and 12 months. 
Self-report was validated through doctors' ratings of health and urinalysis. It was 
interesting that injectable heroin was not always the drug of choice for these patients 
at this time, and it would be really useful to investigate patients’ perceptions of why 
this may have been the case. 
The Metrebian et al. (1998) study was interesting in terms of how the outcomes 
measured varied and developed over time. There were no significant differences in 
measures of health and social behaviour between three and six months, except for 
illicit drug injecting - which increased - although at six months it was still significantly 
lower than at baseline. Between six and 12 months, there were significant reductions 
in HIV risk behaviour, illicit drug-injecting risk behaviour and sexual risk behaviour, 
but no other significant changes. It would be interesting to explore patient narratives 
on why these changes occurred when they did – or did not.  
Results of urinalysis suggest that there were (non-significant) reductions in 
tranquilliser, amphetamine, and cocaine use between entry and three months; 
between three and six months; and which were sustained between three and 12 
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months (Metrebian et al., 1998). Interestingly, few patients receiving injectable 
methadone were using illicit opiates. Measures of health and psychological status as 
reported by clinic doctors suggest that health and psychological well-being 
had significantly improved at three months and these improvements were generally 
sustained (Metrebian et al., 1998). Finally, long-term retention was not significant to 
the results of this study; there were no differences found in drug use, health or social 
status between those leaving treatment before 12 months and those retained 
(Metrebian et al., 1998).  
The study was one of a number demonstrating effectiveness of IOT as a treatment 
option, however it had limitations – and thus helped pave the way for studies including 
this – by virtue of the fact that there was no control condition. It was also limited 
through the self-report nature of patient outcomes, the fact that patients’ doses were 
unsupervised and therefore their medication could be diverted rather than consumed 
as assumed. Ultimately many clinicians became reluctant to prescribe heroin due to 
a lack of evidence for its effectiveness, the lack of national guidance on eligibility, 
dose and delivery, and concerns that it may be diverted into the illicit market and 
therefore seepage into the wider community (Metrebian et al., 2002). 
2.4. Supervised Injectable Heroin treatment 
 
Despite the availability and effectiveness of methadone treatment, many heroin users 
did not improve and failed to cease use of illicit heroin during methadone treatment. 
Consequently, these users are exposed to situations that pose risk to their health and 
lead to social exclusion (March et al., 2006). As illustrated it was this situation that 
gave rise to a search for treatment alternatives, such as the medical prescription of 
heroin, and which targeted this specific profile of users. The profile encompassed 
heroin-dependent individuals who had been consuming heroin compulsively for many 
years, for whom available treatment, including methadone, had failed, and who had 
severe physical and mental health problems because of their drug use (March, 
Oviedo-Joekes, and Romero, 2006). Arising from this need was the development of 
the new supervised injectable heroin (SIH) prescribing facilities. 
SIH treatment emerged over the last twenty years as an important development to 
the earlier unsupervised heroin prescribing practices. In its present guise SIH is an 
intensive unique treatment programme, specifically developed as a second-line 
treatment for those failing to benefit from what became known as conventional OST, 
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such as oral methadone treatment (Strang, Groshkova, and Metrebian, 2012). That 
heroin treatment became supervised was a very important addition to heroin 
treatment prescribing, on the basis of the fact that heroin is a respiratory depressant 
and therefore on-hand prompt medical intervention following dosing is important 
(Oviedo-Joekes et al., 2009). It was envisaged that, through this supervision, the 
disadvantages of the earlier heroin prescribing in the United Kingdom could be 
avoided, whilst maintaining the beneﬁts of it (Metrebian et al., 2015).  
SIH has two specific features which distinguish it from injecting heroin treatment of 
the past. The first being that SIH is a second-line treatment, specifically for, and 
limited to, those users not responding to conventional OST or residential rehabilitation 
(Strang, Groshkova, and Metrebian, 2012). The second is that all doses (typically 
200mg) are consumed under direct medical or nursing supervision (Strang, 
Groshkova, and Metrebian, 2012). The opening of the supervised clinics followed 
publication of the UK Government’s updated Drug Strategy (Home Office 2002b), 
which stated that “The administration of prescribed heroin for those with a clinical 
need will take place in safe, medically-supervised areas with clean needles; and strict 
and veriﬁable measures will be in place to ensure there is no risk of seepage into the 
wider community”. (Home Office, 2002b; Strang et al., 2010).  
The UK Government’s 2008 Drug Strategy (Home Office 2008) states that “rolling out 
the prescription of injectable heroin and methadone to patients who do not respond 
to other forms of treatment”, is subject to the results from the UK RIOTT trial (Strang 
et al., 2010). Strang et al. (2010) subsequently recommended that supervised 
injectable heroin should be provided, with close monitoring, for carefully selected 
chronic heroin users in the UK. This model of delivery ensures protection against the 
diversion of heroin to the illicit market, as well as providing a greater intensity of 
contact with patients (Metrebian et al., 2015). Whilst the practice clearly has a useful 
history, more recently the stigma attached to the substance hindered the 
implementation of heroin treatment (Gartry et al., 2009). This stigma and negative 
connotation is also indicated by news articles in response to the UK RIOTT trial 
(Strang et al. 2010) - outlined later in the chapter - which are in the appendix (see 
appendix 3).  
Laudet (2007) emphasises the role of the media in conveying information about drugs 
and addiction. Public perception may have an impact on policy in the area and vice-
versa. Oviedo-Joekes (2010) outline that policy in Spain, for example, means that 
SIH can only be administered as part of an RCT measuring its effectiveness, thereby 
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deemed as ‘compassionate’ administration. The question might be – and also 
touched on by Oviedo-Joekes (2010) – how useful is it to demonstrate the 
effectiveness of a drug treatment which policy precludes administration of in clinical 
practice. These media messages and policy decisions will invariably increase feelings 
of stigma and ostracism from wider society for drug dependent individuals. This in 
turn may affect if and how patients engage with their recovery. Laudet (2007) also 
highlights the importance of considering the socio-politico context of how recovery is 
defined and experienced. Laudet (2007) argues that how addiction is addressed and 
regarded by a society may influence recovery goals, paths, course and outcomes 
(e.g., harm minimisation versus abstinence-based policies). 
The benefit of this new approach is compliance or adherence to treatment, 
monitoring, safety, and prevention of any possible diversion of prescribed 
diacetylmorphine to the illicit market (Strang, Groshkova, and Metrebian, 2012). This 
requires the clinics to be open for several sessions per day, every day of the year 
(Strang, Groshkova, and Metrebian, 2012). SIH may be less safe than Methadone 
Maintenance Treatment (MMT) and therefore requires more clinical attention to 
manage greater safety issues (Strang et al., 2015). As indicated, SIH is not intended 
for those patients who have never undergone treatment previously; to avoid enrolling 
patients who could benefit from conventional treatments (Perneger et al., 1998). 
Supervised injectable treatments are demanding for both staﬀ and patients, and need 
high monetary and personnel investments. However, the advantage gained from 
reversal of an otherwise adverse disease trajectory is a considerable achievement, 
especially in view of the extensive harm of heroin dependence for the user, family, 
and wider society (Strang et al., 2010). 
 
2.5. Randomised Controlled Trials measuring the effectiveness of SIH 
treatment 
 
Over the past seventeen years there have been seven RCTs conducted worldwide 
all confirming SIH’s efficacy in reducing use of illicit heroin and improving various 
other social, psychological, health and well-being dimensions, as demonstrated by 
means of validated measures, when compared to MMT. Countries conducting these 
RCTs include Switzerland (Perneger et al., 1998); the Netherlands (van den Brink et 
al., 2003); Spain (March et al., 2006); Germany (Haasen et al., 2007), Canada 
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(Oviedo-Joekes et al., 2008) the UK RIOTT trial in England (Strang et al., 2010) and 
in Belgium (Demaret et al., 2015).  
 
2.5.1. Injectable Opiate Treatment research in Switzerland 
 
In Switzerland patients comprised community based out-patients in Geneva who had 
previously failed in at least two previous drug treatments (Perneger et al., 1998). 
Perneger (1998) featured a small sample size, however was the first study to utilise 
the fully supervised approach to administering IOT (Strang et al., 2015). 25 patients 
completed six months of heroin treatment as compared to 24 control patients who 
received any other conventional treatment, which was usually methadone (Perneger 
et al., 1998). Results showed that only one heroin treatment patient continued to use 
illicit heroin at six-month follow-up, compared to ten control patients, with a significant 
difference of 44% (Perneger et al., 1998). Additionally health status, role limitations 
due to emotional problems, and social functioning improved significantly for the heroin 
treatment group (Perneger et al., 1998). Finally, heroin treatment patients also 
significantly reduced their illegal income and drug expenses and committed 
significantly fewer drug and property related crimes (Perneger et al., 1998). The 
efficacy of SIH treatment was clearly indicated through this initial RCT examining 
SIH’s effectiveness.  
Perneger et al. (1998) outline some important limitations to their study which are 
relevant to the SIH literature overall. Firstly, there is clearly a small sample size for 
this RCT, which called for the development of larger SIH RCTs. Perneger et al. (1998) 
make a very valid point that the programme assessed global programme effects and 
therefore differentiation between specific effects of heroin administration and those of 
these other ancillary services provided as part of such an intervention, such as social 
service involvement, mental health care and benzodiazepine substitution is 
problematic. Arguably no quantitative RCT can differentiate these effects, since all 
patients will be entitled to additional ancillary support, yet take up of them will differ 
across patients on the basis of need. In an enhanced usual care (EUC) condition, 
usual care is systematically improved by the research protocol to overcome ethical or 
methodological problems that would accompany ordinary UC (Freedland et al., 2011). 
The degree of enhancement can range from minimal to extensive (Freedland et al., 
2011). In regards to enhanced treatment as usual in the case of SIH and IOT (i.e., 
optimised oral methadone treatment - where the patient in the control condition is 
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provided with the same intensive holistic psychopharmacological treatment as those 
in SIH) these optimised or enhanced control conditions (across trials and even sites) 
were probably subject to a great deal of variability. Despite the significant effects 
between SIH and control groups it is fair to argue that some of the success is due to 
the effective holistic support characteristic of the regimen. This predicates the 
reasonable call for additional qualitative research, alongside RCTs, amongst trial 
patients to unpack the potential effect of these ancillary services in more detail.  
Another methodological criticism outlined by Perneger et al. (1998) is that secondary 
outcome measures are self-reported. However, research shows that self-report data 
is reliable when conducted by individuals with no control or power over the treatment 
process (Darke 1998). Methodologically it is difficult to measure these areas of 
functioning in other ways. Methodologically Perneger et al. (1998) also propose that 
the restriction of eligibility to patients who had a tendency to fail in conventional 
treatments may bias the control group. Not only do results not support the efficacy of 
heroin maintenance as a first line treatment of heroin addiction, but it may also be 
that repeated failure in conventional treatment impacts the positive result – efficacy – 
within trials, and once again the case is made for an exploration of patients’ pre-
enrolment emotions and cognitions. In so doing we may gauge patients’ pre-IOT 
status in relation to how they felt about their drug use and any desire for change. 
Repeated failure in conventional treatment may create a strong emotional and 
cognitive desire to strive for change in a new treatment programme. 
Perneger et al. (1998) specifically call for further research with larger samples and in 
other populations (which did follow), that include outcome variables that are not self-
reported (again this was conducted through use of urinalysis data in other trials), to 
explore the specific contribution of medical and psychosocial services to overall 
programme benefits (this may be explored with qualitative research with trial 
patients), assess the value of alternative routes of heroin administration (the 
intravenous and intramuscular routes were both examined within the Strang et al., 
2010 RIOTT trial), and to examine possible interactions between baseline 
characteristics of patients and relative benefit of heroin treatment. Once again this 
final recommendation can be explored to some extent through qualitative research 
with trial patients, by specifically examining the baseline situation in more detail, 




Following Perneger et al. (1998) proceeded a large cohort study examining the 
effectiveness of SIH, conceived by Ambros Uchtenhagen (Rehm et al., 2001); 
however, this study did not feature a control condition. The study found considerable 
improvements in physical and mental health and various aspects of social integration 
and illicit drug use. Whilst the study indicated that heroin treatment is feasible, efficacy 
was difficult to evaluate because there was no randomised control group. Once again, 
efficacy solely due to drug administration could not be differentiated from other 
positive aspects of treatment – since patients in this study were subject to mandatory 
psychosocial counselling and care. Again, the need for qualitative research to unpack 
these differential aspects of treatment is required, since delivering heroin treatment 
without these ancillary aspects is problematic ethically. To echo these points the 
World Health Organisation (WHO) was unable to determine if the positive effects of 
the research study were a causal result of the prescription of heroin, the extensive 
psychosocial counselling and care, or a combination of these factors; i.e., the overall 
package of care administered (Ali et al., 1999).  
Ali et al. (1999) argue that from a rigorous methodological viewpoint, it was not 
possible to obtain internally valid results with respect to the research question of 
heroin prescription being causally responsible for improvements in health status or 
social functioning in the individuals treated. Arguably these factors cannot necessarily 
be differentiated by means of an RCT either, if all RCTs also provide these highly 
beneficial ancillary support services – even by means of urinalysis one cannot 
definitely gauge that this is entirely due to administration of heroin treatment, over 
and above psychological and social support. Particularly in cases where methadone 
patients are demonstrated to benefit from the treatment overall in ways that the same 
patients had not done so previously. These methodological uncertainties may in part 
be addressed and further explored through the scrutiny of an in-depth interviewing 
methodology – this however, would obviously remain a subjective account. That said, 
it may provide more valuable information on what is beneficial within programmes, 
from patients directly; arguably the most valid source of knowledge on the experience 
of this unique treatment.  
 
2.5.2. Injectable Opiate Treatment research in The Netherlands 
 
Following Rehm et al (2001) was van den Brink et al (2003)’s RCT in the Netherlands. 
van den Brink et al (2003) conducted two open-label RCTs in methadone 
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maintenance treatment (MMT) settings in cities in the Netherlands. Patients were 549 
heroin dependent individuals; 375 of which were assigned to inhalable heroin and 
174 to injected heroin (thereby addressing the recommendation by Perneger et al. 
(1998) that other routes of administration should be examined in future work). It 
should be noted however that whilst inhalable heroin is used by the majority (75–90%; 
Haasen et al., 2007) of street heroin users in The Netherlands, this route of 
administration is not customary to other countries population of heroin users (Haasen 
et al. 2007), and nor was this evidenced in the other SIH RCTs. 
Groups were more complicated within this trial and involved firstly; an inhaling trial 
(comprising three groups; a. a control group receiving twelve months of methadone 
only; b. an experimental group receiving 12 months of methadone plus inhalable 
heroin, and c. a comparison group receiving six months of methadone alone followed 
by six months of methadone plus heroin. This is useful as allows comparison of those 
in long-term SIH (12 months) to those in a shorter (six month) regimen. Secondly; an 
injecting trial comprising two groups; a. a control group receiving twelve months of 
methadone only; and b. an experimental group receiving 12 months of methadone 
plus injectable heroin.  
Once again, within this trial ancillary psychosocial support was offered throughout. 
Outcomes from this trial differed in the sense that the researchers utilised a 
dichotomous multi-domain response index including validated measures of physical 
and mental health and social functioning. In both inhalable and injectable treatment 
conditions, 12 months of heroin (plus methadone) treatment was significantly more 
efficacious than the methadone alone condition with a 22.8% difference for the 
inhalable trial and a 24.3% difference for the injectable trial. Discontinuation of the co-
prescribed heroin resulted in a rapid decline in 82% of those who responded to the 
co-prescribed heroin (van den Brink et al. 2003). In terms of safety of one approach 
over the other, the incidence of serious adverse events (SAEs) was similar across 
treatment conditions (van den Brink et al. 2003). Following up on Perneger et al.’s 
(1998) comments on the question mark over validity through the use of a self-report 
methodology, in van den Brink et al. (2003) self-report criminal data was validated 
through use of police charges – with good congruence - and self-reported illicit drug 




2.5.3. Injectable Opiate Treatment research in Spain 
 
Following van den Brink et al. (2003) was March et al. (2006) in Granada in Spain. 
N=62 patients were randomised; n=31 in each group – oral methadone and injectable 
diacetylmorphine – and a total of n=50 were analysed. The methodology was an 
open-label RCT. Recruitment was directly from the streets using peer outreach within 
known places of use. This is quite a different approach to recruiting through treatment 
centres which was common-place across the other studies. The experimental group 
received injected diacetylmorphine twice a day as well as oral methadone once a day 
for a period of nine months. The control group received oral methadone once a day 
for this period. Once again comprehensive clinical, psychological, social, and legal 
support was given to both groups (March et al., 2006). Groups were measured and 
compared on measures of general health, quality of life, drug-dependence-related 
problems, illicit heroin use, risk behaviour for HIV and HCV, and psychological, family, 
and social status. There were improvements across both groups in regards to the 
dichotomous multi-domain index utilised as primary outcome variable.  
The heroin treatment group showed significant improvements in physical health (2.5 
times higher); risk behaviour for HIV infection (1.6 times higher). The heroin treatment 
group significantly decreased its street heroin use from 25 days per month to eight 
days per month by means of the Addiction Severity Index (ASI), as well as the number 
of days free from drug-related problems (improvement was 2.1 times higher) or 
involvement in crime (from 11 days per month to less than one day per month). Whilst 
the heroin treatment group made gains on a number of variables it was interesting 
that both the methadone and the heroin treatment groups improved with respect to 
physical and mental health, quality of life, social functioning, and legal status. This 
indicated that the structured and holistic care provided across the sample improved 
the situation on some level across both treatment groups. Physical health and factors 
pertaining to harm reduction and crime were reduced or improved for the heroin 
treatment group indicating that SIH lessens some of the chaos and risks associated 
with the drug using lifestyle. The fact that there were no differences between groups 
on quality of life and psychosocial factors indicates protection on these factors by 
virtue of being in a holistic treatment programme or even an RCT. Arguably the 
employment of these ancillary psychological and social support services call in to 
question the appropriateness of these quality of life measures as primary or 
secondary outcome variables. 
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March et al. (2006) also find that within their trial certain patients who had found 
methadone ineffective in the past actually benefited from methadone treatment in the 
framework of the trial. It is important to acknowledge however that patients probably 
received higher doses of methadone compared with the standard methadone 
treatment. Clinical practice presents deviations from evidence-based approaches 
through the use of suboptimal doses (Bell, 2012). This means that treatment as 
delivered in practice may have resulted in poorer outcomes than predicted by 
research (Bell, 2012). Uchtenhagen (2015) has some further commentary on this, 
and this will be described later in a later section of the review. 
It is important to note that within March et al.’s (2006) study a team was set up solely 
for the delivery of medical and psychosocial care for patients. The main activities 
performed were facilitative help with legal problems and invalidity benefit, housing, 
and other social resources (e.g., national identity card and health care card). In 
addition, psychiatric, psychotherapeutic, and medical treatments for concomitant 
disease were made available. It is clear that much important support was made 
available to trial patients in addition to pharmacologic treatment received. 
The number of visits for the purpose of psychological support was higher in the heroin 
group as compared to the methadone group. This is interesting and may suggest a 
greater desire or propensity to access support by those in the heroin treatment group, 
due to the increased stability this treatment provides. The stability may have led to a 
greater desire for patients to recover psychologically. However, it should be noted 
that the number of patients who ‘required’ psychological treatment was the same in 
each group – suggesting that missed appointments were more common in the 
methadone group, which is perhaps not surprising. However, patients attending to 
access these services are arguably at a greater advantage from an effective or 
progressive recovery perspective. On the other hand, psychiatric treatment was more 
often requested by the control group and increased over time (mainly requiring drug 
prescription). Legal and social support was in greater demand at the beginning, which 
is understandable, given that the main problematic issues were solved at that point; 
pensions, pending trials, etc. (March et al., 2006). Speaking more generally, this may 
lead to greater gains in the initial stages of SIH treatment (i.e., within group 
improvements as well as between group), which may then plateaux following a 
substantial period of SIH and when other issues are more likely to have been 




The researchers highlight the proposal that gains were made by the control group as 
well as the heroin treatment group in light of the following features of treatment; the 
high ratio of professionals to patients; the motivation of the staff working in a clinical 
trial; the higher doses of methadone; the medical, psychological, social, and legal 
support; and the possibility of obtaining heroin treatment at the end of the trial under 
compassionate use (March et al., 2006). These are all highly plausible, though 
additional research would be required to examine these aspects – or scrutinise patient 
satisfaction and experience of treatment in more detail - for conclusions or even 
hypotheses to be drawn. March et al (2006) make the important point that these 
outcomes demonstrate the need for improvements to current substitution programs 
to achieve improved results with long-term, socially excluded, opiate dependent 
patients. Also alluded to by March et al (2006), greater scrutiny could be given to 
current opiate substitution treatment before launching heroin treatment trials, to first 
discover whether aspects of this treatment could be improved. 
 
2.5.4. Injectable Opiate Treatment research in Germany 
 
Following March et al. (2006) was Haasen et al. (2007) in Germany. Haasen et al. 
(2007)’s sample involved those in methadone treatment who continued to use heroin, 
as well as those who were not currently in treatment. Haasen et al. (2007) comprised 
an open-label multicentre randomised controlled trial involving 1015 patients (n=500 
received oral methadone treatment and n=515 received injectable heroin treatment), 
across seven treatment centres in seven different cities in various regions of Germany 
for a period of twelve months. Outcome variables comprised improvement of physical 
and/or mental health and a decrease in illicit drug use. Results showed that retention 
to treatment was higher in the heroin treatment group (at 67.2%) compared to the 
methadone group (at 40%). It should be noted that 28.8% of patients assigned to 
methadone treatment dropped out at baseline, compared to 2.3% of the heroin 
treatment group. Average number of treatment days was 290 in the heroin group and 
195 in the methadone group. There were no significant interaction effects of group or 
therapy, and after controlling for these effects significant differences between heroin 
treatment and methadone treatment were still significant. The only meaningful 
interaction was study centre (there were a number of sites – cities - included in the 
study) and drug use, indicating a lack of homogeneity in response rates across sites. 
68 
 
This is interesting to note and qualitative research in future work could explore 
operational differences across localities/sites.  
Haasen et al. (2007) make the point of standardising their programmes of additional 
support, however need - and subsequent take up - of psychosocial ancillary support 
will vary across individuals (some will end up receiving one element of the 
standardised care – because they need it, whereas another person will not need it 
but may need something else; and which dimension is most beneficial cannot always 
be gauged) – making the case again for qualitative research which can focus on 
particular dimensions of the programme relative to the patient being interviewed.  
Unique to the Haasen et al. (2007) trial was the randomisation of groups and sub-
groups – groups involved those who had failed in methadone treatment previously, 
and those who were not in treatment at baseline. Within the two groups were four 
sub-groups each; 1. Heroin treatment + education (group psychoeducation plus 
individual counselling); 2. Heroin treatment + case management (case management 
and motivational interviewing); 3. Methadone treatment + education; 4. Methadone 
treatment + case management. The researchers acknowledge that there was more 
individual flexibility in the case management group than with the more standardised 
psychosocial care in the psychoeducation group.  
The interaction analyses then controlled for target group (in treatment but still using 
illicitly; versus using illicitly but not in any OST at baseline) and additional therapy 
(education or case management). What was also unique about this study was that 
patients could receive heroin treatment up to three times per day. In this study 
patients were considered responders on the health domain if OTI health scores 
reduced by 20%. Patients were considered responders on the drug use domain if they 
had three out of five drug screens negative for illicit heroin in the preceding one month; 
and no increase in cocaine use (determined through hair analysis). Last Observation 
Carried Forward (LOCF) was employed in cases of absence of data (hair or urine), 
and where there was an absence of data at the last observation, this was collected 
via self-report. Within Haasen et al. (2007) there were more SAEs in the heroin 
treatment group than in the methadone treatment group (177 versus 138 
respectively). Of the events 32.8% of those occurring in the heroin group were 
probably, possibly or definitely related to the trial medication; relative to 10.9% of 
those occurring in the methadone group. 
Of pertinence to the argument for the need for a longer-term trajectory, Haasen et al. 
(2007) highlight that the main effect of heroin treatment on outcome measures (illicit 
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drug use and health) was apparent within the first few months of treatment, with 
additional growth over the following months. Haasen et al. (2007) illustrate the 
methodological strength of having two psychosocial interventions as a means of 
demonstrating that the observed differences between the heroin and methadone 
treatment groups were not as a consequence of the differences in psychosocial 
treatment. This demonstrates some indication of this, however it may be that there is 
something about the structure of the programme itself that leads to stability and 
positive outcomes amongst patients – in light of the fact that the methadone group 
also improved to some extent over time – and this needs exploration.  
Haasen et al. (2007) also highlight that there was a low retention rate in the 
methadone treatment group, indicating that the patients who remain in this treatment 
are a highly selective group. That said, it was also the case that their outcomes were 
significantly lower than the heroin treatment group. Patients who remain in 
methadone treatment during IOT trials may be more motivated to remain in treatment 
than those who leave.  
Haasen et al. (2007) usefully caution that the positive effects of heroin treatment must 
be weighed against the higher rate of SAEs; a high number of which appeared to be 
associated with the medication. Haasen et al. (2007) also highlight the fact that given 
the very poor health of patients at baseline, interventions are put in to place to address 
this as soon as patients register on the trial. This may in part contribute to such large 
improvements in outcome at the initial stages of treatment initiation, despite the fact 
that these occur prior to treatment baseline. It is likely that psychosocial intervention 
occurs most commonly in the first six months of treatment, where the need is probably 
highest. Finally of importance methodologically to the field, Haasen et al. (2007) 
highlight the finding by Rounsaville (1993) that self-report measures of drug taking 
are found to be accurate, valid and reliable as long as confidentiality is assured and 
there are no consequential sanctions posed on patients (Rounsaville, 1993). It is 
important that studies take this in to account, and that patients are reassured that this 




2.5.6. Injectable Opiate Treatment research in Canada 
 
Following Haasen et al. (2007) was the Canadian North American Opiate Medication 
Initiative (NAOMI) trial by Oviedo-Joekes et al. (2009). This study comprised N=115 
heroin treatment patients compared to N=111 oral methadone treatment patients in 
Montreal and Vancouver. The study’s duration was twelve months and outcome 
variables measured included retention in treatment; cessation and reduction of use 
of illicit drugs; and criminal activity. Retention to treatment in the heroin treatment 
group was statistically significantly higher (at 87.8%) than the methadone treatment 
group (at 54.1%).  
Oviedo-Joekes et al. (2009) usefully highlight that the fact that patients in the control 
condition were eligible to receive heroin treatment at the end of the trial (the custom 
in some of the other trials too) may have introduced bias in the retention rates for this 
group, hence the relatively high percentage here. This is an example of the downside 
of an RCT, over a case control study; whereby findings in RCTs may not mirror what 
would happen in clinical practice. In terms of reduction in use of illicit drugs and other 
illegal activities; this was 67% in the heroin treatment group relative to 47.7% in the 
methadone treatment group. This once again was statistically significant, though it is 
noteworthy that the methadone treatment group did also reduce their illicit drug use 
and other illegal activity quite significantly.  
It is interesting that this study quantified reduction in illicit drug use together with other 
illegal activity. It may be the case that the overall structure of IOT trials foster a new 
– for this population - culture of law abiding, rather than just by virtue of the fact that 
the patient receives ‘free heroin’, and therefore has no need to engage in criminal 
activity, though clearly this will also be a significant factor. Qualitative research with 
this sample may yield light on structure and process of IOT, as experienced by 
patients. Following twelve months of this treatment patients’ doses were tapered and 
they were switched to conventional treatment such as oral methadone treatment 
(Oviedo-Joekes et al., 2009). 
The Oviedo-Joekes et al. (2009) study had a slight change to the inclusion criteria; 
one aspect of which was that patients could not have been enrolled in methadone 
maintenance treatment in the previous six months; this differed to the European trials 
conducted prior to this one, who enrolled those who were currently in methadone 
treatment. The researchers do not elaborate on the reason for this difference in the 
North American trial but do make the worthwhile point in the conclusion, that within 
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this trial patients who would otherwise remain outside of healthcare provision, 
significantly benefit from this treatment. As well as centre, patients were stratified 
according to number of previous methadone attempts (two or fewer versus three or 
more); this was arguably a pertinent factor to control for, offering information on who 
best benefits from IOT.  
Patients in this trial could access injectable treatment up to three times daily, with a 
maximum dosing of 1000mg. Patients were also permitted to switch partially or fully 
to oral methadone treatment if they wanted to, or if deemed necessary or appropriate 
by physician (Oviedo-Joekes et al., 2009). Once again, patients in this study were 
offered a comprehensive range of psychosocial and medical services. Retention to 
treatment in this study was defined as attendance to receive study medication on 10 
out of 14 appointments prior to the twelve-month data collection point.  
Arguably this does not provide a complete picture of patient retention, or adherence 
to the regimen, for the full 12 months of the trial. In terms of reduction in illicit drug 
use and other criminal activities, patients in Oviedo-Joekes (2009) were considered 
responders at 12 months if they had made an improvement of at least 20% from 
baseline scores of illicit drug use, criminal activity or both. Whilst significant 
improvements were found in the heroin group, improvements in composite scores for 
drug use and illegal activities were found in both groups. Interestingly the number of 
days of cocaine use did not significantly change in either group.  
Oviedo-Joekes et al. (2009) report an overall reduction in the amount of money spent 
on illicit drugs in both groups – this is a worthwhile finding, in the context of a concern 
that heroin treatment may free up funds for patients to spend on other drugs (Oviedo-
Joekes et al., 2009). The fact that this did not appear to occur suggests an overall 
desire on the part of patients to make wider lifestyle changes; to use time in heroin 
treatment as an opportunity to recover more widely, rather than just access ‘free 
heroin’. The heroin group had significant improvements with respect to medical and 
psychiatric status, economic status, employment status, and family and social 
relationships. The fact that improvements were present across these multi-facets of 
life suggests a positive treatment effect beyond reduction in illicit drug use and illegal 
activities. The authors also usefully highlight how advantageous this is in light of the 
time frame and the population of patients under study.  
Oviedo-Joekes (2009) rule out a double-blinding methodology - which is the gold 
standard in RCT designs - on the basis that patients and researchers would likely 
guess which treatment they had been administered, due to the different 
72 
 
pharmacokinetic properties of the drugs. This links to the debate on whether IOT 
efficacy trials are measuring the efficacy of the drug only, or all the nonspecific 
aspects of treatment delivery (e.g., a patient attending the clinic every day, and having 
trained staff on hand to talk to), and specific, yet unmeasured and unstandardised 
aspects, such as therapeutic alliance with keyworker and varying levels of 
psychosocial support. Ethical procedure precludes the removal of these aspects of 
treatment, however it seems important for next steps for IOT research and policy that 
some of these additional, specific and unspecific aspects of treatment are brought to 
the fore, perhaps through standardisation of control conditions. 
Following this RCT, Marchand et al. (2011) conducted a questionnaire study 
examining patient satisfaction with treatment. A total of 232 (92%) and 237 (94%) 
patients completed the Client Satisfaction Questionnaire (CSQ-8) measure at three 
and 12 months, respectively. The CSQ-8 assesses global patient satisfaction using a 
4-point Likert type scale and also provides a general score ranging from 8 to 32. 
Patients in both groups were highly satisfied with treatment. This finding was 
independent of treatment group, and showed that patients satisfied with treatment at 
three months were more likely to be retained in treatment at 12 months. Multivariate 
analyses indicated that satisfaction was greater among those randomised to the 
injection group after controlling for treatment effectiveness. Patients who were 
retained, responded to treatment, had fewer psychological symptoms and were more 
satisfied with treatment. Open-ended comments were made by 149 (60.3%) patients; 
concerns about the randomisation process and the study ending were most 
commonly reported by patients receiving the oral and injectable medications, 
respectively (Marchand et al., 2011). It is useful to know that patients are satisfied 
with treatment but much is left unexplored in terms of why patients are satisfied, and 
how this satisfaction maps on to the treatment trajectory. Additionally, what aspects 
of treatment are patients satisfied with, and are there areas of dissatisfaction that may 
affect engagement and outcomes; these lines of inquiry could be expanded upon with 
qualitative research, in order to better understand the context and process of an IOT 
regimen and meaning making for patients. Clearly worries about treatment ending are 






2.5.7. The UK Randomised Injectable Opiate Treatment Trial 
 
The UK Randomised Injectable Opiate Treatment Trial (RIOTT: Strang et al., 2010) 
is the original study comprising the sample of patients for which this thesis examines 
and describes. Strang et al. (2010) sought to try to understand whether patients 
previously unresponsive to treatment were untreatable or just difficult to treat. Patients 
were recruited between September 2005 and August 2008, and outcomes at six 
months are published in Strang et al. (2010). Strang et al. (2010) outline the fact that 
– the majority of – previous studies utilise self-report illicit measures as their outcome 
variable, whereas Strang et al. (2010) employ use of urinalysis. Whilst self-report is 
found to be reliable when sanctions are not imposed on patients as a result, and 
collected by those with no power and control over the treatment process; urinalysis 
offers a greater level of methodological rigour. However, it may still be the case that 
patients can submit false urine screens, and this should always be considered.  
Strang et al. (2010) also highlight the fact that the various previous IOT RCTs 
employed an array of relatively complex outcome measures, making comparisons 
across studies difficult. It should also be noted that comparison across different 
countries and cultures may affect what constitutes a control condition; since what 
constitutes treatment as usual will likely differ across clinics and countries. 
Uchtenhagen (2015) suggests that heroin treatment policy should include decisions 
about where the priorities for treatment goals and evaluation of outcomes are, in 
response to the main problems in a given country.  
Strang et al. (2010) also highlight the fact that of the five previous studies only Haasen 
et al. (2007) and Oviedo-Joekes (2009) had employed use of optimised oral 
methadone – a more comparable control condition. The need for high doses for 
efficacy sits appropriately within a supervised prescribed setting, where patients can 
be closely monitored post dose. Strang et al. (2010) offer another unique dimension, 
through the use of an SIM condition; the necessity of an examination of this treatment 
is outlined on the basis that in the UK it has been prescribed more widely than SIH 
(Sell and Zador, 2004; Strang, 1996). 
RIOTT was a multi-site, open label, RCT involving heroin dependent individuals who 
were continuing to inject illicit heroin regularly (more than 50% of days in a preceding 
three-month period), and who had been receiving conventional opiate treatment for 
at least six months prior to trial randomisation. RCT data was collected from patients 
for a period of 26 weeks across three supervised injecting clinics in England (in 
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Brighton, London and Darlington). Following the 26-week programme patients could 
continue receiving treatment, and outcomes continued to be collected for a further 30 
months. However, patients could move to different treatments if clinically appropriate. 
The following summary refers to the 26 week RIOTT trial only and subsequent 
analyses and research will be discussed later in the thesis. The primary outcome was 
urinalysis and success was defined as 50% or more of negative specimens for illicit 
heroin during weeks 14-26 of the trial. Secondary outcomes included other drug use; 
injecting practices; psychosocial and general health; and crime. 
Following randomisation N=42 patients were allocated to receive supervised 
injectable methadone (SIM); N=42 to optimised oral methadone (OOM); and N=43 to 
supervised injectable heroin (SIH), and analysis was intention to treat (ITT). Following 
26 weeks of treatment 80% of patients were retained to treatment; N=34 (81%) 
remained in SIM treatment; N=38 (88%) remained in SIH treatment, and N=29 (69%) 
remained in OM treatment. Two considerations are that, firstly, non-SIH patients 
(OOM and SIM) were informed that they may transfer to SIH treatment (if clinically 
appropriate) following this initial 26-week period of either SIM or OOM treatment. This 
may have led to a higher than usual retention within both SIM and OOM groups. 
However, it is interesting that retention was somewhat higher in the SIM group relative 
to the OOM group, suggesting the strength of the injectable route of administration. It 
may be, however, that other – for example psychological - factors also arose from 
randomisation to OOM, as opposed to SIH, such as annoyance or despondency – 
which affected retention to treatment. The retention rate was reasonably high in the 
other two groups; 66% and 81% for OOM and SIM respectively. Retention was similar 
to that in the Canadian trial (Oviedo-Joekes et al., 2008) and was higher than in 
studies from the Netherlands (van den Brink et al., 2003), Spain (March et al., 2006), 
and Germany (Haasen et al., 2007). 
Results showed that patients in the heroin group were significantly more likely to have 
achieved the primary (a reduction in use of illicit heroin; 50% or more negative 
specimens for street heroin on weekly urinalysis during weeks 14–26) outcome (72%) 
than were those on oral methadone (27%) – here the observed difference is fairly 
large and statistically the p=<0.0001 (CI 2.69-20.46); number needed to treat (NNT) 
was 2.17 (CI 1.60-3.97). The analyses comparing OOM to SIM (39%) were not 
significant; SIM compared to SIH was significant (p=0.002), however the study was 
not significantly powered for this comparison.  
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Strang et al. (2010) illustrate that these differences were evident within the first six 
weeks of treatment. Longitudinally it is important to examine whether these benefits 
are maintained over time. The RIOTT study was powered on the assumption that 
regular use of street heroin would reduce in 69% of patients on injectable methadone, 
85% of those on injectable heroin, and 33% of those on oral methadone, on the basis 
of previous trials (Perneger et al., 1998; van den Brink et al., 2003; Strang et al., 
2010). Values were rather different than that predicted – particularly injectable 
methadone; this treatment appeared to maintain patients without the need for illicit 
injecting to a greater extent than was expected. 
Whilst the trial was open label, and therefore there may be instances of bias (for 
example, nurses administering treatment expecting better results from those in 
injectable treatments, and specifically SIH – thereby perhaps behaving differently with 
these groups) some degree of bias may have been minimised through masking of 
laboratory personnel to treatment allocation and masking of statistician to injectable 
group (however not to oral versus injectable group). These individuals were also 
separate to the addictions research team. Strang et al. (2010) accept that since the 
trial was open-label, patients’ awareness of their treatment allocation may have 
aﬀected expectancy and behaviour. Arguably staff and clinicians’ expectations and 
behaviour may have impacted how patients felt and engaged. Experiences and 
behaviour can be examined through qualitative research. 
Strang et al. (2010) outline in slightly more detail psychosocial support that patients 
received; including weekly reviews with a keyworker and monthly medical reviews. 
They also state that patients received access to psychological services, though 
additional support services are clearly not standardised across patients/sites, with no 
controlling for who received psychological intervention. It may be that some patients 
received therapeutic support, and others group therapy, but who received what 
therapies was not outlined nor controlled for. It may be that those in injectable 
treatment were more likely to access psychological support, and the support 
accessed was contributory to successful recovery. Strang et al. (2010) also suggest 
that as well as optimised doses of methadone, an increase in therapeutic engagement 
may have contributed to the finding that one fifth of those assigned to OOM treatment 
had reduced their use of illicit heroin by six months. This is important in the context of 
the long-term heroin use and treatment histories of the sample as a whole, and their 
criminal histories. Qualitative research should investigate in more detail the perceived 
effect of psychological support during IOT to examine whether this was a factor of 
76 
 
importance to patients, and whether they perceived it to be an important mechanism 
of this treatment for recovery. 
 
2.5.7.1. UK Randomised Injectable Opiate Treatment Trial inclusion criteria 
 
The RIOTT trial targeted individuals in methadone treatment who continued to inject 
illicit heroin regularly. Specific criteria were: 1. Aged 18-65. 2. Have at least a three-
year injecting heroin use history. 3. Have been in continuous methadone treatment 
episode of at least 6 months. 4. Regular injecting heroin use in previous three months 
(as demonstrated by opiate-positive urine drug screens and self-report via clinical 
records), and heroin use on at least 50% of days (15 days) in the preceding month 
via self-report. 5. Evidence of regular injecting on clinical examination. 6. No 
significant, active medical (e.g., hepatic failure) or psychiatric condition (e.g., present 
psychosis, severe affective disorder). 7. Not alcohol dependent or regularly abusing 
benzodiazepines according to DSM-IV criteria. 8. Not pregnant, breastfeeding, or 
planning to become pregnant during the trial period. 9. Resident of catchment area of 
participating clinic. 10. Willing and able to participate in the study procedures (e.g., 
no imminent prison sentence) and provide informed consent. 
 
2.5.7.2. Patients included in the UK Randomised Injectable Opiate Treatment 
Trial 
 
A majority of patients were men (93 [73%]), white (122 [96%]), and unemployed (121 
[95%]), had spent time in prison (93 [73%], a mean of 5.9 times [SD 7]), and had a 
mean age of 37.2 years (SD 6.5). Patients had used opiates for a mean of 16·6 years 
(SD 7.3), had injected drugs for a mean of 13.7 years (SD 7.8), and had received 
treatment for a mean of 9.8 years (SD 6.7). 127 (100%) patients had been previously 
treated for opiate use (with a mean of 4·4 times [SD 4.2]), and 52 (41%) had received 
residential drug-free rehabilitation (mean of 1.8 times [1.8]). All were using street 
heroin virtually daily (mean 27.5 days out of 30 days [3.6]), and almost half (54 [43%]) 
also reported regular use of cocaine or crack cocaine. All patients were receiving 
methadone treatment at enrolment (continuously for more than 6 months), and 50 
(39%) were receiving optimised methadone treatment (Strang et al., 2010). 
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2.5.7.3. Description of UK Injectable Opiate Treatment 
 
Lintzeris et al. (2006) outline the methodology and description of trial treatment for 
the RIOTT trial. The full description as described in the paper (Lintzeris et al., 2006) 
is in appendix 1. 
 
2.5.7.4. Injectable Opiate Treatment trial patient retention 
 
At 26 weeks, 101 (80%) patients remained in the assigned trial treatment: 34 (81%) 
on injectable methadone, 38 (88%) on injectable heroin, and 29 (69%) on oral 
methadone. 12 patients did not start treatment, of whom eight continued in their 
previous methadone treatment (outside the trial). Of the 14 patients who discontinued 
their assigned treatment (four on injectable methadone, four on injectable heroin, six 
on oral methadone), four were imprisoned, four discharged themselves from assigned 
treatment, one moved out of the catchment area, two were discharged for medical 
reasons, one violated the protocol, and two missed 28 days of treatment. Patients on 
oral methadone were statistically signiﬁcantly more likely to not start treatment than 
were those on injectable heroin (p=0·030). After exclusion of patients who did not 
start treatment, the proportion of patients retained at 13 and 26 weeks did not diﬀer 
signiﬁcantly between treatment groups (Strang et al., 2010). 
 
2.5.7.5. Abstinence by six months 
 
An eighth of patients on injectable heroin achieved complete abstinence, and two-
ﬁfths achieved almost complete sets of urine samples negative for street heroin, with 
two or fewer positive samples during weeks 14–26. Abstinence or near abstinence 
was higher amongst patients on injectable heroin than amongst those on injectable 
methadone or oral methadone, and patients on injectable heroin were signiﬁcantly 
more likely to be near abstinent from street heroin than were those on oral 
methadone. There were no signiﬁcant diﬀerences in abstinence for injectable heroin 
versus oral methadone, or diﬀerences in abstinence or near abstinence for injectable 
methadone versus oral methadone. 18% (n=8) of patients on injectable methadone, 
37% (n=16) of those on injectable heroin, and 8% (n=3) of those on oral methadone 
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were abstinent from street heroin at weeks 23-26 with corroboration on self-report as 
compared to urinalysis. Signiﬁcantly more patients on injectable heroin were 
abstinent than were those on oral methadone (OR 6∙54, 95% CI 1∙91–22∙34, 
p=0∙003), but the diﬀerences were not signiﬁcant for injectable methadone versus 
oral methadone (2∙37, 0∙63–8∙86, p=0∙199) or for injectable heroin versus injectable 
methadone (2∙76, 0∙98–7∙77, p=0∙055) (Strang et al., 2010). 
 
2.5.7.6. Secondary outcomes 
 
In a separate paper Groshkova et al. (2015) examined differences across secondary 
outcomes (other drug and alcohol use, social functioning and physical and mental 
health) within and between the three treatment groups. By six months, 80% of 
patients were retained in their assigned trial treatment. Comparisons at six months 
found that there were no significant differences between the three treatment groups 
in these secondary outcomes; wider drug use (crack/cocaine, benzodiazepines, and 
alcohol), physical and mental health (SF-36) or social functioning (OTI). However 
there were significant differences within each treatment group (SIH, SIM and OOM) 
in comparisons with outcomes at baseline on these measures. Specifically, significant 
within-group reductions were observed in crime and money spent per week on illicit 
drugs at six months as compared to the baseline situation, and this applied to all three 
treatment groups (the two IOT groups; SIH and SIM, and the control group; OOM). 
The SIH group was also significantly more likely to have reduced money spent on 
illicit drugs as compared to OOM. This latter finding is unsurprising in the context of 
SIH treatment, and accords with the primary outcome; reduction in use of illicit heroin. 
Significant improvements were also found in physical health for SIH and SIM and 
mental health for OOM (Metrebian et al., 2015). The researchers conclude that the 
injectable conditions (SIM and SIH) showed no clearly identified benefit over OOM in 
terms of wider drug use, crime, physical and mental health within a 6-month period, 
despite reducing street heroin use to a greater extent (Metrebian et al. 2015). It was 
interesting to find that all interventions were associated with improvements in these 
outcomes and it is noted that all three groups received high levels of medical and 




2.5.7.7. Randomised Injectable Opiate Treatment Trial patients’ expectations 
and satisfaction 
 
An additional component of the RIOTT study – Groshkova et al. (2013) – comprised 
administration of questionnaires to 113 (of 127 who completed the trial) RIOTT trial 
patients both pre-randomisation and post-treatment to gauge pre-treatment 
expectations and post-treatment satisfaction respectively. Within this questionnaire 
study, which included both fixed response items as well as open text response items, 
patients were asked about treatment preference (patients had to rank order the three 
treatment types in order of preference); and expectations of the treatment’s ability to 
reduce illicit drug (street heroin, crack and other drug use) and alcohol use, with 
response categories: either yes (would reduce drug/alcohol use) or no (would not 
reduce drug/alcohol use) were provided. At baseline patients were also asked 
questions exploring life areas in which help was most needed by the patient during 
this treatment episode. In terms of satisfaction (following six months of treatment) 
patients were asked again to rank order treatment preferences. They were also asked 
about the impact of treatment on illicit drug and alcohol use. Satisfaction questions 
included injecting room, injecting sites, injecting attempts allowed, clinic opening 
hours, twice daily clinic attendance and no take-away doses. Five response 
categories were provided: very dissatisﬁed, dissatisﬁed, mixed, satisﬁed and very 
satisﬁed. 
Results showed that 87% of patients expressed a preference for SIH treatment, with 
11% expressing a preference for SIM. It would be interesting to explore why these 
patients had a preference for SIM, as this deviates from what would be expected. At 
six months there was a marginal increase in those expressing preference for OOM. 
69% expected that SIH would reduce their use of illicit heroin; 55% and 26% thought 
SIM and OOM would achieve this goal respectively. Only 28% thought that SIH would 
reduce their use of crack, and this percentage was lower for SIM (13%) and OOM 
(10%). Patients stated that they desired help with the following areas - reducing their 
drug use (81%); achievement of stability, normality, routine and structure in one’s life 
(16%); improve education and work opportunities (15%); improve housing situation 
(12%), physical health (12%), psychological wellbeing (12%) and ﬁnances (12%). 
While there were few differences between treatment groups, those in the SIM group 
were far less likely to report wanting help to achieve stability, normality, routine and 
structure than those in the SIH and OOM groups (3% vs. 22% and 22%). Why this 
was, is unknown, and should be further explored. 
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Following six months of treatment nearly all of those receiving IOT (SIH: 97%; SIM: 
85%; OOM: 62%) reported that their treatment had led to substantial reductions in 
‘street’ heroin use. Patients (SIH: 52%; SIM: 39%; OOM: 24%) reported that their 
treatment had helped reduce their crack use. Areas of life patients reported that 
treatment had helped them with were reducing their drug use (SIH: 59%; SIM: 56%; 
OOM: 54%); physical health improvement (SIH: 47%; SIM: 17%; OOM: 21%); 
improvement in ﬁnances (SIH: 48%; SIM: 17%; OOM: 21%); family and relationships 
(SIH: 35%; SIM: 17%; OOM: 12%). Patients reported being very satisfied (SIH: 28%; 
SIM: 28%) or satisfied (SIH: 66%; SIM: 59%) with injecting under supervision. 
These data are useful, however neglect to illustrate the treatment trajectory and 
patients’ narratives are not entirely their own through use of a simple questionnaire 
measure. Questionnaires were simple and specific, and open text comments were 
not in-depth. Questionnaire measures were not validated for reliability or validity. 
Additionally these measures were administered by the RIOTT research team 
following six months of treatment and since the treatment was still being administered 
are subject to biases. A full qualitative interview employing rigorous qualitative 
methodology would be beneficial, examining the recovery trajectory in its entirety. 
Inviting patients to share their narratives through a qualitative interview invites a more 
collaborative approach to data collection, which is not possible when questionnaires 
are administered as part of a battery of measures during an RCT. In this sense 
patients may feel they are required to share their perspectives in exchange for 
treatment medication.  
The research study did, however, illustrate patients’ aspirations and expectations and 
these could be expanded upon in detail through in-depth interviewing. The 
researchers acknowledge that it is important to note the dynamic nature of 
aspirations; that having made good progress during their six months of IOT, they ﬁnd 
that a number of trial patients had moved on in their aspirations and sought further, 
wider recovery, thus necessitating a dynamic and responsive treatment system that 
moves with the patient and their progress (Groshkova et al., 2013). This trajectory of 
aspiration and recovery should be explored in detail with patients. Additionally 
questionnaire items may be creating cognitions and ideas for participants rather than 
accessing them (Ogden, 2003), that is, a more open-ended approach may help elicit 
the patient’s account in their own words. 
In January 2012 the Department of Health stated that ‘As a result of this trial and other 
international research, IOT is now evidenced as a clinically effective second line 
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treatment for the small number of people who have repeatedly failed to respond to 
standard methadone treatment or residential rehabilitation’. (Department of Health, 
2012). 
 
2.6. Injectable Opiate Treatment research in Belgium 
 
During the write-up stage of the thesis researchers in Belgium published the results 
of their trial of injectable heroin treatment, which compared this group to oral 
methadone patients (Demaret et al., 2015). This trial involved N=74 patients who 
were assessed every three months for a period of 12-months. The researchers 
specifically state that unlike in other European trials the Belgian trial was strictly 
limited to a 12-month treatment period for political and legal reasons (Demaret et al., 
2015). This specifically illustrates how the social and political can impact trial 
methodology (and perhaps then patient experience and outcome) across different 
regions and countries; further highlighting the importance in-depth work with patients 
across all regions implementing this complex, controversial treatment. In a similar line 
of thought, inclusion criteria across the various trials differed (for example, in Belgium 
it was that patients had to have been using heroin dependently - and daily or almost 
daily - for five years, with one previous methadone treatment attempt. This can be 
contrasted with Oviedo-Joekes et al. (2009) who specified that patients could not 
have been in methadone treatment preceding enrolment on their trial. It could be 
argued that these patients may not constitute treatment failures to the same extent 
as those with virtually a lifetime of previous failed methadone attempts. Arguably, 
differing pre-treatment and referral situations could affect how patients engage with 
treatment. This once again highlights the need to explore pre-treatment and referral 
situations in detail. 
Patients were classified as responders to treatment medication if they improved in 
domains of illicit heroin use, health, and criminal engagement (Demaret et al., 2015). 
Improvement or deterioration was indicated by a difference of 40% between data at 
baseline and at 12-months. Deterioration was also recorded if a patient used 20% 
more cocaine than at baseline. In the Demaret et al. (2015) trial clinics were open 
between 07:30 and 18:30 (for up to three injections per day) and heroin treatment 
patients received their treatment in a specially designed treatment centre; whereas 
methadone patients received their treatment in already existing partner clinics 
elsewhere. The opening hours of this clinic are longer and more flexible than that of 
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the UK clinics, which was a positive development given comments in qualitative work 
across other trials - e.g., Güttinger et al. (2003); Oviedo-Joekes et al. (2014)  - which 
highlighted the difficulty of restricted opening hours on potential employment 
opportunities. Here the benefit of qualitative work for practice development is 
reinforced. Both groups in the Demaret (2015) trial received psychosocial support.  
Demaret (2015) highlight that as part of their recruitment process the media spread 
information on the trial. Response to this treatment by the outside world may impact 
patients’ perceptions and engagement with the treatment. For example, in the UK 
there was some negative portraying of the treatment in the media – headlines are 
included in the thesis appendix (appendix 3) to illustrate the social context. Similar to 
Blanken et al. (2009); March, Oviedo-Joekes, and Romero (2006), primary outcome 
criterion was a dichotomous, multi-domain index based on three domains. In this 
study it encompassed street heroin use (days of use during the previous month), 
health (scores on the MAP-HSS and the SCL-90-R) and criminal involvement 
(number of self-reported activities committed or experienced in the previous month). 
Responders were deemed as such if they showed improvement in at least one 
domain and no deterioration in any domain. This differs to other studies (e.g., Strang 
et al., 2010) which utilise use of illicit heroin as the primary outcome variable. 
Something of further interest was that some patients refused additional – take-home 
– methadone doses “at first”, implying that this changed over time. It would be useful 
to gauge patients’ perceptions of additional methadone in these trials – what are the 
reasons that patients are reluctant to consume additional methadone?  
By 12-months, 75% of patients were retained in the experimental (heroin) treatment 
condition and 34% were retained in the methadone condition, and this difference was 
statistically significant (Demaret et al., 2015). 67% patients in the heroin treatment 
condition and 55% in the control group were responders at the 12-month assessment; 
the difference (11%) was not statistically significant. Very interestingly the number of 
responders decreased at the 12-month assessment in the experimental group while 
it continued to rise in the control group again suggesting support for the protective 
aspect of being in a treatment trial per se. Patients in SIH were treated in a separate 
clinic to those in methadone treatment, throwing a question over the comparability of 
the two conditions with regard ancillary support. 
At each other time point there were 30% or more responders in the heroin treatment 
group relative to the methadone treatment group. There were statistically fewer 
criminal acts at 12-months across both groups, but with no statistically significant 
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differences between groups. Patients in the experimental group showed statistically 
greater improvement with respect to depression and psychoticism dimensions on the 
SCL-90-R, and self-reported use of benzodiazepines in the EuropASI decreased 
significantly more in the experimental group (Demaret et al., 2015). This study usefully 
highlights the negative effects of short-term regimens, and in their case the fact that 
the medication was predetermined to cease at 12-months. The researchers discuss 
the impact this may have on the patient’s recovery. They highlight that in the Dutch 
trial (van den Brink et al., 2003), after 12-months, an interruption of HAT for two 
months also had a negative impact: 82% of the patients who were completers and 
responders deteriorated substantially. 
Of great pertinence to the research pool on SIH, policy, and practice, the Belgium 
researchers facilitated a side-study (yet at the time of this thesis write up it was 
unpublished; results were summarised in Demaret et al. (2015). The study examined 
why those approached, refused participation. Of those 52 heroin users, 25 reported 
that they were afraid of the limited (finite) length of the heroin treatment (i.e., 12-
months in Demaret et al., 2015) and 11 feared becoming more dependent as a result 
of heroin treatment. The latter narrative suggests that possibly these patients may not 
have had the lengthy heroin and treatment histories of other cohorts and studies. The 
researchers conclude that the time-limited nature of the regimen may have 
demotivated heroin users who could otherwise have benefited from this treatment. 
Pre-IOT perceptions should be explored in both research and clinical practice. 
As with other studies the researchers conclude that SIH is efficacious for short-term 
heroin treatment for entrenched heroin users who have previously failed in 
methadone treatment. Since this is the most recent SIH trial conducted to date, the 
researchers make the interesting point that despite the predetermined duration of 
SIH, the longitudinal retention rate (75%) in the heroin group was higher than in other 
trials (e.g., 68% in the Netherlands and 67% in Germany and Canada). This 
difference and the proportion of exclusion for violation of house rules (14% in Belgium, 
15% in the Canadian trial and 6% in the Dutch study) indicate that SIH could be further 
improved (Demaret et al., 2015). Demaret et al. (2015) argue that additional 
international research is needed to identify best practice and to enhance compliance 
with this effective treatment. Any future SIH treatment programme should incorporate 
learning from all seven of these trials, along with the longitudinal research trials and 
the qualitative research studies, as well as wider research discourse. 
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2.7. Systematic reviews and meta-analyses 
 
Several systematic reviews and meta-analyses have been conducted on supervised 
injectable heroin treatment. The first was by (Ferri, Davoli, and Perucci, 2005) and 
included four heroin treatment studies; this was updated in by Ferri et al. (2011) and 
included eight studies. The studies included in the 2006 review were Hartnoll et al. 
(1980) and Perneger et al. (1998). The Hartnoll et al. (1980) study was not a 
supervised injectable facility and nor was it an RCT. Perneger et al. (1998) comprised 
the first RCT in the area, however the sample size was very small. van den Brink et 
al. (2003) was a large RCT with an inhalable component and involved supervised 
dosing. Ferri et al. (2011) conducted a further review – adding March et al. (2006); 
Haasen et al. (2007); Oviedo-Joekes (2009); and Strang et al. (2010).  
Results showed that mortality was better for heroin groups, but this was not 
statistically significant. Other aspects could not be pooled due to varying outcome 
measures. Social functioning improved in all groups, with slightly better outcomes for 
the heroin groups. These results are arguably unremarkable. It is fair to propose that 
differences across studies, from design and sample size, to outcome variables 
utilised, make review difficult. The mechanisms of exactly why SIH is more effective 
still remains unexplored. The Cochrane review concluded that: ‘the available 
evidence suggests an added value of heroin prescribed alongside ﬂexible doses of 
methadone for long-term, treatment refractory, opioid users, to reach a decrease in 
the use of illicit substances, involvement in criminal activity and incarceration, a 
possible reduction in mortality; and an increase in retention in treatment.’ (Ferri, 
Davoli, and Perucci, 2011). 
The Strang et al. (2015) review was published during write-up of the PhD thesis and 
illustrated that the Ferri et al (2006 and 2011) reviews included studies featuring 
heroin provision of various modalities and routes of administration (i.e., supervised 
and unsupervised prescribing practices and prescribing of both injectable and 
inhalable heroin). Strang et al. (2015) regard the SIH approach as a distinct treatment 
necessitating its own specific scrutiny and analysis and thus aimed to undertake a 
systematic review and meta-analysis of a defined narrow group of randomised trials 
of supervised injectable heroin prescribing specifically - and usefully - to examine the 
political and scientific response to the published findings. 
Some useful comments for future research are derived from the Strang et al. (2015) 
review. Strang et al. (2015) highlight that learning needs to be extended to the 
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process and influences on remission of illicit drug use and elimination of related 
problems, and, more importantly, enhanced quality of life and social functioning of 
patients. Arguably these investigations would be most comprehensively explored 
through qualitative research – with patients – which explore patients’ trajectories and 
experiences. Strang et al. (2015) discuss the fact that across all trials recruitment 
proved difficult, posing the hypothesis that for many marginalised heroin users, the 
attraction of prescribed diamorphine is not necessarily sufficient to promote 
engagement in highly structured treatment (Strang et al. 2015). Once again this is an 
area that could be usefully explored with patients directly, through qualitative inquiry 
exploring patients’ pre-trial perspectives and expectations, including how patients 
came to be referred to IOT, and initial motivations. Strang et al. (2015) point out that 
relative to the Cochrane systematic reviews conducted previously, their review 
(including only supervised injectable regimens) illustrates a clearer and stronger 
signal in favour of this approach over traditional OST approaches. Strang et al. (2015) 
do also highlight that the latest 2011 Cochrane review reaches a more positive 
conclusion on SIH than the original 2005 Cochrane review, including fewer studies, 
with different methodologies – the newer review encompassing these, but also six 
international SIH trials, with the exclusion of Demaret (2015). 
 
2.8. Cohort of longitudinal Supervised Injectable Heroin outcome studies 
 
Longer-term data are also available from eight extended follow-up studies in four 
countries with a consistent finding of additional sustained benefit across a range of 
different outcome categories (Strang et al., 2015). 
In Switzerland Rehm et al. (2001) found that a longer (18-month) stay in IOT was 
related to a higher chance of starting abstinence-oriented therapy than a short stay. 
In the subset of patients that were followed for 18-months, the health of those with 
severe somatic or mental health problems at the start (somatic: 22% start; 13% 18-
months; mental: 35% start; 24% 18-months) of treatment improved, and those with a 
low body-mass index put on weight (start: 35%; 18-months: 24%). This study showed 
that 34% of patients were retained in treatment for five years or longer. Whereas only 
nine per cent of the discharges during the first four months switched to abstinence 
treatment, this proportion more than tripled (29%) for patients discharged after three 
years of treatment. This suggests the need for a long period of adjustment and 
stability, and the details of how and why in regards to this trajectory could be explored 
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in qualitative interviews with patients who have undertaken longer-term IOT. The 
proportion of (almost) daily consumers of illegal heroin decreased from 81 to 6% 
during this time period, and the proportion of almost daily cocaine use decreased from 
29 to 5% (Rehm et al., 2001). With respect to changes in social integration, 
homelessness almost disappeared within the first 18-months of heroin assisted 
treatment, and a marked improvement was seen in reintegration into the labour 
market (73% were unemployed at baseline relative to 45% at 18-months). These are 
impressive longer-term changes. 
Research studies have not yet analysed the question of how HAT influences the long-
term living conditions of patients and former patients (Güttinger et al., 2003). Further 
analysis in a separate paper a few years later found that not only is SIH efficacious 
in the long-term course of treatment - with respect to living conditions and use of illicit 
substances - it is still effective after termination of treatment (Güttinger et al., 2003). 
This is of particular importance, and an area little explored to date – the trajectory and 
experience of those who have undergone long-term IOT and who then moved on from 
IOT. It was encouraging that the positive changes which could be achieved in the 
mid-term and long-term course of treatment persisted even if treatment had been 
terminated; and that there was very little difference between the two groups with 
respect to their living situations six years after they first entered treatment. A central 
question in every substitution treatment program concerns the long-term 
consequences of treatment with respect to successful rehabilitation (Güttinger et al., 
2003). This concept of rehabilitation both following long-term retention and post-IOT 
could be explored more thoroughly qualitatively, and with the UK sample (i.e. 
interviewing a sample of those with differing discharge statuses; including those 
retained in long-term IOT, and those who have discharged both positively – e.g., 
voluntarily – and negatively – e.g., compulsorily). 
At long-term follow-up, 43 of the 366 (11.7%) patients who were included in the 
Guttinger et al. (2003) re-examination were deceased. Of those 43 patients, five 
patients were in SIH at the time of death, seven people died within one week following 
discharge from a treatment program, and the remaining 31 died more than one week 
following termination of treatment. A third paper (Rehm et al., 2005) examined 
mortality and causes. Illicit heroin use significantly reduced both long-term and post-
treatment; of those still in treatment n=132 (84.7%) used heroin daily or nearly daily 
at baseline relative to 3.8 at six years. Of those who had left treatment n=122 (76.1%) 
used heroin at baseline relative to 18.9% at six years. There was also a significant 
difference in reductions between the two groups; with a greater reduction amongst 
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the group retained in treatment. Use of other drugs also reduced, benzodiazepines 
and cocaine significantly so, with a non-significant rise in use of cannabis from 
baseline to six years, across both groups (Güttinger et al., 2003). One aspect of this 
study clearly illustrates not just the strong benefit of being in a programme in and of 
itself, separate to the benefit of drug administration, but also the impact of ancillary 
services on outcome and recovery through analysis of patient relationship with 
financial debt.  
Patients who had terminated treatment showed more problematic outcomes with 
respect to debt (Güttinger et al., 2003). The researchers propose that this is likely to 
be due to the great effort treatment centres devote to debt counselling and 
administration of patients’ finances. They also propose that it was due to the lower 
costs for patients to finance substance dependence compared to persons who had 
terminated treatment. Explanatory narratives may arise from qualitative work with 
patients directly, on motivation to enter, and impact of, IOT. Relatedly, a significantly 
lower percentage of patients still in treatment had an illegal source of income to 
finance their lives, with the assumption that the reduction in illegal activities is 
connected with the reduced need for money to purchase drugs (Güttinger et al., 
2003).  
Another area of qualitative interest is the illustration by Güttinger et al. (2003) that 
whilst a reduction in drug-using contacts is positive, these contacts could not 
necessarily be replaced – and that therefore patients have a double fringe group 
identity: they are drug addicts living within society, but also receivers of heroin, albeit 
living away from the drug scene. This may lead to feelings of isolation post-IOT, 
narratives which may arise from qualitative work. Clinically this is something that 
should be explored psychologically with patients as they make progress within 
recovery. It is likely that one of the reasons indviduals begin taking and continue to 
use illicit drugs, historically, is due to feeling disconnected and perhaps ostracised 
from society; being involved in a drug scene may have alleviated these feelings. 
Feeling isolated in recovery may leave an individual vulnerable to relapse. Post-IOT 
trajectories require further exploration. 
In Germany several papers were published on the long-term outcomes of those in 
SIH treatment. In this cohort of studies 54.8% were retained in treatment at 24 months 
and 40.4% were retained after 6 years; 47.8% had discontinued SIH and, as 
previously outlined, 11.7% had died within the observation period (Verthein et al., 
2008). The six-year retention rate is promising. This study was particularly interesting 
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with regards to analyses conducted between variables that differentiated treatment 
drop outs to treatment completers. Of a range of demographic and other variables, 
there was a significant difference, with treatment completers at an advantage, across 
the two groups on the following variables at treatment outset: age (completers were 
older); treatment episode duration in days (completers longer); stable housing 
(treatment completers with a greater number); engagement in illegal activities in the 
past 30 days (fewer number of treatment completers); OTI health symptoms (fewer 
number of treatment completers); mental health score (treatment completers lower 
mean score); cocaine use (fewer number of treatment completers); benzodiazepine 
use (fewer number of treatment completers); sharing heroin equipment (fewer 
number of treatment completers); outpatient detoxification (greater number of 
treatment completers). These analyses are important as subsequent work (Verthein 
et al., 2008; Verthein, Schäfer, and Degkwitz, 2013) on long-term outcomes in 
Germany is based on this particular group of treatment completers who participated 
in SIH for 24 months.  
It was also interesting that the greatest changes occurred during the ﬁrst six months 
following treatment initiation; and that thereafter, the degree of improvement declined 
and health condition stabilised to a satisfying level (Haasen et al., 2007; Verthein et 
al., 2008). The researchers state that the central result of the two-year trial was an 
improvement of physical and mental health and a decline in illicit drug use under SIH 
treatment. Interestingly in these areas, the greatest progress had occurred already 
during the ﬁrst months of treatment, with slight improvements or stabilisation 
thereafter (Verthein et al. 2008). In contrast, improvements to the social situation 
occurred continuously over the entire two-year period, indicating that stabilising the 
housing and employment situation and forging new social (drug-free) contacts 
required more time. This indicates the long-term evolving nature of recovery in this 
context; thereby it may not be appropriate to conclude at a short-term outcome point, 
and once again the need to document the SIH trajectory in detail, in its entirety and 
in its context is highlighted.  
In the Netherlands researchers examined the four-year outcome data of SIH patients. 
The outcome variable for this study was unique; comprising response on a 
dichotomous, multi-domain response index, which encompassed physical, mental 
and social health, and illicit substance use (Blanken et al., 2009). Four-year retention 
was 55.7%. Response was significantly better for patients continuing four years of 
SIH compared to those who discontinued treatment: (90.4% versus 21.2%). 
Continued SIH treatment was also associated with an increased proportion of patients 
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without health problems and who had ceased illicit drug and excessive alcohol use: 
from 12% after the ﬁrst year to 25% following four years of SIH treatment (Blanken et 
al. 2009). The study also examined reasons for discontinuation of SIH treatment and 
these predominantly included insufﬁcient treatment response (according to the 
treatment staff; 21.2%) and repeated violation of house-rules (22.7%); these mainly 
involved attempts to smuggle heroin out of the treatment centre (Blanken et al., 2009). 
This is interesting and suggests that a significant number did not necessarily wish to 
utilise SIH as a means by which they could recover – interviews with patients on 
motivations to enter treatment, and treatment goals would be useful in this context. 
More positively 15 patients discontinued long-term SIH on their own initiative, of 
whom seven (10.6%) patients had opted for abstinence-orientated treatment. This is 
a positive result of longitudinal IOT and more generally, it would be useful to later 
interview patients whose discharge status is abstinence (including from treatment 
based opiates). It would be extremely useful to gauge whether abstinence can be 
maintained some time after finishing SIH. Generally gains made following the RCT 
plateaued and remained stable following 4-years of IOT. For example, at the end of 
the RCT, the percentage of patients without physical health problems had increased 
to 77.1%. During long-term SIH this percentage remained stable, at 81.5% following 
four years of SIH. 
Whilst Blanken et al. (2009) illustrate some ongoing improvements from the ﬁrst to 
the fourth years of SIH for the physical, mental and social health outcome criteria, 
due to the large effect at one year and the ﬂuctuations over the following years of SIH 
none of the linear modelled time effect estimates were signiﬁcant (Blanken et al. 
2009). There were, however, significant further reductions in use of illicit heroin and 
cocaine (Blanken et al., 2009). Usefully the researchers also highlight that despite the 
success of SIH overall, it should be noted that there remains a group of chronic, 
treatment-resistant heroin users who neither respond to methadone maintenance 
treatment nor to heroin treatment or who discontinue long-term SIH. For these 
patients, other potentially effective pharmacotherapeutic treatments or innovative 
psychosocial interventions such as contingency management may be beneficial 
(Blanken et al. 2009). It may be useful to also interview patients who drop out of SIH 
or who continue to use illicit heroin, in order to try to understand the situation and 
experiences of these patients. 
In Spain a follow-up to the RCT evaluated the health and drug use status of patients 
two years post RCT completion. As well as socio-demographic data, data was 
collected on drug use, health, and health-related quality of life. Data pre-
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randomisation was compared to this two-year post trial data for three groups: those 
who were retained in SIH treatment (n=24; 44%); those who had discontinued SIH 
(n=12; 22.2%); and those who had never received it (n=18; 33.3%) (Oviedo-Joekes 
et al., 2010). N=62 patients were randomised in the original RCT and n=54 (87%) 
were included in the follow-up study (Oviedo-Joekes et al., 2010). This methodology 
was particularly useful; the researchers illustrate drug use across the three groups 
24-months post-RCT completion. Results for mean days used heroin were: 2.42 
(retained); 6.56 (discontinued) and 13.92 (never received). It was informative to 
discover that those who had at some point received SIH had a lower rate of drug use 
than those who had never received SIH, though within this cohort there is likely to be 
a mixed picture of those doing well (with little or no illicit heroin use) and those who 
have returned to a high level of heroin use.  
Because of these potentially quite mixed trajectories within sub-samples, it is useful 
to explore trajectory in more detail qualitatively with a mixture of those who are 
retained and those who have discontinued SIH, to obtain a more detailed picture of 
trajectory pre, during and post-SIH in order to inform treatment practice. It would also 
be useful to explore discharge trajectories and summary statuses of those who 
discontinued treatment as it is likely that some patients discharged in a positive 
manner (e.g., decided to move to oral methadone or abstinence therapy) and some 
in a negative manner (e.g., a compulsory discharge due to violations of clinic 
protocols). The researchers themselves also stress the importance of highlighting the 
fact that the group of non-retained patients were discontinued for a variety of reasons 
and represent a mixed group who were not merely ‘non-responders’ (Oviedo-Joekes 
et al., 2010).  
There was a significant reduction in use of heroin across all three groups on the 
within-group comparisons (baseline to two year comparisons), highlighting again the 
overall benefit of intensive treatment programmes. The researchers note in their 
discussion that there was a full-time multi-disciplinary team devoted to care for these 
patients. Both within and between group comparisons indicated statistically signiﬁcant 
differences on the Addiction Severity Index (ASI; psychiatry scale) and SF12 (short 
form general quality of life measure) scores for this group (Oviedo-Joekes et al., 
2010). It was interesting that the group who had discontinued SIH treatment 
significantly reduced their use of cannabis from baseline to two years (and were the 
only group with significant differences here). Once again this highlights the need for 
further exploration of discharge summaries and statuses and patient experience of 
treatment, recovery and discharge. Especially because - on the other hand - those 
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who had never received SIH increased use of cannabis at two years (compared to 
baseline) – this was a marginal, non-significant increase however. 
The results of the Oviedo-Joekes (2010) study also illustrated that those currently on 
SIH were the only group that sustained at two years, their marked improvement in 
health following nine months of treatment during the trial period. This statistically 
significant improvement applied to HIV risk behaviours; mental health outcomes; and 
Addiction Severity Index outcome scores. It may be that even longer-term regimens 
are required for such an entrenched population of heroin users for changes to be 
more permanent post-treatment (i.e., for significant differences to also occur in the 
discontinued group). It is also worth noting that the profile of the Spanish patients was 
slightly unique in the sense that all patients were those using heroin and cocaine 
together (which is known as ‘speedballing’). Differences like these highlight again the 
necessity for follow-up and qualitative research with patients in each region, but which 
perhaps cannot always be generalised to the wider SIH research pool. It may also be 
that SIH is an effective way to attract disengaged, entrenched patients to treatment. 
Along a similar argument Oviedo-Joekes el al. (2010) state that urgent measures are 
needed to make available other substitution options, aside from methadone, in order 
to attract and retain opioid users into treatment. A patient may initially be attracted to 
the idea of receiving free additional heroin, and then following a course of IOT 
treatment have made substantial changes to their drug using and risk behaviours. 
The argument being that even those initially demotivated to enter treatment may 
become motivated to make change to illicit use behaviours during the course of IOT 
– and hopefully beyond. This could be the exact trajectory of one of the Oviedo-
Joekes (2010) patients, and qualitative case study research could identify and 
illustrate this. 
An additional research paper conducted some interesting analyses with the German 
cohort – focussing on those who switched at 12-months from methadone treatment 
to heroin treatment. Those methadone patients with adherence to the first year of 
treatment, could opt to switch to diamorphine treatment at this point. This research 
investigates the effect on patients’ health and drug use (Verthein, Haasen, and 
Reimer, 2011). Of the N=434 patients, who started the second year of study 
treatment, n=90 were methadone to diamorphine switchers, relative to the n=344 who 
received diamorphine for two years. To date this was a less explored area; those who 
switched from methadone to diamorphine during the trial; and investigation with this 
group is useful. The majority of these patients participated in psychosocial care 
regularly (at six months: 94.3%, at 12-months: 92.2%, at 18-months: 92.8%, and at 
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24-months: 84.7%. It may be that the longer patients remained in treatment the less 
they needed these services).  
After switching to diamorphine, significant improvements in health and drug use 
behavior (reduction in drug using days and increase in abstinence rates) are observed 
in the course of one year of diamorphine treatment and match the pattern of those in 
the heroin condition (Verthein, Haasen, and Reimer, 2011). The results of the course 
of methadone–diamorphine switchers are a methodologically independent 
contribution toward conﬁrming the positive effects of diamorphine treatment for 
difﬁcult-to-treat heroin dependent patients (Verthein, Haasen, and Reimer, 2011). 
This study supports the hypothesis that changing from optimised methadone 
treatment under the conditions of the clinical trial to diamorphine treatment is 
associated with improved outcomes. This study also demonstrates the benefit of 
diamorphine treatment specifically, in the context of the optimised nature of (e.g., 
ancillary services within) the trial. The combination of studies and debate indicate that 
both the administration of diamorphine and the intensive, holistic, and structured 
nature of treatment contribute to effectiveness, however, the relative contribution of 
each is still not clear. 
A further (German) research paper from this work examined social integration by 
means of the Opiate Treatment Index (Darke, 1991) and the European Addiction 
Severity Index (McLellan et al., 1992). In these analyses there were significant 
improvements in all domains following long-term treatment. The percentage of 
patients employed or currently working had increased three-fold up to 40% after four 
years (Verthein, Schäfer, and Degkwitz, 2013). We can view this finding in the context 
of Rehm et al. (2001) who also found a significant improvement in this area; 73% 
were unemployed at baseline, relative to 45% at 18-months. Moreover, living situation 
and leisure behaviour improved, and criminal activities markedly declined. The 
authors assert that the main influencing factor for successful social integration 
following four years of treatment is the ability to work (Verthein et al., 2013). Of 
relevance to the current thesis, the researchers argue that their results demonstrate 






2.9. Some limitations of Randomised Controlled Trial research 
 
In an American Psychological Association (APA) feature article Clay (2010) argues 
that RCT patients typically do not represent the population as a whole, for example, 
results from RCTs may not apply more generally. Clay (2010) argues that even if they 
did, it’s impossible to tell from an RCT which subset of patients actually benefited 
from the intervention being studied. Clay (2010) explains that critics don’t want to 
reject RCTs altogether; rather, they want to supplement their findings with evidence 
from other methodologies, such as epidemiological studies, single-case experiments, 
historical controls or clinical experience. Qualitative research amongst patients is a 
useful addition to RCT research on this basis. Clay (2010) outlines the perspective of 
Steven J. Breckler, executive director of APA’s science directorate, which is that 
patients in RCTs tend to be a rarefied population that are not representative of the 
real-world population an intervention would eventually target. Breckler’s (Clay, 2010) 
comments are that the individuals who enrol on drug trials are patients who have 
probably, to date, tried everything else, and are desperate for some kind of new 
treatment. Breckler (Clay, 2010) also makes the point that researchers winnow out 
would-be patients who have exclusion criterion co-morbid conditions. In the case of 
SIH treatment RCTs, it may not be that the results are not generalisable, as such, but 
that the pre-baseline condition – as outlined; having reached a point of potential 
desperation to try something new – may mediate initial engagement and then 
eventual efficacy across patients in the trial.  
As highlighted by Breckler (Clay, 2010) there is a population of people who would 
never have enrolled in an RCT to begin with (e.g., who are not as desperate or 
motivated), and it may not be possible to generalise results to this group. Whilst SIH 
is recommended as a second-line treatment, inclusion criteria for the trials, and 
criteria for receiving an injection on any given day also stipulated that patients not be 
pregnant, and not intoxicated (for example through alcohol consumption) 
respectively. Arguably controls on both of these aspects of life automatically reduce 
chaos and distress amongst this sample of patients. Uchtenhagen (2015) further 
highlights that effectiveness of treatment under real-world conditions differs from 
efﬁcacy under experimental conditions, again indicating a question mark over the 
generalisability of RCT research to clinical practice. It was interesting that in the 
McCusker and Davies (1996) case control study, neither treatment groups ceased 
use of illicit heroin, or other drugs such as crack. This perhaps suggests an effect 
from simply enrolling on to an RCT specifically, rather than the collection of data from 
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those already in respective treatment regimens. This again suggests the power of the 
RCT itself on affecting change amongst patients. Qualitative research with patients 
may add value to RCTs which may be subject to these conceptual issues. 
 
2.10. Qualitative studies with injectable opiate treatment patients 
 
In addition to the quantitative outcomes measured across RCTs there has been a 
small amount of qualitative work conducted with IOT patients to date (outside of the 
UK IOT sample) – one previous to the qualitative work in the current thesis, and one 
which was published after design of the thesis and data collection, but prior to write-
up of the thesis, thus did not inform design of the studies within this thesis. These will 
be outlined forthwith. 
Firstly, however, it should also be acknowledged that there are a number of qualitative 
research studies which focus on various aspects of the patient experience of 
methadone and buprenorphine OST, examples of which should be briefly mentioned. 
Gourlay, Ricciardelli, and Ridge (2005) examined users’ perceptions of methadone 
treatment in the context of their personal and social circumstances, in Australia in 
2003, and found that perceptions differed according to their self-concepts. What 
constitutes good quality of life during methadone treatment was qualitatively explored 
by De Maeyer, Vanderplasschen, Camfield, Vanheule, Sabbe and Broekaert (2011) 
in Belgium. Themes emerging were social relationships; holding an occupation, 
feeling good about one’s self, being independent, and having a meaningful life (De 
Maeyer et al., 2011). Stigmatisation, discrimination, dependence on methadone and 
the drug’s paralysing effects on one’s emotions were mentioned as common negative 
consequences (De Maeyer et al., 2011).  
These findings are useful in the context of the heroin use history chapter of the thesis, 
where failings of conventional treatment are explored. In Scotland, Best, Gow, Taylor, 
Knox, and White (2011) qualitatively (though using questionnaires) examine patients’ 
accounts of recovery from heroin or alcohol dependence. Results showed that users 
viewed recovery as a transcendence from dependence, and that recovery was an 
ongoing process rather than a time-defined milestone (Best et al., 2011). These 
findings accord well with academic debate in the field of what constitutes recovery, 
however, a UK picture is required, and with particular reference to the unique 
experience of injectable opiate treatment. 
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In terms of injectable opiate treatment, a qualitative study in Spain (Romo, Poo, and 
Ballesta 2009) examined patients’ and relatives’ attitudes, opinions and experiences 
of IOT, following completion of the programme and subsequent shift to receiving IOT 
in a therapeutic environment. The study was conducted in the final months of the 
RCT. Researchers within this study employed an ethnographic approach (using 
observation and interviews) and analysed the data using grounded theory, including 
21 patients and relatives. Researchers in the study spent time at the clinics, 
purportedly establishing rapport and gaining trust from patients before recruiting an 
intentional sample to interview. The researchers interviewed family members, a 
method which was proposed to triangulate data collected from patients. Romo et al. 
(2009) state that they held the interviews outside the hospital so as to differentiate 
themselves from the actual clinical team, and also to provide the respondents with a 
relaxed atmosphere to express their ideas, opinions and expectations. It is 
questionable whether the patients saw the researchers as separate to the clinical 
team, since the trial was still running and researchers had spent time in the treatment 
centre prior to recruitment. 
Romo et al. (2009) provide sound rationale for the conduct of qualitative research with 
patients to gauge their perspectives, as an important addition to the IOT RCTs. Romo 
et al. (2009) make the point that – to date - in the various studies examining a 
medicinal heroin prescription (regardless of the results obtained), the opinions of the 
people involved, including those of their families, have been ignored. Romo et al. 
(2009) highlight that this absence has been illustrated in well researched programs, 
such as the methadone trials, where they highlight lack of reference to the perceptions 
of the users themselves (Trujols and Perez de los Cobos, 2005; in Romo et al., 2009). 
Romo et al. (2009) further assert that this is common in other areas of medical 
research, contending that medicine is slowly beginning to recognise the importance 
of the perspective of the patient in health care. Romo et al. (2009) suggest that more 
investigations are needed to understand the importance of the symbiotic nature of 
health need, and patient satisfaction (Asadi-lari, Tamburini, and Gray 2004; Romo et 
al., 2009). Overall, Romo et al. (2009) aimed to provide a culturally relevant account 
of patients’ perspectives and understanding. 
The overall theory created from this data was that through the treatment process and 
by administering heroin therapeutically patients were able to break the habit of 
consuming heroin illicitly. This changed the significance attached to the substance, 
which meant that patients could make improvements in wider areas of life such as 
family, work, physical and mental health (Romo et al., 2009). The conceptualisation 
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from substance addiction to chronic illness was the main narrative from this work, and 
allowed previously treatment resistant heroin users to integrate in to society again 
(Romo et al., 2009). The researchers outline that the social consequences of 
considering heroin addiction as a chronic illness occurred as a result of the changes 
perceived in social and family relations, in the workplace and, in social acceptance 
experienced by both patient and family. Social acceptance seems to be key to this 
theme and to recovery in this context. Narratives changed from ‘illegal poison’ to ‘legal 
medicine’ (Romo et al., 2009) and this change in perception may link to more adaptive 
self-perceptions, creating confidence and motivation.  
Family purportedly began to see patients as ‘chronically ill’ (Romo et al., 2009) again 
illustrating wider acceptance of the patient’s predicament and perhaps how patients 
are then treated. One mother drew parallels between a diabetic patient who has to 
take insulin to be well (Romo et al., 2009). Another narrative was that by injecting in 
a clinical facility it is less exciting than taking heroin illicitly. Patients report 
psychological and physical health improvements and were grateful for the holistic 
nature of treatment. Flexibility, choice and involvement in service delivery were 
valued. As illustrated by Neale et al. (2012) towards the end, a sense of hope is 
apparent – from both families and patients.  
Narratives collected may have been slightly limited by the fact that patients were 
speaking about their current situation (in the latter stages of treatment) rather than 
the whole trajectory of experiences, such as from those who were ejected from 
treatment, those in long-term IOT, and those who had progressed away from IOT, 
and were either abstinent or stable in oral treatments. Where it is possible to access 
this range of patients - and these more complete narratives, representing the whole 
trajectory of experiences, would be useful. Additionally, all narratives reported were 
positive, and it would be worthwhile to conduct a study which included the less 
positive narratives or elements of treatment that patients found difficult. However, 
Romo et al. (2009) do acknowledge – and suggest - that the data they collected 
represent an exploratory picture of users’ experiences with limited generalisability, 
but can easily form the basis for further qualitative research in other clinical trials with 
heroin. To provide evidence of the need for a more complete picture of patients’ 
perspectives – including less positive narratives - Dursteler-MacFarland et al. (2006) 
explored patients’ perspectives using questionnaire data and found that patients 
ascribed numerous symptoms to heroin treatment, with the most frequently reported 
including skin itching, sweating, and constipation. Among potentially more 
problematic complaints included irregular menses, cognitive deficits, muscle twitches, 
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laboured breathing, pains in the cardiac region, and temporary paralysis of limbs 
(Dursteler-MacFarland et al., 2006).  
Romo et al (2009) illustrate that whilst focusing on the addictive or therapeutic 
properties of particular chemicals has engaged quite a lot of research energy, it may 
not be the critical issue in neither the aetiology nor treatment of drug dependence. 
Further, the successful use of medically prescribed heroin in reducing the problems 
associated with addiction suggests that it is not primarily the pharmacology of the 
drug which is the issue in an effective treatment (Bell et al., 2002). This type of 
qualitative data provides greater insight into the social aspects of recovery, helping to 
ensure the success of such treatments in certain groups of heroin users (Bell et al., 
2002). 
The next qualitative research project with SIH patients was by Blanken et al. (2010). 
Here it was assumed that the outcome of the RCTs could not be fully understood only 
by the quantitative trial’s invoked difference between co-prescribed heroin - without 
the need for illicit heroin use (experimental condition) - and ongoing methadone 
maintenance treatment and the use of illicit heroin (control condition) (Blanken et al., 
2010). Thereby it was recognised that supervised heroin treatment did not only offer 
patients pharmaceutical grade heroin, it also radically changed the situation in which 
heroin was acquired and administered by the patients (Blanken et al., 2010). Patients 
were those participating in one of the SIH trials in the Netherlands and involved N=27 
patients. Interviews took place: pre-SIH treatment; during treatment (at six or 12-
months); and several months following SIH. These interviews were specific and 
addressed non-prescribed drug and methadone use (amount, route of administration, 
perceived availability, rituals); inter-relatedness between heroin and other drug use; 
setting (places, persons, times, situations, etc.) and (positive and negative) effects of 
drug use; living situation and daily activities (employment, illegal activities, sex work, 
etc.); and physical and mental health, and social functioning.  
Patients narratives were not uniform; some were very positive about SIH, and some 
were negative; complaining that they were overly lethargic, and others still, cited 
allergic reactions (Blanken et al., 2010). Once again the restrictions around opening 
hours were cited. Patients derived comfort and stability from the assured availability 
of heroin; this also linked to feedback patients received from the outside world which 
was that they seemed less agitated. Some patients spent the money they saved on 
books and computers, and others on cocaine. Others were able to cease prostitution 
and crime.  
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There was an important distinction drawn between those who already had a relatively 
structured day – and therefore were sometimes inconvenienced by the need for twice 
or thrice daily attendance – and those who had no routine and structure at baseline - 
and who therefore derived routine and stability for their lives through mandatory clinic 
attendance. In one of the earlier longitudinal Swiss studies researchers found that 
patients who give up on their treatment after only a few months did so mostly because 
of difficulties they encountered with the rules and regulations imposed by clinics or 
because of lack of compliance (Rehm et al., 2001). Other themes within this study 
involved the positive reinforcing effects of heroin, and treatment as a negative 
reinforcer (i.e., alleviates both negative mental states and physical symptoms that 
would be experienced without this treatment (Blanken et al., 2010) linking the success 
of IOT back to theories of behaviourism (Watson, 1913). 
In Canada Oviedo-Joekes (2014) also conducted qualitative research with patients 
on their trial. The researchers hypothesised that the demanding nature of the IOT 
regimen may mean that adherence to IOT is compromised, arguably affecting overall 
effectiveness of the treatment. Oviedo-Joekes (2014) cites a social researcher’s 
earlier recommendation that calls for qualitative research to understand how and why 
a heroin treatment prescription works so effectively (Bourgois, 2002). Oviedo-Joekes 
(2014) highlight a number of studies indicating the need for an evaluation of the IOT 
intervention’s process; including outcomes reported by the patients themselves to 
guide clinical decisions and demonstrate effective engagement with person-centred 
clinical care (Oviedo-Joekes et al., 2014). 
Oviedo-Joekes (2014) illustrate that there is only a small research pool of qualitative 
research examining patients’ perspectives; and interviewed 29 patients from the 
North American IOT trial (Oviedo-Joekes et al., 2008) using a phenomenological 
framework and thematic analysis to analyse the data. Oviedo-Joekes (2014) highlight 
the usefulness of a qualitative study with patients in order to understand the 
effectiveness of this treatment; the impact of it on patients’ lives; and – importantly – 
the model of care. Understanding the model of care and how patients relate to it is 
vital for such a unique programme of treatment. The research sample involved 
patients who had gone beyond the 12-month period of IOT treatment to avoid 
interference with this study, yet appeared to be conducted while patients were still in 
IOT, and not long after the IOT trial had completed. Interviewing patients some time 
after the RCT has completed may provide more time and space for reflection on the 
overall recovery journey, pre-IOT, post- and beyond.  
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Research interviewers within Oviedo-Joekes (2014) had met patients several times 
previously prior to interviewing, during data collection for the Oviedo-Joekes (2008) 
IOT RCT. It may be useful to employ a research interviewer independent to the main 
RCT; this may yield more honest and reliable data from patients. Patients were 
stratified on several criteria, one of which was the inclusion of those who had received 
the methadone arm of the RCT treatment; patients cite disappointment with this 
treatment allocation. Patients do, however, cite positive aspects to this form of oral 
methadone treatment with favourable perceptions about the quick titration time and 
the availability of ancillary services (Oviedo-Joekes et al., 2014). 
Overall themes were that patients found the supervised delivery model stringent, yet 
it provided valuable stability to their lives (Oviedo-Joekes et al., 2014). Interestingly, 
the researchers applied a gender stratification to the reporting of their themes; with 
females discussing the adjustment required for the clinical setting; males too focussed 
on the challenging clinic schedule, and more specifically, the impact of this on their 
employment abilities (Oviedo-Joekes et al., 2014). Where possible this makes the 
case for a flexible schedule, involving either early morning or late opening access, for 
before or after work. Support for this is provided in the longitudinal study in the 
Netherlands – whereby following six years of treatment patients were more likely to 
be unemployed than at baseline, or following shorter-term regimens (Güttinger et al., 
2003). The researchers argue that patients may find the intensive, highly structured 
nature of treatment too cumbersome alongside employment, and that employers are 
probably very unenthusiastic about employing an individual in IOT (Güttinger et al., 
2003). If this is the case then it is a matter that should be explored in the context of 
holistic treatment and psychosocial support programmes, since reintegration and 
recovery may meet a plateaux if patients are unable to access employment during 
long-term treatment. 
Oviedo-Joekes (2014) found that some patients were motivated to enter IOT to obtain 
‘free heroin’, whereas others wanted to get their life back. Patients express wanting 
to still be in IOT (indicating that some of them no longer were). Some themes mirrored 
the quantitative work across the various RCTs (e.g., Strang et al., 2010 and Oviedo-
Joekes, 2008) such as improvements to housing, health, illicit drug use, and 
financially. Patients also spoke favourably about their interactions with healthcare 
professionals during IOT, with only a few citing negative interactions. Bias may be 
apparent, with motivation for more positive reporting, since researchers - including 
qualitative interviewers - were those from the original Canadian IOT RCT research 
team. Interestingly, patients assigned to OM treatment cited preference for this 
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treatment within the context of NAOMI (the Canadian study; Oviedo-Joekes et al., 
2008) because services and staff were more easily available – i.e., no waiting times, 
and pharmacy available on site. This patently illustrates how different this version of 
methadone treatment was to what had failed for so many heroin users internationally 
previously. 
Patients stated that the titration protocol was preferable; that physicians increased 
doses in a manner that was more appropriate – allowing the arrival at a more stable 
and comfortable dose quickly (Oviedo-Joekes et al., 2014). In more detail patients 
explain that this was critical at the beginning of treatment as it reduced withdrawal 
and illicit heroin use. This sheds light on previous research and commentary 
(Metrebian et al., 2015 and Uchtenhagen, 2015, respectively) illustrating the 
improvements in the OM conditions, which were surprising for a sample with such a 
prominent failure rate during previous OM episodes. It should be noted however that 
there was a difference in Strang et al. (2010) and Oviedo-Joekes (2008)’s inclusion 
criteria, with the former including those in OM immediately prior to enrolment in IOT 
and the latter including only those who had not been in OM treatment in the previous 
six months prior to IOT enrolment.  
As well as the recommendation to have flexible clinic opening times (also separately 
recommended by Oviedo-Joekes, 2014) an optimised and reliable methadone 
treatment programme appears to be beneficial in light of the Oviedo-Joekes (2014) 
findings. Some patients spoke about finding injecting in front of other people difficult. 
Patients also highlighted positive perceptions of the quality and purity of the medicinal 
heroin. Interestingly patients mentioned that they had just started to stabilise when 
IOT came to an end, and that they thought that they may have been able to make 
further gains within recovery (in wider aspects of life, e.g., education) if they could 
have remained in IOT for longer. An examination of a long-term IOT trajectory would 
clearly be useful and beneficial to investigate the patients’ hypotheses in this respect. 
Narratives on the ending of IOT encompassed gratitude and hope (Oviedo-Joekes et 
al., 2014). 
In discussion, Oviedo-Joekes et al (2014) report that one area of consideration is 
filling the time that was previously spent acquiring heroin. As Oviedo-Joekes et al 
(2014) highlight in the context of the Andalusian patients who also expressed that 
their needs beyond heroin became evident, such as their lack of skills to find 
employment. This indicates a need for holistic care, during and beyond IOT, to 
potentially reduce the risk of relapse. Patients in Oviedo-Joekes (2014) expressed 
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the need for vocational and skills training in the context of being confronted with the 
need to plan for their future. 
In synergy with the parent study’s (Oviedo-Joekes, 2008) findings, use of cocaine did 
not decrease; this was conferred through patients’ reports in the qualitative work 
(Oviedo-Joekes, 2014). This offers some validation of the honesty of reporting 
amongst IOT patients conducting qualitative interviews about their experiences. 
Overall, patients were grateful for a period of stability, where they could engage with 
life beyond the level of thinking about how to acquire a drug, and were happy to have 
been able to contribute to IOT’s evidence base (Oviedo-Joekes et al., 2014). That 
patients saw the treatment as a research trial specifically suggests that they may have 
seen it, and engaged with it, differently to that of how they would engage with 
treatment in clinical practice. This adds weight to the idea that results from RCTs 
cannot necessarily be directly generalised to clinical practice settings. 
Previous studies outline much of what the quantitative measures revealed during the 
IOT RCTs – an improvement to family relations, reduction in crime activities, use of 
illicit drugs, improvements to housing, etc. It would be useful to go beyond these 
outcomes and investigate the trajectory of experiences, intricacies of treatment 
trajectory and associated psychology, including the patients’ own conceptions about 
recovery - and what recovery means to them in the context of an IOT regimen. 
Feelings about, and goals for, the future should also be explored, and this was topical 
with the threat to IOT in the current (that is, at the time of the research’s inception) 
day. 
 
2.11. Literature review summary and rationale for current research 
 
As well as introduce addiction and heroin, this literature review outlines the RCTs 
conducted to date, the qualitative research in this area conducted to date, includes 
research on quantitative patients’ perspectives, examines long-term outcomes, 
secondary outcomes, and includes information obtained through the three systematic 
reviews. Throughout the review, areas of possible further inquiry are illustrated, 
arising from the research studies conducted to date.  
The most common routes in to treatment for patients in 2013-14 were self-referrals. 
Through interviewing patients about their complete treatment trajectory including 
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route in to treatment it is possible to obtain useful information about what attracted 
patients to IOT, and what their pre-IOT situation and status was. It is useful to uncover 
pre-treatment motivations and goals, and examine how these may evolve through 
treatment. Hartnoll et al. (1980) argued that users may be reluctant to approach 
treatment services, feeling that it would be ‘giving up’ and that there are too many 
restrictions and conditions on IOT. If these narratives are relevant to the UK IOT 
sample these will likely arise through qualitative interviews about pre-treatment 
perceptions and motivations. Patients will be asked about their goals and motivation 
upon entering IOT. 
In Neale et al. (2012), treatment history was a theme that patients discussed in 
relation to recovery. This was likely of great pertinence to the IOT trajectory and 
therefore should be addressed in the qualitative exploration of this trajectory. This 
forms a specific line of inquiry in the thesis (in study two the patients’ heroin use and 
treatment history will be explored). Neale (2012) did not elaborate on patient 
typologies and their current situation, and this will be addressed in the qualitative work 
within the thesis. 
More detail about the pre-treatment lives of heroin using and heroin treatment 
samples might be useful in order to explore potential patterns and themes amongst 
this unique group. This is of particular use to this unique sample of users for whom 
methadone has historically failed – an exploration of treatment history may give more 
clarity to this situation. We know that methadone failed for this group but we do not 
know why. Perneger et al., (1998) suggest that the inclusion criteria of the trials 
presented a biased control group. It may also be the case that repeated failure in 
treatment may have created a strong cognitive and emotional desire to strive for 
change in a new programme. This increased motivation would invariably effect 
efficacy, and as such an exploration of the experience of referral to IOT, motivations 
and the pre-IOT situation would be useful. The work by Hser (2007a) illustrates the 
importance of obtaining a sample’s pre-treatment history and how they came to use 
heroin habitually. 
It may be argued that research findings with conventional OST patients cannot be 
generalised to IOT patients, and particularly not RIOTT patients; some of which who 
remained in IOT for episodes of three years and more. Hartnoll et al. (1980) also 
highlight the potential relevance of pre-treatment hopes and expectations on outcome 
(the suggestion in this context being that illicit use may be a behavioural 
representation of frustrated hopes). The idea of patient typologies was also illustrated 
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in the Hartnoll (1980) study whereby methadone patients were polarised by being 
users of large amounts of heroin through OST or not using illicitly at all. The heroin 
group tended to use smaller amounts but more regularly. Responder status during 
RIOTT will be taken in to account in the analysis of patients in the current thesis; 
through case note review data and typologies. Thereby the qualitative work with 
patients in the current thesis is interpreted in the context of the RIOTT trial. 
In the context of general recovery, the substitution hypothesis stated that one 
addiction is simply replaced with another. This idea may be examined with UK IOT 
patients through a long-term exploration of treatment trajectory, including the patient’s 
current situation and current drug and alcohol use. Changes in treatment philosophy 
in the wider recovery discourse (such as the move from abstinence to harm 
minimisation) are important and it would be useful to explore how IOT patients view 
recovery – does recovery mean harm minimisation, abstinence, or something else, to 
them? This forms a specific line of inquiry in the thesis (through exploration of 
trajectory, perceptions, and direct questions about recovery and what recovery 
means to patients in this context).  
Haasen et al. (2007) demonstrated statistically significant differences across clinic 
sites and a number of researchers (e.g., Wilks, 1989) illustrate the importance of the 
social, cultural and clinical considerations. Patients in some other countries have 
been interviewed, and there is a need for qualitative work with UK IOT patients; as 
findings from other countries cannot necessarily be generalised to the British context. 
Similarly, the benefit of peer support in recovery generally has a large evidence base, 
discussion of which is outside the scope and relevance of the current thesis; however, 
it must be recognised that by its very nature IOT occurs in a social context (with clinics 
open every day of the year – sometimes allowing for up to three administrations per 
day; two in the UK). This will be addressed in the current thesis (through an 
exploration of patient experience of the clinic and other patients and any impact this 
may have had on recovery). 
Clearly a topical and very prominent (e.g., Uchtenhagen, 2015) debate is how much 
effectiveness is attributed to administration of heroin and how much is attributed to 
ancillary psychosocial services that are requisite to SIH treatment. This was the case 
even in earlier research – for example, McCusker and Davies’s (1996) research 
stipulated that heroin treatment patients were required to attend more frequent 
meetings with their keyworker. This intense therapeutic contact was a feature of the 
newer SIH clinics. It may be proposed that requisites such as these are implicated in 
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treatment effectiveness and recovery. IOT potentially allows those who may not have 
otherwise engaged in this type of support again to benefit from these wider aspects 
of the programme which lead to more long-term and sustained recovery. Through 
exploration of the complete trajectory these nuances may be illustrated. The inability 
of the RCTs to separate the effects of treatment drug administration from the effects 
of additional support services is relevant to all of the RCTs evaluating SIH; since all 
offered this intense holistic programme of support. Through qualitative interviewing 
with patients the effect and role of psychosocial and other holistic support will be 
discussed.  
McCusker and Davies (1996) also highlight the impact of unwelcome dose reductions. 
Dosage and its impact will be explored within a discussion about treatment procedure 
in qualitative work with IOT patients in the thesis. Demaret (2015) highlight resistance 
to additional methadone – the qualitative work on treatment procedure will explore 
whether this is the case, and importantly, why, for UK patients. Strang et al. (2015) 
highlight that learning needs to be extended to the process and influences on 
remission of illicit drug use (and elimination of related problems), and, more 
importantly, enhanced quality of life and social functioning of patients. Verthein et al. 
(2011) examine those switching from methadone to diamorphine during their trial, and 
the impact of this switch will be explored with the UK sample, qualitatively and in the 
context of the case note reviews. 
March et al. (2006) specifically propose that SIH is efficacious for a variety of reasons, 
hence the control group making gains as well as the heroin group is on the basis of: 
the high ratio of staff to patients; the high motivation of staff working with this group; 
higher methadone doses; medical, psychological, social and legal support; and the 
possibility of obtaining heroin following the trial phase of the treatment. These are 
also highly relevant and important aspects of treatment that are likely not present in 
general OST practice, and it would be useful to identify if patients themselves attribute 
gains made during treatment to these factors. This may arise from qualitative 
research on treatment trajectory and perception. 
Hartnoll et al. (1980) state that they are aware that patients modified drug use prior 
to attending the clinic for testing, or failed to attend to conceal drug use. Hartnoll et 
al. (1980) suggest caution over the reliability of urine drug screening as an indicator 
of drug use. Qualitative work with IOT patients by a researcher completely separate 
to the RIOTT research team, and several years following the trial may elicit honest 
and open responding by patients, including the less socially desirable aspects of 
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patient experience of IOT. Criticisms of other qualitative work conducted with IOT 
patients to date is that researchers conducting this work were sometimes part of the 
original RCTs research team. This is not the case in the current research. 
The theory of relapse prevention is also likely to be incorporated in to psychological 
work during pharmacological treatments – it is necessary to conduct qualitative work 
with this population in order to understand psychological processes involved in 
relapse prevention in this context. Edwards (1987) highlighted that relapse prevention 
is individualised and that treatment must be person-centred. Qualitative research is 
needed to capture the individualised nature of each patient’s trajectory. From this 
perspective, quantitative research would not be a good fit in trying to understand the 
nuances and specifics in an individual’s recovery journey through this niche 
treatment. 
Relatedly how the patient perceives the outside world (including those they are close 
to) view their addiction and injectable treatment may impact the individual’s recovery 
journey. Romo et al. (2009) find social acceptance (through work and family relations) 
to be a pertinent theme in their interview work with IOT patients. The qualitative work 
within the thesis will explore patients’ social and familial relationships and 
perceptions, over the course of the IOT trajectory. 
Metrebian et al. (1998) showed that 36% chose injectable methadone treatment over 
injectable heroin treatment and that few patients receiving injectable methadone were 
using illicit opiates. These findings are interesting, and since injectable methadone is 
unique to the UK treatment system, an exploration of patient perceptions of this 
treatment is useful. Interviews will be conducted with those who at some point 
received injectable methadone, in addition to patients who received injectable heroin. 
Metrebian et al. (1998) also highlight that different changes occurred at different 
stages of the IOT trajectory, however we are not aware of why this was; qualitative 
interviews encompassing the treatment trajectory might yield more information on 
this. 
In relation to treatment timeline, there have been suggestions through research (e.g., 
March et al., 2006) that initial gains may plateaux in longer-term analyses, and this 
will be explored through qualitative interviews – which are conducted a number of 
years post-the UK IOT - and also through quantitative descriptive analyses which will 
be conducted on long-term (up to three years) outcomes, and presented within this 
thesis. Oviedo-Joekes (2009) find that patients did not spend the extra money saved 
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through IOT on other drugs, and the drug-using profile of patients in IOT will be 
examined thoroughly in case note reviews and qualitative interviews within the thesis. 
Overall, research conducted to date does not provide a complete experience of 
patients’ trajectory and experience of IOT; and the thesis is well placed to explore 
this. As indicated, inviting patients to share their narratives through a qualitative 
interview invites a more collaborative approach to data collection. During the UK RCT, 
patients may have felt that they were required to share their perspectives in exchange 
for treatment medication. Patients’ aspirations and expectations may be expanded 
upon in more detail through in-depth interviewing. Groshkova et al. (2013) 
acknowledge that it is important to note the dynamic nature of aspirations; and that 
patients who had moved on in their aspirations sought further, broader recovery. 
Qualitative research will explore this trajectory of aspiration and recovery in detail with 
patients. Semi-structured interviews will allow patients to speak more freely about 
elements of individual importance. 
It will be useful to investigate the post-IOT trajectory with available patients for whom 
this applies. In the Dutch trial (van den Brink et al., 2003) found that after 12-months, 
an interruption of HAT for two months had a negative impact: 82% of the patients who 
were completers and responders deteriorated substantially. Qualitative research can 
investigate the effect of treatment interruptions and patients’ perspectives and 
experiences of life post-IOT.  
Qualitative research conducted to date, has included relatively small sample sizes, 
has been in countries outside of the UK population, has been at the time of the trials, 
and in some cases conducted by members of these trials’ research teams. The 
current research will explore the entire trajectory, with a researcher completely 
separate to the RIOTT clinical team, a number of years after the trial completed, in 
the context of a UK social and political situation. It will utilise a larger sample size, 
illustrating the range of typologies and discharge statuses, and will outline the 
negative as well as the positive narratives when these arise. Uchtenhagen (2015) 
usefully highlights the point made by Miller that the cessation or reduction of addictive 
behaviour is often a good starting-point in examining a patient’s recovery, but if that 
is where treatment ends, it may be ﬁnishing just when a person needs help the most 
(Miller & Miller, 2009).This will be explored. 
Overall, the mechanisms of why SIH was effective for the UK sample remains 
unexplored. On the basis of this need and the specific recommendations derived from 
107 
 




Chapter 3 – Methodology 
 
Following a full literature review of previous IOT research, which allowed identification 
of knowledge gaps in research conducted to date; the following aims and objectives 
were derived which guide the following seven chapters of analysis. 
 
3. Thesis aims 
 
Overall the thesis will contribute to the scientific understanding of injectable opiate 
treatment, and specifically, determine the role of IOT in the patient’s overall journey 
of recovery. 
The primary aim of the research is to determine the long-term treatment trajectory 
and to describe the experience of patients receiving injectable opiate treatment (IOT). 
Study one determines the long-term treatment trajectory of patients receiving IOT and 
study two describes the experience of patients receiving injectable opiate treatment. 
Methodology for study one will be outlined, followed by methodology for study two. 
 
3.1. Study one 
 
3.1.1. Overview of study design 
 
Method: Study one involves a longitudinal descriptive exploration of patient trajectory 
during the RIOTT trial. Initial charts, graphs and analyses include all N=127 patients 
who participated in this trial, for whom complete data was available. The study begins 
by outlining patient movement during IOT using flowcharts for each treatment group 
and describes outcome data. Following six months of assigned treatment (either SIM; 
SIH; or OOM) patients were able to move to one of the other treatment groups; for 
example, if a patient started on, and completed six months of optimised oral 
methadone (OOM) treatment, they could move to SIH at six months, and may then, 
for example, have continued on SIH for another 30 months. Another patient may have 
completed six months of Supervised Injectable Methadone (SIM) treatment, then 
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moved on to OOM for six months, and then on to SIH for the remaining 24 months. 
Because of the high level of movement between treatment groups over the 36 months 
that data was collected, inferential statistics were not conducted on this data. It was 
decided that the most useful way to meaningfully illustrate this data - in consistency 
with study aims - was through the use of flowcharts chronicling the trajectory of 
movement for all patients, and descriptive outcome data. 
Analysis plan: Following these initial representations of patient trajectory through IOT, 
statistical analyses by means of t-tests were conducted on outcome variables, with 
duration of treatment episode (baseline - 0 months; three months; six months; nine 
months; 12 months; 15 months; 18 months; 21 months; 24 months; 30 months; 33 
months; and 36 months) as the independent variable. See section on analysis for 
further detail. Duration of heroin treatment episode was defined as the total time spent 
in heroin treatment during the trial. In other words, if, for example, a patient completed 
six months of SIH treatment, then switched to oral treatment for a period of three 
months, before returning to heroin treatment for an additional period of 12 months, 
heroin treatment episode duration was coded as 18 months in this case. Mapping and 
descriptive statistical data address objectives 1-5. 
 
3.1.2. Study one aim 
 
To determine the long-term treatment trajectory of patients receiving IOT. 
 
3.1.3. Study one objectives 
 
1. To illustrate broad patient outcomes over 36 months for those receiving 
Injectable Opiate Treatment (IOT); 
2. To determine the length of time patients receive IOT and whether they move 
away from IOT to oral treatment routes or abstinence; 
3. To determine treatment outcome (including drug use status, health status, 
social functioning status, discharge status) of patients receiving IOT (SIH and 
SIM) long term; 
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4. To describe IOT received (including mean dose, number of injections per day); 
5. To determine whether IOT treatment duration affects treatment outcome 
status (including drug use status; alcohol use status; health status and social 
functioning status). 
Objectives one and two will be achieved through descriptive statistics of UK IOT 
patient outcomes, and flow diagram mapping participants’ movement through 
treatment. Patients were assigned to one of three treatment groups and patient 
movement is chronicled using flowcharts, in order to illustrate patients’ treatment 
trajectory. Objectives three to five will be achieved through descriptive statistics of UK 
IOT patient outcomes. 
 
3.1.4. Overview of analysis 
 
The prediction across all outcome variables (use of illicit heroin, use of crack, alcohol 
use, crime status, social functioning status, and quality of both physical and mental 
well-being) is two-sided; that the length of treatment duration will affect status or 
outcome. For the Short Form 362 (SF36; Ware and Sherbourne, 1992) quality of life 
data (mental and physical well-being) higher scores indicate better status and for the 
Opiate Treatment Index3 (OTI; Darke, 1991) data, lower scores denote better status. 
All data refers to those patients who ever received injectable heroin treatment. 
Treatment episode may be several different episodes combined to form one period 
of time (e.g., an initial SIH treatment period of six months, with a break for another 
treatment or time spent out of treatment, followed by another 12 months of SIH 
treatment; hence treatment episode is 18 months, for this patient). 
  
                                                          
2 The Short Form 36 (SF36) questionnaire was designed to survey health status in the Medical 
Outcomes Study and was designed for use in clinical practice, health policy, and general population 
surveys (Ware and Sherbourne, 1992). 
3 The Opiate Treatment Index (OTI) is a structured interview designed to provide a measure of the 
effectiveness of drug treatments; it measures six treatment outcomes including drug use and social 
functioning. Some studies employ use of the sub-scales only and for the RIOTT and UK IOT data the 









3.1.6. Research design 
 




The independent variable was duration of heroin treatment episode (with up to 12 
levels: baseline - not yet received; three months; six months; nine months; 12 months; 
15 months; 18 months; 21 months; 24 months; 30 months; 33 months and 36 months) 
and the dependent variable was treatment outcome. There were numerous 
dependent variables, these comprised: heroin use status; crack use status; alcohol 
use status; social functioning status; mental health status and physical health status. 
Table one outlines outcome variables and the associated questionnaire measures 
utilised to obtain the results. 
 
3.1.8. Explanation of the within-subjects factor: Duration of treatment episode 
 
The within-subjects factor was duration of treatment episode. This variable requires 
explanation - as will be indicated by the use of the later flowcharts - there was a lot of 
movement across treatment groups over the 36-month study period of treatment and 
outcomes. The variable of interest in study one differs to time in treatment in RIOTT 
analyses. Since for these longitudinal analyses we are defining treatment episode 
length as the total time spent in heroin treatment. The prediction is that treatment 
episode length will affect outcome (regardless of breaks in treatment and movement 
to other treatment groups). Figure one illustrates the formation of the outcome 
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variable ‘duration of treatment episode’, within one possible patient treatment 
trajectory. 
            
            
            
   
Figure 1. An illustration of outcome variable ‘Duration of treatment episode’ using one possible 
patient trajectory 
 
Therefore, by the study end point (36 months) on predictor variable ‘duration of 
treatment episode’ the above patient will have had an SIH treatment episode duration 
of 27 months. The RIOTT study end point was 36 months following an individual’s 
entry into the RIOTT trial – as this is how long data were collected for. 
Another example may be a patient who begins the study (study baseline) in heroin 
treatment and drops out (e.g., because he/she goes to prison) at six months and does 
not return to RIOTT. This patient returns to oral methadone treatment in prison and 
upon return to the community. This patient’s total heroin treatment duration is six 
months. One further example is a patient in the above case, but who then who returns 
to SIH treatment (and RIOTT) upon release from prison, and continues in SIH for a 
period of 24 months. Therefore, their total time in SIH treatment is 30 months. 
Baseline involves outcome data for those who have not yet received heroin treatment. 
In the analyses, only patients for whom there is complete data on the outcome in 
question, are included. There was a significant amount of missing outcome data. A 
final example of a patient in the dataset is somebody who never receives heroin 
treatment during RIOTT. This patient may start on OM or SIM treatment and perhaps 
he/she remains in OM or SIM treatment for the duration of the time that they are in 
RIOTT. These patients’ data will not be analysed. 
Patients completed research interviews at various time points during the RIOTT trial; 
i.e., three months; six months; 12 months; 18 months; 24 months and 36 months. In 
reality there was very little data collected at time points 12 and 18 months and 
therefore numbers will be very low at these time points. If a patient did not complete 
a research interview at the time point in question their data will not be included in 
analyses. Participants’ data may appear in more than one treatment episode 
category, if they have a research interview available for several categories (for 
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example both six months and 12 months). In this way the treatment episode 
categories are between-subjects (and should be viewed as separate samples), 
however they are within-subjects’ samples by virtue of the fact that data for one 
participants may appear in both categories. Comparison baseline data is only that of 
those included in the treatment episode variable for which it is being compared to. 
 
3.1.9. Sample and participants 
 
Patients comprise N=127 who completed the RIOTT trial. T-test statistics examining 
outcome over time involve a within-subjects N=135. N=135 comprises baseline data 
(i.e., before patients entered IOT) and their associated treatment episode (length of 




Flowcharts chronicling patient movement between treatments was created using 
Microsoft Visio. The table below indicates quantitative outcome measures utilised - 




Table 1. Study one outcome variables and corresponding data collection measure 
Variable Measure 
Mean treatment dose Collected manually and analysed 
descriptively 
Heroin use status Dichotomous variable obtained through 
use of the Opiate Treatment Index 
(OTI) 
Crack use status Dichotomous variable obtained through 
use of the OTI 
Alcohol use status Dichotomous variable obtained through 
use of the OTI 
Social functioning status Continuous variable obtained through 
use of the Drug Use section of the OTI 
Quality of life – Physical health Continuous variable obtained through 
the SF36 (quality of life) measure’s 
physical health sub-scale 
Quality of life – Mental health Continuous variable obtained through 
the SF36 (quality of life) measure’s 




Within-subjects’ statistics included descriptive statistics describing mean scores and 
status on outcome variables (such as heroin treatment dose; alcohol use status; 
health status and social functioning status) using Stata. T-tests were conducted on 
outcome variables with duration of heroin treatment episode as the independent 
factor. Analyses were conducted using Stata Standard Edition version 13. Data and 
spreadsheets were managed using Excel, SPSS and Stata. 
In congruence with Rehm et al. (2001) no adjustments are made for multiple testing 
of effects, since the aim here was to illustrate effects of SIH over time, rather than to 












6. To formulate and describe patient typology (including treatment allocation and 
discharge status) for each patient interviewed; 
7. To describe patients’ drug use and treatment histories; 
8. To determine patients’ goals for, motivations, and expectations of IOT 
9. To explore patients’ experience with IOT 
10. To explore patients’ satisfaction with IOT; 
11. To explore patients’ views on impact of IOT; 
12. To explore patients’ views of, and goals for, their recovery. 
 
Objectives 7-12 will be achieved through qualitative interviews with IOT patients and 
analysed using thematic analysis. Objective 6 will be achieved through formulation, 
development and illustration of patient typologies; a chapter in its own right (chapter 





3.2.3. Rationale for choice of research method 
 
To date, the UK RIOTT trial examined broad quantitative outcomes, such as use of 
illicit heroin through opiate treatment (measured through urinalysis) and retention to 
treatment (Strang et al., 2010). The RIOTT trial also examined secondary outcomes 
(Metrebian et al., 2015), finding that outcomes improved across all treatment groups 
at six months following baseline (as detailed in the introduction). In-depth interviews 
are recommended for the following reasons: generating in-depth personal accounts, 
to understand the personal context, to understand complex processes and issues - 
e.g., motivations; decisions; impacts; outcomes - for private subjects, for sensitive 
issues, for subjects concerning social norms, and for those studying processes 
occurring over time (Lewis, 2003). These are all pertinent facets of the patient’s 
trajectory through IOT.  
As outlined in the introduction, the major area which required further study and 
research following a series of injectable opiate treatment trials was an in-depth 
examination of the different components that make up injectable opiate treatment, 
including the holistic and ancillary support services. It was clear that there was more 
to efficacy and effectiveness than simply the administration of IOT, however an 
analysis of what constituted effectiveness had not been conducted. The most useful 
– and interesting - way to explore the treatment experience in detail was through in-
depth interviews with patients, on the various dimensions of this unique treatment. 
Since this treatment is so unique, qualitative research was most appropriate 
methodology as it allows focus on nuanced aspects of a process or experience, for 
example, patients’ goals, and treatment procedure. This level of detail will provide 
useful information not only for future IOT policy, but for OST policy and practice more 
generally. 
From the study outset and conceptualised through study design, the aim was to 
describe the different types of changes which had taken place over the course of 
patients’ journey through IOT, the different outcomes that resulted, to illustrate and 
describe how they had arisen, to explain how and why there were differences 
between sample members and to understand motivations and decisions. These are 
all specific aims of thematic analysis, and it was therefore the appropriate method for 
this analysis. Understanding motivations and decisions, and exploring impacts and 
outcomes require the detailed personal focus that in-depth interviewing allows. Since 
there was a potentially large pool of patients (N=127 in the RIOTT trial; final qualitative 
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n=41 - a relatively large number for a qualitative research project), it was appropriate 
to interview a larger number of patients to illustrate as broader range of experiences 
as possible. 
The quantitative research with RIOTT patients revealed useful yet limited information 
about the effectiveness of IOT and the patients’ experience and journey through IOT. 
Neglected in the data on efficacy was why it was effective, and what exactly 
constituted effectiveness for these patients. Langer and Abelson (1979 in Spinelli, 
1989) find that context affects interpretation and judgement. As discussed in the 
introduction, the context of the IOT trial was inherently related to patient experience, 
perception, and progress through IOT, given the unique nature of this treatment 
programme. For example, the need for daily attendance, and supervised dosing. It is 
proposed that this context was implicated in the effectiveness of IOT, yet this had not 
been formally explored with patients. A qualitative study allowed full exploration of the 
intricacies of the delivery and experience of this treatment. In the case of quantitative 
research, the influence of context is purposely minimised and the researcher adopts 
a stance of objectivity (Mcvilly et al., 2008). 
Qualitative researchers suggest that they can get closer to the participant’s 
perspective through detailed interviewing and observation (Denzin and Lincoln 2000). 
They argue that quantitative researchers are seldom able to capture participants’ 
perspectives because they have to rely on remote, inferential empirical records and 
materials (Denzin and Lincoln, 2000). The thesis benefits from both approaches and 
the need for a qualitative investigation was derived from what lacked from the 
quantitative analysis, and therefore gaps in the knowledge base useful for further 
development of policy in this area. In relation to IOT research and addiction treatment 
research per se, the individual lived experience of a daily regimen is likely to be highly 
relevant to its efficacy and clinical effectiveness. In terms of analysis, overall themes 
from this work are useful for policy and practice development. 
Quantitative research may investigate specific processes within a disorder or disease, 
and categorise common processes and behaviours; conversely, the phenomenologist 
would be sensitive to behaviour that falls outside of the typical model and attempt to 
illustrate it specifically (MacGhee, 2001). The qualitative dimension of the current 
thesis illustrates both the common and less common narratives. Finally, thematic 
analysis can offer a more accessible form of analysis, particularly for those early on 
in a qualitative research career (Braun and Clarke, 2006). The PhD candidate had 
conducted a little previous research using thematic analysis – yet is still an early stage 
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researcher - and one of the PhD supervisors (TW) was very knowledgeable with the 
approach. In addition to the fact that the approach encompasses a degree of flexibility 
(Braun and Clarke, 2006) in the technical conduct of the process of coding and 
analysis, the approach was chosen for pragmatic reasons, on the basis of knowledge 
and expertise of the student and, in particular, PhD supervisor. The researcher 
wished to capture a great range of experiences from as many participants across the 
three IOT sites as she could, since there were a number of possible trajectories of 
movement through IOT (as illustrated in the quantitative data in chapter four), 
therefore practicality was key in the time scales for analysing and writing the thesis, 





3.2.5. Research design 
 
The research design is qualitative and its analytic method is thematic analysis. The 
epistemological approach taken to this thematic analysis is a realist approach. 
 
3.2.6. Study setting 
 
The three clinics that hosted the qualitative interviews were situated in one city and 
two towns in England. Clinics were treatment centres traditionally providing oral 
substitution treatment, as well as psychosocial support programmes. For the purpose 
of the qualitative interviews, interviewing either took place in one of these clinics or at 
another treatment centre convenient to the patient, including a GP surgery and an 
alcohol treatment service. In such cases, interviews were arranged through the 






3.2.7. Clinic locations 
 
Interviews were conducted in the three locations of the clinics included in the RIOTT 
trial; Darlington; Brighton and London. 
 
3.2.7.1. Darlington clinic 
 
Darlington is a market town in County Durham in the North East of England and is 
also part of the Tees Valley region. Darlington has a population of 105,600 (ONS, 
2012). The clinic was out of the centre of town, but near to it, in a quiet side street. 
Patients had a time limited slot of ten minutes each day where they could attend for 
their injections. If they arrived outside of these times they were not permitted to 
receive their injection. The clinic was part of a wider drug treatment service and 
patients entered in the reception round the back of the building and spoke to a 
receptionist who had the list of IOT patients and what time they were due to attend 
for their injections. The clinic reported that, in the main, patients would attend on time. 
 
3.2.7.2. Brighton clinic 
 
Brighton and Hove is a city in East Sussex on the South East England coast. The 
population of Brighton and Hove is 273,400 (ONS, 2012). The clinic is very near to 
the centre of Brighton but away from it, on a main road not close to shops, but close 
to residential houses. Patients were not required to attend at a particular time of day 
for their injections, just during a specified morning period for morning injections and 
a specified afternoon period for afternoon injections. If attending for one injection 
patients could attend at any time during the clinic’s opening hours. The injecting clinic 
was part of a wider methadone prescribing clinic, in a specially created injecting 
facility on the basement floor. Patients were required to enter through the back door 
to the main clinic and were breathalysed by nurses upon attendance. If there was a 
queue, patients could either queue outside (or two could wait in the clinic). Generally, 
the clinic did not get unmanageably busy. 
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3.2.7.3. South East London clinics 
 
London has a population of 8.5 million (ONS, 2014). London clinics were based in 
Camberwell and Blackfriars. Additional treatment centres for qualitative interviewing 
included an alcohol service and a GP surgery, in Central, and South, London. The 
injecting clinic in London was initially in an NHS building on a busy high street in a 
built-up inner city district location, and then moved to a hospital annex in a mental 
health hospital in the same neighbourhood. The location is a busy south London 
district; however the hospital complex is set back from the main street. In the initial 
location, similarly to Brighton, patients could attend at any time of day during the clinic 
opening hours (morning and afternoon – and as with the Brighton the clinic it was 
closed for lunch). In both clinics patients would ring the doorbell and CCTV would 
reveal to the receptionist who was at the door – patients would also state their name 
– though generally all patients were familiar to all staff. In the first clinic, the building 
was a very inconspicuous one, and it would not be known by people walking past that 
it was an NHS service, nor a drug treatment service. In the second location it was 
part of the hospital complex but that it was a drug treatment service was not apparent. 
A third location came into operation during the RIOTT trial and this had a very small 
injecting facility with only 4-5 clients who received their injectable dose there. It was 
located in a central London drug treatment clinic on a busy main road. This clinic had 
a sign outside to state that it was a drug treatment clinic. Patients were not required 
to attend at a particular time, however, through choice, those in the central London 
clinic would attend for their injections every day first thing in the morning. 
Qualitative interviewing took place at all three London clinics, although the first had 
become a smoking cessation clinic by the time of qualitative interviewing. 
 
3.2.8. Sampling method for qualitative research study 
 
A purposeful sample of patients from the following identified subsamples of the RIOTT 
cohort were included:  
1. In receipt of IOT: Participants were those who had at some stage received 
injectable opiate treatment; those only receiving oral methadone treatment 
were not recruited; 
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2. Treatment trajectory: The primary sampling variable was Treatment trajectory, 
comprising those assigned to IOT during RIOTT; those who remained in IOT 
thereafter; and those initially assigned to OOM and then moved to IOT 
sometime post the six-month RCT; 
3. Site: To recruit from London, Darlington, and Brighton; 
4. Gender: Male, female. 
At study design the aim was to recruit a more equal balance of patients across 
treatment sites (ideally with approximately 13 patients recruited from each site). In 
practice the method of recruitment became opportunistic and all available, and willing 
patients across sites were approached to take part in the qualitative interview. Ideally 
the aim would have been to recruit an even number of males and females, however 
this again was not possible in practice, particularly as the current population (the 
RIOTT cohort) was composed of more males than females. The final aims were to, 
firstly, stratify equally according to whether patients were assigned to OOM and then 
moved on to IOT, or remained in IOT throughout their treatment episode. Secondly, 
the intention was to stratify qualitative patients according to responder status (with an 
equal balance of those who responded to RIOTT trial treatment in the first three 
months – by reduced use of illicit heroin – as outlined in the introduction (RIOTT trial 
section), and those who were non-responders – by virtue of the fact that they 
persisted use of illicit heroin during this time. In practice, because the available 
number of patients in the sample was limited, and an opportunistic approach was 
taken, this was not possible. However, as is demonstrated in the sample and 
participants section, these groups balanced naturally. 
 
3.2.9. Sample and participants for qualitative study 
 
Qualitative research commonly employs purposive sampling (samples within 
samples; Patton, 2001) to ensure representation of the range and diversity of a study 
population. The aim was to recruit a balance of those who had begun on IOT and 
remained in IOT and those who had moved to IOT at some point during data 
collection. This balance emerged naturally during recruitment. In the design stages of 
the study another aim was to recruit a balance of patients across the three localities, 
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but time, budget and other practicalities meant that this was not possible in practice 
– as discussed in more detail. 
The final sample comprised 41 (32% of the N=127 Intention to Treat RIOTT cohort) 
patients from the RIOTT trial. In the overall RIOTT cohort, patients comprised 51 
patients in London, 31 in Brighton and 45 in Brighton. The qualitative study with 
RIOTT patients involved 23 patients in London (45% of the original London cohort) - 
across six different treatment centres, including those no longer in treatment - 11 in 
Brighton (35% of the original Brighton cohort) and seven in Darlington (15% of the 
original Darlington cohort).  
29 (71%) patients were male and 12 (29%) were female. At the time of interviewing 
(July 2013 – January 2014) 19 (46%) were in oral methadone treatment; 13 (32%) 
were in injectable heroin treatment; 4 (10%) were in Slow Release Oral Morphine 
(SROM or MXL) treatment; 4 (10%) were no longer in any treatment (abstinence); 
and 1 (2%) was in buprenorphine (subutex) treatment. In terms of treatment group 
breakdown 17 (41%) started with injectable methadone; 15 (37%) injectable heroin; 
and 9 (22%) oral methadone – with all of these patients at some stage switching to 
one of the injectable treatment groups. All patients were those who had at some stage 
received injectable treatment. 
During the RIOTT trial patients were classified as either responders or non-
responders during months 3-6 of treatment – this was on the basis of number of urine 
drug screenings that were positive for illicit heroin. Responders were those who 
‘responded’ to the trial medication by means of significant reduction in illicit heroin 
(50% or more negative drug screenings in months 3-6). 19 (46%) of the qualitative 
cohort were responders; 19 (46%) non-responders and 3 (7%) had unknown status 
on this domain (either due to a clinical error or a planned absence at the time of the 
drug screenings). As illustrated in later sections of the thesis, there was a lot of 
movement from one treatment to another amongst patients, at various points during 
the three-year data collection period. The decision about movement was made on the 
basis of patient response to the treatment drug they were receiving, and through a 
process of clinical decision-making. For this sample, 20 (49%) patients moved from 
their assigned treatment at least once and 21 (51%) remained in their original 





3.2.10. Position of the interviewer 
 
‘The qualitative researcher’s perspective is perhaps a paradoxical one: it is 
to be acutely tuned-in to the experiences and meaning systems of others - to 
indwell - and at the same time to be aware of how one’s own biases and 
preconceptions may be influencing what one is trying to understand.’ 
(Maykut and Morehouse, 1994, p. 123). 
The interviewer was an independent researcher completing a PhD in the department 
for addictions and had no involvement in the RIOTT trial. She was completely 
separate to the clinical team delivering IOT. This was advantageous and the 
interviewer felt that she was able to build a good rapport with participants, and one 
reason for this may have been her identity as an outsider. The interviewer was very 
aware of her context (‘researcher’s context’ – such as class, ethnicity, gender; 
Angrosino, 2005), that is, certain factors about her own identity that could have had 
an impact on how patients responded to her during recruitment and qualitative 
interviewing. There was clearly a high level of ‘social distance’ (as coined by Georg 
Simmel in the 1890s; Ethington, 1997) between qualitative participants and the 
researcher. The researcher is a young female from London. All of the participants 
were older than the researcher and there was a much greater majority of male 
patients interviewed for the qualitative study. The researcher is from a different socio-
economic status to the sample of patients interviewed. She was dressed in smart-
casual attire, which may have reinforced the social distance.  
The researcher is also quite clearly different to the clinical team who administered 
care to patients on IOT, by virtue of the fact that she is not a medical professional and 
was a student. The information sheet demonstrated to participants that the project 
was part of a PhD research project, illustrating the researcher’s status as a PhD 
student. The researcher has often been told that she looks younger than she is, and 
this was something that she held in mind – that participants may interpret her as 
younger than she actually is. The researcher interpreted quite a playful 
communication style from patients (particularly male) in her interactions with them, 
which is possibly different to the way that they may interact with a doctor or 
psychiatrist working on the trial or handling their clinical care. That the researcher was 
from London, and had travelled to Brighton and Darlington was also of relevance to 
these two clinics, and this was information that the participant was aware, may have 
further reinforced the researcher’s outsider status to participants. This power dynamic 
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also applies to clinic staff. When organising interviews, it was clear that the staff were 
particularly helpful and respectful, perhaps also interpreting the power dynamic of a 
researcher who is supervised and directed by senior members of the clinical team. It 
is argued, however, that the conduct of ethnographic or qualitative research goes 
some way to reduce ‘social distance’ (as compared to a questionnaire methodology) 
or status gap between researcher and participants (Silverman, 2013). 
However much of a rapport the researcher may have created with patients, it was 
clear that she had outsider status, whereby she was an outsider to the patients’ 
culture. As has been evidenced, there were pros and cons to this. As outlined by 
Corbin and Dwyer (2009), membership status (outsider versus insider) in relation to 
the participants does not necessarily negatively affect the interviews, however, it 
raises an important point that must be considered in research with participants who 
identify with a group, based on shared experience, gender, sexuality, ethnicity, race, 
et cetera. This issue confronts both researchers who are members of the group they 
are studying, and those who are not, for there are costs and benefits to each of these 
statuses (Corbin and Dwyer, 2009). 
What is clear, however, is the fact that there will invariably be a power dynamic at 
play in the conduct of qualitative interviews in this study. A power dynamic is created 
through the subjective position made apparent for both researchers and participants 
by the research process (Riley, Schouten, and Cahill, 2003). This applies generally 
speaking, however in the current case, participants had gained from IOT, and this 
may have reinforced the power dynamic, whereby the researcher could have been 
seen as somebody influential in the process of IOT either continuing or coming back 
into clinical practice. The status gap and power dynamic are important to consider 
when interpreting the following qualitative analyses. The influence of the relationship, 
the researcher, and the co-construction of the narrative (Davidsen, 2013) are 
important areas to explicitly address, particularly from the critical position (of 




3.2.11. Qualitative IOT patient characteristics 
 
Table 2. Qualitative Injectable Opiate Treatment patients’ characteristics  
Variable N % of qualitative sample 
Gender   
Male 29 71 
Female 12 29 
   
Site / clinic   
London 23 56 
Brighton 11 27 
Darlington 7 17 
   
Current treatment status   
OM 19 46 
SIH 19 46 
MXL 4 10 
No longer in treatment 4 10 
Buprenorphine 1 2 
   
Original treatment assignment   
SIM 17 41 
SIH 15 37 
OOM 9 22 
   
Responder status   
Responder 19 46 
Non-responder 19 46 
Unknown 3 7 
   
Moved to IOT/Remained in IOT   
Moved 29 49 





Interviews were based on topic lists drafted following a literature review and 
consultation with key researchers and clinicians involved in the RIOTT trial, but were 
also responsive to issues emerging from patients’ accounts. Interviews were further 
informed by the findings of initial thematic interviews with qualitative patients. 
All interviews were tape-recorded, transcribed and downloaded for coding and 
analysis using NVivo. At the stage of code refinement Excel was used, in order to 
easily group codes in to their relevant themes and sub-themes. Transcripts were 
typed into Word and a digital dictaphone was used for recording interviews. 
 
3.2.13. Interview schedule 
 
The interview schedule comprised the following sections. 
Table 3. Topic guide for qualitative interviewing 
Item Topic 
1.  Background (including questions on patients’ heroin use history, and treatment 
history);  
2.  Referral - Motivations and goals – what promoted patients to enter IOT; 
expectations; goals; hopes; 
3.  Experience of treatment journey and perceptions of personal progress through 
treatment; 
4.  Experience of medication administered (including medication, dose, route of 
administration, and views about any changes, and additional methadone); 
5.  Perspectives on timeline – how long patients spent in injectable treatment and 
views about this; 
6.  The clinic (process, the need for everyday attendance, support provided, clinical 
decision-making, social connections, and patient behaviour); 
7.  Social support – friends/relatives, and the perspective of friends/relatives; 
8.  Impact – of treatment (significant changes to personal situation, use of drugs, 
treatment decisions, physical/medical complications); 
9.  Goals – for the future 
10.  Recovery – specific views on recovery in the context of IOT. 
 
Section one of the topic guide began with a question about patients’ heroin use 
histories as a way to allow the participant to begin talking and put them at ease (Rubin 
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and Rubin, 1995). General open questions such as ‘Can you start by talking about 
your heroin use history?’ helped start the interviews and gain trust. This then ended 
up forming a useful section of the analysis in its own right (chapter 6 – Heroin use 
history). 
Section two addressed motivations and goals at treatment outset, and whether these 
goals developed over time. This was of interest and deemed relevant to patient 
trajectory and progress through recovery and IOT. What motivated patients to engage 
with IOT was of interest to the field of recovery. Whether patients’ initial perceptions 
affected ongoing engagement with the treatment was explored within this section. 
Specifically a thesis objective, patients’ experiences of this unique treatment were 
explored. Additionally, patients’ views about their own progress through treatment 
was explored, which also encompassed patient satisfaction with treatment. Similarly, 
sections 4-6 examined treatment process, as this was hypothesised to be connected 
to the success and efficacy of IOT overall. As well as the impact of treatment, outside 
support was examined. 
The final sections were on goals for the future - it was hoped that through this order, 
patients could hopefully leave feeling calm and in a positive frame of mind (Rubin and 
Rubin, 1995) – and recovery. To end, patients were asked if they had anything to add 
which had not been mentioned previously (Rubin and Rubin, 1995), bringing the 




3.2.15. Recruitment – design 
 
When designing the study, the aim was to recruit equal numbers of patients across 
sites, however the researcher was limited on both time and funding for travel. 
Recruitment in Darlington involved the researcher spending a week in this locality and 
the DNA rate for patients attending for their booked research interview was relatively 
high (50%). Recruitment in Brighton involved a long commute from London to 
Brighton, and once again the DNA rate could sometimes be high (approximately 
40%). The majority of these missed appointments were booked for another time, 
however, this was not possible in Darlington, due to travel constraints to this locality. 
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London recruitment was less problematic, as the researcher was based in South 
London, and the majority of the interviews and recruitment took place at the three 
main clinics in South East London (two at Denmark Hill - where the researcher was 
based - and one at Blackfriars Road). Recruitment also took place at four other sites 
across central and South East London, for ease for patients. Other sites included a 
medical centre in central London, a treatment clinic in South London, and an alcohol 
treatment centre (where one client out of opiate substitution treatment was attending 
for key-work sessions through an alcohol treatment requirement; ATR) in South 
London. Throughout, it was made clear that participation would be kept anonymous, 
was confidential, and voluntary. 
 
3.2.16. Recruitment procedure 
 
Patients were those who participated in the UK RIOTT trial during 2005-2008. The 
intention was to recruit a sample of those from the RIOTT trial for the purposes of 
retrospective qualitative interviews on their perceptions and experiences, both prior 
to, during, and post their time on the IOT trial. Ethical approval was sought from May 
– July 2013 and recruitment for the qualitative study began at the end of July 2013 
and ended in January 2014. The PhD candidate was the only researcher recruiting 
and interviewing participants for the study. 
By way of ethical legitimacy RIOTT lead clinicians contacted patients initially, and 
sought consent for the researcher to contact patients. Only once this consent was 
given did the researcher contact patients. Patients who were still in treatment were 
recruited from the respective clinics. In Brighton, the clinic (and RIOTT) lead 
consultant either telephoned or wrote to patients both in and out of treatment 
explaining the study. In this case patients could either send a second consent form 
back in the post stipulating that the researcher could make contact directly, or they 
could get in touch with the clinic to give this consent. Patients who were still in IOT 
were approached by their keyworker and invited to take part in the interview. The 
same process applied, whereby initial consent was gained for the researcher to then 
approach the patient directly. 
In London the recruitment procedure was the same, except patients had dispersed 
across a number of treatment centres in South East and central London by the time 
of recruitment, and recruitment took place mainly via keyworkers at each locality. 
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Ethical approval permitted the displaying of a poster in a number of treatment centres 
in South East London where former RIOTT patients were likely to have still been 
receiving treatment. Patients could then speak to their keyworker about participation 
and keyworkers made contact with the researcher to give consent for her to contact 
patients directly. Ethical approval also granted permission for the consultant in 
London to send out a flyer to patients who were no longer in treatment; they could 
then contact the researcher directly to consent to participation. 
In Darlington all patients had been discharged, following the closure of the IOT clinic 
at that locality by the time of recruitment and interviewing. These patients were 
transferred back on to oral methadone through a non-statutory treatment provider 
with charitable status (non-NHS). The researcher made contact with this provider and 
the manager at this clinic contacted all known RIOTT patients and recruited them to 
the study. The manager of this service then booked consenting patients in over the 
period of the week that the researcher spent at this locality. It was not possible to 
contact the patients at this locality who had dropped out of oral methadone treatment 
by the time of interview as there was no way for consent to be obtained. Therefore, 
in Darlington, only those still in OST were interviewed. 
All interviews were conducted in a private room of the respective treatment clinic and 
patients were reimbursed with a £20 store voucher for their time. Patients were 
informed that they would be reimbursed through a store voucher when they were 
recruited to the study and it is important to note that this may have influenced their 
decision to take part in the study. However, for ethical reasons it was important that 
patients were reimbursed for what could sometimes be a long research interview. 
Only two approached patients (across all three localities; one in London and one in 
Brighton) declined participation. When approached both participants said they would 
take part another time, but did not follow-up on this. One patient in Darlington who 
very much wished to participate got in touch too late – the researcher had left the 




3.3. Case note reviews 
 
To support and validate findings from study two, a case-note review of the research 
files of patients included in study two was conducted. These were conducted prior to 
interviewing so that they could be referred to during interviewing, for example, in 
reference to the patients’ treatment trajectory (highlighting which treatment drug 
patients were on at which point and to aid memory on topic areas, such as when illicit 
drug use ceased or reduced). Patients checked a particular box on the consent form 
to give permission for the case note review to be conducted prior to their interview. 
All patients in study two consented to this, and case note reviews for each patient 
appear in the appendix. Case note reviews include patient pseudonym and ID, for 
easy referral back to qualitative quotes in the qualitative chapters. The case note 
reviews address objective 12 and provide context for the findings of study two.  




Interviews lasted between 25 and 90 minutes, with most interviews taking 45 minutes 
– one hour. Interviews were conducted in a private room in clinics where patients 
either received care or had previously received care. These were usually prescribing 
clinics, in some cases drug and alcohol treatment services, and in one case a GP 
medical centre. 
 
3.5. Confidentiality and anonymity 
 
All interviews were conducted by the PhD candidate. Aside from when she explained 
the study to potential participants, the researcher had never previously met the 
participants. This was felt to be an advantage and the researcher emphasised her 
lack of connection to the RIOTT trial and current treatment service. The researcher 
emphasised that she was not part of the research or clinical team and that all 
responses would be kept in strictest confidence, and that only she would have access 
to recordings and transcripts – along with a professional transcriber who would 
transcribe anonymised interviews. It was emphasised that these recordings would not 
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be linked to patient names and that all names would be replaced with a pseudonym 
in any academic or professional reports derived from the interviews. Honest and open 
responding was important for the research, and this point was emphasised to 
patients. It was felt by the researcher that the fact that recollections were retrospective 
allowed the participants to feel more comfortable about speaking openly and honestly 
about their experiences of the treatment programme.  
The researcher has worked in the addictions field for ten years, including in both a 
research and in an assistant clinical psychologist capacity, and has received 
academic training in motivational interviewing. The researcher met with the academic 
supervisors at regular intervals during data collection and analysis to review and 
discuss the design of the interview schedule and the data collected. Supervisors were 
RIOTT trial Principle Investigator (JS) and Trial Coordinator (NM), both academic 
supervisors for the PhD thesis, along with the third academic supervisor (TW) who 
was particularly experienced in both the fields of addiction and qualitative research. 
The supervisors and site clinicians also inputted into design of the interview schedule, 
to include questions derived from clinical observation as well as the evidence base. 
NM and TW triangulated (multiple observer triangulation) the analysis phase by 
reading and coding participant transcripts to ensure that interpretations were in 




The researcher informed the site clinician, clinic receptionist, and nurses on duty who 
she would be interviewing, when and where. Interview rooms had panic buttons in 
case of emergency, though there was never a problem during interviewing for this 
study. One patient in Darlington seemed quite intoxicated during the interview, and 
his keyworker was aware of this. He was able to engage with the interview and answer 
the questions however. Generally speaking, if there were any concerns the 





3.7. Managing disclosure  
 
Patients were informed that everything they spoke about during interviews would be 
held in confidence, that only the researcher had access to recordings, and all 
transcripts and quotes would be anonymised and labelled with pseudonyms. The 
researcher made clear that the only time confidentiality would be broken would be if 
the patient mentioned that they wished to harm themselves or another person, or if 
they or another person were at risk in some way. 
 
3.8. Data security 
 
Anonymised transcripts and recordings were stored on a password protected King’s 
College London computer and will be destroyed in line with ethics committee 
requirements at the appropriate time following PhD submission and publication of 
research papers. This data is stored in an office requiring swipe card access.  
 
3.9. Analytic method 
 
The research design is qualitative, its methodology phenomenological, and its 
analytic method is thematic analysis. 
 
3.9.1. Theoretical account of data analysis approach 
 
As outlined in the ‘Position of the interviewer’ (section 3.2.10. in the Methods chapter), 
qualitative methods take a critical stance toward knowledge, and recognise the 
influence of history and culture and appreciate how such knowledge is constructed 
inter-subjectively (Davidsen, 2013). 
Phenomenology is the study of structures of consciousness, as experienced from the 
first-person point of view (Woodruff-Smith, 2013). The phenomenological 
methodology aims to describe, understand and interpret the meanings of experiences 
of human life (Bloor and Wood, 2006). It focuses on research questions such as what 
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it is like to experience a particular situation (Bloor and Wood, 2006). As a concept, 
‘phenomenology’ attempts to clarify a way of viewing human beings and their lives, 
which identifies the essential uniqueness of the human experience (McPhail, 1995). 
In order to develop a conceptual framework for the concept of phenomenology, 
Husserl drew on the Kantian distinction between ‘noumenon’ and phenomenon 
(McPhail, 1995). Husserl argued that there are two kinds of reality: (1) ‘noumenon’ – 
that is, being in reality itself and (2) phenomenon – the appearance of reality in 
consciousness (McPhail, 1995). According to the phenomenologists, explanation of 
the mechanisms of ‘noumena’ seemed the appropriate subject for the natural 
sciences, and the description of phenomena should be the focus of study in the 
human sciences (McPhail, 1995). Using phenomenological methods, focus is on rich 
description of some aspects of contextualised experience, described through 
language (Davidsen, 2013). Qualitative research recognises that descriptions of 
phenomena are unavoidably conditioned by interpersonal, social and cultural 
eventualities, and that theory and method must therefore be combined (Davidsen, 
2013). 
Phenomenology intends to turn towards the topic itself, whilst releasing itself from 
pre-existing prejudices (Speilberg, 1978), but in a reflexive way (Toombs, 1992). In 
the present study the researcher states her experience, perspective and standpoint 
(in the ‘Researcher reflections’ section on page 344) and held them in mind 
throughout the process of data collection and analysis. Phenomenology also 
encompasses a scientific approach to subjectivity (Natanson, 1974). Braun and 
Clarke (2006) argue that a realist view of qualitative research where researchers can 
simply “give voice” (Fine, 2002) to their participants is naive. Braun and Clarke (2006) 
highlight that as Fine (2002: 218) describes, even a “giving voice” approach “involves 
carving out unacknowledged pieces of narrative evidence that are selected, edited, 
and deployed to border the arguments”. During qualitative interviewing and analysis 
for the current study the researcher remained mindful of this perhaps unconscious 
tendency to select and edit narratives, and aimed to present accounts as objectively 
as one is able to in the process of qualitative analysis. The aim was to represent both 
the convergent and divergent views, perspectives and experiences, whilst illustrating 
patterns across the entire data set (University of Auckland, 2016). The aim of 
phenomenological qualitative research is to examine experiences and meanings and 
to illustrate as closely as is possible, the way in which phenomena is experienced 
within its context (Georgi and Georgi, 2003). 
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As with the Oviedo-Joekes (2014) North American qualitative study of experiences of 
IOT (which also employs use of thematic analysis as its analytic method), a 
phenomenological theoretical framework was employed. This study design was most 
appropriate for providing a rich description of the meaning and significance of both 
participants’ pre-IOT experiences and judgements, and the treatments received 
(Oviedo-Joekes, 2014), during the clinical trial, the pragmatic trial, and experiences 
of IOT, and other treatment following RIOTT. 
 
3.9.2. Thematic analysis 
 
Thematic analysis may be underpinned by phenomenology (University of Auckland, 
2016). Heidegger (1967) made the important point that interpretation cannot be 
avoided and that all descriptions necessarily involve interpretation. Thematic analysis 
focusses on the subjective human experience and aims to illustrate participants’ 
feelings, perceptions and experiences.  
Thematic analysis is a process of identifying themes that arise as being important to 
the description of the phenomenon (Daly, Kellehear, and Gliksman, 1997). The 
process involves the identification of themes through “careful reading and re-reading 
of the data” (Rice and Ezzy, 1999, p. 258). It is a form of pattern recognition within 
the data, where emerging themes develop into categories for analysis (Fereday and 
Muir-Cochrane, 2006). It minimally consolidates and describes the data set in rich 
detail. However, it also often goes further than this, and interprets various aspects of 
the research subject (Boyatzis 1998; Braun and Clarke, 2006). Of importance to 
phenomenology, Braun and Clarke (2006) emphasise the active role of the 
researcher in identifying and analysing themes in qualitative research that uses a 
thematic methodology. 
One of the benefits of thematic analysis is its flexibility. Qualitative analytic methods 
encompass both those that are tied to, or stem from, a particular theoretical or 
epistemological position, as well as those that are essentially independent of theory 
and epistemology, and can be applied across a range of theoretical and 
epistemological approaches (Braun and Clarke, 2006). The latter applies to thematic 
analysis. Through its theoretical freedom, thematic analysis provides a flexible and 
useful research tool, which can potentially provide a rich and detailed, yet complex 
account of data (Braun and Clarke, 2006). In contrast to thematic analysis, 
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Interpretative Phenomenological Analysis (Smith, 1996) is a phenomenologically 
based qualitative method, but one that necessitates a focus on the unique 
characteristics of individual participants (University of Auckland, 2016). This might not 
have been pertinent to this slightly less homogenous sample of participants – as 
chapter four illustrates – whose location, trajectory and current situation was rather 
varied, despite the homogeneity of all having, at some point during the RIOTT trial’s 
operation, undertaken IOT. 
The Braun and Clarke (2006) guidelines were used for analysis of the data and will 
be discussed in detail. 
 
3.10. Step-by-step process of conducting the thematic analysis 
 
The step-by-step process of conducting the thematic analysis is in appendix 2. 
 
3.11. Study strengths and limitations 
 
The study benefits from a retrospective methodology, therefore, the entire treatment 
trajectory is explored and outlined. The researcher was completely independent to 
the IOT clinical and research team, and it is proposed that this was beneficial for 
gaining trust and eliciting open and honest responding. The researcher had never 
previously met patients and the researcher remained consistent across all 41 
interviews. Research interviews were conducted a number of years following data 
collection for the IOT trial, and therefore participants were not at danger from suffering 
from research fatigue. In the main, participants seemed keen to share their 
experiences with the researcher, and were given at least a few days to decide if they 
wished to take part in the research. This allowed space and time for participants to 
reflect on their experiences of IOT. It is proposed that this methodology elicited rich 
and detailed interview data. 
Study limitations include the fact that numbers of patients from the Darlington clinic 
were low, with a fewer number of patients remaining in treatment at this locality and 
a higher DNA rate for those attending research interviews. This is likely because 
these patients were less motivated to take part, since they had experienced IOT clinic 
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closure, and those who could be contacted and invited to take part in a research 
interview were back on oral methadone treatment. It is likely that if a greater number 
of patients were recruited from this locality, responses across the dataset might be 
slightly different. An additional limitation was that study two was extremely time-
consuming, at both the stage of recruitment (in part due to the travel involved), and 
also analysis and write-up, due to the large number of patients included in the study 
and the length of the research interview – in some cases up to an hour. A further 
limitation is that interviews were conducted a number of years following patient 
experience of IOT, and therefore patients’ memories for events may not always be 
completely accurate. 
Finally, the original intention was to extract data from medical records for the case-
note reviews (which were useful during interviews, in cases where patients could not 
remember specific elements of their treatment trajectory – such as when they moved 
from one drug treatment to another; and which appear in the appendix), however due 
to time and budgetary constraints, this was not possible. Therefore, data included in 
the case note reviews are taken from the research files, and are less comprehensive 
(for example omit data on mental and physical health difficulties that may have 
occurred during treatment). 
 
3.12. Research ethical approval 
 
National NHS research ethical approval was sought and granted for the overall study. 
The research ethics committee was NRES Committee London – Dulwich. Local R&D 
approval was sought and granted in Brighton (Sussex NHS Partnership NHS 
Foundation Trust) and London (King’s College London and South London and 
Maudsley NHS Foundation Trust). Ethical approval was sought on the basis of clinics 
and clinicians contacting former RIOTT trial patients to inquire into consent for the 
researcher to contact them to invite them to take part in the qualitative interview study. 
At this initial stage the researcher did not make any direct contact with patients 
herself; this only occurred once patients had been briefed by clinical staff, and given 





Chapter 4 – Findings: A description of Injectable Opiate Treatment process 
and the effect of treatment duration on outcome 
 
The following chapter aims to describe treatment process and the effect of treatment 
duration on outcome for participants who took part in the RIOTT trial and subsequent 
long-term IOT. Specific objectives (1-5) are listed in the methodology chapter. 
 
4.1. Introduction to the chapter 
 
Following the six-month randomised phase of the RIOTT trial, all trial patients in the 
three supervised injecting clinics (in south London, Darlington and Brighton) 
continued to receive Supervised Injectable Heroin (SIH) or Supervised Injectable 
Methadone (SIM) treatment if clinically appropriate. The basis of this decision was the 
extent to which each patient had demonstrated a positive clinical response and had 
obtained significant benefit from SIH or SIM. Those patients who had not significantly 
benefited from treatment with SIH or SIM were transferred back to conventional 
therapies (OST such as oral methadone or buprenorphine treatment). Patients who 
had completed a period of optimised oral methadone treatment (OOM) during the trial 
and were not responding to this treatment were offered SIH or SIM, as recommended 
in the NTA 2003 Guidance Report (NTA, 2003). Where possible, patients were 
followed-up at 24 months and again at 36 months. Caution should be used when 
interpreting data due to small sample sizes. Missing data was prominent with fewer 
resources available for collection of research data at 24 months and 36 months 
across the three clinics. 
The following section describes data which were collected during the RIOTT trial and 
analysed by the PhD student. The aim of the chapter is to illustrate the trajectory of 
movement of patients who took part in the RIOTT trial, and in particular illustrate the 
complexity of movement undertaken by patients. This provides the context to the later 








The first sample includes N=127 who took part in the RIOTT trial. The second sample 
includes those who consented to be followed up for longitudinal analysis and who 
completed quantitative research interviews during the longitudinal data collection 
points. The later t-test analyses data comprises those who consented to follow-up 
and for whom there was research interview data available; additionally, these 
analyses are only of those who received SIH treatment during the RIOTT trial. 
 
4.2.2. Flowcharts of patient movement 
 
Patients were assigned to one of three treatment groups and subsequent patient 
movement is chronicled using flowcharts, in order to illustrate patients’ complex 
treatment trajectory. The following flowcharts illustrate the frequency of movement 
from one treatment group to another over the three years that patients were observed 
during the RIOTT trial. Unknown data includes incidences of missing data (data was 
missing from the research files). Why data was missing was not always known as the 
PhD student was conducting secondary analyses on data collected during RIOTT, 
rather than data she had collected herself, for all quantitative analyses. The flowcharts 
illustrate the trajectory of movement for patients assigned to Optimised Oral 
Methadone (OOM), Supervised Injectable Methadone (SIM) and Supervised 

































Between baseline and 6 
months:
30 continue in OOM;
5 move from OOM to 
DNA/missing data.
Between 12 and 18 
months:
3 OOM  remain on OOM;
1 OOM moves to SIH;
14 SIH remain on SIH;
1 SIM moves to SIH;
1 SIM remains on SIM;
2 SIH DNA/missing data;
16 DNA remain missing/
DNA;
4 OOM DNA/missing 
data.
Between 18 and 24 
months:
3 OOM remain on OOM;
15 SIH remain on SIH;
1 SIM remained on SIM;
1 SIH moves to OM;
2 DNA are on SIH;
10 DNA are on OM;
10 DNA/missing remain 
DNA/missing.
Between 24 months and 36 
months:
6 OST remain in OST;
10 SIH remain in SIH;
1 OM becomes abstinent;
1 SIM moves to OST;
2 SIH move to OST;
5 SIH are missing/DNA;
1 DNA is OST;
7 OST are DNA/missing;
9 DNA/missing remain DNA/
missing. 
Between 6 and 12 
months: 
7 OOM remain on OOM;
16 OOM move to SIH;
2 OOM move to SIM;
1 DNA is OM;
5 OOM DNA;































































Between baseline and 6 
months: 
38 assigned to SIH 
remain in SIH; 
1 moves from SIH to 
OST;
4 assigned to SIH at 
baseline have missing 
data or DNA at 6 months.
Between 12 and 18 
months: 
28 continue on SIH; 
2 move from SIH to OST; 
2 move from OST to 
DNA; 
7 DNAs remain DNAs at 
12 months;
2 move from SIH to DNA; 
2 on OST at 12 months 
remain on OST.
Between 18 and 24 
months:
23 continue on SIH;
2 continue on OST;
4 move from SIH to OST;
2 DNAs are in SIH;
1 OST DNAs;
6 DNAs are on OST;
1 DNA reaches 
abstinence;
2 DNAs remain DNAs;
1 OST & 1 SIH die.
Between 24 months and 36 
months: 
19 continue on SIH;
2 move from OST to SIH;
2 patients are deceased;
1 moves from SIH to OST;
5 remain on OST;
1 DNA is on OST;
5 from SIH are discharged;
1 abstinent is discharged;
5 on OST DNA;
2 DNAs are discharged.
Between 6 and 12 
months: 
32 on SIH at 6 months 
continue on SIH at 12 
months; 
1 on OST at 6 months 
continues on OST at 12 
months;
3 move to OST;
4 with missing data/DNA 
remain missing data/DNA 
at 12 months; 3 on SIH are 









Figure 3. Trajectory of movement through the 36-month treatment programme amongst those assigned to the supervised injectable heroin (SIH) 





































Between baseline and 6 
months: 
35 SIM continue on SIM;
3 SIM move to OST;
4 DNA/have missing 
data.
Between 12 and 18 
months: 
7 SIM remain on SIM;
10 SIH remain on SIH;
1 SIH moves to SIM;
2 SIH move to OST;
7 OST remain on OST;
3 SIH DNA/missing data;
12 DNA remain DNA.
Between 18 and 24 
months:
7 SIM remain on SIM;
1 OST moves to SIM;
8 SIH continue on SIH;
8 OST remain on OST;
8 DNAs are on OST;
1 SIH moves to OST;
2 DNAs are on SIM;
1 DNA is on SIH;
1 SIM DNA/missing;
1 SIH DNA/missing;
4 DNA remain DNA.
Between 24 months and 36 
months: 
1 SIM remained on SIM;
3 SIM moved to SIH;
6 SIH remained in SIH;
2 SIM moved to OST;
13 OST remained in OST;




4 DNA remained DNA.
Between 6 and 12 
months: 
7 SIM remain on SIM;
16 on SIM move to 
SIH;
6 SIM move to OST;
1 DNA is on OST;
6 SIM DNA;
3 OST DNA;














Figure 4. Trajectory of movement through the 36-month treatment programme amongst those assigned to the supervised injectable methadone (SIM) 
treatment group  
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4.2.3. Describing the longitudinal IOT trajectory 
 
The first flow chart maps the trajectory of movement of those assigned to the oral 
methadone treatment group. The table below outlines treatment status for these 
patients at 24 months and 36 months. Further analyses were not conducted on those 
who remained in OOM at 24 months and 36 months, as the thesis focusses on those 
patients who received injectable opiate treatment only. The second section of the 
chapter describes the various outcomes of all those patients receiving longitudinal 
injectable opiate treatment. 
 
4.2.4. Outcome measures 
Outcome measures include the following. 
1. Heroin use status – self-report (use in the last 30 days; yes or no); 
2. Crack use status – self-report (use in the last 30 days; yes or no); 
3. Alcohol use status – self-report (use in the last 30 days; yes or no); 
4. Mean daily dose of SIH – collected by RIOTT researchers and research 
nurses and abstracted from research files by the PhD candidate; 
5. Mean daily dose of Oral Methadone – as above; 
6. Crime status – self-report (crime committed in the last 30 days; yes or no); 
7. Alcohol use status – self-report (use in the last 30 days; yes or no) 
8. Short Form 36 (which is a generic quality of life measure utilised in health 
populations) – self-report mental health and physical health sub-scores; 





4.2.5. Optimised Oral Methadone 
 
Overall status at 24 and 36 months for the Optimised Oral Methadone (OOM) 
treatment group. 




 36 months  
Drug treatment status N Percent N Percent 
SIH 17 40 10 24 
OM 14 33 10 24 
Detoxed/drug free   1 2 
Prison 1 2   
Did not start 7 17 7 17 
Missing 2 5 14 33 
Total 42 100 42 100 
 
Forty-two patients were assigned to oral methadone treatment. Seven patients did 
not start treatment and 35 remained on OOM. Between baseline and six months 30 
patients remained on OOM, and a further five did not attend. This meant that there 
were 12 with missing data by six months. Between six months and 12 months, seven 
remained on OOM, 16 more from OOM moved to SIH, two from OOM move to SIM, 
one DNA is on OOM, five OOM DNA, and 11 who were DNA at six months remain so 
by 12 months. By 12 months eight are on OOM, 16 are on SIH, two are on SIM, and 
16 have missing data. Between 12 and 18 months three remain on OOM, one OOM 
moves to SIH, 14 SIH remain on SIH, one SIM moves to SIH, one SIM remains on 
SIM, two SIH DNA, 16 DNA remain missing, four OOM are also DNA/missing. By 18 
months three remain on OOM, 16 are on SIH, one is on SIM and 22 are missing/DNA. 
Between 18 and 24 months, three OOM remain on OOM, 15 SIH remain on SIH, one 
SIM remains on SIM, one SIH moves to OOM, two DNA are on SIH, and 10 DNA are 
on OM, 10 DNA /missing remain so. By 24 months 14 are on OST, 17 are on SIH, 
one is on SIM, and 10 are missing/DNA. Between 24 and 36 months, six on OST 
remain on OST, 10 SIH remains on SIH, one OST becomes abstinent, one SIM 
moves to OST, two SIH move to OST, five SIH are missing, one DNA is on OST, 
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seven OST are missing, and nine DNA/missing remain so. By 36 months ten are on 
OST, one is abstinent, ten are on SIH, and 21 have been discharged. 
At 36 months one of the patients who had remained in OOM for 24 months was illicit 
drug and maintenance drug free at 36 months. It is noteworthy that this patient was 
drug free at 36 months and was still drug free at the time that recruitment for the 
qualitative study took place. He was not eligible for participation in the qualitative 
study since he did not undertake injectable treatment. 
 
4.2.6. Supervised Injectable Heroin 
 
These data pertain to those patients originally allocated to Supervised Injectable 
Heroin (SIH; n=43) and who were retained in SIH treatment at 24 and then 36 months. 
The first table outlines the 24 and 36-month status for those originally allocated to 
SIH. Where missing data occurs for a particular variable, this means that data was 
missing for a particular patient at that time point for the variable in question (for 
example, there may be drug treatment status data for participants at a given time 
point, but no dosage data). This may be the case when a patient is absent on a day 
that data was collected. Reasons for instances of missing data were often not 
recorded. The missing data likely reflects the realities of data collection within a 
longitudinal multi-site RCT, and also the fact that the data was not collected and 





4.2.7. Overall status at 24 and 36 months for the SIH treatment group 
Table 5. Drug treatment status at 24 and 36 months for those assigned to the SIH 
treatment group  
 24 
months 
 36 months  
Drug treatment status N Percent N Percent 
SIH 25 58 21 49 
OM 11 26   
MXL 1 2   
OST   7 16 
Buprenorphine 1 2   
Did not start 1 2 1 2 
Deceased 2 5 2 5 
Detoxed/drug free 2 5 1 2 
Discharged   6 14 
Missing data / unknown   5 12 
Total 43 100 43 100 
 
43 patients were assigned to SIH treatment. 42 started this treatment and one 
dropped out. Between baseline and six months, 38 continued on SIH, one moved to 
OST, and four were DNA/missing data. By six months, 38 are on SIH, four are 
missing/DNA, and one remains on OST. Between six months and 12 months 32 
remain on SIH, three move to OST, three are DNA/missing, one remains on OST 
and four remain missing/DNA. By 12 months 32 are on SIH, seven are missing and 
four are on OST. Between 12 months and 18 months 28 continue on SIH, two move 
to OST, and two are missing/DNA. Of the four from OST, two remain on OST, and 
two are missing/DNA. Of the seven who were missing/DNA at 12 months, all remain 
so by 18 months. At 18 months 28 are on SIH, 11 are missing/DNA, and four are on 
OST. Between 18 months and 24 months 23 continue on SIH, two continue on 
OST, four move from SIH to OST, two DNAs are on SIH, one OST DNA, six DNAs 
are on OST, one DNA reached abstinence, two DNA remain so, and one OST and 
one SIH are deceased. By 24 months 25 are on SIH, three are missing, 12 are on 
OST, one is abstinent and two are deceased. 
Between 24 months and 36 months, 19 continue on SIH, two move from OST to 
SIH, two patients are deceased, one moved from SIH to OST, five remain on OST, 
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one DNA is on OST, five from SIH are discharged, one abstinent at 24 months is 
discharged, five on OST DNA, and two previous DNAs discharge. By 36 months 21 
are on SIH, and five who were on SIH are discharged. Seven are on OST, and a 
further eight are discharged (meaning 13 in total have discharged). A total of two 
patients are deceased. 
 
Table 6. Mean daily (mg) dose of SIH at 24 and 36 months for those assigned to SIH 
treatment 
Heroin dose        
24 months    36 months    
Valid N Mean SD Min-
Max 
Valid N Mean SD Min-
Max 




       
24 months    36 months    
Valid N Mean SD Min-
Max 
Valid N Mean SD Min-
Max 
21 61.7 41.8 10-195 11 56.8 33.3 20-140 
 
The mean daily SIH dose at 24 months was 343mg and the mean daily 
supplementary oral methadone dose was 62mg. The mean daily SIH dose at 36 
months was lower, at 267mg; and the mean daily additional OM dose was also slightly 
lower at 57mg. 
 
Table 7. Number of patients attending the clinic once daily versus twice daily for 
injections at 24 months and 36 months 
24 
months 
  36 
months 
   
Valid N Once a day 
N (%) 
Twice a day 
N (%) 





25 11 (44) 14 (56) 21 9 (43) 7 (33) 5 (23) 
 
At 24 months there were a slightly higher percentage of participants attending the 
clinic twice a day for SIH injections than at 36 months, where there was a slightly 
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higher percentage attending once a day for injections. There was missing data on this 
variable at 36 months however. 
 
Table 8. Mean SIH dose (mg) at 24 months and 36 months for once a day and twice a 
day patients 
Once a day 
injection 
       
24 months    36 months    
N Mean SD Min-
Max 
N Mean SD Range 
11 202.7 52 80-270 9 139.4 69.5 55-250 
Twice a day 
injection 
       
24 months    36 months    
14 462.7 218.2 80-760 7 371.4 172.3 160-700 
        
 
Those attending the clinic for twice daily injections had almost double the daily dose 
of SIH compared to those attending the clinic once per day (203mg versus 463mg 
respectively), at 24 months. Both groups had reduced their daily dose by 36 months 
(by 64mg for the once daily group and 92mg for the twice daily group). 
 
Table 9. Mean additional OM dose (mg) at 24 months and 36 months for once a day and 
twice a day patients 
Once a day 
injection 
       
24 months    36 months    
N Mean SD Min-Max N Mean SD Range 




       
24 months    36 months    
N Mean SD Min-Max N Mean SD Min-Max 




The oral methadone dose had increased at 36 months (78mg) from 24 months (56mg) 
for the once a day injecting groups. The oral methadone dose had decreased from 
24 months (65mg) to 36 months (37mg). 
 









   

















  36 
months 
   

















  36 
months 
   












21 12 (48) 9 (36) 4 (16) 21 9 (43) 7 (33) 5 (24) 
 
Heroin use slightly increased from 24 months (4% using illicit heroin; 80% not using 
illicit heroin) to 36 months (19% using illicit heroin; and 57% not using illicit heron). 
Missing data remained around the same level at both time points. Crack use very 
slightly increased at 36 months (19%) compared to 24 months (12%), with missing 
data at roughly the same levels within and between groups. Alcohol use slightly 
decreased by 36 months (43%) compared to 24 months (48%).  
Table 11. Number of patients reporting criminal activity in the preceding 30 days 
24 
months 




   
















Crime rates increased by 36 months (with 19%) reporting crime, compared to (only 
4%) at 24 months. 
 
Table 12. Mean Quality of Life Score (SF36) at 24 and 36 months for those assigned to 
SIH 
24 months   36 months   














Mean 44.6 46.5 Mean 38.1 45.5 
SD 9.5 13.8 SD 16.1 14.8 
Min-Max 19-57 18-64 Min-Max 12-62 18-64 
NB. Higher scores denote better status 
Quality of life (mental health) was slightly higher at 24 months (M=45; SD=9.5) 
compared to 36 months (M=38; SD=16), with not much variation in physical health 
score from 24 months (M=46.5; SD=13.8) and 36 months (M=45.5; SD=14.8). 
 
Table 13. Mean social functioning score (OTI) at 24 and 36 months for those assigned 
to SIH 
24 months    36 months    
N Mean SD Min-Max N Mean SD Min-
Max 
24 14.25 5.8 4-28 17 12.8 4.8 3-24 
NB. Higher scores denote worse functioning 
Social functioning had improved by 36 months (M=13; SD=4.8) compared to 24 
months (M=14; SD=5.8). On this measure lower scores denote better status. It may 
be that this measure is more sensitive for use with an illicit drug using population, 







4.2.8. Supervised Injectable Methadone 
 
24-month data 
These data pertain to those patients originally allocated to Supervised Injectable 
Methadone (SIM) treatment (n=42). Of those originally allocated to SIM treatment four 
stratified SIM patients did not start treatment. This is slightly higher than those 
assigned to SIH – whereby only one patient dropped out of treatment. However, this 
is lower than those assigned to OOM, where seven patients dropped out following 
randomisation. The following describes data at 24 months only, since only one SIM 
patient remained in SIM at 36 months. 
 




 36 months  
Drug treatment status N Percent N Percent 
SIH 9 21 9 21.4 
SIM 10 24 1 2.1 
OM 17 40 17 40.5 
Did not start 4 10 4 10 
Missing 2 5 11 26 
Total 42 100 42 100 
 
42 patients were assigned to SIM treatment. 38 continue in SIM treatment and four 
DNA/are missing data. Between baseline and six months 35 continue on SIM, three 
move to OST, and four are DNA/missing. By six months 35 are on SIM, three are on 
OST, and four are DNA/missing. Between six and 12 months seven remain on SIM, 
16 move from SIM to SIH, six move from SIM to OST, one DNA is on OST, six move 
from SIM to DNA, three move from OST to DNA, and three DNA/missing at six months 
remain so by 12 months. By 12 months seven are on SIM, 16 are on SIH, seven are 
on OST and 12 are missing/DNA. Between 12 and 18 months seven remain on SIM, 
10 remain on SIH, one SIH moves to SIM, two SIH move to OST, seven on OST 
remain on OST, three SIH DNA/are missing and 12 DNA remain so. By 18 months, 
eight are on SIM, ten are on SIH, nine are on OST, and 15 are missing/DNA. Between 
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18 months and 24 months, seven remain on SIM, one OST moves to SIM, eight SIH 
continue on SIH, eight on OST remain on OST, eight DNAs are on OST, one SIH 
moves to OST, two DNAs are on SIM, one DNA is on SIH, one SIM is DNA/missing, 
one SIH is DNA/missing and four DNA remain so by 24 months. By 24 months, 10 
are on SIM, nine are on SIH, 17 are on OST and six are missing/DNA. 
 
Between 24 and 36 months, one SIM remains on SIM, three SIM move to SIH, six 
SIH remain in SIH, two SIM move to OST, 13 OST remain in OST, two DNA were on 
OST, four SIM DNA, three SIH DNA, four OST DNA and four DNA remain so. By 36 
months one is on SIM, four discharge from SIM, nine are on SIH, 17 are on OST and 
a further 11 discharge (a total of 15 are discharged by 36 months). 
  
 
Table 15. Mean daily dose of SIM at 24-months 
Daily SIM dose    
N Mean SD Min-Max 
6 88.3 38.7 30-150 
Daily additional OM 
dose 
   
N Mean SD Min-Max 
6 55 39.4 20-110 
 
The daily SIM dose was 88.3mg at 24 months and the additional OM dose was 55mg. 
 
Table 16. Number of SIM patients attending the clinic once daily versus twice daily for 
injections at 24-months 
Once a day N Twice a day N Missing data / unknown 
8 0 2 
 








      
N Yes % No % Missing data/ 
Unknown 
% 
10 4 40 2 20 4 40 
Crack use       
N Yes % No % Missing data/ 
Unknown 
% 
10 2 20 4 40 4 40 
Alcohol 
use 
      
N Yes % No % Missing data/ 
Unknown 
% 
10 3 30 3 30 4 40 
 
Table 18. Number of patients reporting criminal activity in the preceding 30 days 
N Yes No Missing data/ 
Unknown 
10 0 6 4 
 
No participants retained in SIM treatment for 24-months report criminal activity at 24 
months, however there was a relatively large amount of missing data. 
 
Table 19. Mean Quality of Life Score (SF36) at 24-months for those assigned to SIM 
N = 5 (missing N=4) Mental Component Score 
(MCS) 
Physical Component Score 
Mean 31.20 46.8 
SD 11.6 8 
Range 17-49 39-59 




Table 20. Mean social functioning score (Opiate Treatment Index; OTI) 
N Mean SD Min-Max 
6 19.5 4.1 15-25 








The previous section illustrates the complexity of movement amongst patients who 
undertook the three year RIOTT trial. The previous section outlines descriptive data 
for those patients who began in one of the injectable treatment conditions (either SIH 
or SIM) and who remained in their assigned treatment at 24 and 36 months. The 
following section aims to identify whether treatment episode length is associated with 
better outcome status amongst a sub-sample of those in the RIOTT trial; comprising 
those who ever received injectable heroin treatment during the RIOTT trial. Sample 
sizes for the following data are small, since there was a large degree of attrition from 
the RIOTT trial over time and research interviews were not comprehensively collected 
from all participants at the various data collection points. Since sample sizes for these 
data are small the intention is for the data to be descriptive only and illustrate patterns 
and trends that emerged as well as the complexity of movement over the three year 
RIOTT trial. These data provide the context for the later qualitative interview data with 





The sample relates to those who ever received injectable heroin treatment only. The 
following section includes data for those who consented to long-term follow-up, who 
remained in treatment at the various longitudinal data collection points, and for whom 
complete data was available (i.e., those who completed research interviews).  
 
4.3.3. Predictor variable 
 
Treatment episode may be several different episodes combined to form one period 
of time (e.g., a treatment period of six months, with a break for another treatment or 
time spent out of treatment, followed by another 12 months in treatment; hence 
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treatment episode is 18 months, for this patient). This variable differs to the different 
data collection points of relevance to the RIOTT trial – whereby data was collected at 
3 months, 6 months, 12 months, 18 months, 24 months and 36 months for each 
patient. The predictor variable here relates to how long the treatment episode is for 
the patient (e.g., those in treatment for 3 months in total, 12 months in total, and 36 
months in total). One patient may have several treatment episodes: one of 3 months, 
one of 6 months and one of 24 months, for example. Another patient may have only 




The prediction across all outcome variables (use of illicit heroin, use of crack, alcohol 
use, crime status, social functioning status, and quality of both physical and mental 
well-being) is two-sided; that the length of treatment duration will affect status or 
outcome.  
 
4.3.5. Outcome measures 
 
Outcome measures include the Opiate Treatment Index Social Functioning sub-scale 
and the SF36 quality of life scale (encompassing a mental health composite score 
and a physical health composite score). 
For the SF36 quality of life data (mental and physical well-being) higher scores 
indicate better status and for the Opiate Treatment (OTI) Index data lower scores 






Table 21. Illicit heroin use status in the context of heroin treatment episode length 
 
Length of heroin 
treatment episode 
Illicit heroin used N 
(%) 
 Total N (%) 
 Yes No  
Baseline (Not yet 
received) 
80 (100) 0 80 
3 months 26 (60.5) 17 (39.5) 43 
6 months 14 (38.9) 22 (61.1) 36 
9 months 2 (50) 2 (50) 4 
12 months 3 (15) 17 (85) 20 
18 months 2 (25) 6 (75) 8 
24 months 4 (16.7) 20 (83.3) 24 
30 months 1 (25) 3 (75) 4 
36 months 3 (27.3) 8 (72.7) 11 
 
Of those who had received heroin for a treatment episode length of three months (and 
for whom there was research data available for) 60% had used illicit heroin (in the 
preceding 30 days) and 40% had not. Of those with a treatment episode length of six 
months and for whom we had research data available for 38% had use illicit heroin 
and 61% had not. Of those who had a treatment episode length of nine months 50% 
had used illicit heroin and 50% had not. Of those with a treatment episode length of 
12 months (and for whom there was research data available) 15% used illicit heroin 
and 85% had not. Of those with a heroin treatment episode of 18 months 25% had 
used illicit heroin and 75% had not. A similar pattern continues, and of those with a 
treatment episode of 36 months 27% had used illicit heroin and 73% had not. This 
indicates that generally speaking heroin use decreased the longer patients remained 
in SIH treatment. There were fluctuations between those with a treatment episode of 





Table 22. Illicit crack use status in the context of heroin treatment episode length 
Length of heroin 
treatment episode 
Crack used N (%)  Total N (%) 
 Yes No  
Baseline (Not yet 
received) 
62 (77.5) 18 (22.5) 80 
3 months 27 (62.8) 16 (37.2) 43 
6 months 23 (63.9) 13 (36.1) 36 
9 months 2 (50) 2 (50) 4 
12 months 12 (60) 8 (40) 20 
15 months 1 (100) 0 1 
18 months 4 (50) 4 (50) 8 
21 months 0 2 (100) 2 
24 months 2 (8.7) 21 (91.3) 23 
30 months 2 (50) 2 (50) 4 
33 months 0 1 (100) 1 
36 months 2 (18.2) 9 (81.8) 11 
  
Crack use remained consistent over time, with meaningful reductions only occurring 













Table 23. Alcohol use status in the context of heroin treatment episode length 
Length of heroin 
treatment episode 
Alcohol used N (%)  Total N (%) 
 Yes No  
Baseline (Not yet 
received) 
42 (52.5) 38 (47.5) 80 
3 months 26 (60.5) 17 (39.5) 43 
6 months 19 (52.8) 17 (47.2) 36 
9 months 3 (75) 1 (25) 4 
12 months 9 (45) 11 (55) 20 
18 months 2 (28.6) 5 (71.4) 7 
24 months 10 (41.7) 14 (58.3) 24 
30 months 2 (66.7) 1 (33.3) 3 
36 months 7 (63.6) 4 (36.4) 11 
 
Overall the pattern indicated that there were two groups; those who used alcohol and 
those who did not. 
  
Table 24. Crime status in the context of heroin treatment episode length 
Length of heroin 
treatment episode 
Crime status N (%)  Total N (%) 
 Yes No  
Baseline (Not yet 
received) 
52 (65) 28 (35) 80 
3 months 14 (12.6) 29 (67.4) 43 
6 months 9 (25) 27 (75) 36 
12 months 2 (10.5) 17 (89.5) 19 
18 months 1 (12.5) 7 (87.5) 8 
24 months 2 (8.3) 22 (91.7) 24 
36 months 3 (27.3) 8 (72.7) 11 
 
Interestingly as well as crime status being highest before participants had received 




Table 25. Physical wellbeing (quality of life) in the context of heroin treatment episode 
length 
Length of heroin 
treatment episode 
Quality of life: 
Physical 
Component Score 
   
 N Mean SD Min-Max 
Baseline (Not yet 
received) 
84 45.9 11.3 19-70 
3 months 38 47.2 13 22-69 
6 months 36 49 12.2 22-67 
12 months 11 48.4 12.3 27-67 
15 months 1 32   
18 months 9 50 12.4 25-63 
21 months 2 41 32.5 18-64 
24 months 26 48.2 12.6 20-68 
30 months 4 47 9.4 33-53 
33 months 1 18   
36 months 9 46.7 13.2 20-60 

















Figure 5. Physical wellbeing (SF36) in the context of heroin treatment episode length 
status 
 
The graph illustrates that there was no noticeable change in quality of life (physical 
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Table 26. Mental wellbeing (quality of life) in the context of heroin treatment episode 
length 
Length of heroin 
treatment episode 
Quality of life: 
Mental 
Component Score 
   
 N Mean SD Min-Max 
Not yet received 84 35 12.9 6-64 
3 months 38 38.7 13 14-64 
6 months 36 41.2 12.2 10-61 
12 months 11 32.8 15.1 6-56 
15 months 1 15   
18 months 9 37 13.9 11-58 
21 months 2 31 17.7 19-44 
24 months 26 43.6 10.9 14-57 
30 months 4 40.5 13.2 27-58 
33 months 1 35   
36 months 9 42.9 16 12-62 
*A higher score denotes better status 
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The graph illustrates that there was a slight increase in mental wellbeing status score 
the longer participants had spent in heroin treatment. 
Table 27. Physical wellbeing (quality of life) in the context of heroin treatment episode 
length 
Length of heroin 
treatment episode 
Quality of life: 
Physical 
Component Score 
   
 N Mean SD Min-Max 
Not yet received 86 19.5 5.4 8-36 
3 months 44 17.8 5.9 6-31 
6 months 37 17.6 5.3 6-28 
9 months 3 13.7 2 12-16 
12 months 18 15.5 6.1 6-28 
18 months 9 16.1 5.3 9-24 
21 months 2 13 1.4 12-14 
24 months 27 13.3 4.9 4-25 
30 months 5 11.8 2.6 8-15 
33 months 1 10   
36 months 13 11.9 4.3 3-20 
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Once again there was an increase in social functioning status (lower scores denote 
better status on this measure hence the reversing of scores on the x axis). 
 
4.4. Paired samples T-tests examining length of treatment episode on outcome 
status 
 
Following descriptive illustration of mean scores - as illustrated above - further 
analyses (using t-tests) examined differences between mean baseline (OTI and 
SF36) scores, and scores at the respective longitudinal time points - length of 
treatment episode: 3 months, 6 months, 12 months, 18 months, 24 months and 36 
months. It should be noted that t-tests analyses will only include participants for whom 
we have complete questionnaire data for and patients who have remained in 
treatment for the entire duration for which the analyses apply to (for example, they 
have remained in treatment from baseline through to three months, or from baseline 
through to six months, et cetera). The T-test data is within-subjects’ (those who are 
in SIH treatment at baseline, and have remained so at the longitudinal data collection 
point) data, and the previous analysis of means is between-subjects (each participant 
has been classified according to their treatment episode length). Previous tables of 
means (tables 21-27) include all participants who have a treatment episode of the 
respective time stated (e.g., three months), therefore will include those who may have 
left and re-entered treatment, yet their overall treatment episode length is the time 
stated. Hence sample sizes and mean scores differ slightly different in some cases 
(tables 28-30 have slightly smaller sample sizes, beyond the three-month episode 
length as only includes those who have remained in treatment consistently over time, 
rather than dropping out and re-entering as per some participants included in tables 
21-27). These analyses are illustrated in tables 28-30 and discussed in section 4.4.1 
below. 
It is cautioned that due to the complicated nature of movement across treatment 
conditions, and the need for the creation of a treatment episode length variable 
(encompassing all participants with that treatment episode length in tables 21-27 and 
only those who have remained consistently in treatment over time in tables 28-30), 
these data are illustrative only - to indicate movement and trends of improvement over 
time - rather than statistically conclusive.
164 
 
Table 28. Comparing baseline mental health scores (using the SF36 quality of life measure) to mental health scores over time 
SF36 Mental 
health status 
Baseline - 3 
months 
Baseline – 6 
months 
Baseline – 12 
months 
Baseline – 18 
months 
Baseline – 24 
months 
Baseline – 36 
months 
N 38 34 7 7 24 9 
Mean (SD) 36 
(11.2) 




















SE 1.8 2.1 1.9 2.3 6 5.6 19.9 14.6 2.5 2.2 4.9 5.3 



























2.7 (13.6) 4.9 (15.2) -4 (22.5) 6.14 (11.7) 5.3 (18.8) 3.9 (26.5) 
95% CI -1.7 – 7.2 -.4 - 10.2 -24.8 – 16.8 -4.7 – 17 -2.6 – 13.3 -16.5 - 24.3 
SE 2.2 2.6 8.5 4.4 3.8 8.8 
T, df, p t(37)=1.2. p=0.2 
(ns) 






**Significant at the 0.10 level (i.e., approaching significance).
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Table 29. Comparing baseline physical health scores (using the SF36 quality of life measure) to physical health scores following over time 
SF36 physical 
health status 
Baseline - 3 
months 
Baseline – 6 
months 
Baseline – 12 
months 
Baseline – 18 
months 
Baseline – 24 
months 
Baseline – 36 
months 
N 38 34 7 7 24 9 




















SE 1.7 2.1 1.8 2 4.3 4.4 2.6 3.4 2.5 2.5 3.6 4.4 



























2.6 (11.7) 5.2 (10) -2.7 (15.8) 5.6 (4.5) 2.4 (14) 0.3 
SE 1.9 1.7 6 1.7 2.9 2.5 
95% CI -1.2 – 6.5 1.7 – 8.7 -17.3 – 11.9 1.4 – 9.7 -3.5 – 8.4 -5.4 – 6.1 




t(6)= -0.4, p=0.7 
(ns) 
t(6)=3.3, p=0.02* t(23)=0.8, p=0.4 
(ns) 
t(8)=0.1, p=0.9 (ns) 
*Significant at the <0.05 level
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Baseline - 3 
months 
Baseline – 6 
months 
Baseline – 12 
months 
Baseline – 18 
months 
Baseline – 24 
months 
Baseline – 36 
months 
N 44 36 15 8 26 13 




















16.7 (6) 12 
(4.3) 
SE 0.8 0.9 1 0.9 1.6 1.5 2.7 1.9 1.1 1 1.7 1.2 


























0.8 (5.8) 1.6 (5.6) 5.4 (8.2) 5.9 (9.7) 5 (7.9) 4.8 (7.8) 
SE 0.9 0.9 2.1 3.4 1.5 2.2 
95% CI -1.0 – 2.5 -0.3 – 3.5 0.8 - 10 -2.2 - 14 1.8 – 8.1 0.03 – 9.5 










*Lower score denotes better status 
**Significant at the <0.10 level (i.e., approaching significance) 
***Significant at the <0.05 level 
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4.4.1. T-Test results 
 
The T-tests again illustrate the trend for status to improve the longer the treatment 
episode. There were statistically significant p-values across the following 
comparisons: 
The mental health status comparison approached significance: Baseline (M=36.6; 
SD=11) to six month (M=41.4; SD=13.5) comparison: t(33)=1.9; p=0.07. 
The physical health status variable was significant for the baseline (M=44.3; SD=10.7) 
to six month (M=49.6; SD=12) comparison: t(33)=3; p=0.005. 
The social functioning status variable was significant for the baseline (M=19.4; 
SD=6,2) to 12 month (M=17.8 SD=5.2) comparison: t(14)=2.5; p=0.02; the baseline 
(M=18.5; SD=5.6) to 24 month (M=12; SD=4.3) comparison: t(25)=3.2; p=0.005; and 
the baseline (M=16.7; SD=6) to 36 month (M=12; SD= 4.3) comparison: t(12)=2.2; 
p=0.05. 
 
4.5. Discussion of the results 
 
Overall the chapter addresses objectives 1-5: to determine the long-term trajectory of 
patients receiving IOT; to illustrate broad outcomes over 36 months for those 
receiving IOT; to determine the length of time patients receive IOT and whether they 
move away from IOT to oral treatment routes or abstinence; to determine treatment 
outcome (including drug use status; health status; social functioning status; and 
discharge status) of patients receiving IOT long-term; to describe IOT received 
(including mean daily dose; and number of injections received per day); and to 
determine whether IOT treatment duration affects treatment outcome status 
(including drug use status; alcohol use status; health status; and social functioning 
status).  
The first section of the chapter outlines descriptive data across both injectable 
treatment groups over the 36-month data collection period. This illustrates the 
complexity of movement by patients through the treatment trajectory. It illustrates that 
there are general trends of improvement; and that gains made by six months of 
treatment are sustained longer-term. The results of the T-tests show that there was a 
significant improvement in mental health quality of life score for comparisons of these 
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measures at six months, when compared to baseline. The t-tests also show a 
significant improvement in physical health status from baseline to six month 
comparisons, and significant improvements from baseline to various longitudinal 
episode durations for the social functioning scale. It appears that the OTI social 
functioning scale may be more sensitive to detect meaningful changes in an illicit drug 
using population than the SF36 quality of life surveys. 
One of the central findings of this chapter is that a large number of patients from both 
the SIM (N=16) and the OOM (N=16) groups moved onto SIH treatment as soon as 
they were able to (between six months and 12-months of the trial). The fact that 
patients remain in their assigned condition until this point and then move to SIH is 
very interesting and has implication for research examining factors affecting retention 
to treatment. From this data it is clear that simply the promise of SIH was a strong 
motivator to keep patients engaged with treatment. It could be argued that remaining 
in treatment for the initial six months of the trial (albeit in a less appealing treatment) 
may have had a positive effect on participants’ engagement with the treatment 
process, and benefitted overall outcome. This is very useful information for the 
research field, and accords to some degree with the contingency 
management/incentives for sobriety literature. Contingency management is the 
systematic reinforcement of desired behaviours, and the withholding of reinforcement 
or punishment of undesired behaviours, and is found to be an effective strategy in the 
treatment of alcohol and other drug use disorders (Higgins and Petry, 1999). When 
the motivation is strong enough and the reward reinforcing enough, participants are 
able to remain in their treatment programmes. This is in the context of 32 (of the 
original 43 in this condition) patients who were originally assigned to SIH treatment, 
remaining in this treatment during the six and twelve-month data collection points. 
Once again, this is a very important finding. Patients are clearly very motivated by 
SIH, to remain in their assigned treatment long-term, and for others in other 
treatments to continue in their assigned treatment until the point at which they are 
able to move to SIH. The promise of SIH at a later date appeared to be a hugely 
motivating factor to treatment retention for patients, and thereby, likely overall 
wellbeing and eventual recovery. 
It is noteworthy that one patient assigned to OOM remained abstinent from illicit and 
maintenance medication from 24 months onwards – until the time of qualitative 
interviews, which was a number of years later. The researcher spoke to this patient 
on the phone during recruitment to the qualitative study. Unfortunately he was not 
eligible to be interviewed for the qualitative study, since he did not undertake 
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injectable treatment at all during the RIOTT trial. Further research may wish to 
examine with patients, their perspectives on why optimised oral methadone treatment 
is more effective than oral methadone treatment, or why this treatment was 
successful, when in the past methadone had not been. Whilst it is very interesting to 
view the trajectory and complexity of movement amongst patients undertaking the 
IOT trial, this quantitative mapping does not outline the reasons why patients moved 
when they did. This will be explored to some degree in later chapters through 
qualitative interviewing with patients. The chapter usefully provides the context for 
which the experience of IOT can be explored with patients directly, through qualitative 
interviewing. 
Overall, due to the complicated nature of the treatment trial (i.e., whereby patients 
frequently moved from one treatment to another over the 36-month period of 
observation) the quantitative analysis does not yield additional information about 
longitudinal IOT. The quantitative chapter usefully illustrates and describes the 
sample’s activity and movement during IOT, and highlights the need for qualitative 






Chapter 5 – Injectable Opiate Treatment patient typologies 
 
The following chapter describes the formation of patient typologies for those taking 
part in the qualitative research, detailed in the subsequent six chapters of findings. 
Patients are those who were assigned to receive six months of specified treatment 
(either SIH, SIM, OOM) and who could then move to other treatment modalities, 
following appropriate clinical review. The trajectory was different for different patients; 
with some, for example, beginning their treatment trajectory on SIM treatment, moving 
to SIH at 6 months and then moving to Slow Release Oral Morphine (MXL) or oral 
methadone at 24 or 36 months. Another patient, for example, may have begun on 
SIH treatment and remained on SIH for a period of 36 months, and then in the years 
beyond, right up until the point he or she was interviewed.  
Of particular pertinence to the patient qualitative data and analysis was the 
conception of a patient typology. The dataset for the qualitative patient data was 
analysed as a whole, using thematic analysis (as outlined). However, to view this data 
in the context of the patient’s overall trajectory, typologies were created and are 
identified for each patient that is subsequently quoted. The following section outlines 
how these typologies were formed in more detail (in type and number) and highlights 
each patient’s overall typology designation. Analysis of qualitative data was 
interpreted in the context of the patient’s typology (that is, what treatment they were 
assigned to at referral to IOT, and whether their discharge status was positive: i.e., 
voluntary; negative: compulsory; or ongoing: long-term IOT). All patients interviewed 
were those who had, at some point over the 36-month trial period, received injectable 
treatment. 
 













N=13 N=8 N=3 N=4 N=13 N=41 
 
Positive discharge status included voluntary movement to other treatment types – 
such as oral methadone (OM) and MXL), and voluntary movement to residential 
detox. This also included patients who declined the offer of SIH treatment at six 
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months, and either stayed on OOM or SIM or moved on to SIM or OOM instead. 
Negative discharge status included being ejected from treatment – such as for 
protocol violations (for example, attempting to take medication home or hostile 
behaviour), or illicit use (including benzodiazepines, heroin and crack). 
Those categorised as ‘discharge other’ included patients who were sent to prison, 
hospitalised for other (unrelated to trial medication) health conditions, or who 
experienced adverse reactions during IOT. A full table of patient trajectories is 
illustrated in table 35 which demonstrates on what basis typologies were created. 
Typologies were created in collaboration with academic supervisors, one of whom 
was trial coordinator for the RIOTT trial, to ensure clinical meaningfulness of this 
process. Within all subsequent qualitative chapters, typologies will be indicated for 
each patient in analysis and write-up. This allows interpretation of findings in relation 
to the specific treatments patients received, and interpretations can be made in the 
context of the treatment trajectory. This procedure is in congruence with the aim of 
the thesis (to describe the long-term treatment trajectory of these patients). 
Clinic closure applied to patients in long-term treatment in Darlington who were 
compulsorily moved back on to OM following the Darlington IOT clinic closure. Long-
term SIH included those patients still in SIH treatment at the time of interview (in some 
cases for up to seven years). In the present day these patients will no longer be in 
SIH, following recent (March 2015) closure of all IOT clinics at the three sites, yet they 
were maintained in IOT at the time of interview (August 2013 – January 2014). 
Table 32. Participants by discharge status for those originally assigned to SIH 
treatment (N=16) 
Positive discharge status (N=7) Clinic closure (N=3) Long-term SIH (N=5) 
Jack (ID 2) Robert (ID 28) Ben (ID 15) 
Charlie (ID 3) Wes (ID 31) Oliver (ID 16) 
Serina (ID 6) Kevin (ID 33) Gerry (ID 20) 
Tom (ID 9)  Lee (ID 36) 
Nicholas (ID 14)  Josh (ID 41) 
Pam (ID 19)   
Ellie (ID 22)   
NB. There were no ‘Negative (other)’ statuses in this treatment group. 
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Stacy (ID 6) Matthew (ID 17) Daniella (ID 1) Wayne (ID 1) Sammy (ID 11) 
Harry (ID 8) Euan (ID 38) Jacob (ID 4)  Fran (ID 13) 
Iain (ID 25) Rita (ID 29) Clara (ID 7)  Shane (ID 21) 
Elena (ID 37) Richard (ID 34)   Ron (ID 27) 
Cheryl (ID 40)     
 






Clinic closure (N=0) Long-term SIH (N=4) 
Andy (ID 23) Luke (ID 18)  Fay (ID 10) 
 Trevor (ID 24)  Reg (ID 12) 
 Jason (ID 26)  Scott (35) 
 Susie (ID 32)  Patrick (ID 39) 
    
    
NB. There were no ‘Negative (other)’ statuses in this treatment group. 
Overall there were 13 different patient typologies: 
1. Positive discharge; SIH 
2. Positive discharge; SIM 
3. Positive discharge; OM 
4. Negative discharge; SIH 
5. Negative discharge; SIM 
6. Negative discharge; OM 
7. Negative discharge (other); SIM 
8. Discharge clinic closure; SIH 
9. Discharge clinic closure; SIM 
10. Discharge clinic closure; OM 
11. Long-term IOT; SIH 
12. Long-term IOT; SIM 
13. Long-term IOT: OM
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Jack (ID 2) M 
 
41 
Brighton SIH SIH 
Voluntary 
detox 
























Jacob (ID 4) M 
 
46 












Stacy (ID 5) F 
 
35 
Brighton SIM SIM 
Voluntary 
detox 








Serina (ID 6) F 
 
37 
Brighton SIH SIH 
Voluntary 
move to OM 







Clara (ID 7) F 
 







Harry (ID 8) M 
 
50 
London SIM Both 
Voluntary 
move to OM 








Tom (ID 9) M 
 
47 Brighton SIH SIH 
Voluntary 
detox 
Buprenorphine 36     6 years Responder 
Positive 
Fay (ID 10) F 
 
43 
























Reg (ID 12)  M 
 
57 








Fran (ID 13) F 
 
46 













London SIH SIH 
Voluntary 
move to OM 







Ben (ID 15) M 
 
47 







































Luke (ID 18) M 
 
 













Pam (ID 19) F 
 
48 





































Ellie (ID 22) F 
 
41 











Andy (ID 23) M 
 
38 





























Iain (ID 25) M 
 
 
49 London SIM SIM 
Voluntary 
move to OM 
(declined 
SIH) 



























Ron (ID 27) M 
 
49 













Darlington SIH SIH 
IOT clinic 
closure 













54 Darlington SIM SIH 
Discharged 


















Darlington SIM SIM 
IOT clinic 
closure 









Wes (ID 31)  M 
 
39 
Darlington SIH SIH 
IOT clinic 
closure 


























Kevin (33) M 
 
40 
Darlington SIH SIH 
IOT clinic 
closure 



























Scott (35) M 
 
43 








Lee (36) M 
 
50 








Elena (37) F 
 
51 
London SIM Both 
Progressed 
to MXL 







Euan (38) M 
 
47 








Patrick (39) M 
 
39 








Cheryl (40) F 
 
38 
London SIM SIM 
Voluntary 
move to OM 







Josh (41) M 
 
36 










Final typologies included for reference against all quotes outlined in the following six 
chapters of qualitative findings included: participants’ discharge status (positive 
discharge; negative discharge; long-term IOT, and clinic closure), and original 
treatment assignment (SIH, SIM, OM). 
 
5.1. Analysis and tabulation of qualitative themes by patient typology 
 
The original intention for the creation of typologies was to illustrate main similarities 
and differences (in themes) emerging across the typologies. However, following the 
analysis of themes by typology it was only in rare cases where a theme was not 
applicable to the majority – if not all – of the typologies, and where this was the case 
it was most often the clinic closures who did not fall under a particularly theme. The 
conclusion for this was that the clinic closures were a very small sub-sample, 
encompassing four patients in Darlington whose discharge status from IOT had been 
because the Darlington clinic had closed. It was decided that it was not useful to 
structure the qualitative findings according to typology, and that typologies would be 
referred to in the text of each section instead, where there was something that 
occurred that was possibly relevant to typology. 
The following section outlines main similarities and differences that were found across 
themes as a function of typology. The ‘Heroin use history’ chapter was not analysed 
by typology as this encompassed the period of time prior to participants entering IOT, 
and so not relevant to subsequent IOT typology. Referral to IOT, Experiences with 
IOT, Impact of IOT, Recovery, and Current situation and goals for the future were 
analysed according to typology. The following tables will assist interpretation of the 




5.1.2. ‘Referral to Injectable Opiate Treatment’ chapter themes tabulated by 
typology 
 
Table 36. ‘Referral to IOT’ chapter themes tabulated by typology 
















 Free heroin Long-term IOTs Clinic 
closures 
  Positive 
dischargers 
 
  Negative 
dischargers 
 
 Motivated by 
others 
All  









  Positive 
dischargers 
 








 Scepticism and 
resistance 
All  
Goals Stability and 
normality 
Long-term IOTs Negative 
dischargers 
  Positive 
dischargers 
 
  Clinic closures  
 Cessation and 




with the drugs 
subculture 
All  
 Improve family 
relationships 
Long-term IOT Positive 
dischargers 
  Negative 
Discharges 
 
  Clinic closures  
 Harm reduction Long-term IOTs Clinic 
closures 




 The absence of 




As is illustrated, free heroin was not a theme mentioned by the small sample of clinic 
closures, but this is likely due to the small sample size of this typological group. Sub-
theme IOT maintenance (within the ‘Expectations theme) was also experienced by all 
patients, aside from clinic closures. Long-term IOT’s had particular prominence in this 
sub-theme. Interestingly, the only typology not mentioning the desire for stability and 
normality (as part of the goals theme) were the negative dischargers. To ‘improve 
family relationships’ was a goal to all typologies, aside from positive dischargers. It is 
of note that the harm reduction typology is only of pertinence to long-term IOTs and 
positive dischargers. This is later discussed.  
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5.1.3. ‘Experiences with IOT’ chapter themes tabulated by typology 
 
Table 37. ‘Experiences with IOT’ chapter themes tabulated by typology 




















  Long-term IOT  
  Clinic closures  





aspects of SIH 
treatment 
All  
 Experiences with 









  Negative 
dischargers 
 
  Long-term IOT  
 Experiences with 






 Negative aspects 
of SIM treatment 
All  











  Negative 
dischargers 
 
  Clinic closures  







  Negative 
dischargers 
 
  Long-term IOTs  
Frequency of daily 
clinic attendance for 
supervised injecting 
Preference for 
once a day 
attendance 
Clinic closure Long-term 
IOTs 
  Positive discharger  
  Negative 
discharger 
 
 No objections to 
twice a day clinic 
attendance 
Clinic closure  
  Long-term IOTs  




Components of the 


































  Long-term IOTs Negative 
dischargers 
 Lack of autonomy 







  Long-term IOTs  









  Long-term IOTs Negative 
dischargers 
 Ambivalence about 
abstinence 
All  























  Positive 
dischargers 
 
  Clinic closures  
 
Positive experiences with SIH were reported by nearly all participants interviewed, 
including all typologies. In terms of comparing IOT to illicit heroin, only the negative 
dischargers did not make reference to this factor in their analysis of SIH. All 
typologies, aside from clinic closures, spoke about negative aspects of additional oral 
methadone doses. Positive comments about the intravenous route of administration 
was spoken about by all typologies aside from long-term IOTs. Negative comments 
about the intravenous route of administration occurred across all typologies aside 
from the clinic closures. In terms of preferences about the number of times required 
to attend the clinic for dosing, only the long-term IOTs did not express a preference 
for once a day dosing. Those with no objections to twice a day injecting included clinic 
closures and long-term IOTs, indicating flexibility in this regard amongst both of these 
groups. Those citing service-user involvement activities as relevant to their recovery 
trajectory were positive dischargers and long-term IOTs. Negative dischargers and 
clinic closures did not mention this as a relevant aspect of their recovery. Clinic 
closures did not cite negative aspects relating to lack of control or autonomy, however 
this may again be due to small the sample size for this typology. The need for an 
individualised programme of recovery was cited by positive dischargers and long-
term IOTs, but not negative dischargers or clinic closures. Typology was relevant to 
thoughts about treatment duration, with long-term IOTs anxious about IOT ending 
and positive and negative dischargers proponents of time-limited regimens. A return 
to OM treatment was experienced by all typologies (aside from long-term IOTs), albeit 
for different reasons, and typology was often relevant (e.g., violations to protocol or 
clinic closure, versus choosing to move back on to OM – i.e., a positive discharge). 
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5.1.4. ‘Impact of Injectable Opiate Treatment’ chapter themes tabulated by 
typology 
 
Table 38. ‘Impact of IOT’ chapter themes tabulated by typology 





Reducing or ceasing 
illicit drug use 





Improved quality of life  All  
Psychological 
recovery 
 All  
Leaving the drugs 
subculture 







   Long-term 
IOT 
   Clinic 
closures 
Education and courses  All  




  Negative 
dischargers 
 
  Long-term IOTs  






  Negative 
dischargers 
 
  Long-term IOTs  
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Improved housing  All  
Achieving and 
maintaining stability 







  Negative 
dischargers 
 
  Long-term IOTs  
Feeling grateful  Long-term IOTs Clinic 
closures 




Protective factors Service-user 
involvement 
Long-term IOTs Clinic 
closures 








  Negative 
dischargers 
 
  Long-term IOTs  







  Negative 
dischargers 
 
  Long-term IOTs  






  Negative 
dischargers 
 
  Long-term IOTs  
 
The majority of the dimensions of ‘Impact of IOT’ were experienced by all typologies. 
The development of a non-using identity was only highlighted by positive dischargers, 
which is perhaps not surprising. Improved relationships and health applied to all, 
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aside from the clinic closures. This could either be because these participants did not 
reach a point of experiencing these benefits, that they could not recall them, or 
because of the smaller sample size of this group. All but clinic closures indicated a 
self-reflective ability or awareness of their recovery journey. Whether this is due to 
the smaller sample size or an inability amongst this group to reflect positively following 
a forced discharge is unknown. Perhaps not surprisingly, the ‘feeling grateful’ theme 
applied to positive dischargers and long-term IOTs, however not to negative 
dischargers or clinic closures. Whether gratitude is a cause or effect/self-fulfilling 
prophecy is unknown and it may well be a combination of both that affects this aspect 
of recovery – that is, either a positively or negatively (reinforcing) cycle. The same 
pattern applies to those citing service-user involvement as a positive impact of IOT, 
however again, cause and effect is unknown. That caring for pets was a protective 
factor in recovery, and caring for dependents – or family relationships - was relevant 
to all typologies, aside from the clinic closures. A reduced quality of illicit drugs as a 
protective factor from illicit use (irrespective, or concomitant to) IOT was cited by all 
patients aside from the clinic closures. It may also be that geographical region was a 
factor here (with all clinic closures living in Darlington) in terms of the quality of illicit 
drugs, however this is obviously only speculation. 
Overall, clinic closures did not appear to benefit as much as other treatment 
typologies had from the impact of IOT, however it was difficult to separate out 
negative effects arising because of forced clinic closure, from the clear smaller 
sample size of this group. It was likely that both factors had a role to play in the 




5.1.5. ‘Recovery’ chapter themes tabulated by typology 
 
Table 39. ‘Recovery’ chapter themes tabulated by typology 













 All  






  Negative 
dischargers 
 











 All  






  Negative 
dischargers 
 
  Long-term IOTs  
Ongoing maintenance 
treatment 
 All  

















  Negative 
dischargers 
 
 Psychotherapy Positive 
dischargers 
 
Reintegration  All  
Making progress in 
treatment 
 All  
Protective factors and 
activities 
 All  
Barriers to recovery Instability All  
 Dissatisfaction All  




  Negative 
dischargers 
 
  Clinic closures  




That Recovery was seen as individual and personal was expressed by positive 
dischargers and long-term IOTs only. It may be that these typologies are better able 
to reflect on this than those who were discharged negatively or due to clinic closure. 
Once again it is not clear if this is a cause or effect/positive reinforcement relationship. 
Health and harm reduction as indicators of recovery were cited by positive and 
negative discharges and one long-term IOT. Clinic closures did not cite this aspect of 
recovery. Employment and financial stability were cited by positive dischargers and 
long-term IOTs. Whilst abstinence was conceived as effective recovery for all 
typologies, all but the clinic closures cited cessation of use of illicit opiates as how 
they conceived recovery. Additionally, all typologies conceived recovery as ongoing 
maintenance treatment. Only positive dischargers felt that ongoing support was part 
of what constituted recovery. Recovering self-esteem as part of psychological 
recovery was cited by both positive and negative dischargers, and psychological 
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therapy was mentioned by positive dischargers only. Health problems, either past or 
current, applied to both positive and negative dischargers, and clinic closures, 
however not long-term IOTs. Current health problems were all cited by positive 





5.1.6. ‘Current situation and goals for the future’ chapter themes tabulated by 
typology 
 
Table 40. ‘Current situation and goals for the future’ chapter themes tabulated by 
typology 





The current situation Instability and 
difficulties 
All  
 Stability and 
improvements 
All  
 Current drug use All  
Goals for the future Abstinence from 
illicit heroin use 
All  














 Employment, work 
and other activities 
Long-term IOTs Negative 
dischargers 










  Long-term IOT Clinic 
closures 









Buprenorphine (subutex) as a goal for the future was cited by positive and negative 
dischargers only. Education or courses as a goal for the future was envisaged by 
positive dischargers and one long-term IOT, but not clinic closures or negative 
dischargers. This pattern applied to artistic aspirations as a goal for the future. A 
more positive discharge situation seemed to be more likely to be linked with a 
positive or creative aspiration. 
  
5.2. Chapter summary  
 
In summary, whilst the typologies were not necessarily a useful way to visually 
illustrate the data, and were not always valuable conceptually (for example, the fact 
that continued use of illicit drugs applied across all typologies does not really tell us 
anything useful) it was clear that certain themes were more accessible to positive 
dischargers and long-term IOTs - perhaps including, and due to, a greater ability to 
reflect and to reflect more positively on the journey - than they were for the clinic 
closures or negative dischargers. This is useful for IOT research, policy and practice, 
as well as for the wider OST policy and practice, and emphasises patient choice and 
autonomy over treatment trajectory, length, clinical decision-making and exit route 
from treatment. It perhaps lends significance to the importance of a ‘satisfied’ 
customer in drug treatment services, perhaps with a positive perception/relationship 
with the clinic and staff as instrumental to this. It is indicated that a forced clinic closure 
is detrimental to an ability to reflect, and perhaps reflect positively, on the journey to 
recovery. As illustrated, however, there were no themes that were only cited by 
negative dischargers or clinic closures. The next chapter outlines the themes in much 
greater detail, but also discusses the relevance and impact of the typologies in the 
context of the thematic findings.  
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This chapter provides a description of patients’ personal experiences of their heroin 
use and treatment history pre-IOT. It is derived from retrospective qualitative research 
interviews with 41 Injectable Opiate Treatment (IOT) trial patients. This project was 
necessary in order to illustrate the context from which entrenched heroin addiction 
began and continued for these patients, up until they entered the IOT trial. This pre-
IOT context is necessary for a full description and interpretation of the recovery 
journey. The findings reported here are based on the coding of qualitative transcripts 
and clustering of codes into themes and sub-themes (as described in the 
methodology chapter and in Appendix 2). Patients were asked to begin the interviews 
by talking about their heroin use history; these data are relevant to later aspects of 
recovery, and are the opening chapter to the description of patient trajectories. 
Quotes are referenced with a pseudonym, patient number - which can be linked to 
the case note review data in the appendix (appendix 4) – and typology (including 
discharge status; e.g., long-term IOT; positive discharge; negative discharge; clinic 
closure); as outlined in chapter 5 and the drug treatment group the patient was 
assigned to at referral to IOT: SIH; SIM; OM). 
It is known that these IOT patients were those with long and entrenched heroin use 
histories, and who had consistently failed to benefit from conventional opiate 
maintenance treatment. Failure was defined through continued habitual use of illicit 
heroin despite a methadone maintenance programme (commonly expressed by 
patients as ‘using on top’ of methadone). It was not known why conventional 
treatment had consistently failed to work for this group or how and why patient heroin 
use histories were so extensive and entrenched. This chapter aimed to explore this, 
and at the time of interviewing, set the scene for the rest of the interview. It allowed 
connections and parallels to be drawn to later themes and chapters (including 
parallels to sections ‘Impact of IOT’ and ‘Recovery’), and allowed examination of 
common themes in patients’ transition to heroin use, addiction and treatment. This 
was an open-ended question – ‘Can you start by talking about your heroin use 
history’. Patients were also prompted to speak about the transition to habitual use or 
addiction, and treatment, if this narrative did not ensue organically. The chapter aims 
to highlight both similarities and differences across patients’ accounts.  
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Structure of the analysis 
 
There was a clear chronological structure to patients’ narratives, as directed by the 
topic guide. Interviews naturally followed this sequential structure and analysis and 
presentation follows this. Patient heroin use history was mainly grouped around six 




Table 41. Outline of ‘Heroin use history’ chapter themes and sub-themes 
Reference Theme Sub-theme 
6.1. Initiation and exposure  
6.1.1.  The influence of others 
6.1.2.  Vulnerability, exposure 
and fatalism 
6.2. Continuation  
6.2.1.  Positive reinforcement or 
positive outcome 
expectancy 
6.2.2.  Transition to injecting 
6.2.3.  Transition to addiction 
6.3. Consequences  
6.3.1.  Loss of employment 
6.3.2.  Loss of home and 
homelessness 
6.3.3.  Loss of non-using identity 
6.3.4.  Criminal justice 
involvement and prison 
6.3.5.  Decline of attachment 
relationships 
6.3.6.  Health problems and 
decline 
6.4. Protective factors and 
periods of abstinence 
 
6.5. Use of other drugs 
including alcohol 
 
6.6. Treatment  
6.6.1.  Transition to treatment 







The question on heroin use history also served as an appropriate warm-up question, 
for the interviewer and respondent to connect and build an initial rapport of trust and 
openness for the ensuing discussion. In a number of cases this was a detailed section 
of the interview and led to a much clearer understanding of the patient’s case and 
history. 
 
6.1. Initiation and exposure 
 
The heroin use history narratives began with how and why patients were initiated into 
heroin use. 
 
6.1.1. The influence of others 
 
The influence of others on initiation into heroin use was a prominent theme across 
the sample. Romantic relationships or peer groups had particular presence within 
initiation into heroin use for many of the IOT patients. This was particularly clear 
amongst female patients, whereby a male boyfriend or partner influenced use, though 
in several cases men were also influenced by female romantic partners. Romantic 
involvement was implicated in use, through using together and also when 
relationships were not going well; triggering use as a coping mechanism. Some 
patients also spoke about the other influences this relationship had – such as 
introducing the patient to the crime sub-culture and the associated criminal justice 
consequences. Other patients spoke about the influence of friends and peer group, 
and ‘getting in with the wrong crowd’. Sometimes patients began their habitual use 
whilst in prison and continued use upon release; contextually, a peer group was 
alluded to in this case too. 
“I got involved with someone who was 12 years older than me; I was 17. He 
was 12 years older than me; I worshipped the ground he walked on. I didn’t 
know anything about heroin at the time but I was a very inquisitive child, so I 
just got involved in it that way. Nothing bad happened to me; I just got involved 
with him really.” Stacy (P5); positive discharge; SIM 
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“...relationship problems. I’m not very good with relationships. 
…I was single when I started my treatment and I was doing really well.” Fran 
(P13); long-term IOT; SIM 
“I met an even worse boyfriend, and he got me involved in crime and I ended 
up in prison.” Clara (P17); positive discharge; SIM 
“…that’s when I started using heroin a bit more regularly. And then I got even 
more regularly when I carried on seeing my prison friends when I got 
released.” Ellie (P22); positive discharge; SIH 
Romantic and peer group influence on initiation perhaps implies either trust, the 
desire to impress – perhaps to the detriment of making healthy decisions and 
respecting/looking after one’s self - or peer pressure. This may have been 
exacerbated by the absence of healthy or stable role models – themes which arose 
later on. That other people were so influential may have been indicative of patients’ 
low self-esteem and sense of self. Complementary to this theme, and linked to 
recovery, peer-group was cited again later on, when patients spoke about not having 
friends or peer groups comprising non-users (and the association with lapse or 
relapse). This was likely a factor in continued use and persisting use, despite 
substitution treatment regimens. 
“Well, I haven’t really got any friends that don’t use. The nearest to people I’ve 
got that don’t use are people that drink in pubs and smoke cannabis. I just 
don’t know anyone round here that don’t use anything, you know; whether it’s 
fat women on speed, or mum’s on valium, or, whatever. I don’t know anybody 
that don’t take anything.” Luke (P18); negative discharge; OM 
Linked to the influence of others was the desire for connection or community and this 
longing featured as the rationale for using: “…. I think the most predominant thought 
in my mind was, ‘Well how do I go about getting the family that I never had?’” Harry 
(P8); positive discharge; SIM 
Another patient, however, explained that he always took drugs alone and kept use 
hidden from the people around him.  
“Yeah 'cos I didn’t know any addicts before I come in here. …No I've took 
drugs on me own.” Ron (P27); long-term IOT; SIM 
198 
 
That use was kept secret was also highlighted by several other patients. This 
suggested a typology of those who were influenced by others and those who took 
heroin alone – perhaps representing both the desire to impress others and feel a 
sense of belonging and the desire to escape from life. Also within the exposure theme 
– and linked to vulnerability (the next sub-theme) was the implication of family use on 
initiation. 
“My father; he has given me money and helped me out and made my brother 
drive me to school and all the rest of it. He brought me a lump of pot in prison, 
when I was in prison. He wouldn't bring heroin, but he brought me a lump of 
pot, which was fine. So they do understand. They do understand. Whether it 
does any good, when they're understanding, I'm not so sure that it's done any 
good. It might have made things worse. But there you go. I don’t think you 
should take people pot in prison. Even though my dad was doing it for me.” 
Oliver (P16); long-term IOT; SIH 
This suggests that where family use or complicity was pertinent, the patient’s family 
and peer group may have normalised drug taking, which in turn may have contributed 
to a patient’s vulnerability to addiction or continued use.  
“Well the first time I actually used it was when I was 15, I was living in Israel 
and my sister, my late sister; she met someone that was using it.  
…Because my sister she’d had a lot to do with the whole thing of heroin and 
everything. She died when she was 15 from an overdose of Valium.” Kevin 
(P33); clinic closure; SIH 
The narrative above also suggests that the negative and fatal consequences of drug 
use did not necessarily put patients off using heroin, introducing the concept of 
fatalism within the patients’ narratives. 
 
6.1.2. Vulnerability, exposure and fatalism 
 
Negative life events around the time of initiation were highlighted by a number of 
patients. As described earlier, this illustrated a clear typology – of those who began 
using heroin to escape or release themselves from a difficult life or history. A difficult 
or chaotic childhood was a distinct narrative in some patients’ accounts, and in some 
199 
 
cases linked to their drug use. Within the narratives were vulnerability factors such as 
family poverty, absent or unstable parenting and care, homelessness and 
disengagement with education.  
“And I did burglaries, but not to fund my drugs - which is cranky - I did 
burglaries to feed my brothers because my mother was an alcoholic, she 
drank all the money, and her husband; he was the most awful piece of 
garbage you’ve ever come across in your life. And he used to torture my 
brothers, he was a vile, nasty person.” Oliver (P16); long-term IOT; SIH 
“Yeah, I started using when I ran away from home.” Fran (P13); long-term 
IOT; SIM 
Additionally, and in several cases, difficulties seemed to be accepted as a fact of life 
and, as such, patients did what they could to get by. A few patients spoke about 
feeling resigned to the lifestyle and in some cases, resigned to addiction, highlighting, 
again, an overall sense of fatalism. 
“From school I was in foster care; I never had a father. I never had any 
direction in my life. It was just, ‘Do what you want.’ My mother was in prison 
for a lot of the time, so I grew up around – doing what I wanted. So yeah, but, 
at the age of sixteen I was in prison, so it’s one of those things.” Jack (P2); 
positive discharge; SIH 
Bereavement and loss were prominent themes across the sample, particularly in 
terms of initiation into heroin use, why patients used – perhaps to fill the void of 
something that was missing; such as losing family members (either through 
bereavement or difficult social situations and backgrounds) or absent parents – why 
use continued, and why patients relapsed following a period of abstinence. 
“One of the people I was living with was doing a party in London and jumped 
off a building and killed himself. Things got a bit bad after that and one day I 
was like walking down… ‘Do you want to score a bag?’, ‘Yeah fuck it; go on 
then’. I started smoking again.” Jacob (P4); negative discharge (other); SIM 
The narrative above provides an example of the link between vulnerability and 
initiation, whereby loss of control occurred in the context of a difficult life event; and it 
was the combination of these factors that precipitated consequential habitual use. 
This illustrates the multi-faceted nature of factors implicated in initiation to heroin use, 
200 
 
which was really clear throughout. As illustrated above, for a proportion of patients, 
drugs seemed to be a replacement for missing connections with family. 
“So it all coincided with the death of me mum… 
….I got three older brothers, I’m the youngest.  They all inevitably left and 
settled down with their partners and raised families. I was left with my dad who 
wasn’t really…he was a bit violent, an alcoholic, he suffered from 
schizophrenic paranoia.  So that didn’t help my life at the time and I just felt 
really lost, abandoned, didn’t have absolutely no one or anyone I thought I 
could turn to for help or just really, really lost and confused, I suppose, looking 
back and that was it. It just seemed like I was on a road where I just felt like I 
was on a ship with no sails and that I had no control, it was just chaos from 
thereon in and then it just got worse and worse.” Harry (P8); positive 




That patients continued to use heroin following initiation was obviously a pivotal stage 
in the heroin use and treatment trajectory. The fact that use was habitual, consistent 
and in large quantity was clear. One patient illustrated the point ‘I used a lot, I used 
consistently’. It was possible to unpack the factors that contributed to habitual 
dependence through the sub-themes that emerged from the analysis of patients’ 
narratives. 
 
6.2.1. Positive reinforcement or positive outcome expectancy 
 
The perceived positive aspects of using heroin were often cited as the reason why 
patients continued to use heroin following initiation, and transitioned to addiction. A 
prominent theme was the continued chasing of the initial high.  
“With a new heroin user, your first hit’s the best hit. So you’re always chasing 
that first hit, as you know. You’ve probably heard it a thousand times. You’re 
always chasing that first hit.” Jack (P2); positive discharge; SIH 
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“That’s one thing that people chase to start with. You know, that’s the golden, 
you know, that’s chasing the drug, you know, following, you know, the first 
high that you get.” Elena (P37); positive discharge; SIM 
Some patients also spoke of a positive first experience with heroin. In several cases 
the experience was interpreted with such profundity that the patient knew right away 
that they would develop a heroin ‘problem’. As also captured in the transition to 
injecting and addiction sub-themes, there was a sense of feeling resigned to 
addiction. 
“And after a month or two, whatever, it was a long, long time, he gave me a 
hit. And it was the first hit I'd ever had. And I have to tell you this, I will never 
forget that hit as long as I live. And when they say you cannot get addicted to 
heroin like they seem to now, they have one hit and they're: ‘I'm ill, I'm ill’, no, 
you're not. They're not. 
….So it was the most intense thing I'd ever had, even to this day. It's more 
marvellous than watching your child being born. That's the only way I can 
describe it.” Oliver (P16); long-term IOT; SIH  
The end of the first paragraph of the quote illustrates an assumption of superior 
knowledge and judgement over other people’s experiences, which was surprisingly 
common across the sample – particularly when evaluating other people’s experiences 
with IOT; this will be covered and illustrated again later on. The quote also illustrates 
the domino effect of contributory factors to use; in this case, the influence of a peer, 
coupled with a positive first experience of heroin. 
“I can only describe it as like I was walking in a cloud. All of a sudden I was 
weightless. I had no, I suppose, no inhibitions, no worries. Some people 
describe it as being cold in a warm blanket being wrapped around you. Which 
you can imagine, what? … that’s nice. I turned, I turned to my friend. After 
snort … I sniffed a tiny amount and forgot I had took it, and on the way home, 
about twenty minutes later, I turned to my friend on the bus and my words 
were gonna be “What’s all the fuss about?” but as I started speaking my words 
changed to “I’m gonna have a problem with this” and that was 33 years ago. 
I instantly knew that … it was almost like I … it was missing from my life.” 
Shane (P21); long-term IOT; SIM 
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“And this come along it just suited me; it was like everything I’d ever want.” 
Lee (P36); long-term IOT; SIH 
“Once you do it once, it’s like, wow, do you know what I mean? The feeling’s 
just like nothing else.” Patrick (P39); long-term IOT; OM 
In the context of difficult histories, absent parents, bereavement, the normalising of 
drug use amongst peers, and peer or partner influence on use, the overall sense was 
that heroin provided something that patients perceived had been missing from their 
lives. 
 
6.2.2. Transition to injecting 
 
There was a distinct narrative around the transition to injected heroin use – i.e., from 
smoking heroin or other drug use. Increased tolerance was a factor in injecting 
practices – patients explained that once they started injecting they had to maintain 
this route of administration to receive the desired level of intoxication or high, i.e., 
tolerance to the effect of the drug increased. The bioavailability of a drug is the degree 
and rate at which the drug is absorbed into the system or made available at the site 
of physiological activity. By definition, when a drug is administered intravenously, its 
bioavailability is 100%. In the case of heroin effects will be felt more quickly and 
apparently, and with repeated exposure to the intravenous method, the higher the 
level of tolerance will become. Patients also justified that less went further through 
the injected route of administration – increasing motivation to inject, and for it to later 
become habitual. In other interviews patients spoke about particularly memorable and 
positive first experiences with heroin; however others still, stated that it was simply 
exposure to the intravenous route of administration, availability (or lack thereof, e.g., 
in the case of smoked heroin), and that it went further, that they persisted with 
injecting. Often it was a combination of these factors that contributed to the transition 
to injecting. 
“I smoked it on the tin foil for a week and started injecting and basically I never 
stopped because I tried to go back to smoking it but I had to smoke a lot more 
than I would if I was injecting it.” Nicholas (P14); positive discharge; SIH 
“I couldn’t get hold of any gear from my normal dealers; I went into [market 
name] Market and met a guy there. And he bought some gear and he was – 
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like a homeless injector, so I took him back to my place but the gear that we’d 
got wasn’t smokable and I was in such desperate, it was my second day into 
withdrawal so it was quite bad. So I just had an injection, I thought I’ll just have 
an injection because that was the only way. …I kind of just started doing it as 
a habit from there, rather than smoking. And, as well, because the gear I was 
getting at the time, like I say, wasn’t smokable.” Andy (P23); positive 
discharge; OM 
“I came out [of prison] and I found it easy to get heroin on the streets; tenner 
bags. I started smoking it at first because obviously you weren't… You know, 
needles and stuff and that in the jails, it wasn't a good thing to do and in fact I 
didn’t even see any needles, but silver foil and stuff, you would get off the 
wrappers, and when I came out I started injecting heroin.” Wayne (P30); clinic 
closure; SIM 
 
6.2.3. Transition to addiction 
 
A number of patients recalled that their heroin use escalated very quickly and that 
they had to start using larger amounts of heroin to achieve the desired effect (i.e., 
tolerance developed quickly). The transition to addiction was often characterised by 
the transition to habitual use, and the transition to the injected route of administration. 
That use was consistent, in large quantity, long-term and habitual was particularly 
clear. Some patients explained that they became habitually dependent on heroin 
almost as soon as they started using it. 
“I found it lasted longer than the smoking, I kind of just started doing it as a 
habit from there, rather than smoking.” Andy (P23); positive discharge; OM 
“And for three months I was, was taking it every day.” Shane (P21); long-term 
IOT; SIM  
“My heroin use began in about the late ‘90s. My heroin use, kind of, like, 





6.3. Consequences  
 
The consequences of illicit heroin use formed a significant part of the discussion at 
various stages of the interviews, and was a particularly prominent sub-theme within 
heroin use history. Loss and decline were overall threads within these discussions; 
for example, loss of employment, loss of a home, loss of a previous career, loss of 
educational opportunities, loss of safety, loss of freedom, loss of identity, financial 
loss, health decline, and loss or decline of family and attachment relationships.  
 
6.3.1. Loss of employment 
 
Patients felt that job loss in the context of their addiction beginning to take over their 
lives was particularly pertinent. Patients also spoke about other losses, such as the 
loss of a home, leading to homelessness. Being unable to perform in vocational roles 
due to the impact of drug use was often the cause of job loss; obtaining and taking 
heroin then became the sole focus of patients’ lives, perhaps to fill that increasing and 
ever apparent sense of loss. One patient held the perspective that the negative cycle 
of addiction begins at the point that users lose their jobs, and this idea was reinforced 
through other narratives. This is likely a particular dimension of loss of the non-drug 
using identity, whereby prior to this point patients perceived that their drug use was 
at the level of acceptable social functioning. 
“Then I’d lost my job, I’d lost my job in [inner London district] but I went away 
for a few days and came back a day late and they decided that I wasn’t reliable 
enough which I wasn’t, because I was terrible, I’d come in late and I’d often 
come in late and take days off when I couldn’t go in, things like that, because 
I was too ill, just withdrawals or feeling really bad. So I lost that job and just 
went to sign on and ended up staying on forever.” Andy (P23); positive 
discharge; OM 
“I got myself in a complete and utter mess and then I lost my last job and I…so 
that had been about ten or twelve years straight that I'd been doing that and 
then I lost my last job and I'd been sleeping in the work’s van.” Ron (P27); 
long-term IOT; SIM 
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“And, as I say, we were homeless, we were penniless, we didn’t know what to 
do, you know, we were on benefits. I lost my job, he lost his job, and everything 
like precipitated from that. And that went on for a few years.” Elena (P37); 
positive discharge; SIM 
It was clear that amongst several patients, awareness of their addiction began at the 
point that work and finance were severely impacted. This again suggested the 
perception that if one is able to perform at the level of socially acceptable functioning 
then addiction is not yet perceived to be a significant problem. 
“But you don’t become an addict until you lose your job. It’s only when you 
ain’t got no money that you realise you’re an addict. When you’ve got money 
you don’t … if you can afford it you don’t really realise how much trouble you’re 
in, you know.” Cheryl (P40); positive discharge; SIM 
Some patients lost professional careers, and in several cases, careers in a caring 
profession, perhaps further undermining (and replacing) the self-identity that such 
careers may have previously provided. 
“Prior to that I had a successful job, a very good job, but I met the wrong crowd 
and I started to use heroin.” Clara (P7); negative discharge (other); SIM 
Clara (P7 above) was a former nurse. Here the impact of simultaneous contributory 
factors are again illustrated. 
“You’ll never believe it. I was a drugs worker… I was working in a drugs 
agency like this.” Cheryl (P40); positive discharge; SIM 
 
6.3.2. Loss of home and homelessness 
 
Loss of home and homelessness was common; this was both a symptom and cause 
of instability and chaos, and the transient nature of patients’ housing status was 
emphasised. 
“I’ve moved from homeless centre to homeless centre.” Clara (P7); negative 
discharge (other); SIM 
“I was homeless and I went into, like, a B&B. I was there for, I think, three or 
four months, but each time you’ve gotta renew your agreement, so they evict 
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you – this is how chaotic things were – from the B&B, they evicted me and 
packed all my stuff up, and I couldn’t even get in; they’d locked the door. I had 
to go back down to the council the next day and say, ‘Well, they’re not letting 
me in. They said that I’ve been evicted.’ So, one of the other tenants let me 
sleep on their floor, you know, overnight.” Fran (P13); long-term IOT; SIM 
“At that time I was in a hostel. I had been homeless. I had been sleeping 
rough, and I was referred into – it’s just round the corner from here – [name 
of street] Street. It’s like a temporary hostel, from where they allocate you into 
a more permanent place.” Pam (P19); positive discharge; SIH 
 
6.3.3. Loss of non-using identity 
 
Perhaps already implicitly implied through loss of career and employment, patients 
explicitly cited the loss of their (non-using) identity, and relatedly, the impact of heroin 
use on their ambitions (for example, Cheryl, P40) and education (for example, Tom, 
P9). It was clear that acquiring and using heroin became the sole reason for 
existence. Embroiled within this was a move towards involvement in crime, arguably 
a lifestyle which serves to further emphasise the loss of the non-using identity 
(illustrated again in the next section). 
“That’s the thing that when you start here [in IOT], like I remember there were 
things about my past and about my life that I had completely forgotten, totally 
forgotten, and my sense of self was only a junkie, and I didn’t see anything 
else, and a busker, I wouldn’t even call myself a violinist, it was, ‘I’m a busker 
and a drug addict’.” Ellie (P22); positive discharge; SIH 
“And I know it might sound silly but, yeah, not having done that for so long, 
living the life which just passes you by and you’re not really living, it’s just an 
existence when you’re using, you’re not interacting in no way, you’re not 
socialising.” Harry (P8); positive discharge; SIM  
Mentions of prostitution (for example, Serina, P6 and Fran P13) further highlighted 
loss of freedom and identity, as well as a threat to personal safety. The threat to 
personal safety was also emphasised through a number of reports of adverse events 
and chaos as a consequence of using heroin. Financial decline was also highlighted, 
which again denotes threat to the non-using identity, personal safety and freedom. 
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6.3.4. Criminal justice involvement and prison  
 
A significant proportion of the sample spoke about involvement in criminal activities 
and a large number spoke about time spent in prison; loss of freedom. This led to a 
repetitive cycle of chaos and instability, and again linked to the absence of non-using 
aspects of patients’ identities. Patients appeared to speak openly about their 
involvement in criminal activities. One patient felt that by committing, and being 
punished for, crime, they were finally being noticed and recognised. A number of 
patients spoke about committing acquisitive crime, and one recalled his lack of regard 
for the impact this had on the victims of crimes committed; the acquisition of funds for 
drugs being the priority. In contrast this theme was starkly polarised by a group of 
patients who spoke of a strong unwillingness to commit crime or acquisitive crime, on 
moral or ethical grounds, and which will also be illustrated. 
“I started getting into crime. As well as funding my habit, it was also almost 
like I was rebelling, it was like I was trying to blame someone for all that was 
going on in my life, so I ended up getting in trouble. It was almost like I think I 
wanted to because, like, I was being recognised, I was being noticed, I was 
getting arrested and…does that make sense?” Scott (P35); long-term IOT; 
OM 
“I'm not going to run round shoplifting to get money. I'd rather be involved in 
somewhat more heavier things and one advantage I do have is coming from 
[name of British city] where the heroin is generally half the price of the rest of 
the country, or it certainly was when I first came down to [British city], and by 
moving amounts of drugs around it's quite easy to make sums of money, and 
I did a few dodgy things I don’t really want to go into. But yes, I did used to 
commit crime, but I've never spent a day in jail, so it sort of sounds like I’m 
bigging myself up, but I never got caught. That's the basics of it; I never got 
caught.” Tom (P9); positive discharge; SIH 
A strong underlying theme for one patient was the loss of the moral compass, with 
retrospective regret and guilt about former drug taking behaviour. In the context of 
recovery, time away from heroin and the drug using lifestyle appeared to provide time 
and space for patients to reflect on past behaviour, what they wanted to change and 
what they wanted from their future lives. Emphasised with this, and by a number of 
patients, was the sense of desperation and the apparent imperative drive to acquire 
money for heroin at all costs. 
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“I was committing crime every single day, three or four times a day and it didn’t 
matter what it was, and I’ll be honest; it could be an old woman’s bag, I’d have 
stolen her purse, it didn’t matter to me where the money come from, as long 
as I felt better afterwards, but after I’d done it, I used to feel guilty at what I’d 
done and as time went on, the guilt would last a bit longer and longer and 
longer than when I first done it, I was ashamed, but anyway, I’d just do the 
same thing again. I was taking more and more and more and it got to the stage 
where I was £300-400 a day habit and I had to find that seven days a week 
and...things were getting desperate, desperate, desperate, when I mean that 
I mean I was doing more things where I wouldn’t have done before, where I 
was going to, standing up behind someone at a cash point and pulling a knife 
out and saying you know, draw out the maximum you can draw, all things like 
that, but as I say, that if I could see everybody who I’d done it to, I’d tell them 
how sorry I was and I genuinely would mean it, because how did I know how 
I affected them, you know, it’s like he might never have went to a cash point 
again, you know, but basically, it sorted my problem out, so who gives a damn 
about anybody else’s problems.” Nicholas (P14); positive discharge; SIH 
Some patients had spent time in prison; whilst for some this was a period of 
decreased use or abstinence, for others it was a place where use continued and even 
began. Several patients explained that they began heroin use in prison because they 
previously used cannabis, however cannabis would remain in their system for longer, 
and thus detectable through in-prison regular drug screening, whereas heroin left their 
system much more quickly. 
“So a lot of people decided to use heroin rather than cannabis because 
cannabis stayed in your system for 28 days whereas heroin stayed in your 
system for four, five days.” Wayne (P30); clinic closure; SIM 
Prison was also a time where some patients were first introduced to methadone 
treatment; of particular relevance is the fact that this treatment may have been forced 
upon patients in this setting. 
“I got out of prison 2000, that's the first time I ever went on methadone. I 
always avoided methadone.” Kevin (P33); clinic closure; SIH 
 
With prison as the context to relapse, one patient illustrated that one of the triggers 
was the lack of structure to return to upon release. This may have undermined any 
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motivation to attempt abstinence. For others there was no intention of avoiding 
returning to prison; as before, it became an accepted way of life (illustrating the sense 
of fatalism again). 
“A lot of prison; a lot of institutions; a lot of moving about the country.” Charlie 
(P3); positive discharge; SIH 
“Yeah so it was in prison, coming out, straight back at the same thing. 
…back in prison, back out and I think it was also not having any structure to 
come out to.” Scott (P35); long-term IOT; OM 
“And then prison come and then people were saying, it’s a deterrent, but it 
wasn’t a deterrent, basically I was in there getting an MOT...come out of there, 
fully better, straight back on the drugs again. I was phoning the dealers before 
I’d left the prison, you know.” Nicholas (P14); positive discharge; SIH 
The group of patients who spoke of a strong unwillingness to commit crime to fund 
their habit, cited moral dissonance with this way of life. This moral reasoning was 
sometimes the fuel behind patients initially accessing treatment, introducing and 
cross-cutting the transition to treatment, in some cases. 
“I’ve never been a shoplifter or thief or anything like that. Never been to 
prison.” Cheryl (P40); positive discharge; SIM 
“And I was brought up morally that it wasn’t really the done thing to thieve, you 
know, I didn’t really like thieving, and I used to think at one time, no one’s got 
a drug problem, but everyone’s just got a financial problem.” Luke (P18); 
negative discharge; OM 
“I had two choices, try treatment or start thieving and I weren’t willing to thieve 
to pay for drugs because it’s bad enough taking drugs anyway but thieving to 
get the money to take the drugs and then spend half your time inside, I 
thought, you know what, I'm stupid enough as it is; that is just pathetic.” Ron 
(P27); long-term IOT; SIM 
Once again the above indicates an underlying theme of judgement of those engaging 
in different lifestyle choices (i.e., criminal activities), perhaps as a way of creating 
distance between one’s own sense of self and the stereotyped perception of the 
criminal heroin user. This was also emphasised during patients’ time in the IOT clinics 
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– the judging of other patients’ behaviours and trajectories – referenced later on (in 
chapter eight: experience of IOT). 
 
6.3.5. Decline of attachment relationships 
 
Family or relationship breakdown and isolation was commonly cited, both as a 
consequence of, and implicated in, heroin use. Some patients alluded to the fact that 
they had not been able to have children because of their heroin use and associated 
lifestyle – and others talked about losing parental responsibility entirely, or at best, 
contact with children during this period. One patient illustrates the impact of his heroin 
use on his marriage. 
“The most traumatic stuff for me has been around my kids being taken into 
care.” Pam (P19); positive discharge; SIH 
“No, I’ll tell you how powerful drugs are...my wife says to me ‘Either the drugs 
or me’...I chose the drugs. …We divorced.” Nicholas (P14); positive discharge; 
SIH 
Patients clearly suffered great loss as a consequence of their addiction and it was 
evident that the more patients lost, the more entrenched their addiction became, and 
vice versa. 
6.3.6. Health: Problems and decline 
 
Health problems at IOT’s inception were common amongst patients, in particular, 
those illnesses where patients’ drug use was implicated. This was something that, in 
many cases, radically improved for patients – as captured in later sections of the 
interviews (and later chapters) – as a consequence of being in injectable treatment, 
and the holistic nature of the support this offered. Impact was a strong meta-theme 
across the dataset and the health sub-theme evidences this particularly; health was 
negatively impacted by heroin use and later positively impacted by injectable 
treatment. This was an interesting and useful finding, particularly as quantitative 
health questionnaires (for example, the SF36 quality of life scale) yielded no 
statistically significant changes over time (see chapter four; a quantitative description 
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of outcomes following longitudinal IOT). Some patients highlighted that the effects of 
illnesses and injuries caused by habitual use were still apparent, in the present day. 
“My health’s not very good, as in I’ve contracted two viruses through sharing 
needles and sharing works. Sharing needles and sharing works is the same 
thing. As a result of those viruses I’ve had offshoot illnesses. I just came out 
of hospital yesterday, as a result of an exacerbation of one of those illnesses.” 
Clara (P7); negative discharge (other); SIM 
“And like I say, I was going to the doctors quite often and I ended up getting a 
thrombosis of the veins in my legs, so I had to stop. And another thing, I could 
hardly walk because… I mean, now I can, but at the time I was using a stick 
and that, and some days I just couldn’t get to the [Name of treatment centre] 
because I was in that much pain with the abscesses and stuff.” Wayne (P30); 
clinic closure; SIM 
 
6.4. Protective factors and periods of abstinence 
 
A number of patients highlighted periods of abstinence during their heroin use history.  
“So anyway, for about six or seven years, never even thought about it.” Elena 
(P37); positive discharge; SIM 
A number of patients spoke about factors which initially, or at times, protected them 
from the throes of their addiction. Eight patients spoke about initial sporadic use (for 
example, Elena, P37 and Josh, P41) and being careful with levels of use to begin with 
(for example, Shane, 21 and Andy, 23). Patients also spoke about access problems 
affecting how much heroin they took, at first feeling sick, during initiation to heroin 
use, and a long period of time between first use and the second time/subsequent use. 
Several patients described the impact that the negative connotation associated with 
heroin use had on them (for example, Scott, P35, Harry, P8 and Andy, P23) and their 
initial caution. Other protective factors included family support, pregnancy, or the 
presence of dependents or a non-using partner, detoxification and rehabilitation 
programmes and maintained employment. Some patients spoke about prioritising 
safe injecting practices and not engaging in criminal activities. Again peer group was 
sometimes implicated in the return to heroin use.  
212 
 
“And so I gave up the heroin and didn't touch it again at all for four or five 
years, or so. And then in 1972 or '73 I think it was, I can't quite remember 
when, I got in to trouble, ended up in Amsterdam, living in Amsterdam, and it 
was a seaman I knew, and it doesn't matter how I knew him or anything, and 
he introduced me into the world of drugs on the continent. That was 
completely different in terms of heroin.” Oliver (P16); long-term IOT; SIH 
This quote also links back to the ‘positive reinforcement’ sub-theme, whereby – along 
with peer influence - more potent heroin motivated the patient to use again (and 
illustrated again are the multi-dimensional nature of triggers). This patients also 
alludes to difficulties in his life at this time – ‘I got in to trouble’ – which may have been 
another contributory factor. Several patients mentioned children as a protective factor 
– either the fact that they were pregnant or the presence of children in their lives. This 
sub-theme appeared later on, either in the context of the injectable stage of their 
treatment or at the time of interview, as motivation to maintain the level of stability 
that had been achieved. 
“I mean I had a couple of months of clean time a few times, but never longer 
than a couple of months. Then I had a couple of, about two years, while I was 
on a methadone script, that I wasn’t using, but then I did start using again.  
…I had my daughter around that time so, obviously, it was mainly that.” Pam 
(P19); positive discharge; SIH 
Pam is reflecting on a two year period of abstinence from illicit heroin. Periods of 
abstinence were sometimes in the context of community or residential rehabilitation 
or detoxification, indicating that in the right circumstances, with the right support, 
patients were able to abstain. 
“It was completely detoxing. And if you got really, really ill, then obviously, like, 
someone would drive you to the hospital or they would like get a doctor there. 
Do you know what I mean? It’s not as though they said “Oh you’re dead. Sorry, 
no”. But the ideal way was that; they didn’t use any kind of medicines. And I 
was there for two years. I stayed there for two years.” Iain (P25); positive 
discharge; SIM 
“I went into [name of residential rehabilitation] again and I managed to get 
funding for a place in [English town name] so I went to rehab in [English town 
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name] called [name] House, which was, it was really good; I lasted five months 
there.” Andy (P23); positive discharge; OM 
The fact that rehabilitation and detoxification was successful, whereas community 
methadone treatment was not, highlights the need for a holistic supportive treatment 
programme – i.e., an illustrative dimension of IOT’s success. 
 
6.5. Use of other drugs including alcohol 
 
A proportion of qualitative IOT patients also consumed crack and alcohol, though a 
proportion did not. A few patients stated that other drugs did not lead to the desired 
level of intoxication that heroin provided, and another few stated that they transitioned 
to heroin use through use of other drugs. A small proportion of patients used 
cannabis, benzodiazepines and cocaine. Use of other drugs occasionally led to a 
curiosity about heroin – and this curiosity was a clear narrative for a few patients. 
There were clear typologies, with some patients with extensive other drug and alcohol 
histories, others who did not drink or use any other drugs at all, and others who 
occasionally drank alcohol or used other drugs, though purportedly not to problematic 
levels. Speed-balling was alluded to in several cases. 
“Now getting to this point in my life now, I know the only way for me is 
abstinence, because it’s like everything I touch I just go to the extreme. And 
then after the drugs it was drink which I had a major problem with, and 
although I’m still drinking I don’t like to use that term ‘control; I’ve got it under 
control’, but I’ll just say I’m nowhere near as bad as I was.” Harry (P8); positive 
discharge; SIM 
This illustrates some reflective capacity and insight in to one’s own relationship with 
addiction. When questioned about use of other drugs, patients sometimes illustrated 
the sense of identity as a heroin addict in particular. 
“Well, I’ve never really been into that. It was just now and again really, it wasn’t 
– I’m more a heroin addict. I wouldn’t say, really, that was a problem.” (On 
crack use) Stacy (P5); positive discharge; SIM 
214 
 
In contrast, one patient spoke about using heroin to ‘come down’ from crack, and this 
was mentioned in the context of a peer group of other users following the same 
pattern of use. 
“But, yeah, basically, being around people who were using heroin to come 
down off of crack, yeah, because that’s what a lot of people do. Crack will be 
their preferred drug of choice, and heroin would be something that you use to 
come down off...because, with crack you come down really harshly, but when 
you take heroin it’s, like, it’s more peaceful, you know… not so chaotic and 
erratic.” Jason (P26); negative discharge; OM 
As discussed in the UK RIOTT paper (Strang et al., 2010), the thesis introduction 
(chapter two), and the quantitative work outlined in chapter four, patients significantly 
reduced use of heroin during the IOT trial, yet not always their use of other drugs at 
this time, for example crack cocaine. Contextually, use of other drugs during IOT was 
also explored through the qualitative interviewing. This was another cross-cutting 




Narratives around treatment history, from initially accessing treatment and why 
patients did so at the point they did, to accounts about why methadone had failed to 
work for patients (as defined through continued use of illicit heroin) was a key section 
of the interviews. That patients still craved illicit heroin despite being on methadone 
programmes was the reason why they were invited to take part in the IOT trial. 
Research had not explored why methadone had failed to work for this group of heroin 
users. Narratives began with an initial transition from habitual heroin use, to accessing 
treatment and the subsequent (and ongoing) failure of conventional treatments, 
prompting patients to eventually access IOT. 
6.6.1. Transition to treatment 
 
A significant proportion of patients declared long-term methadone treatment histories, 
with a number of patients also mentioning that they entered treatment right at the 
beginning of their heroin using trajectories. Motivation for entering treatment varied, 
from financial – i.e., patients could no longer afford heroin (for example, Cheryl, P40), 
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to family encouragement (for example, Wayne P30). Narratives also included a 
diminishment of the enjoyment derived from heroin use, to job loss and to avoid 
committing crime and incarceration (for example, Wayne, P30). Some stated that they 
did not want to access support or treatment initially (for example Nicholas, P14 and 
Jason, P26) – that the need to access treatment came later on in their drug use and 
treatment trajectory. Patients mentioned that they were on oral methadone prior to 
IOT, and in a number of cases they received this treatment from the clinic where they 
received IOT. An appreciation of methadone’s stabilising effect was also highlighted. 
“Because...it [heroin] wasn’t enjoyable no more. It was a necessity.” Nicholas 
(P14); positive discharge; SIH  
“I think it was more the state I would get myself in if I couldn’t get hold of 
heroin. I’m depressed and I’m inclined to self-harm and suicide. And a few 
times I tried doing away with myself because I felt so bad and couldn’t get 
nothing. So that’s why I say the methadone’s a life saver, because it keeps 
me straight.” Rita (P29); negative discharge; SIM 
 
6.6.2. Failings of conventional treatment 
 
That conventional treatment had consistently failed was a key attribute of IOT 
patients’ histories, and inclusion criteria for the RIOTT trial. Failings of conventional 
treatment was a prominent theme across interviews, and discussed in patients’ 
narratives. The lack of affinity with methadone was strongly emphasised by patients 
and is described here, and this is a useful addition to findings from research 
conducted to date – it was clear that conventional treatment had not worked for this 
sample of opiate users, however, patient perspectives on why this was the case had 
not been previously explored. A negative perception of methadone was reported by 
the majority of patients, with a smaller proportion and/or mentioning something 
positive about methadone. Why traditional treatments had consistently failed for this 
group formed an interesting line of inquiry in its own right. This discussion developed 
naturally through inquiry into patients’ treatment histories. 
Narratives mainly focussed on methadone’s failings, or negative experiences with 
methadone and other treatment regimens. The majority of patients spoke about 
methadone’s inefficacy. It was interesting to hear one patient allude to the lack of the 
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holistic nature of methadone treatment – that methadone did not address the 
underlying causes of her addiction. Patients commonly spoke about the need to ‘use 
[illicit heroin] on top’ [of OST] and one patient said that he always sold his methadone 
prescription. The dominant narrative was that whilst methadone alleviates the 
symptoms of withdrawal and that without it things would have been much worse, 
heroin provided something that methadone did not, and patients still desired this 
effect. 
“For quite a lot of years I had a private script; when I was about 18/19, a 
methadone script. I never really liked it. It never coped with my emotions or 
mental state. It just kept the illness away.” Charlie (P3); positive discharge; 
SIH 
Some patients expressed disenchantment with the perception that by using 
methadone they had two addictions. 
“I was in a methadone clinic down the road and I was getting nowhere, I had 
two habits in the end.” Jacob (P4); negative (other); SIM 
“I was given methadone and although I did end up injecting that at the time… 
I mean, after a period of time. I didn’t know what to do with it at first and I didn’t 
like drinking it.” Tom (P9); positive discharge; SIH 
Patients highlighted that with methadone they felt the need to use illicit heroin ‘on top’ 
of methadone; that methadone alone did not stabilise them. The following quote is 
interesting because the patient highlights that her use of heroin ‘on top’ of methadone 
was something that aggravated problems that she already had in her life. 
“I’ve been on that before and that’s where I fucked up. It was no good. It wasn’t 
keeping me straight. I was using on top which just made things worse.” Fran 
(P13); long-term IOT; SIM 
“Third prize, sort of, thing. Better than a poke in the eye with a sharp pencil, 
but that’s about all.” Elena (P37); positive discharge; SIM 
Whilst some patients mentioned that they used methadone to stop feeling sick, 
another group of patients highlighted that they continued to feel unwell whilst using 
methadone. 
“Yeah, I suppose, I mean with the methadone, it was really always, it was the 
least worst option, if you see what I mean. It was a compromise. During those 
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whole two years I don’t think there was ever a day when I really felt well, if you 
see what I mean, when I really felt fully able to function. I functioned to a 
certain extent but it was a struggle. I had to make myself, more or less.” Pam 
(P19); positive discharge; SIH 
It was clear - and is indicated in the quotes above – that patients had ambivalent 
feelings about methadone, whereby they felt things may have been worse without it, 
but the fact that it did not prevent them wanting to acquire illicit heroin meant that they 
also felt resentful towards it. Patients did point out that methadone did alleviate 
withdrawal experiences. 
“Although I wasn’t sick during the day, there was something like an itch that 
wasn’t being scratched; there was something missing. So I always ended up 
using. Even though I wasn’t physically sick, I wasn’t physically withdrawing.” 
Gerry (P20); long-term IOT; SIH 
“It just stopped me…give me a security to know that I weren’t going to be sick 
and I just carried on using, but it weren’t going to stop me using, no matter.” 
Ron (P27); long-term IOT; SIM 
As highlighted above, ultimately patients mentioned that with methadone they felt like 
something was missing – they weren’t achieving the high that they chased through 
the use of heroin, and without heroin there was the feeling again that something was 
missing. 
“I did try, there were lots of times when I reduced the methadone, came off 
the methadone, went into rehab, came out of rehab, was clean, worked, did 
all the normal stuff, but it always felt like there was something missing.” Gerry 
(P20); long-term IOT; SIH 
“The problem with methadone is because you do not get a little rush that you 
get off of heroin, people tend to take something else just to get that, so they 
might do a bit of whizz, or quite a lot of people have a hit of whizz, because 
that gives them a rush you see.” Oliver (P16); long-term IOT; SIH 
Some patients felt that methadone stopped them from feeling unwell, however it did 
not completely eliminate cravings. 
“All it done, it stopped you being sick, but it did nothing for the cravings of 
wanting the feeling that heroin gave you. And so that would lead to you 
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wanting to inject heroin, or take it somehow, but I’d have to inject it because 
smoking it didn’t work anymore. When I first started taking it I’d smoke it. But 
methadone has some effect where it numbs the feelings of heroin. It takes 
some of the goodness…” Shane (P21); long-term IOT; SIM 
“The United States President, Clinton, said he was smoking but he didn’t 
inhale. You know, he was smoking pot but he didn’t inhale so what’s the point 
and methadone is a little bit similar in the sense that, you know, yeah okay it 
does do the job, you know, you don’t get ill, you don’t withdraw, but you don’t 
get that slightly, you know, euphoric feeling that you’re always chasing when 
you first start taking heroin. So it’s frustrating, that’s why people use on top.” 
Elena (P37); positive discharge; SIM 
It was clear that the sense that something was missing was interwoven through a 
number of patient narratives. That loss was experienced in the lives of these opiate 
users was highlighted earlier on in their narratives, heroin filled this void, yet 
methadone was not an efficacious substitution. It may be that as time went on 
achieving the euphoria or high that heroin provided became less of a drive for patients 
and this will be discussed further in chapters eight and ten (Impact and Effect of IOT 
and Recovery). The dominant narrative was that whilst methadone alleviates the 
symptoms of withdrawal and that without it things would have been much worse, 
heroin provided something that methadone did not, and patients still desired this 
effect. 
“Although everyone is glad to get it, life would be terrible without it, you can 
go to work, you can function, but there's always something missing.” Gerry 




Chapter summary and discussion 
 
Overall this chapter illustrates more comprehensively the instability and chaos that 
was particularly characteristic of the lives of the IOT sample. It demonstrates how 
heroin use began, how use continued, and became habitual and destructive. This 
illustrates the entrenched nature of the heroin dependence of this sample. There were 
a number of factors that led to initiation into, and maintenance of, habitual heroin use, 
with these factors feeding in to each other and the overall cycle of habitual 
dependence. Significant negative life events, family breakdown and the influence of 
a peer group, or influential individual, were dominant themes across the sample. 
Some patients used other drugs, and sometimes this was implicated in transition to 
heroin, either as a natural progression from habitual drug use or by using one drug to 
alleviate the negative effects of another. From here patients had distinct narratives 
around the transition to injecting, habitual use, and then treatment. Again the 
influence of others was a factor here, along with an increased tolerance; requiring 
more of the drug to achieve the desired effects of the drug.  
Once dependence was established the impact of the addiction was strongly 
experienced – through loss in other elements of patients’ lives; such as the loss of a 
home, loss of a job, involvement in crime and the criminal justice system. Alongside 
this, conventional treatment failed for patients and the desire for the high that heroin 
provided was still sought. Positive experiences (including initial experiences) with 
heroin and the desire for the euphoric effect heroin provided was emphasised 
consistently, perhaps providing a sense of relief from negative life events and the 
growing sense of loss. A sense of loss and a feeling of emptiness were strong overall 
themes in patients’ accounts of their heroin use history. However, patients also 
reported periods of abstinence and protective factors, for example when children were 
conceived or born, or during periods of residential rehabilitation. This demonstrated 
an ability to achieve maintenance or abstinence if there was particular – and perhaps 
meaningful enough – motivation, and the right support was in place. Overall it was 
useful to have reflections on heroin use history from those at various stages of 
recovery – including those former entrenched, refractory users who are now 
completely abstinent from both heroin and maintenance treatment. 
Following on from heroin and treatment history; chapter seven provides an outline of 




Chapter 7 – Findings: Referral to Injectable Opiate Treatment 
 
This chapter begins the description of patients’ trajectory through IOT. This 
examination of trajectory begins with factors and perspectives associated with referral 
to IOT. The chapter allows the illustration of synergy and conflict between factors and 
perceptions at treatment outset and at the time of interview (i.e., following longitudinal 
IOT) and thereby illustrates the evolving nature of the recovery journey through IOT. 
These analyses may provide useful information for policy on IOT practice and 
regimen duration, and OST treatment generally. Some sub-themes were expressed 
across various sections of the trajectory – such as hopes and goals, and worries and 
fears – these occurred at both IOT outset and following (and reflecting upon) long-
term IOT. 
Themes identified within the Referral to IOT chapter include: motivations (and for 
which sub-themes comprised: failings of conventional treatment - as also outlined in 
chapter five – ‘free heroin’; motivated by others; desire for change; and positive 
expectations); expectations (including both positive expectations and - an expectation 
of - IOT maintenance); perceptions (again encompassing positive expectations, and 
also scepticism and resistance). Goals were a prominent feature of the referral to IOT 
process and analysis and are outlined in detail. Goals included: stability/normality; 
cessation or reduction of illicit use; disengagement with the drugs subculture; to 
improve family relationships; harm reduction; and some patients described the 
absence of goals at treatment outset. These sub-themes are illustrated, analysed and 
discussed in the context of the IOT trajectory. A timeline or trajectory was particularly 
pertinent in the context of IOT policy, and the unanswered question with respect to 
IOT treatment duration. Trajectories were often clear and sequential and the chapter 
aims to illustrate both the similarities and differences across patients’ trajectories and 
perspectives. The trajectory is further illustrated through several following chapters: 
experience of IOT; recovery; current situation and goals for the future. 
To ascertain how patients had come to injectable treatment and the RIOTT trial, 
patients were asked about this; often this discussion progressed organically following 





Table 42. Outline of ‘Referral to Injectable Opiate Treatment’ chapter themes and sub-
themes 
Reference Theme Sub-theme 
7.1. Motivations  
7.1.1.  Failings of conventional treatment 
7.1.2.  ‘Free heroin’ 
7.1.3.  Motivated by others 
7.1.4.  Desire for change 
7.1.5.  Positive expectations 
7.2. Expectations  
7.2.1.  Positive expectations 
7.2.2.  IOT maintenance 
7.3. Perceptions  
7.3.1.  Positive expectations 
7.3.2.  Scepticism and resistance 
7.4. Goals  
7.4.1.  Stability and normality 
7.4.2.  Cessation or reduction of illicit drug use 
7.4.3.  Disengagement with the drugs subculture 
7.4.4.  Improve family relationships 
7.4.5.  Harm reduction 





Referral to Injectable Opiate Treatment 
 
This chapter describes patients’ experiences and perceptions of their referral to IOT. 
This encompasses how patients first heard about IOT, who they heard it from, their 
initial perceptions of IOT, and their motivations and goals. 
 
A description of the Injectable Opiate Treatment referral process 
 
To provide context to the account of referral to IOT as described by patients, the 
referral process, as outlined in Strang et al. (2010) is first described. Chronic heroin 
addicts (aged 18–65 years) receiving conventional oral maintenance treatment (for at 
least six months) were eligible for the RIOTT study if they were continuing to inject 
illicit heroin regularly (more than 50% of days in the preceding three months). In 
practice the discussions were only initiated with individuals with extensive history of 
repeated failure to benefit properly from treatment (John Strang, personal 
communication, January 2016). Patients were enrolled from the local catchment 
areas of supervised injecting clinics in south London, Darlington, and Brighton. 
Patients were enrolled and screened for eligibility by the doctor or lead nurse at the 
study site, and patient eligibility was double-checked by a research worker. Patients 
provided written informed consent after they were screened for eligibility and before 
randomisation. The following chapter describes patients’ experiences and 
perceptions of encountering and beginning IOT. 
 
Motivations, expectations, perceptions and goals 
 
Analysis of the results found that the Referral to IOT data could be divided into four 
sections: motivations; perceptions; expectations and goals. 
Patients’ motivations involved several meta-narratives which were based on both past 
and present experiences and situations, and perceptions appeared to be both 
internally and externally driven. Motivations stemming from past experiences included 
the fact that conventional treatment had historically failed; and motivations stemming 
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from present experiences included an explicit and strongly expressed desire to 




By way of context, and by definition, patients in the qualitative study (and the UK IOT 
trial) were those who were all in conventional opiate treatment (i.e., usually oral 
methadone) at the time of referral to IOT. 
 
7.1.1. Failings of conventional treatment 
 
A number of patients highlighted failings of conventional treatment in their narrative 
around referral to IOT. Expressed within this was a sense of desperation with their 
current situation with a parallel expectation of great success with IOT. Reaching the 
end of the line with the lifestyle and difficulties requisite for acquiring and taking 
heroin, along with despondency about conventional treatment and a strong sense of 
hope around effectiveness and outcome of IOT sometimes appeared to be the 
springboard from which IOT patients were able to embrace IOT and later make 
changes. Failings of conventional treatment was expressed by the entire sample 
encompassing all typologies; including those who were retained in long-term IOT, 
those who were subject to clinic closure, positive dischargers and those who were 
negatively discharged (as defined in the typology chapter). 
“Well, I just thought… I'd tried everything else that had been offered, because 
I can't cope with detox.” - Richard (P34), negative discharge; SIM 
“I was down in the queue, in the queue with all of these hundreds of people 
waiting to get their methadone down at [service name] or whatever it's called, 
and this geezer; big lump of meat, decided that he wanted to get in front and 
so we started arguing, so I pointed out to him that it didn't matter what he was 
going to do he'd still have no bollocks left after I'd cut them off, and Stephen 
pulled me to one side and said ‘Listen, we've got this treatment, how do you 
fancy doing it?’ And I looked at all these people, and I thought do I really want 
to suffer this every day? No I don’t. And I don’t care what it had been, what it 
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would have been, I didn't care, just get me out of there. And that was how it 
came to be.” - Oliver (P16), long-term IOT; SIH 
The above quote indicates desperation for change without fully knowing the detail of 
what was involved; simply the opportunity and – perhaps hope - for a change to the 
current situation appeared to be a sufficient motivator. 
“I told you it was chaotic and there was nothing, it was like a shining light, 
there was nothing apart from this, there was nothing on the horizons.” - Lee 
(P36), long-term IOT; SIH 
In the case of the above patients, IOT was still being received at the time of interview. 
A number of patients expressed that prior to IOT they were in a desperate state and 
that nothing currently available would or could help them. From a number of 
perspectives, IOT appeared to provide patients with the sense that finally their needs 
were being understood and addressed.  
“When I found out what it was, I thought ‘Ah, the government is finally going 
to treat an illness like it is an illness.’” - Oliver (P16), long-term IOT; SIH 
 
7.1.2. Free heroin 
 
Across the sample a proportion of patients explained that motivation stemmed from 
the fact that by entering IOT they would have access to ‘free heroin’; but, without the 
chaos associated with sourcing and acquiring illicit drugs. This was expressed by 
those with both positive and negative discharge statuses and – at the time of the 
interview - long-term IOTs; and by those originally allocated to both SIM and SIH. 
‘Free heroin’ as a motivator was not indicated by the small sample of clinic closures. 
“Greed. So, I was using, it was more drugs, so it was just a way of knowing I 
wasn’t gonna wake up sick, and I had injectables, that was my mentality at the 
time, you know what I mean? It was just a street drug mentality. I was in a 
hostel. I was using as much as I could get my hands on, and this was just a 
little top up…No, it was just more drugs, to be brutally honest with you.” - 
Charlie (P3), positive discharge; SIH 
Across the sample the baseline situation was illustratively chaotic, and patients 
expressed difficulty with disentangling themselves from this chaos. At this stage 
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patients may not have had any reflective awareness of recovery, or motivation for 
change – both factors which were illustrated within patients’ narratives on recovery, 
and will be illustrated thematically and contextually in later sections. The idea that 
some patients did not have reflective awareness for their recovery at this stage was 
further corroborated by the assertion that the patient perceived that he was still in a 
‘street drug mentality’ - as illustrated above.  
“Yes, it worked really quite well, but I was selling Big Issues at the time to fund 
my heroin use and …when I didn’t have to sell Big Issues to fund my heroin 
use that was quite nice.” - Sammy (P11), long-term IOT; SIM 
Patients illustrated that their situation was made a little easier through IOT. That their 
main goal was to gain access to ‘free heroin’ was illustrated by a number of patients 
in the context of there being three treatment conditions, and as summarised by one 
patient ‘A one in three chance’ of receiving heroin. Subsequent analysis, quotes and 
case note reviews illustrate how this mentality progressed over time. 
“It was still a trial then, so my main concern is whether I’d be allocated to the 
heroin group or not... Mainly, the question was, ‘Do I get heroin or will I be 
allocated to one of the other groups?’” - Pam (P19), positive discharge; SIH 
The overall contextual relevance is that, later on, some patients highlighted that as 
they progressed through IOT, this motivation changed; that the motivation for 
recovery and abstinence was preceded by an initial attraction to ‘free heroin’. It was 
useful to gauge perceptions at treatment outset in this context. Similarly, some 
patients highlighted that initially they did not have any goals; that goals developed 
over time, following an episode of stability, and as a consequence of being in IOT. 
That goals evolved over time will be illustrated again later on (in chapter nine: Impact 
of IOT) as it was a key overall theme. The evolving nature of goals was highlighted 
by all typologies: positive and negative dischargers; clinic closures and those in long-
term IOT. 
 
“Not at that time, because I was still in an environment that wasn’t conducive 
to positivity; do you get what I mean? It was only when I moved out of that 
environment, and I, kind of, was in my own environment, thinking, ‘Well, this 
is not what I want no more - using.’ So it was only then that I, kind of, come 
here and, kind of, took it seriously, what I was gonna do. Then I started coming 




Leading on from this – and covered in further detail in the goals theme - was the 
illustration that whilst goals may not have been made by every patient at treatment 
outset; being in IOT over time was conducive to the development of goals and 
engaging with the prospect of recovery. The above patient illustrates the need for a 
period of adjustment and reflective space for personal recovery and goals. 
“I just thought ‘Oh I’m not that lucky, I’m not going to get the morphine’, [patient 
is referring to diamorphine] like. That’s as far as I thought it out really. Yeah, 
no that was my goal; to be on diamorphine. At the time. Then I went up and 
thought this was great and then I thought later on that, you know, well I ain’t 
going to do this for the rest of my life. So, you know. I sort of saw it, or hoped 
it was, you know, something that, you know, I could use, you know, to come 
off of like heroin. That was the goal eventually.” - Josh (P41), long-term IOT; 
SIH 
This quote illustrated the shift; from initially being motivated by ‘free heroin’, to the 
aspiration that IOT would facilitate total abstinence; Josh (P41) remained in SIH for a 
number of years - up until the point of interview. Overall participants were significantly 
motivated by the prospect of receiving medicinal heroin. This supports the quantitative 
indication from chapter four, that participants were very motivated by the promise of 
SIH, to both enter the trial, and remain in their assigned treatment condition until they 
reached the point where they could change to SIH. 
 
7.1.3. Motivated by others 
 
As indicated above, there was a very personal and individual narrative around making 
changes on the basis of repeated negative experiences, as a consequence of, and 
the chaos associated with, a long-term heroin addiction. An additional factor for a 
large proportion of the qualitative sample was the influence of another person on the 
decision to enter IOT. Influential individuals included other IOT patients – for example, 
seeing how well an associate, friend or partner already in IOT was doing – other 
treatment services, keyworkers in other services, and staff at the IOT clinic itself – for 
example, in cases where patients were receiving oral methadone treatment in the 
same clinic. Significant others as a motivating factor was expressed by patients 
across all typologies. 
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“Well it was like a new thing, everyone was talking about it and a close friend 
of mine; an ex-partner, was on it and she was recommending it to me…” - 
Harry (P8), positive discharge; SIM 
Once again, the fact that the treatment was something new is also highlighted in the 
context of significant others. 
“There was a needle exchange plan that used to come on a Sunday. It was 
run by [service name] at that time. And I went out to use the needle exchange, 
and I got talking to one of the guys there, and he was saying to me about this 
RIOTT. I mean, I had heard about it. I’d, sort of, heard rumours and, oh, they 
give you £20 vouchers, and that was, like, that was the most important thing 
about it. But, yeah, he was, sort of, asking me questions about my, sort of, 
using and how long, and what treatment I’d been on, et cetera. And he was 
saying, ‘Oh, it sounds, like,’ you know, ‘you’d be an ideal candidate,’ were his 
words, and he took my mobile number and he said he’d get them to give me 
a call. And, yeah, someone contacted me and I went in for an assessment.” - 
Pam (P19), positive discharge; SIH 
In some cases patients first heard about IOT through seeing somebody they knew 
achieve success with IOT – and this had often been perceived as both surprising and 
inspiring. 
“I couldn’t believe that Andy [patient’s partner and also on RIOTT] was going 
to get through it and he completely transformed, I’ve never known anybody go 
through a transformation like what he went through. And if it worked with Andy 
I knew it would work with me because I knew he’d be… addiction is more 
entrenched in his identity.” - Ellie (P22), positive discharge; SIH 
The fact that from the outset the patient appeared convinced that IOT would work for 
her may have been a significant aspect of her recovery trajectory. 
 
7.1.4. Desire for change 
 
In partnership with the citing of conventional treatment’s failings was a strong desire 
for change; patients expressed that they had tried everything and had reached the 
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end of the line with their heroin using history – to this end, IOT appeared to provide a 
renewed sense of hope: 
“I got to a stage when I was in a hostel that I just didn’t enjoy using in. I didn’t 
enjoy the situation I was in.” - Charlie (P3), positive discharge; SIH 
“Just all the ups and downs; getting bashed with lumps of wood; getting 
robbed. Just everything just seemed to come at once and it was, ‘No, that’s 
enough.’” - Matthew (P17), negative discharge; SIM 
 “Well basically I was willing to try anything at that time and...how do you know 
if something is going to work unless you try it?” - Nicholas (P14), positive 
discharge; SIH 
More specifically patients also spoke about the desire to avoid prison, and health 
issues that had arisen as a consequence of injecting and entrenched addiction. 
“It’s to keep me from keep going to prison and, you know, because I was in 
and out like a yo-yo.” - Fran (P13), long-term IOT; SIM 
“What prompted me was I'd been injecting methadone for over thirty years 
and I had a groin sinus - which is basically a hole in your groin going straight 
through into the vein - and it became… I'd stopped injecting methadone for a 
week and I was using heroin, and where I was pushing the needle in it caused 
a fistula where the two veins meet, and I nearly lost the leg, so I spoke to… I 
was told about the RIOTT trial and I was put forward for it and accepted.” - 
Tom (P9), positive discharge; SIH 
The quote illustrates the collaborative nature of recruitment to the trial, which may 
have been new for patients – the patient outlines that he was informed of the trial, put 
forward for it, and then accepted a place. As well as feeling as though patients no 
longer wished to continue in the chaotic and unhealthy situation, some patients 
appeared grateful for the opportunity to enter IOT and illustrated motivation for 
change on this basis. 
“They let me in and I really wanted to clean my act up.” - Jacob (P4), negative 
discharge (other); SIM 
That the concept of IOT offered hope may have also been linked to the earlier finding 
that patients finally felt listened to and that health care professionals wanted to help, 
following a long period of feeling that treatment was ineffective, and as such, patients’ 
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needs were not prioritised and they were not being listened to. This narrative was 
also illustrated in an earlier section; on patients’ accounts of methadone’s failings –  
“I'd tried every sort of treatment you can imagine, in my own way, although I 
found that the treatment that they offer, I'm going to use the word, I don’t care, 
it's crap. I don't care, I'm sorry for the niceties. But it's absolute bobbins, it's 
absolutely bobbins, it's a waste of time and money and effort, what the 
government is doing I do not know, I don’t care. Their aim was to treat drug 
addicts when really it turns out their aim is to persecute people, prolong agony, 
and ignore the needs of individuals. The only thing that matters with drug 
treatment in this country is that the government is seen to be heavy on people 
that use drugs. What a load of old twaddle; bobbins.” - Oliver (P16), long-term 
IOT; SIH 
Overall there was a strong sense that patients were finally motivated and excited 
about making change, and that they had reached the end of the line with the current 
situation. It was suggested by a few patients that users need to reach this point, of 
desperation or motivation, before change can take place. 
“I’d just had enough, enough of life, prison, everything, you know; and it was 
time to grow up basically, it took a long time to realise but. 
…You just get fed up of doing it, the same old shit every day, stealing. You 
know I went away for the last time for nine months for one car stereo and it 
was just, I just woke up one morning and I thought ‘No this is it; that is it, I’ve 
had enough’, and so far it’s worked.” - Scott (P35), long-term IOT; OM 
“But it’s almost like my philosophy has always been that you will only stop 
when you really want to, you could have all the help in the world but unless 
you’ve really had enough or you’ve really got to want it, well that’s how it was 
for me and I’m sure a lot of other people.” - Harry (P8), positive discharge; 
SIM 
Whilst IOT provided a renewed sense of hope, it appeared that many of these patients 
had already reached a point of motivation to make change; as a consequence of 
years of addiction and associated negative and difficult experiences. The desire to 
change or make a change was expressed across the entire sample; narratives 
encompassing all typologies and treatment groups. 
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7.1.5. Positive expectations 
 
Linked to desire for change (and touched upon within ‘Failings of conventional 
treatment’) was a strong sense of hope, and an expectation of success with IOT. 
Success was conceptualised as a treatment that would be sufficiently reinforcing to 
alleviate the desire to use illicit heroin and thereby reduce the chaos and instability in 
patients’ lives, as a consequence of the heroin using path. Patients had positive 
expectations about the effectiveness of IOT. 
“I expected 100% success from it. I knew it was the answer to all my dreams. 
I put it right at the top of a pedestal.” - Shane (P21), long-term IOT; SIM 
“I’d heard so many good things about RIOTT, I just thought this could be my 
chance to kind of get some kind of order in my life yeah.” - Andy (P23), positive 
discharge; OM 
Both Shane (above) and Ron (below) were originally assigned to SIM treatment, and 
are long-term IOTs. 
“But they told me about this trial that was going on and I said ‘Well that sounds 
interesting’ and I prayed; for the first time in about 15, 20 years, that this might 
give me the strength to stabilise me self.” - Ron (P27), long-term IOT; SIM 
Within patients’ narratives was an expectation of effectiveness with IOT. 
Effectiveness was conceptualised through allusions to perceived purity and potency, 
the injectable nature of administration and a more favourable comparison to 
methadone treatment. Effectiveness was conceived as a regimen which alleviated 
the desire to use illicit heroin during OST. 
Following referral to IOT, prominent themes included positive expectations, a sense 






7.2.1. Positive expectations 
 
Positive expectations are covered above in the motivations theme, and is a cross-
cutting sub-theme within the expectations theme. 
Linked to this was the narrative of one or two patients who specifically wished to 
demonstrate IOT’s effectiveness. That patients knew they were in a trial evaluating 
the effectiveness of a treatment that they believed in, may have motivated desire for 
change. Patients demonstrated that they wished to perform well through IOT. This 
may have been a powerful force within patients’ recovery journeys. 
“I'll tell you why if you're interested. It's just that I wanted to change things and 
the only way you can change things is by being attractive to them, by standing 
out. You won't stand out if you were carrying on dabbling, and you're just one 
of the crowd. But if you can be the one that is clean, they might be interested.” 
Oliver (P16), long-term IOT; SIH.  
The quote suggests that the patient perceives an improved situation if he conforms, 
through cessation of use of illicit heroin. A positive expectation as a motivating factor 
at treatment outset was expressed by the whole sample, including all typologies and 
treatment groups. 
 
7.2.2. IOT maintenance 
 
Length of IOT treatment was an inconclusive yet topical discussion. Patients were 
asked for their perceptions of this, following their experience of IOT. A significant 
proportion of the sample expressed that they specifically had the expectation of IOT 
maintenance or long-term IOT at treatment outset. Some patients altered their views 
on this – as mentioned earlier and covered later - since goals sometimes changed 
over time. 
“Although I was looking for maintenance at first but in the back of my mind I 
knew I could use this to get off.” - Tom (P9), positive discharge; SIH 
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That this view shifted was illustrated by several patients. 
“Well like my goals have sort of changed through my treatment. I wanted it to 
be maintenance and now, you know, I sort of see the impracticalities of that 
now.” - Josh (P41), long-term IOT; SIH 
In contrast, a number of patients held the view that IOT should be a maintenance 
treatment, and this view had not changed by the time of interview. 
“The only thing I wish I could change is: I don’t know what their expectations 
are but my expectations is that I wanted a maintenance dose. I wanted it 
forever until I said “I don’t want it no more”. - Shane (P21), long-term IOT; SIM 
The perception or hope of IOT as a maintenance treatment was an expectation across 
all typologies, aside from the clinic closures. There was particularly strong 




7.3.1. Positive expectations 
 
As previously positive expectations was a cross-cutting theme and has been outlined. 
 
7.3.2. Scepticism and resistance 
 
Whilst the majority of patients were excited by IOT, it was interesting to discover initial 
resistance to the concept of IOT from a smaller sample of patients. Whilst smaller, 
the theme of scepticism and resistance was indicated by patients across all 
typologies. 
“And my worker here, Penelope, she kept suggesting RIOTT and I kept saying 
“No I’m not going to go on it, I can’t see how injecting is going to stop me 
injecting”, but it did.” - Trevor (P24), negative discharge; OM 
Once again, the progressive nature of the patient’s perception is illustrated, and 
implicated – in this case through experience. Several patients cited specific fears, 
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such as the structure of an IOT regimen, and in particular, the requirement for every 
day attendance at the clinic, as the cause of their resistance. Patients feared that they 
would not be able to adhere to the required structure. 
“At the beginning I wasn’t totally convinced that it was really what I wanted, or 
that it was really – well, I wanted heroin but I wasn’t really that convinced about 
having to go there seven days a week, twice a day, whether I’d actually 
manage it, and whether it would, yeah, whether I would just find it too much, 
simply. Initially, I was quite apprehensive about going there twice a day.” - 
Pam (P19), positive discharge; SIH 
That attending a clinic for a medicinal dose of heroin removed the associated lifestyle 
aspects of addiction was initially the source of resistance for one patient – Ellie (P22); 
upon hearing about IOT this patient initially perceived it as giving up, or – in her own 
words - the equivalent of being emasculated. 
“It’s a difficult habit to break isn’t it, the whole lifestyle side of it, being able to 
earn the money, I mean, I think the thing that puts addicts off coming here is 
the, you know like the equivalent of being emasculated, you know, like, you 
make the money, you earn it, you get your drugs, you go home, you don’t 
have to answer to anybody, that kind of thing. I can see why a lot of addicts 
think, well if you go there it’s almost like you’re selling out, in – you’re prepared 
to be in the system and you’re losing your, you’re going there like a scrounger, 
you’re going every day and getting it for free without putting any work in, do 
you know what I mean? I definitely had a sense of that; I remember the first 
time hearing about it I did think ‘Oh well that’s just giving up; that’s just the 
most depressing thing I’ve ever heard of in my life’, I didn’t possibly conceive 
then that it could be a way to recover.” - Ellie (P22); positive discharge; SIH 
It was useful to discover that some patients viewed IOT unfavourably upon initially 
hearing about it, and that this then progressed to a strong motivation to recover. By 
way of illustration using a specific trajectory; in Ellie’s (P22) case this was a 
progression away from IOT and on to slow release oral morphine (MXL). That patients 
had some initial resistance to IOT was expressed by patients across all typologies 
and both injectable treatment conditions. 
Linked to fears and uncertainty, several patients spoke about fears of making goals 
at treatment outset, in case these fears subsequently failed. This is also a cross-
cutting sub-theme in the next theme: goals. With such an entrenched, unremitting 
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history of heroin addiction, a number of patients did not appear to have an example 
of abstinence that they could envisage, perhaps undermining confidence that they 
could break the cycle of addiction. This was illustrated by the comments of one patient 
who highlighted the fact that he had not ever met anyone in successful recovery. 
Patients demonstrated a lack of faith in their own ability to cease use of heroin 
because their internal resources and confidence appeared to be low, yet they did not 
feel supported by the external world, with conventional treatment failures, peers with 
similarly entrenched addictions, and likely perceived judgement from wider culture or 
society. The strength of the impact of a peer group was also highlighted in the 
previous chapter, in the context of initiation into heroin use.  
Several patients experienced ambivalence about whether to change their IOT at the 
point where they were able to move from their assigned treatment group (for example, 
SIM) to SIH, and ultimately decided to remain in their assigned treatment. This was 
an interesting finding and applied to those with both positive and negative discharge 
statuses. Examples included being satisfied with SIM - for one - with another 
experiencing some anxiety around injectable diamorphine due to a parent dying due 




A large majority of patients spoke about the goals that they had made at treatment 
outset and these goals had clear themes. These themes are as follows. 
 
7.4.1. Stability and normality 
 
That patients’ experience stabilised and remained stable throughout IOT was cited 
by a large number of patients at various stages of the interview; this will also be further 
outlined later on in thesis (in the recovery and goals chapter). A large number of 
patients directly alluded to the concepts of stability and normality. Stability was a 
prominent goal across the sample; interestingly though, the only typology not making 
reference to stability or normality were negative dischargers. Otherwise this was a 
prominent theme and mapped across all other typologies. 
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“I made it clear from the start, I just wanted to feel comfortable… I want to just 
feel normal - whatever normal is - but I just wanted to feel normal...” - Nicholas 
(P14), positive discharge; SIH 
“I was just seeking a normal lifestyle; I wanted away from it all.” - Gerry (P20); 
long-term IOT; SIH 
“This was my big chance to sort my life out.” - Fran (P13), long-term IOT; SIM 
In addition to achieving stability, patients spoke about more specific goals that they 
had made. These centred around reducing or ceasing illicit use (which was reported 
by a large majority of qualitative patients), disengaging with the drugs sub-culture and 
the criminal justice system, improving health, harm reduction, improvements to family 
and attachment relationships, engagement with work, education and activities, and to 
improve housing. A commonly reported phrase was the desire to get one’s life in 
order. 
“Well, like, getting everything sorted out: my housing, and sorting things out 
with my family; all my court cases; stop going to prison; stop ending up in 
hospital, you know, and stop ending up with all these fines, and no more 
shoplifting, you know, so there’s a lot of things.” - Fran (P13), long-term IOT; 
SIM 
“When I came here like my goals was, you know, to be stable… and, you 
know, to have as much morphine as I needed to like live a, what I thought 
would be, a normal life.” - Josh (P41), long-term IOT; SIH 
Overall patients had a large number of important goals they wished to achieve 
through IOT. A number of patients mentioned that they wanted to change, or to make 
change. Introduction to the idea of IOT may have prompted motivation for change. As 
also indicated, patients may have felt that their needs were being understood through 
the introduction of IOT. 
“I just knew the time was here; it’s time to change. I just knew it was time and 




7.4.2. Cessation and reduction of illicit drug use 
 
A large proportion of the qualitative sample voiced the desire to cease use of illicit 
heroin at treatment outset, with a smaller number of patients mentioning the desire to 
reduce illicit use. Some patients wanted to make clear that they saw IOT as a 
treatment and not just as an opportunity to obtain ‘free heroin’. Sometimes 
respondents perceived that other patients in IOT were primarily motivated by ‘free 
heroin’. The desire to completely cease use of illicit heroin was prominent and applied 
thematically across all typologies.  
“But I really wanted to get off it, I really wanted to get clean, I didn’t want to, it 
was a free hit, do you know what I mean, I never looked at it like that like when 
I know some people did, get a ‘free heroin’ hit, go down the road spend it on 
crack. I didn’t do that, you know.” - Jacob (P4), negative discharge (Other); 
SIM 
The tendency to judge other patients’ experiences and trajectory arose at various 
points across interviews. In the case of reduction as the goal, this was sometimes 
followed by the reflection that this would, or had then, led to the desire to cease illicit 
use completely – once again indicating the importance of the space for a trajectory of 
recovery. 
“Yes it was to reduce, it was definitely to reduce. 
…basically cut down as much as I could. If not with a view to stop completely, 
but at least to take as little as possible and that’s why it’s been good to switch.” 
[to oral morphine tablets; MXL] - Elena (P37), positive discharge; SIM 
Patients also had goals around other drug use and the implication of heroin use (and 
ultimately IOT) on this. 
“I knew that once I didn’t have to score heroin I wouldn’t be vulnerable to 
crack, and that was the thing that was really harming me.” - Shane (P21), long-
term IOT; SIM 
This quote introduces the perception of IOT as a harm reduction approach – a sub-




7.4.3. Disengagement with the drugs subculture 
 
Disengagement with the drugs sub-culture was a prominent goal and links to the 
above goal; to cease illicit use. In the main, narratives about disengagement with the 
sub-culture centred around interactions with dealers, other drug users, and the 
criminal justice system. A significant proportion of patients explained that, through 
IOT, the goal was to stop cycling in and out of prison. Others mentioned keeping the 
dealers at bay and others still wished to cease criminal activity; such as shoplifting in 
order to source money for drugs. Through ceasing engagement with these activities 
patients’ lives became less desperate and chaotic, providing more space – physically 
and psychologically - for engagement with recovery. 
“Well, I knew that I wouldn’t have to go out shoplifting every day, because 
that's what I was doing before I had the injectables. I was out burgling. 
Anything to make money.” - Wayne (P30), clinic closure, SIM 
“So I weren’t spending every waking hour making money and spending it on 
drugs.” - Ron (P27), long-term IOT; SIM 
Once again this theme was pertinent to patient narratives across all typologies. 
 
7.4.4. Improve family relationships 
 
Several patients mentioned that by stabilising through IOT they hoped to improve 
family and attachment relationships and fulfil familial roles – including parental roles 
– in ways that they would like to, and that had become fractured or unfulfilled because 
of dependent heroin use. 
“Sort things out with my mother and father and stuff, because my dad doesn’t 
talk to me. He still doesn’t now. My mum and dad's separated because of all 
this.” - Kevin (P33), clinic closure; SIH 
“I just wanted to get my life back to normal. I don’t even remember what it's 
like to have a normal life. But when I got on the morphine I got a taste of it, 
what it was like to be normal again, you know what I mean? I had money in 
my pocket, buy myself new clothes, treat my son and stuff like that. Stuff that 
I can't do anymore. So it was a better, positive, and that's what I wanted to do; 
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I wanted to get off it and then eventually get myself a job. So I had goals.” - 
Susie (P32), clinic closure; OM 
The above quote illustrates a number of factors. The first that whilst unspecific goals 
were sometimes made by patients at treatment outset – for example, to ‘get my life 
back to normal’, which was a commonly reported phrase across the cohort – 
experiencing IOT illustrated a taste of holistic stability. This is directly highlighted by 
Susie, and is a theme that was illustrated across the dataset. This taste of stability – 
perhaps for the first time in these patients’ lives (a point which is validated by findings 
in the ‘heroin use history’ chapter) – appeared to subsequently introduce an ability 
and motivation to make more concrete goals, and inspired longer-term engagement 
with recovery. The quote illustrates the evolving nature of patient goals, as they 
progressed through an IOT trajectory. Secondly, it illustrates that gains made during 
IOT were negatively affected by the disruption and cessation of IOT (most illustratively 
in the case of Darlington patients) – i.e., “I had money in my pocket, buy myself new 
clothes, treat my son and stuff like that. Stuff that I can’t do anymore.” It also suggests 
the sense of an unfulfilled aspiration (perhaps because IOT ceased before patients 
felt ready to leave, for this region’s cohort) – for example the comment, ‘So I had 
goals’. 
The desire to improve family relationships was reported across the following 
typologies – long-term SIH, negative discharge and clinic closure - and all three 
treatment groups. This theme is outlined again in narratives on the ‘Impact of IOT’ – 
in a preceding chapter. 
 
7.4.5. Harm reduction 
 
A number of patients perceived IOT as a mechanism by which they could reduce the 
harm that they were causing to themselves through dependent intravenous drug use. 
Overall IOT was perceived as clean and clinical and therefore less likely to cause the 
harms associated with illicit injecting. Patients highlighted the damage that illicit 
injecting had caused them to date, and the hope that IOT would halt this trajectory of 
harm. Narratives centred around the physical harms caused by illicit injecting. 
“And I thought oh I might be lucky, I might be able to get like morphine then, 
and that, and really whack away all my problems with heroin and cocaine and 
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all that, because I used to inject left and right. I’ve got scars all over, at the 
back of my neck and everything, yeah.” - Iain (P25), positive discharge; SIM 
“Just really to sort of stop injecting. My long term was just to stop injecting, 
stop hurting myself. Because as you get older your body just does not repair 
itself as quick, and I don’t know why but I kept getting abscesses. And I was 
careful, like, everything was clean all the time.” - Cheryl (P40), positive 
discharge; SIM 
The above quotes indicate an awareness of the dangers of illicit injecting, even when 
needles and equipment are not being shared, and therefore the appreciation of a 
clinical injecting setting. This is illustrated and discussed again in the next chapter; 
‘Experience of IOT’. Harm reduction was also a theme cited within the ‘Impact of IOT’ 
chapter. The harm reduction narrative was only expressed by those who had 
originally been assigned to SIM treatment. Relevant discharge typologies for which 
the harm reduction theme applied to included only long-term IOTs and positive 
dischargers. 
 
7.4.6. The absence of goals at treatment outset 
 
A number of patients spoke about their lack of goal-making at treatment outset – as 
highlighted earlier- and this centred around the idea that patients for whom this related 
to were not in a stable enough place at treatment outset to psychologically engage 
with the concept of goals. For some, ‘free heroin’ drew them to IOT, and others feared 
that goals would just fail and thus feared making them. This was in contrast – and has 
been illustrated – to those who appeared to have reached the end of the line with their 
heroin using trajectories, and saw IOT as a shining light at the end of a dark tunnel. 
It is important to represent both trajectories. 
“You cannot have any goals when you’re living unhealthily, can you? You 
come in and you poodle in the mornings, you leave here, your head’s not with 
it, you come in...” - Jack (P2), positive discharge; SIH 
“When I first entered RIOTT I had no aims, I had no, I was living on the streets, 
I was living in a bin cupboard basically and I just like… I don’t really have 
expectations with anything I just – didn’t know what to do and where to get out 
of, I knew I needed help and I was just, it was one of the directions I found 
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and so I headed that way, and thank God I did really.” - Jacob (P4), negative 
discharge (Other); SIM; 
Jacob is clearly thankful for IOT – Jacob was in injectable methadone treatment, and 
as illustrated had a negative discharge (other) discharge status, in this case due to a 
skin reaction to SIM. This demonstrates the usefulness of IOT for a shorter period (in 
this case 18 months) to interrupt the cycle of entrenched addiction and harm. The 
absence of goals at treatment outset applied to patients within all treatment conditions 
and discharge typologies. 
Other goals highlighted by a smaller number of patients included the desire to save 
money, the desire to get a pet (commonly a pet dog – and the responsibility of this 
was also later alluded to in connection to motivation for maintained stability, i.e., a 
protective factor from relapse or lapse), to stabilise housing and to engage (or re-






At referral to IOT, patients described that, to date, they had tried everything they could 
in efforts to cease use of illicit heroin. These efforts had historically failed. Patients 
expressed a feeling of misery and hopelessness with their current situation, 
excitement about IOT and a sense of hope – that IOT was a shining light on a bleak 
horizon. Patients highlighted that, through IOT, their needs were finally being 
understood and met. From another perspective ‘free heroin’ was a strong initial 
motivator for some patients – and the fact that they would no longer feel sick. Patients 
were clearly able to start making wider lifestyle changes once they were receiving 
IOT. Indeed, some patients highlighted that as they progressed through IOT their 
motivation evolved; that the motivation for recovery and abstinence was eventually 
preceded by an initial attraction to ‘free heroin’. This progression to more healthy 
goals added strength to the proposal that entrenched heroin users benefit from 
longitudinal IOT specifically, and that recovery is a trajectory. 
Additionally whilst some patients illustrated that they did not have goals at treatment 
outset, specific goals did develop over time for these individuals. This was also the 
case for those who perceived IOT less favourably at treatment outset. At treatment 
outset, patients were also influenced by other individuals, to enter IOT. Again within 
this sub-theme there was a strong sense that IOT was something new and different 
that represented a sense of hope where previous treatment had not. That IOT was 
new and caught patients’ attention was clear. Both professionals and personal 
contacts were motivating factors to patients entering IOT.  
The backdrop to these external motivators appeared to be a strong internal motivation 
to make a change, across the sample. This appeared to arise out of a felt sense of 
having tried all the alternative options, as well as no longer being able to tolerate the 
chaos associated with illicit heroin use. Patients were motivated by wider issues such 
as health and criminal justice involvement and the desire to change the unhealthy 
cycle they were in. Alongside this was a sense of gratitude and a desire to make a 
change through the context of the structure and support that IOT provided. That 
patients were primed at treatment referral to make change added weight to the use 
of IOT as a second line treatment; and more specifically, the prescribing of this unique 
treatment to those already at this motivated stage of recovery. 
Many patients viewed IOT in a positive light from the outset, and had a high 
expectation of success with the regimen. Here the strength of being in a trial itself is 
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highlighted – as is found and debated across IOT treatment of the past (outlined in 
the introduction) – and is illustrated clearly within patients’ narratives. Patients 
asserted that they wished to illustrate support for IOT’s effectiveness. It was likely the 
case that patients had the same intention when undertaking the qualitative interviews 
and this will be further reflected upon in the discussion, from a policy perspective. The 
future of IOT was a question mark at the time of interview and this was the perception 
held by a number of patients interviewed. It was interesting to find, however, that 
some patients may have refrained from using illicit heroin in order to demonstrate the 
effectiveness of the treatment.  
Treatment timeline was discussed with two main narratives, one with individuals 
perceiving that IOT needed to be an ongoing maintenance treatment, and others who 
perceived that IOT should be time-limited. There was particular prominence of the 
wish for ongoing maintenance treatment amongst those in long-term IOT; it could be 
the case that the longer patients remained in IOT, the more anxious they became 
about leaving IOT. However this was not demonstrated by those with positive 
discharge statuses, and therefore not all IOT patients. 
Whilst many patients perceived IOT favourably, and with a sense of hope, there were 
others who had felt resistant to the structure of IOT at treatment outset. In one case 
this was linked to an attachment to the identity of an illicit drug user, and in this case 
IOT was seen as ‘selling out’. This patient later discharged positively, by means of 
Slow Release Oral Morphine (MXL) treatment. Resistance to IOT also revealed itself 
through a fear of making goals in case they failed. Whilst a number of patients were 
excited by the prospect of IOT at RIOTT’s inception, patients commonly demonstrated 
low levels of internal and external resources and support and this may have 
undermined faith, confidence and the ability to make productive goals, until they had 
consistent evidence that IOT could be a way to recover. A smaller number of patients 
also experienced resistance at a later stage in their trajectory, and decided to remain 
in their assigned treatment condition, namely SIM treatment, as opposed to switching 
to SIH treatment following six-months of their assigned treatment. 
As discussed in the introduction (and also by Uchtenhagen, 2015) an interesting 
finding of the RIOTT trial was the poor outcome of conventional methadone treatment 
for these patients, as experienced prior to enrolment onto IOT, in comparison to 
optimised oral methadone treatment (the control condition within the RIOTT trial). 
Overall it appeared that the promise of SIH gave renewed hope to patients and this 
sense of hope was the springboard for beginning a journey of recovery. This validates 
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the quantitative finding that patients were very motivated by SIH (as demonstrated in 
chapter four by patient retention to SIH treatment, and the prominent movement – as 
soon as patients were able – to SIH from other modalities, and retention to non-
preferred treatment modalities until this point). As discussed later, positive 
psychological processes were specifically demonstrated in ongoing recovery. Internal 
motivations included positive expectations – perhaps connected to past failure, desire 
for change and a sense of hope – and external motivations included motivation by or 
because of significant others. Some patients had clear goals at treatment outset, and 
as will be illustrated later on, these goals remained constant at later stages of 
recovery. 




Chapter 8 – Findings: Experiences with Injectable Opiate Treatment 
 
Following patients’ referral to Injectable Opiate Treatment, this chapter provides a 
description of patients’ experiences with IOT. The chapter outlines what patients 
perceived to be important elements of the treatment experience and includes aspects 
which involved more than just the administration of medication. Experiences divided 
into three superordinate themes; Components of the regimen (comprising both 
injectable opiate medication, and the holistic and psychosocial dimensions of 
treatment) and treatment duration.  
Sub-themes involved in components of the regimen – medicinal and clinical - 
comprised the following sub-themes. The first was ‘Medication experiences’. This 
firstly begins by outlining experiences of Supervised Injectable Heroin. Sub-themes 
here include: Positive experiences; Comparisons to illicit heroin; Comparisons to SIM; 
and Disappointments or negative aspects of SIH. Secondly, experiences of additional 
doses of oral methadone are outlined. Finally, experiences of Supervised Injectable 
Methadone are described. Sub-themes here include: Effectiveness; Comparisons to 
Supervised Injectable Heroin; and Negative aspects of Supervised Injectable 
Methadone treatment. 
The second overall sub-theme within the Injectable Opiate Medication theme is: 
Getting the right dose. This is followed by Route of administration; and then 
Frequency of daily clinic attendance for supervised injecting. The final sub-theme 
within the Injectable Opiate Medication theme is Clinical injecting environment. 
The second overall theme is Components of the regimen – Holistic and psychosocial. 
There are a number of sub-themes. The first is Holistic and psychosocial (this forms 
a specific sub-theme within its own theme); the second is Supportive environment. 
This theme breaks down in to four further sub-themes; Staff and environment 
(including and followed by negative perceptions of staff); and other patients (including 
and followed by negative perceptions of other patients). The next theme within Holistic 
and psychosocial is Gratitude. This is followed by Person-centred care and autonomy 
over treatment decisions. This is (linked to and) followed by Service-user involvement. 
Then Lack of autonomy and control over treatment decisions, and finally 
Individualised treatment journeys. The final theme is Treatment duration. This 
encompasses the following sub-themes: Ambivalent about abstinence; Desire for 
long-term Injectable Opiate Treatment; Patients control over treatment duration; 
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Short-term Injectable Opiate Treatment and Returning to Oral Methadone Treatment. 
The themes and sub-themes in this chapter are listed and referenced below. 
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Table 43. Outline of ‘Experiences with Injectable Opiate Treatment’ chapter themes 
and sub-themes 
Reference Theme Sub-theme 
8.1. Components of the regimen  
8.1.1. Components of the regimen – 
Injectable Opiate Medication 
Experiences 
 
8.1.1.2.  Medication experiences 
8.1.1.2.1.  Experiences with Supervised 
Injectable Opiate Treatment 
8.1.1.2.1a.  Positive experiences 
8.1.1.2.1b  Comparisons to illicit heroin 
8.1.1.2.1c  Comparisons to Supervised 
Injectable Methadone 
8.1.1.2.1d  Disappointments or negative 
aspects of Supervised 
Injectable Heroin treatment 
8.1.1.2.2  Experiences with additional 
doses of Oral Methadone 
treatment 
8.1.1.2.3.  Experiences with Supervised 
Injectable Methadone 
treatment 
8.1.1.2.3a  Effectiveness and comparisons 
to Supervised Injectable 
Methadone 
8.1.1.2.3b  Negative aspects of 
Supervised Injectable 
Methadone treatment 
8.1.2.  Getting the right dose 
8.1.3.  Route of administration 
8.1.4.  Frequency of daily clinic 
attendance for supervised 
injecting 
8.1.5.  Clinical injecting environment 
8.2. Components of the regimen – 
Holistic and psychosocial 
 
8.2.1.  Holistic and psychosocial 
8.2.2.  Supportive environment 
8.2.3.  Staff and keyworker 




8.2.5.  Positive perceptions of other 
patients 
8.2.6.  Negative perceptions of other 
patients 
8.2.7.  Feeling grateful 
8.2.8.  Person-centred care and 
autonomy over treatment 
decisions 
8.2.9.  Service-user involvement 
8.2.10.  Lack of autonomy and control 
over treatment decisions 
8.2.11.  Individualised treatment 
journeys 
8.3. Treatment duration  
8.3.1.  Ambivalent about abstinence 
8.3.2.  Desire for long-term Injectable 
Opiate Treatment 
8.3.3.  Patient control over treatment 
duration 
8.3.4.  Short-term Injectable Opiate 
Treatment 






8.1. Components of the regimen 
 
Patients’ accounts of their experiences of Injectable Opiate Treatment were divided 
by two main elements; medical or clinical aspects of receiving IOT and the holistic 
and psychosocial elements of the treatment programme. 
 
8.1.1. Components of the regimen – Injectable opiate medication 
experiences 
 
To provide context, specific detail about treatment received during the RIOTT trial is 
outlined in section 1.8.1 of the introduction. Overall, patients described experiences 
with the medicinal and clinical elements of the treatment. 
 
8.1.1.2. Medication experiences 
 
8.1.1.2.1. Experiences with Supervised Injectable Heroin 
 
When directly asked about this treatment medication, as opposed to the overall 
experience of IOT, overall themes about Supervised Injectable Heroin encompassed 
the following sub-themes: Positive experiences; Comparisons to illicit heroin; 
Comparison to SIM; and Disappointments or negative experiences. 
 
8.1.1.2.1a. Positive experiences 
 
There were a lot of generally positive comments about SIH, with some degree of 
vagueness about why and how this was. 
“And I tried it and I’ll be honest with you, and I don’t say this just willy nilly, it 
was like...something I’ve never had before. …but when I first done it...I went 
‘Jesus Christ, I’ve never felt like that before’.” [VB: “Was it a good 
experience?”] “It was a, I don’t know how you explain what the experience 
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was, but it was an experience where brown could never give me; heroin could 
never give me.” Nicholas (P14); positive discharger; SIH 
Additionally, patients explained that Supervised Injectable Heroin numbed emotional 
pain. 
“It made you mellow a little bit. I stopped anxiety and that, you know, because 
after my mam and dad died, my brother died as well, do you know what I 
mean? So I was left on my own really, and that battered my head, so I get a 
bit anxious and that now and again and that sorted it out. It was just a mellow… 
thing, you know?  …After about twenty minutes you felt a little bit mellow.” - 
Richard (P34); negative discharge; SIM 
 
8.1.1.2.1b. Comparisons to illicit heroin 
 
A number of patients conceptualised their views and perspectives about the 
Supervised Injectable Heroin treatment they received through comparisons to illicit 
heroin. There was often some degree of neutrality about the experience of the 
medication. In the case below it was perceived as better than both methadone and 
illicit heroin, though interestingly, not as something the patient would actively go out 
and buy.  
“Oh, completely different. It was two different drugs. It’s a different drug; 
morphine and heroin are completely different; you know what I mean? One 
gives you a buzz. One, kind of, maintains you, but it does what it says on the 
box. … It wasn’t nothing great; it wasn’t something I’d go and buy, do you 
know what I mean, but it was better than methadone and it was better than 
using.” - Charlie (P3); positive discharge; SIH 
Overall perspectives were very mixed. 
“…even though it wasn’t what I did expect, my expectations, as in it wasn’t the 
heroin I was using on the street, it wasn’t the same feeling; it wasn’t….” - Harry 
(P8); positive discharge; SIM 
“The fact that you’re injecting it … I mean it wears off after eight hours like 
that, really quickly.” [VB: Is that different to street heroin?] “Yeah it’s … street 
drugs wears off more gradually because it’s got other things in it like sedatives 
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and hypnotics and they’ll bulk it out with anything.” - Shane (P21); long-term 
SIH; SIM 
Some patients outlined satisfaction with the purity of medicinal diamorphine. 
“It was as good, if not better, than street stuff. At least you knew it was clean.” 
– Wayne (P30); clinic closure; SIM 
 
8.1.1.2.1c. Comparisons to Supervised Injectable Methadone Treatment 
 
When compared to Supervised Injectable Methadone comments were generally in 
favour of SIM, as outlined in detail in the SIM section (which follows). 
 
8.1.1.2.1d. Disappointments or negative aspects of Supervised Injectable 
Heroin Treatment 
 
In contrast, several patients outlined disappointment with SIH, often by virtue of the 
fact that SIH did not live up to their expectations, or was strange or unpleasant. 
“I found it pretty weird because I didn’t know what to expect, but I felt safe 
because I was with professionals. I wouldn’t have done so in somebody else’s 
house. It seemed weaker to me…. Weaker than the methadone.” Clara (P7); 
positive discharge; SIM 
It was interesting that a number of patients explained that they would not have paid 
for, or taken the clinical diamorphine they received through the IOT treatment 
programme recreationally.  
“I thought I’ll take diamorphine and stop using the street gear altogether. But 
never worked.” - Euan (P38), negative discharge (other); SIM 
“Well all you kept hearing was that it was 100% heroin, and that, and you just 
thought oh that’s going to smash you out of your head. And it wasn’t; it was 
totally different. It’s a weird feeling but you used to be able to put it in your vein 
but it was instant then, it was horrible, it was just all in one, the rush that was 
totally different from a gear buzz.” - Scott (P35), long-term IOT; OM 
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Some patients highlighted non-adherence to protocol in the initial stages of treatment. 
For example, several patients spoke about the fact that they had previously submitted 
false urine samples and therefore were not adhering to the required structure of the 
programme at that particular time. 
“I mean, to be perfectly honest, because of the benzos, I was not always 
honest, and my urine samples were not always mine...but I was, I think, 
reasonably discreet about it, and, I mean, probably they know that sort of stuff 
goes on.” - Pam (P19), positive discharge; SIH 
SIH was, nevertheless, satisfactory for the majority of patients. 
 
8.1.1.2.2. Experiences with additional doses of oral methadone treatment 
 
Those on SIH were prescribed additional doses of oral methadone since injectable 
diamorphine is not as long-acting as oral methadone treatment, and therefore patients 
may have suffered withdrawal before their next morning’s diamorphine injection. 
Comments about being on oral methadone were often negative – and specifically that 
it was not sufficiently reinforcing to reduce the craving, desire or need for illicit heroin. 
Patients gave their perspective on additional doses of methadone. 
“Methadone has a very good use but only one use, what I believe, and it's 
working for me, it is working for me, is that what you need to do is breakaway 
from the street gear completely, have a short time on your methadone, to use 
as little as possible, to stay well. Now you can use the 24 hour cycle now, to 
your advantage and not the advantage of GlaxoSmithKline, or whoever these 
drug dealers are, and you stay away from the street drugs, and it keeps you 
well.” - Oliver (ID 16), long-term IOT; SIH 
A different set of comments were elicited about the efficacy of methadone, when it 
was prescribed in addition to IOT, with some patients perceiving it as necessary for 
their recovery, and others’ opinions perceiving it as unnecessary or ineffective. 
Patients typically came from a perspective whereby they had come to strongly dislike 
methadone, and perceived that it wasn’t fit for purpose, however another sample saw 
it as absolutely necessary and - as also illustrated earlier – that life with a heroin 
addiction would be much worse without it. 
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“It was like when they give you the methadone at the end of the night, no one 
needs it, no one needs it, and if people come in and say they do, I’d say, 
‘You’re a liar,’ do you know what I mean, because you don’t. Everything you 
get here will hold you for the next day.” - Charlie (ID 3), positive discharge; 
SIH 
“Whether I needed it or not. I doubt if I needed it. But I think I could probably 
have done without it….I think a lot of people didn't use it, you know. I know at 
least one person handed it back after a while. Yeah.” - Reg (ID 12), long-term 
IOT, OM 
“I used to get 50ml of methadone to take home…. And then eventually I 
started cutting down, but then I got a bit too eager, you know, like, ‘I’m cured,’ 
sort of, thing. I was, like, ‘Yeah, I’m gonna cut down 10 ml a month,’ and I was 
doing that, and I think that’s when I relapsed, because I went too quick.” - Fran 
(ID 13), long-term IOT, SIM 
The above quote illustrates the need for a structured and gradual reduction 
programme – from additional methadone doses as well as from IOT. Once again, 
aside from clinic closures (for reasons previously outlined) all discharge statuses were 
represented within the negative comments about methadone sub-theme. 
 
8.1.1.2.3. Experiences with Supervised Injectable Methadone treatment 
 
The two main themes from discussions about Supervised Injectable Methadone 
concentrated on, firstly, the effectiveness of this treatment (which was often 






8.1.1.2.3a. Effectiveness of Supervised Injectable Methadone treatment and 
Comparisons to Supervised Injectable Heroin treatment 
 
Interestingly several patients spoke about the decision to remain on Supervised 
Injectable Methadone at the six-month point (i.e., the point at which patients could be 
assessed with a view to switching to SIH). This was often because patients felt the 
treatment was effective enough. Naturally the majority of patients within this theme 
were those who began on Supervised Injectable Methadone, with a much smaller 
number who had started in another treatment group (one OOM and one SIH) and at 
some point in their trajectory had switched to Supervised Injectable Methadone. The 
theme spanned all discharge statuses however. 
“Yeah. I could have gone onto that [SIH] after six months, but I decided to stay 
on methadone. [VB: Why was that?] Because the injectable methadone, that 
worked for me and I used to see people really out of their nuts and gouching 
as soon as they’d done it and I didn’t want to be going home, sitting on a bus 
or going anywhere and be gouching in front of people.” - Daniella (ID 1), 
negative discharge (other); SIM 
This is contrary to the narratives of other patients who stated that some degree of 
intoxication was desired and appreciated. This again indicates the importance of a 
treatment or recovery trajectory perspective, and how priorities changed during IOT, 
but at different stages for different people. At the beginning patients may have craved 
the effect of heroin, but the further they progressed through their journeys of recovery, 
the less they desired this effect, and stability became more of a priority. 
“When I was sat in the waiting room listening to them all saying how great it 
was and it didn’t cost you now’t and you’d see them yourself off their faces. 
And I was very tempted to give it a try but, as I say, the doc … didn’t have to 
persuade me very hard, he just said I was doing well as I was so I said ‘Right, 
fine, I’ll stay as I am’”. - Rita (ID 29), negative discharge; SIM 
Some patients stated that it was the injectable nature of the treatment that had the 
biggest impact on their recovery and this applied to injectable methadone treatment 
also. 
“But what the injectable methadone did for me was make me aware that I 
didn’t have to find a vein for, I don’t know, because I was still taking street 
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drugs. It had a big effect on me that first six months. It got something … maybe 
it got the heroin, or my injecting, under control, I can’t remember. But I know 
thinking, thinking back it was, wasn’t as bad. You see it was the fact that I was 
injecting it, you know, psychologically … the big thing, yeah. …Don’t take 
away the injection.” - Shane (ID 21), long-term IOT; SIM 
Here the significance of the injectable nature of this treatment is clearly illustrated –
this element of the treatment appeared to be enough to keep some patients satisfied 
with SIM. Favourable comparisons were sometimes presented in the context of SIH 
not fully meeting patients’ expectations, as well as the desire to function and achieve 
greater stability in other areas of the patient’s life. 
“There was a point, I do remember, at a later stage in the treatment that I 
noticed a couple of patients were reverting back to the injectable methadone 
and I thought about it, I was having serious thoughts of going back on it myself 
because I did see how good it was, having experienced diamorphine and 
realising it wasn’t all that it was hyped up to be or what I expected it to be and, 
like I say, it being once a day because I started wanting some time back to 
start getting into other things in society but yeah, I thought it was really good, 
really positive.” - Harry (ID 8), positive discharge; SIM 
 
8.1.1.2.3.b. Negative aspects of Supervised Injectable Methadone treatment 
 
In equal balance to the effectiveness sub-theme were negative comments about SIM. 
The majority of negative comments related to physical reactions and complications 
caused by SIM treatment. The following quote indicates the ambivalent nature of 
these negative perceptions, in the context of being treated by a drug that was keeping 
the patient well. 
“Well I was having bad effects off it, really bad, all my skin was going hard, I 
couldn’t get a needle into my legs no more it was just bending the needles 
because like I’m solid all over, there’s nowhere else I could get the needle in 
me anymore. Had to go on to oral…. bad reaction I was getting through 
injecting with methadone; it was like putting poison in me, it was, but I needed 
it to be well, I can’t function when I’m ill like and it wasn’t making me well, so 
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with all the bad effects I was getting off it I was still getting a benefit.” - Jacob 
(ID 4), negative discharge (other); SIM 
Once again the majority of patients were those who of course were assigned to SIM, 
and the theme cut across all discharge statuses in equal measure (with slightly less 
clinic closures, as usual, because this sample was so much smaller than those other 
discharge statuses). 
“Basically, the methadone was okay, but I found that it burnt out my veins very 
quickly. …It’s very toxic.” - Clara (ID 7); negative discharge (other); SIM 
In the quote below, ambivalent feelings about SIM are clear, with the comment that 
whilst the patient felt that SIM ‘held’ him, he still had the desire to use illicit heroin, 
whilst on SIM, indicating that SIM was not sufficiently reinforcing to cease this urge.  
“It was holding you, doing its job, but I was, nevertheless, still using 
unfortunately but again that went for a lot of patients that were on it at the 
time.” - Harry (ID 8), positive discharge; SIM 
Once again, this quote illustrates the tendency to compare one’s progress to the 
progress of other patients in the trial, and in this case by a process of normalising 
their experience. This also signifies that for some patients injectable methadone was 
not sufficiently reinforcing to alleviate the urge to use illicit opiates. 
“The first six months of my treatment I was on injectable methadone. …And 
that was my excuse to carry on with the street drugs and all that lot.” - Shane 
(ID 21), long-term IOT; SIM 
“I had bad veins in those days when I first got injectables down here, I was 
put onto injectable methadone initially but because I was using very small 
surface veins the alcohol that the methadone’s suspended in leaves you with 
sort of ulcers and blisters and things, so I went to see Doctor Smith about it 
and he swapped me over onto diamorphine.” - Fay (ID 10), long-term IOT, OM 
Overall, the analysis of injectable methadone treatment adds further weight to the 
idea of progressive recovery and stability, and illustrates its role in the context of IOT 
and the patient’s overall journey of recovery - and notably, the divergence of views 




8.1.2. Getting the right dose 
 
Patients described the process of getting the right dose and a positive experience of 
this process was interpreted favourably. Patients felt that getting the right dose was 
a factor that contributed to cessation of use of illicit drugs. A number of patients stated 
that they had then subsequently chosen to reduce their dose. 
“Yeah, definitely. They were really good. You were always asked about if you 
wanted to go up or you wanted to go down.” - Stacy (ID 5), positive discharge; 
SIM 
“The dosage came up to a point where I wouldn’t feel the street drugs but this 
is a point where I don’t know how much of this is going to be lost because the 
reason for it is because it was a trial, it’s the fact that it was an optimised 
thingy, as long as it was safe you were able to say you wanted your dose 
increased. … I was able to say I want to increase my dose, it wouldn’t happen 
overnight but the fact that option is there and it happened and I did keep 
increasing my dose and the point of that is that then because all the time in 
the meantime because you haven’t got the whole life of having to survive as 
an addict on your six hour treadmill.” - Ellie (ID 22), positive discharge; SIH 
The patient above compares routinely provided IOT to IOT that was provided as part 
of a research trial (RIOTT). This was a common comparison throughout interviews 
and will be discussed in greater detail in the discussion chapter. 
Low doses and reductions had a role in triggering lapse or relapse. 
“I’ve only really started having a problem again with it [illicit heroin] as my dose 
has been reduced.” - Sammy (P11) long-term IOT; SIM 
 
8.1.3. Route of administration 
 
When patients began IOT they administered their treatment injection intravenously, 
unless they had no available veins. As time went on intramuscular injection was 
encouraged. The majority of patients spoke favourably about intramuscular injecting, 
with a smaller number mentioning negative aspects to this route of administration. 
Equal numbers of patients spoke favourably about the intravenous route, as 
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compared to negatively; overall, preferences were mixed. Positive comments about 
the IV route of administration occurred across all typologies aside from the long-term 
IOTs, and negative comments about the IV route occurred across all typologies aside 
from the clinic closures. Positive comments about IM cut across all typologies aside 
from long-term IOTs, and negative comments about IM were by those on injectable 
methadone only – including all discharge statuses aside from long-term IOTs. This is 
perhaps expected as those in long-term IOT all moved over to SIH, with no patients 
(in the qualitative sample) remaining in long-term SIM. 
Interestingly one patient explained that by continuing to inject intravenously he felt 
that he was still connected to ‘using’ (illicit heroin). It was interesting and encouraging 
that patients eventually wished to sever this connection, and suggests a desire to 
move away from this way of life – this is another example of progression along the 
treatment trajectory, and illustrates the subtle nature of factors relevant to recovery 
within the treatment regimen. This is an interesting contrast with the – earlier - 
narratives that highlighted initially finding it difficult to break away from the drugs sub-
culture and to be receiving their heroin in a clinical setting, and those too, who were 
initially put off joining RIOTT for this reason. 
“I was one of the only ones that was doing it intravenously, as well, because I 
could still get a vein, so I was still doing it intravenously. So I still, kind of, had 
that connection to using. That’s the way I, kind of, thought and then it got to a 
stage where I didn’t want that connection any more with using, so I started just 
intramuscular.” - Charlie (ID 3), positive discharge; SIH 
This aspect of recovery was further emphasised by other patients. 
“I mean when I was using I’d cry if I couldn’t get it but I got used to it and I also 
realised it was part of sort of getting away from injecting heroin, even though 
I was still putting the needle in me; it was all just different…” - Harry (ID 8), 
positive discharge; SIM 
One patient spoke about the difference in the type of ‘hit’ obtained through 
intramuscular injecting. The instantaneous nature of the ‘hit’ achieved by the 
intravenous method was removed through intramuscular injecting. This patient 
received SIM treatment only during RIOTT because he experienced some anxiety 
about SIH and thus decided not to change to SIH at six months. 
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“Because you don’t get a kind of a like that, that pain and then that satisfaction 
straightaway. You just get like the pain and then you sit with the pain and then 
after like ten, fifteen minutes or twenty minutes and you’ve kind of forgot about 
it anyway then and you feel comfortable.” - Iain (ID 25), positive discharge; 
SIM 
Some patients mentioned that the IV hit was too strong, and caused itching, others 
spoke about the fact that the level of sedation from the intravenous route of 
administration was too high for them. Some patients spoke favourably about the IM 
route of administration on the basis that the effect lasted longer. 
“Well IV comes on quick, goes away quick, but intramuscular, even 
subcutaneous, but intramuscular’s better, it comes on slow and stays longer.” 
- Trevor (ID 24), negative discharge; OM 
Other patients spoke about the fact that IV injecting would leave marks on their arms, 
whereas IM injecting did not cause this. Overall, IM injecting was preferred, although 
in some cases it took a period of being in treatment for this perspective to be arrived 
at – again, indicating the specific relevance of a treatment – and recovery - trajectory, 
and perhaps again, indicating the requisite for longer-term injectable treatment for this 
historically hard to treat population. Longer-term treatment allows for this necessary 
period of adjustment. 
“And also actually I found that if anything IM was a lot better. The intravenous. 
Because people that was doing intravenous, okay they were getting a hit 
straightaway. But then, because the time limits of attendance at the clinic was 
twenty minutes, they had to go. So they … it would ruin their buzz; if you got 
one. Whereas with the intra-muscular, you know, you put it in, you get back 
on the bus, you do a little bit of shopping. Within an hour it comes on and by 
then you’re at home and you’re nice and relaxed and you watch Jeremy Kyle.” 
- Elena (ID 37), positive discharge; SIM 
The above quote signifies an ongoing desire for some degree of intoxication from the 
IOT dose, at least at that stage of the patient’s recovery trajectory – this particular 
patient progressed to MXL treatment and was retained in MXL treatment at the time 
of interview. By way of later context this patient had also previously spoken about the 
benefits of being a service-user representative and feeding in to policy work, which 
she said gave her a sense of purpose. 
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8.1.4. Frequency of daily clinic attendance for supervised injecting 
 
In a number of cases, those patients attending the injecting clinic for twice daily 
injections chose to reduce to once daily injections following a period of stabilisation 
and the relevant clinical review. When mentioned, the majority of patients preferred 
attending the clinic once per day as compared to twice per day. Patients cited the 
inability to get on with other tasks during the day and the fact that one’s day would 
then revolve around attending the clinic as a reason for this preference. It is 
interesting – and encouraging – that, over time, patients came to find this 
burdensome, considering the long heroin use histories of this sample of people whose 
lives had previously primarily centred around acquiring and taking heroin. The fact 
that patients came to prefer fewer injections and thereby time free to engage in other 
tasks is a relevant and important aspect of treatment trajectory.  
This contrasts to the perception of some who were initially (at referral to IOT) attracted 
to ‘free heroin’ and were unable to make goals, and demonstrates the progressive 
nature of the trajectory. Typologies specifically mentioning a preference for once a 
day injecting included a positive discharger, a negative discharger and a clinic 
closure, cutting across all three treatment groups. It may well be that negative 
dischargers and clinic closures may not have remained in the RIOTT trial long enough 
to experience the option of switching to once a day injecting, if they discharged at or 
around six months. 
“Because I think the diamorphine is a bit much, to have two injections a day. 
I do think that’s a bit much because your life has to revolve around that.” - 
Stacy (ID 5), positive discharge; SIM 
It was interesting to hear the range of experiences about SIH from patients who did 
not receive SIH during RIOTT, but who instead received SIM – indicating strong 
opinions were formed on the basis of observing other patients in SIH treatment. A 
negative perception of SIH, prior to having had experience with IOT also featured at 
treatment outset, by those who asserted negative or ambivalent feelings towards IOT 
– for example, the idea that accessing this treatment was ‘selling out’. 
Other patients spoke about the fact that diamorphine was not long-acting enough to 
see them through a 24-hour period. Linked to this – and commonly cited by other 
patients in later sections of the interview - was the desire for a take-home dose of 
IOT, and dissatisfaction around additional methadone doses. 
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“For one reason or another they won't give you a takeaway dose, to have at 
night. And it only lasts a maximum of eight hours, then there's three eight 
hours in 24, but you only come here twice, and that’s the maximum. And I only 
come here once. So they have to give you methadone for the times when the 
stuff wears off before you can come here again…. that was a bit of a knock 
back really because now I'm addicted to methadone still.” - Gerry (ID 20), long-
term IOT; SIH 
“I mean honest the only pain about that was going up there twice a day every 
day and that means Christmas, New Year. That was the only down bit, yeah. 
If I had the choice I’d stay on oral methadone now. [VB: Why is that?] I don’t 
know, I just … probably more the fact it’s going up there twice a day every 
day, do you know what I mean?” - Euan (ID 38), negative discharge (other); 
SIM 
In contrast, two patients mentioned that they did not object to attending twice per day 
– one explaining that they would have done anything for the treatment. 
“I didn’t mind, I would have done anything, I would have walked over glass 
bare footed”. - Lee, (ID 36), long-term IOT; SIH 
“I found it all right. I went at half past nine in the morning and I got my first hit. 
I went home. Basically gouched, which is what everyone wants to do anyway, 
and then I went back down at half past one, got my second hit, went back 
home and did that.” - Wayne (ID 30), clinic closure; SIM 
The above quote implies less engagement, for the patient at that stage, with more 




8.1.5. Clinical injecting environment 
 
The majority of patients within the sample spoke favourably about the requirement for 
daily clinic attendance, injecting in a clinical environment, and the positive impact this 
had on recovery in this context. For some, this provided a sense of stability and 
security, which was a source of comfort. 
“Coming into somewhere where you’re used to injecting, say, outside in a 
public toilet, or something, and coming somewhere that’s very clinical and 
people helping you and it’s all clean. You know you’re not going to overdose. 
It was really good. Yeah, so I think it’s really helpful and I think there should 
be more places like it. …You feel safe. Because I’m quite panicky. I suffer 
from anxiety, so when you suffer from that, it’s nice to feel safe.” - Stacy (ID 
5), positive discharge; SIM 
“And it also, it takes away a lot of the – drug use was, sort of, like, it was a 
way of life, and it made it something a bit more clinical and matter-of-fact in 
general.” - Pam (ID 19), positive discharge; SIH 
The rationale in the above quote may be a pertinent factor in patients moving away 
from the drugs subculture whilst in IOT; a goal for a number of patients at treatment 
outset, and the effect of which is considered again in later chapters (as will be 
demonstrated). The appreciation of the need – and the stability that arose as a 
consequence of this requisite - for daily clinic attendance was a prominent theme 
expressed across the sample, including all typologies and treatment groups. 
Generally patients spoke favourably about the clinic and its surroundings; and a 
number of patients spoke of calmness and stability within and around the IOT clinic, 
however a number of patients expressed neutral feelings about this aspect of 
treatment. 
‘It was fine, it was fine. I mean there was nothing wrong with it. - (Elena, P37), 
positive discharge; SIM.  
In addition to this, a number of patients highlighted the fact that they grew to accept 
attending the clinic for injections, or even like doing so, but that initially it was difficult 
to get out of the routine of going to score heroin illicitly.  
“No it was just, as I said, finding it difficult to get out the routine. Doing that 
every day, do you know what I mean?” - Patrick (ID 39), long-term IOT; SIH 
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“I enjoyed … I liked it. I liked going. Well I didn’t to begin with but, you know, I 
got … as soon as you get to know everyone it’s like a nice little social club.” - 
Cheryl (ID 40), positive discharge; SIM 
“And I should imagine that, you know, from going from a hectic lifestyle to 
something like, you know, after three or four months; it was quite a challenge.” 
- Josh (ID 41), long-term IOT; SIH 
Commonly, patients cited positive feelings about coming to the clinic for treatment, 
asserting that it offered stability and routine. This also links to sub-themes in the next 
section where patients spoke favourably about the social side of attending the clinic, 




8.2. Components of the regimen - Holistic and psychosocial 
 
8.2.1. Holistic and psychosocial 
 
Patients appeared to be recovering various dimensions of their whole lives rather than 
just from their addiction and this was explicitly stated by patients in their accounts of 
satisfaction with treatment. Patients made general comments about the holistic nature 
of the treatment. 
“In every way, I think in every aspect to do with a drug addict, it addressed a 
whole lifestyle, not only…” [drug use] - Harry (ID 8), positive discharge; SIM 
“You know, but at the end of the day, you know, as I said, you’re in a clinical 
setting it wasn’t necessarily a medical model because it was very much a 
holistic approach because they were looking at all aspects of your health and 
your situation. And they, you know, they were doing referrals to the liver clinic, 
to the dietician, to this, that and the other. Anyone that had any issues they 
were all addressed.” - Elena (ID 37), positive discharge; SIM 
The fact that the treatment was holistic, and not just ‘a medical model’, appeared to 
be instrumental to the success of IOT for patients. Patients perceived that IOT gave 
them a chance to take stock and start to analyse their previous experiences in a safe 
and stable environment. 
“If nothing else it has benefitted me greatly in experience and opening me up 
to, it’s like a jigsaw puzzle, if that makes sense, when your life’s fragmented 
after what you’ve been through, the front’s at the back, the back’s at the front 
and it’s sort of, even with the rehabs; that confused me even more. It was like 
coming there, everything was laid out and finally being put back in the right 
place.” - Harry (ID 8), positive discharge; SIM 
The above quote suggests that the regimen was appropriately paced for the patient, 
and allowed time for him to explore recovery on his own terms. 
An overall positive mention was the most prominent sub-theme. 
“Just it was probably one of the best things to happen to me.” - Trevor (ID 24), 
negative discharge; OM 
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“Yeah, listen, if anybody said to me about it, I’d say ‘Go and do it now’. That’s 
Dr. Strang; that was the best thing he ever brought.” - Nicholas (ID 14), 
positive discharge; SIH 
Positive comments about the IOT programme were communicated across all 
treatment groups and discharge status typologies. Positive dischargers and long-term 
IOTs were the most prominent of those expressing positive comments, however there 
were a few negative dischargers across this sub-theme also, and one clinic closure. 
 
8.2.2. Supportive environment 
 
The receipt of support through IOT was of great pertinence. Most notably this 
comprised support patients received from the clinic, however, support from friends, 
family, partner and other organisations were highlighted as important and relevant to 
the journey; outside support is outlined in chapter 10: Recovery. 
As indicated, support from clinic staff and other patients were very relevant to patients’ 
experiences.  
 
8.2.3. Staff and keyworker 
 
Patients illustrated that they had enough trust with the clinic staff to report their 
situation (for example, illicit use) honestly, and this appeared to further propagate 
feelings of security within the regimen. Positive mentions about staff, or the 
importance of a positive relationship with staff was pertinent to the narratives of those 
in long-term IOT and positive dischargers (including those from both the SIH and SIM 
treatment groups, though not OM). 
“I pick up my methadone every week. And I dole myself out daily. And I've 
never, in five years, however long I've been here, I've never come here and 
said ‘Oh, I've run out of methadone, I spilt it, I dropped it, the dog ate it.’ It 
hasn’t happened, people tended to tell the truth when they came here. It was 
good. It still is. It is a good place.” - Gerry (ID 20), long-term IOT; SIH 
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The relationship with the keyworker and clinic staff was specifically cited as an 
important aspect of treatment satisfaction and effectiveness, with a range of diverging 
responses. Specific mentions about keyworker and staff had strong prominence 
across the sample. Positive comments were more common than negative, however 
both perspectives were clearly apparent. There were slightly more positive comments 
about staff than negative, and double the number of positive comments about 
keyworkers than negative – however, still a significant proportion of both. It was 
apparent that this relationship was really key to the trajectory of experiences, and the 
impact of judgemental staff was specifically cited; as well as an even greater number 
of patients specifically highlighting the importance of a positive relationship with 
keyworker. Positive comments were expressed most prominently by positive 
dischargers and long-term IOTs, however positive comments were also expressed by 
several negative dischargers and clinic closures. 
“We’ve been really lucky staff-wise. We’ve had a really good set of staff here 
that …They really believe in their patients. They’ll support you as much as 
they’re able to and although being on injectables went a long way towards me 
stopping using class As illegally, it was also the sort of intensive key-working. 
Not so much individual sessions with the key-worker but knowing that I could 
turn up here between sort of nine in the morning and four in the afternoon 
seven days a week if I needed, just to sit down and talk to someone, I know 
that I can pick up the phone or turn up here and someone will always see me.” 
- Fay (ID 10), long-term IOT; OM 
The above quote captures two of the two main elements of the treatment experience 
that this chapter aims to illustrate; holistic and psychosocial support, in addition to 
medicinal and clinical, and their synergistic effect and power. 
“One thing I can say is, all the nurses there were dedicated staff, and people 
who wanted to learn. It’s not down to them, the reasons why patients mess up 
or they don’t, yeah. All the nurses and staff are lovely people.” - Serina (ID 6), 




8.2.4. Negative perceptions of staff and keyworker 
 
A proportion of patients illustrated negative experiences with staff and keyworkers. 
“One of the workers - I can't remember her name - she used to like…  I used 
to get the feeling she used to treat you like a smack-head, if you know what I 
mean? You know: 'You've come for your daily smack' and stuff like that.” - 
Richard (ID 34), negative discharge; SIM 
Negative experiences appeared to produce feelings of helplessness and anger, both 
of which could hinder engagement and recovery. Some of the criticism arose from 
instances of clinical decisions that were made that the patient did not agree with. 
“I started off injecting intravenously, and I chose - I, me - chose to go 
intramuscularly. And did so for three or four months. And then one day I just 
fancied going intravenously. I wanted to; my injection, my body, my thing. And 
I said ‘Please give me a short orange needle’, and then some bloody 
busybody down there said ‘Oh, have you asked permission to go 
intravenously?’ And I said ‘Well no, I haven't actually. And nor do I have to.’ 
And so she flounced off to see the person next door, Dr. Smith, who said ‘Oh 
no, that would be a retrograde step.’ Well it wouldn't be a retrograde step, it's 
my decision, I'm still sticking a needle in my body!” - Gerry (ID 20), long-term 
IOT; SIH 
This links to the strength of the therapeutic alliance, and how key this is within 
pharmacological treatment as well as psychological. Another perspective was an ‘us 
versus them’ perception of doctors and staff versus patients. This signified a lack of 
trust in doctors and senior staff, and perhaps an attitude of simply playing the game 
to one’s advantage, rather than engaging in a collaborative relationship of trust. 
“The powers that are running this thing. They have got these ideas that we're 
born from some Freudian dream of theirs way back when they were at college 
and they believe it to be true. The trouble is, it's not true. To compound this 
error, they have paid a lot of money to promote the lie, to compound it even 
further they believe the lie, even though they can see that there's something 
wrong because it's not doing what it should be doing, so they ignore it. To 
further compound this they ignore everybody else, because who else is getting 
£200,000 a year, who else is looked upon as a god? Definitely not the junkies. 
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And all that does is compound the myth that they're right. And they're not 
right.” - Oliver (ID 16), long-term IOT; SIH 
The opening line suggests that the above quote is specifically referring to senior 
doctors and management, rather than nurses and keyworkers who worked with 
patients daily. Negative comments about staff and keyworkers were expressed 
across all treatment groups and discharge status typologies. 
 
8.2.5. Positive perceptions of other patients 
 
Relationships with other patients in the IOT community was also an important aspect 
of IOT for some patients. Minor within-client issues (such as within-patient romantic 
relationship difficulties) were highlighted, but little impactful disharmony was cited. 
The majority of patients highlighted how positive within-client interaction was, and in 
some cases the beneficial effect this had for their recovery. 
“Because when you ain’t got no work or nothing, it’s something to look forward 
to; you meet people outside; speak to people; come upstairs; have a banter 
with the staff; sit down, sit and have a cup of tea or whatever and then go. So 
if you’re not working, which I was working most of the time, but a lot of the 
time it was quite a nice experience. You had something to do. If you didn’t 
have that you would literally be sitting indoors all day. So you could sit there 
and meet up with a couple of guys, walk round one’s house, have a cup of tea 
or the local charity shop. …There was three people that I used to mix with on 
a regular basis. We all used to meet here early, because I used to have to go 
to work, and the other one used to pretend he used to have to go to work most 
of the time, and then the other two just used to turn up early anyway.” - Charlie 
(ID 3), positive discharge; SIH 
For Charlie, support from other patients appeared to be of significant importance to 
his recovery. 
“I say this was the biggest thing that helped me give up drugs; do you know 
what I mean? Like, the people; the staff; the environment; coming here every 
day; the friendship, the kindness of the staff and the people and that, because 




As mentioned earlier, a number of patients spoke of calmness and stability within and 
around the IOT clinic, with positive relations between patients and staff and within the 
client group.  
 
8.2.6. Negative perceptions of other patients 
 
In contrast, a smaller number of patients highlighted the lack of trust with or dislike for 
other patients in IOT. 
“Other patients. I find them really unhelpful. A bit like I said earlier there’s 80 
people [inaccurate figure] that attend that clinic we should be a really tight knit, 
we should have some power, but each one will stitch the other one up at the 
drop of a hat. There’s no solidarity, there’s no bond. I only have a loy’… like a 
loyal trust. I only trust one person, one other patient there. The rest I don’t 
trust. They’d either get you in trouble for their own benefit at the drop of a hat, 
you know.” - Shane (ID 21), long-term IOT; SIM 
The above quote was particularly interesting, as the patient in question seemed on 
very friendly terms with both staff and patients alike, from the researcher’s 
observations within the clinic waiting room. The above quote may have been referring 
to the current day IOT clinic, which included some RIOTT trial patients, along with a 
number of newer patients who had entered IOT post-RIOTT. Patients sometimes 
expressed neutrality on the topic of connections and friendships with other patients in 
the treatment programme. 
“I knew everybody, but it was on a basis of, ‘Alright?’; ‘Goodbye’.” – Nicholas 
(P14); positive discharge; SIH 
Overall, and unsurprisingly, this experience varied across the sample, but when 
patients did perceive support and trust amongst patients, this was attributed as a 
contributory factor to effective recovery. A positive or neutral experience was 





8.2.7. Feeling grateful 
 
A powerful motivator for change – and perhaps a change from previous experiences 
- for patients was the fact that they felt supported, respected and listened to. 
“Again, I’m just very, very grateful for the support and help that I got here, and 
how they understood not - like, as I said - not to rush in, not try to implement 
things without my say-so, and even if it didn’t work, we was allowed to go back 
again and start again. That’s what I’m grateful for; being listened to.” - Charlie 
(ID 3), positive discharge; SIH 
A sense of gratitude for IOT, and the clinic and staff was described by numerous 
patients. It is likely that the experience of gratitude is a psychological process 
implicated in successful and progressive recovery. The above quote also introduces 
the next sub-theme: Person-centred care and autonomy over treatment decisions. 
 
8.2.8. Person-centred care and autonomy over treatment decisions 
 
That treatment and care was person-centred and patients had autonomy over 
decisions that were made during their journey through IOT was a prominent theme 
across the sample and permeated multiple sections of interviews.  
 “That’s actually the thing about it that I think this treatment offers that no other 
treatment can offer, that it gives you the opportunity to actually look at your 
relationship with heroin and to genuinely make a choice. I think Pam’s [another 
patient on the RIOTT trial – qualitative ID 19] the first person who said that to 
me and that really hit home; you can’t choose not to have something if you’re 
not given the choice.” - Ellie (ID 22), positive discharge; SIH 
The power of having the option to say no to a drug that patients had spent decades 
of their life addicted to, was highlighted in other parts of interviews. That these 
patients perceived that they had never had the option to say no to the drug previously 
– and that this ability to make a choice was implicated recovery - was a powerful idea.  
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A number of patients articulate the realisation that the choice to stop using heroin is 
theirs – that there was no expectation for them to cease illicit use and remain in 
treatment - and this realisation carried great weight.  
“It was almost like, for me, it was like given that choice it was like, well look, 
no one is telling you you can’t, you’re not in prison, you’re free of will, you can 
do it this way or go back to…so it was just great in every way.” - Harry (ID 8), 
positive discharge; SIM 
The above and following quotes clearly articulate the power of treatment autonomy 
and the role this had in recovery. Patients felt that they discovered the importance of 
autonomy and control as they progressed through IOT. 
“As far as making my own decisions, it wasn’t really like I went in there, ‘Oh, 
this is a principle of mine and that’s the way it’s gonna be.’ It was just 
something that I discovered during the treatment, that it made a difference. 
That the fact that I no longer felt like I had to, so it felt like my decision, and 
it’s really more a matter of hindsight, looking back, that I’m thinking, ‘Well, 
that’s what made the difference,’ if you see what I mean...and it wasn’t really 
at the time so much that it felt like that, it’s just, sort of, looking back over the 
process. For me I think that’s what made a big difference. Yeah, that it came 
from me; that it wasn’t something that was outside pressure, ‘Oh, you’ve gotta 
stop.’” - Pam (ID 19), positive discharge; SIH 
A number of patients cited the fact that having the control to make decisions about 
their treatment – such as dose changes – was a pertinent factor in subsequent 
recovery. As is demonstrated, the majority of these comments were by patients 
classified as positive discharge within patient typologies, perhaps indicating that 
reflections on the strength of treatment autonomy were only realised by those who 
had made their own decisions through to discharge from IOT. Person-centred care 
and autonomy applied to both injectable treatment groups (SIM and SIH). 
 
8.2.9. Service-user involvement 
 
Within each clinic there was a system whereby a pool of patients could take on the 
role of service-user representative, or a service user representative group who would 
work together for a period of time. This individual or group would liaise between 
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service-users and clinic staff in efforts to improve elements of the treatment service. 
A number of the patients who were interviewed for the qualitative study had at some 
stage taken on this role in their respective clinic. This role was highlighted as a 
prominent feature of individual recovery. This role gave patients more control over 
their treatment and provided a meaningful and important activity following the 
cessation of an activity (using heroin) that had been so central to their lives. The quote 
below is an example of one patient commenting on being a service-user 
representative; and the role this activity had in her recovery. 
“But it’s more like having found another direction because before, you know, 
although I was comfortable, I’ve never been in trouble, I’ve never been to 
prison, I’ve got a clean everything, you know, clean record and all that. But I 
was a bit floundering. I was, you know, ‘What am I going to do? Where am I 
going?’ You know. Now I’m stable.” - Elena (ID 37), positive discharge; SIM 
The patient describes the need for – and importance of - recovery in dimensions of 
life above and beyond cessation of use of illicit drugs. Patients were recovering wider, 
holistic areas of their life. Those who identified as service user representatives or who 
alluded to this role within their recovery trajectory were all positive dischargers or 
long-term IOTs, and across all three treatment groups.   
 
8.2.10. Lack of autonomy and control over treatment decisions 
 
In contrast, several patients cited a lack of service-user involvement or control, or that 
the idea of service-user control was an illusion that wasn’t real. When perceived this 
way, this was a factor of great dissatisfaction for patients. These narratives permeated 
clinical decision-making, including dosage and dosage changes and the decision to 
leave IOT and/or move on to Slow Release Oral Morphine (SROM or MXL). 
“No, they like to bend over backwards to make you think that you’re involved, 
but you’ve got shit input; no input whatsoever. It’s, like, ‘We listen to you but 
that’s about all. At the end you do what we say,’ which is how it goes, isn’t it?” 
- Luke (ID 18), negative discharge; OM 
“I'm doing everything, anything they ask me I do, everything. I've never said 
no, they’ve never had to punish me or force me or nothing. But when I ask for 
something, it's usually refused.” - Gerry (ID 20), long-term IOT; SIH 
272 
 
Lack of patient control or autonomy was a feature of patient dissatisfaction with 
treatment. The following quote illustrates the detrimental effect lack of autonomy or 
person-centred care had on the patient’s recovery. 
“There was a little bit of peer pressure as well. Dr Jones wanted something 
back from me, in order for me to get, you know, to stay on the dose I was on, 
like, the treatment that I was on, because he wanted me to have extra days 
off. And I said to him, ‘I’m not ready.’ I was having one day off, I’d already lost 
my afternoons, and it was all going too quick. And then I started getting a bit 
stabilised, and then he wanted me to have another day off, and I said, ‘No, I’m 
not ready,’ and he said, ‘Well, you know, you’ve gotta bite the bullet.’ It was 
the worst thing he could have done for me, because I ended up using.” – Fran 
(P13), long-term IOT; SIM 
It was interesting that some patients perceived a system of give and take with 
clinicians, whereby they had to make changes stipulated by clinicians in order to 
maintain other areas of treatment. The quote illustrates the negative effect of 
attempting to move patients through the regimen more quickly than they are ready to 
make particular changes. This again adds imperative to person-centred, flexible, and 
individually paced regimens. 
Negative experiences around patient control (and lack thereof) included negative 
experiences with clinical decision-making, such as perceived forced dose reductions. 
Some other patients mentioned that they felt their current dose could be reduced, and 
yet this was not encouraged. Other negative aspects of decision-making included 
being discharged from IOT (e.g., for violations of clinic rules), being moved on to MXL 
and being encouraged to reduce the number of injection days per week. Finally, some 
patients perceived that there was a lack of service-user involvement, and that 
perceived incorrect or unfair decisions led to a temptation to use.  
“In the prescribing policy, say it's a weekend and there's not a doctor here, so 
if something happens at the weekends you're going to be suddenly put out in 
the cold and saying 'No, you can't have an injection today', so I think… Just 
on those few occasions that's where I've heard a lot of other people say 'Oh, 
right, I'm going to go and buy a bag of heroin'.” - Tom (ID 9), positive 
discharge; SIH 
Below is the narrative from one patient who was prevented from injecting 
intravenously, and hence needed to inject intramuscularly, as a one-off, and illustrates 
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the unhappiness that this caused. The potential effect of restricting patient control and 
autonomy over treatment decisions was illustrated within this narrative. 
“I was very close to just going outside and getting hold of anything, score off 
the first person that I saw, that I thought might sell drugs, and getting some, 
just so I could go intravenously. It was a stupid attitude.” - Gerry (ID 20), long-
term IOT; SIH 
Overall, perceived lack of control and autonomy was demonstrably detrimental to 
engagement and recovery, and this applied across the sample, including those with 
both long-term IOT, negative, and positive discharge statuses.  
 
8.2.11. Individualised treatment journeys 
 
Linked to autonomy over treatment decisions, was the realisation and reflection on 
the need for individualised programmes of recovery. By way of example, one patient 
highlighted that she felt like she was perceived as a “star pupil”, and as such received 
favourable treatment, perceiving that other patients were treated differently. 
“I did, sort of, have the feeling, because I was, sort of, a little of a, maybe, I 
dunno, a star pupil there, sort of thing, doing really well and all that. And, yes, 
I can, sort of, understand it all, so you don’t wanna mess someone up who is 
doing really well, but then when I’d see other people in the same situation and 
they didn’t get their dose, I’d, sort of, feel a little bit, hmm, you know, like, ‘So, 
what’s different about me, sort of thing?’” - Pam (ID 19), positive discharge; 
SIH 
By way of possible explanation, another patient highlighted the importance of an 
individualised treatment regimen, and highlighted the fact that in practice this could 
be perceived as different treatment (in both senses of the word) for different patients. 
This links to the idea – and importance - of an ongoing reflective awareness of the 
individual recovery journey. 
“The fact that they know you really well and that you could be truthful and they 
do like plant seeds for ideas of ‘Don’t you think that you’re being a little bit lazy 
sitting on your arse for a bit?’ And then I’d think, well why is he not saying it to 
that person, that person’s been on this programme for longer than me, but 
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then it’s obvious; because that person’s not there yet.” - Ellie (ID 22), positive 
discharge; SIH 
This quote directly illustrates the need for, and strength of, an individualised treatment 
trajectory. Perhaps, also, the need to highlight the rationale for the importance of the 
individualised nature of care-plans to IOT patients, to avoid confusion and resistance. 
 
8.3. Treatment duration 
 
How long patients should be maintained in IOT was unexplored in the literature and 
an exploration of this was one of the thesis objectives. Perspectives on treatment 
duration involved ambivalence about abstinence, a desire to remain in IOT for longer, 
concerns and ambivalence about long-term IOT, a desire for take-home IOT or MXL 
and the alternative, yet relatively prominent, perspective that IOT should not be long-
term. 
 
8.3.1 Ambivalent about abstinence 
 
Anxiety was apparent and ambivalence was clear in the narratives on the goal of 
abstinence. 
“My key worker at the moment keeps going on at me about going into detox, 
but I don’t want to go into detox. So I really have to keep fobbing her off, 
saying, “Yeah. After Christmas, after Christmas,” but I know it’s just such a 
horrible feeling coming off that methadone.” – Daniella (P1), negative 
discharge (other); SIM 
This quote illustrates the strength of the apprehension about detoxing from 
methadone. 
“So I personally wouldn’t change anything. Actually I think there were probably 
two choices there; there's a choice to either move forward and detox or take 
the choice to become a lifelong injector of diamorph and just stay safe that 
way. So yes, that's the two options there, the options to come off entirely or I 
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would have stayed on using diamorph for ever more.” - Tom (P9), positive 
discharge; SIH 
The quote below illustrates the sense of the polarisation of treatment choices 
available to patients. 
“Where I am now, I’m happy to say goodbye, in a way. I just hope that that’s 
not me kidding myself, if you know what I mean. I just hope that when I’m 
completely off the needle I don’t then end up using street heroin again. I don’t 
want to. I definitely don’t want to.” - Sammy (P11), long-term IOT; SIM 
Here again the sense of hope is contrasted with quite apparent anxiety. On the one 
hand patients wish to feel positive and motivated by the idea of a new life without 
heroin or diamorphine treatment, on the other hand they are very afraid of what will 
happen when they discharge. The sense of not knowing how things will end up, and 
the anxiety this causes, is apparent. 
“I’m scared that I’m going to use, because I’ve got too much to lose these 
days.” - Fay (P10), long-term IOT; OM 
Patients felt they had gained a lot in their lives through IOT and are afraid of losing all 
that they have gained. Ambivalence about abstinence was expressed by patients 
across all typologies. 
 
8.3.2. Desire for long-term Injectable Opiate Treatment 
 
The desire for long-term IOT mainly applied to those who had left IOT, though a few 
patients still in IOT expressed anxiety, again, about the prospect of having to leave 
IOT. The desire to remain in IOT for longer was expressed across all typologies. 
Perspectives were either regretful (about the past – i.e., the decision to leave) or 
anxious (about the future – i.e., that IOT would end). 
“I was a little bit…sad that the injectable… I didn’t really stop because it was 
my choice, I had to stop because I was in hospital, yeah, and I was a little bit 
sad about that because there was nothing I could do about that.” - Andy (P23), 
positive discharge; OM 
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The above patient returned to the IOT clinic following his stay in hospital and 
eventually progressed to MXL treatment. 
“At least for the next five years, because at the moment the thought of coming 
off it scares me, especially when it’s being put up against a sort of timescale.” 
- Fay (P10); long-term IOT; OM 
The patient is referring to the Brighton clinic’s newer 18-month treatment policy (i.e., 
18-months left of IOT for those in long-term IOT and an 18-month regimen for those 
beginning IOT at that time). In contrast, another perspective was that whilst the patient 
still desired IOT, he did not envisage this timeline as indefinite. 
“Not forever because I would have wanted to eventually stop, you know, I 
didn’t want a straight line where I’d never ever stop, you know, I wanted a view 
to be able to complete that, finish, you know. My main aim was to get back to 
my normal self, you know.” - Robert (P28); clinic closure; SIH 
It was interesting to hear from a clinic closure, and particularly that this perception 
was still that the main goal was to eventually leave IOT. 
 
8.3.3. Patient control over treatment duration 
 
Another prominent sub-sample posed that IOT should be available to patients until 
they no longer wanted it; that the decision to leave IOT should be made by the patient, 
perhaps reflecting a perceived lack of control over treatment or concerns about the 
future.  
“For me, I thought round about the five year mark was actually needed, 
because I'd had 27, 28 years of addiction; I first put a needle in myself at the 
age of 12 - vodka, and to get out of some of the heavier parts of the drug world 
I needed that time. The other thing was I had a fascination with needles and I 
needed time to get away from that as well, so I needed that extra time.” - Tom 
(P9), positive discharge; SIH 
The above quote again illustrates why, for some patients, long-term IOT was 
necessary for gains made from IOT to contribute to longer-term recovery. In response 
to views on IOT timeline, other patients’ comments included ‘Forever’ (Luke, P18, 
negative discharge; SIH), ‘Till I’m ready to give up – I’ve never thought about giving 
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up’ (Ben, P15, long-term IOT; SIH) and ‘I want to leave, but I want to leave when I am 
ready’ (Oliver, P16, long-term IOT; SIH). The anxiety about imminent departure was 
especially felt by the Brighton patients, because they had been put on a new time-
limited policy (of 18 months, for those currently in IOT – 18 more months of treatment, 
and for those starting IOT – whom I did not interview, as of course were not RIOTT 
patients, an 18 month regimen). 
“Not…do you know what, I'd rather…I'd rather be on this and satisfied that I'm 
saf…that I'm safe and secure than…than risk going back to what I was like 
and losing everything that I've got, back again, 'cos it’s like the…you don’t 
realise how much chaos you can cause in…in your life until you've been an 
addict, it’s like everything goes to shit, nothing else matters, it’s just like…I'd 
rather be safe in me own mind and be on this, I'd rather stay on this for the 
rest of me life knowing that I can keep my life under control.  It’s not going to 
happen but I would ra…that’s what my…I would rather happen.” - Ron (P27), 
long-term IOT; SIM 
“So, you know. I sort of saw it or hoped it was, you know, something that, you 
know, I could use, you know, to come off of like heroin. That was the goal 
eventually but for it to be there for as long as it was needed because the 
change in my lifestyle like afterwards.” - Josh (P41), long-term IOT; SIH 
Faced with the prospect of treatment ending, patients currently in IOT expressed a 
desire to continue. 
“Actually I would. I'm not going to fight or argue to stay on it because I think 
five years and six months, or however long they’ve given me, is a fair crack of 
the whip. It's a fair shake of the dice. But I think that people stop when they 
stop, to put it like that doesn't make much sense, but I've known lots and lots 
of addicts and lots and lots of them have just seemed to come to the end of it 
somehow.” - Gerry (P20), long-term IOT; SIH 
The above quote again relates to Brighton’s newer 18-month policy. This policy 
allowed for a lengthy exit strategy – a notion which received mixed responses 
throughout interviews. That heroin users reach the end of their heroin-using careers 
eventually was corroborated by other patients who said they had grown too old to 
continue with the drug using lifestyle – that it was a ‘younger person’s game’. This, 
along with the stability that injectable treatment provided, was sometimes also the 
factor leading to long-term abstinence from illicit use. 
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Patients spoke about the specific benefit of IOT over the longer-term, and the idea 
that gains made would further improve, over a longer time-period. This contrasts with 
comments made by other patients who felt the initial gains plateaued within a shorter 
period of time, indicating that the IOT regimen, and associated care-plans, should 
always be individually tailored. It appeared that some patients felt that a finite course 
of IOT was beneficial, to reduce chaos, and gain some stability in their lives, whereas 
others felt that a long-term course of treatment was required to combat the decades 
of experience with heroin dependence. The theme was dominated by accounts from 
those who had been in long-term IOT. This links with fears around leaving IOT, which 
did not appear to appease amongst those who had been in IOT long-term.  
 
8.3.4. Short-term Injectable Opiate Treatment 
 
Another group of patients expressed their feeling that IOT was a short term treatment 
programme. As covered previously in discussions around the need for daily clinic 
attendance, patients cited the inconvenience of attending every day, as the reason 
they did not view IOT as a long-term treatment. This theme was dominated by those 
who had discharged from IOT – mostly those with positive discharge statuses, but 
also included some with a negative discharge status; there was an overall theme of 
acceptance, and the perception of reasons why IOT was not practical or necessary 
long-term. 
“No. I think it was about the right amount of time. Because it’s like your life is 
just controlled by it, every single day having to go there at a certain time in the 
day.” - Daniella (P1), negative discharge (Other); SIM 
Other patients alluded to the necessity of a care-plan which incorporated IOT timeline 
from the outset, and in some cases that IOT should be time-limited. 
“You know what, I wouldn’t say how long should anyone be on it, but what I 
believe is; there should be a, kind of, action plan. It’s not, ‘Here take 
injectables. Have it for the foreseeable future.’ It should be, like, ‘You’re gonna 
be on injectables for 18 months, then you go on to, like, half and half, and then 
you go onto tablets.’” - Charlie (P3), positive discharge; SIH 
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The above quote incorporates an eventual move to MXL (‘tablets’) in the envisaged 
trajectory. Judging other patients’ treatment trajectory was tied into this, and was also 
common. 
“And I believe you should offer short treatments of six months to people. 
People will either put the work in or they won’t. I mean there’s people still 
hanging around and on it to this day, whereas you should have made them 
come down a bit more.” - Serina (P6), positive discharge; SIH 
Patient typology is pertinent here, with those with positive discharge statuses being 
proponents of time-limited regimens, and those with negative discharge statuses 
being resentful of those in long-term IOT. 
“And there’s people doing it now. November’s eight years. Some people are 
still on it. That, kind of, niggles me because that’s not a maintenance 
treatment, but, you know, everyone to their own.” - Matthew (P17); negative 
discharge; SIM  
That initial gains had plateaued was an interesting comment by one client. 
“…it was just becoming repetitive, I’d achieved all the initial stages of what it 
was supposed to do for me, and it had been a success, so it was just about 
keeping me stable now and getting on with doing whatever I had set up at the 
time, so there was no more I could gain from being here, so just put me on a 
stabilised script and that’s it…” - Harry (P8), positive discharge; SIM 
“No, no, no, no, basically...I felt it had run its course. It couldn’t do no more for 
me...” - Nicholas (P14), positive discharge; SIH 
Timeline policy for IOT appeared to evoke some very divergent views – with some 
very clear ideas contrasted with their respective opposing view. There was a clear 
split across typology, with fears and the desire for long-term IOT arising from long-
term IOT patients, and acceptance and the perception that IOT should be time-limited, 
from those who had – in the main - discharged positively from IOT, with inclusion of 
two who had a negative discharge status, yet were abstinent from IOT, and stable at 
the time of interview. This demonstrates the possible benefit of a time-limited regimen 
for some individuals, and actively working through fears and anxieties, about the 




8.3.5. Returning to Oral Methadone treatment 
 
There were a variety of different reasons for the return to methadone, such as a 
hospital admission, violations of the protocol, clinic closure (in the case of the 
Darlington IOT clinic), and moving out of the area. 
 
“I went into hospital because I had a blood clot in my leg. Because I was 
getting oral methadone, I used gear and the gear that I had, had benzos in it, 
so they wouldn’t give me the injectable. Where I wasn’t getting the injectable 
I started using again and all the gear I had, had benzos in it, so I couldn’t get 
back on the RIOTT. So that stopped for weeks and so I never ended going 
back on it.” - Richard (P34); negative discharge; SIM 
Sometimes patients outlined how treatment exit led to lapse and relapse. Narratives 
involved a mixture of factors implicated in lapse and relapse. Richard’s quote 
continued. 
“Yes, because the methadone wasn't holding me, and I think I got it upped, 
and that, and then I stopped for a while taking heroin - I don’t know how long, 
my memory's not that good anyway, with all this carry on with the hospitals - 
but I used for maybe a month and then sporadic use and then finished for I 
don’t know how long, and then got in with the wrong crowd again.” - Richard 







Overall, the ‘Experience with injectable opiate treatment’ section culminated in three 
superordinate themes: Components of the regimen – Injectable opiate medication; 
Components of the regimen - Holistic and psychosocial; and Treatment duration. 
Patients described components of the regimen that had facilitated recovery. These 
narratives encompassed two separate concepts: Injectable opiate medication (the 
medicinal and clinical), and the holistic and psychological aspects. Both elements 
were key to effectiveness of, and satisfaction with, treatment.  
Patients outlined their experience with the various medications they received. When 
questioned about medication, the tendency was to evaluate the medication through 
comparison to one of the other treatment medications – such as comparing SIM to 
SIH – or by comparing SIH to illicit heroin. It was interesting to discover that the latter 
two drugs were perceived very differently. It was of further interest to discover that 
whilst SIH was seen as satisfactory as – and sometimes better than - both OM and 
illicit heroin – some patients stated that they would not have purchased this form of 
heroin for recreational use. This is a very interesting finding, and perhaps the 
differentiation between effective IOT and illicit heroin contributed to the reduced 
desire to use illicit heroin. The drug was sufficiently reinforcing and alleviated 
withdrawal, yet was suitably different from illicit heroin to remove the attachment with 
the desire to use illicit heroin. This is a very important finding for IOT research; and 
the unanswered question: why is IOT so effective. 
In contrast there were a few patients who found SIH unpleasant or strange. Opinions 
about additional doses of methadone were divided, with some vehemently convinced 
that it was not necessary – that SIH was sufficient in the sense that patients would 
not suffer with withdrawal before their next dose – and others who perceived that a 
small amount of additional methadone was necessary. Patients often wanted to move 
away from additional methadone doses and one patient describes reducing 
methadone too quickly, which led to a relapse. Overall, patients had negative and 
varied perceptions of additional methadone doses. 
A number of patients stated that they had decided to remain on SIM treatment, rather 
than move over to SIH, since it was effective enough. Some patients described those 
on SIH as overly intoxicated or sedated, and asserted that they did not wish to be in 
this state. One interesting comment was by a patient who had begun on SIM 
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treatment and who moved to SIH at six months; this patient stated that the initial six 
months on SIM (positively) altered his relationship with illicit injecting practices. The 
benefit of the injectable nature of IOT is illustrated by this patient. The longer-acting 
nature of SIM was also viewed positively – with patients preferring attending the clinic 
only once per day for their dose. In contrast, a number of patients identified adverse 
events that occurred while they were in treatment, or continued their illicit heroin use. 
In one case the patient states that being on SIM was an excuse to continue using 
illicitly. 
Dosage and achieving the right dose was an important and prominent theme. Patients 
cited autonomy in this process and one outlined a fear that the optimised nature of 
dosing may be lost in clinical practice (i.e., outside of the pragmatic trial). In support 
of the importance of adequate dosage were accounts of lapse and relapse following 
dose reductions. 
There was a balance of both positive and negative comments about the IV versus IM 
route of administration, but overall IM was satisfactory to patients. Patients 
appreciated the fact that the IM route of administration was another way to sever the 
connection to illicit use; the fact that it was different (similarly, the drug itself was 
perceived as different) was appreciated. This also applied to the perceptions of the 
difference in the type of ‘hit’ obtained intramuscularly – once again, this was 
experienced differently to the experience of illicit heroin, and this was valued. IM 
administration also reduced track marks on patients’ limbs, which came to be 
important. In contrast one patient appreciated that sedation only took effect once she 
had made the journey home. Similarly, the majority of patients came to appreciate 
attending the clinic once per day as opposed to twice per day. This is a positive step 
in light of those who, at treatment outset, were attracted primarily to ‘free heroin’, and 
who would have previously sacrificed everything for illicit heroin. Following a period 
of adjustment, patients came to appreciate the clinical environment that SIH was 
administered in and appreciated that, again, this was a way that the connection to 
illicit use could be altered or severed. 
The other aspect of the experience of IOT that was of importance to patients was the 
holistic nature of the treatment, and that it encompassed psychosocial elements. This 
manifested itself through various sub-themes. Positive relationships with keyworker 
and staff were important, as was the sense of community created with other patients; 
in a few cases the latter was seen as instrumental to later recovery. This is another 
way in which IOT is very unique, and perhaps partly why it was effective. Additionally, 
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the impact of negative relationships with staff and other patients was an area of 
difficulty and, in the case of staff, may have been connected to the desire to use illicit 
heroin. 
Patients expressed gratitude for the support they received through IOT, and the fact 
that they were respected and listened to during the process. Linked to this was the 
value of patient autonomy and control over treatment decisions. Patients articulated 
the interesting reflection about the power and strength of the ability to say no (e.g., 
through dose changes or switching to MXL) to a drug that they would have once done 
anything for. Patients reported that they were not being forced into anything through 
IOT, that the decision not to use illicit heroin, and to remain in treatment was theirs, 
and that this fact carried a lot of weight in effective recovery. Patients stated that they 
had made these reflections following IOT, which emphasised the value of reflective 
space, perhaps for effective recovery. For those who were service-user 
representative, this role was significant. The autonomy and control over treatment this 
provided was important, however the role itself served as a meaningful activity; and 
perhaps a protective factor. 
In contrast, a perceived lack of control over treatment decisions, or lack of patient 
autonomy caused annoyance, distress and dissatisfaction. In one case the patient 
links this to the desire to use illicit heroin. The importance of the flexibility and 
individuality of pace of the regimen was highlighted by patients. Linked to this was 
the next theme; treatment duration. There was a reasonable amount of ambivalence 
about abstinence. Whilst it was a goal for some patients, the perception of it also 
caused some degree of anxiety and stress, to others. One patient expressed 
apprehension about detoxing from methadone. Patients feared that they would 
relapse in this process and lose everything that they had worked so hard to achieve. 
The fact that patients had achieved a lot through IOT allowed them to perceive also, 
how much they had to lose. 
Some patients expressed a desire to remain in IOT. This was often expressed by 
those who had discharged – for example, in the case of a hospital admission. Patients 
expressed regret over these situations and/or decisions. Perceived control over 
treatment was important in this context also. Patients wished to have some degree of 
control over treatment duration. Some patients perceived that they needed to 
undertake long-term IOT, since their addiction history was also so lengthy. In this 
context also, patients expressed high levels of anxiety about leaving IOT. Some 
patients perceived that gains achieved had plateaued, whereas others believed that 
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the longer they remained in IOT the more gains they would make. Some patients 
perceived that the requirement for everyday clinic attendance was unsustainable 
longer term. 
One patient expressed a desire for the trajectory to be mapped out at treatment 
outset. There was clearly a high level of anxiety about the unknown, which is 
reasonable. This perhaps add weight to a finite IOT trajectory, with a stipulated end 
date made clear at treatment outset. Patient typologies were pertinent in this final 
theme, with negative dischargers resentful about having to leave IOT; positive 
dischargers proponents of time-limited IOT; and long-term IOTs expressing 
significant amounts of anxiety about leaving. For those who had transferred back on 
to oral methadone treatment there was some degree of lapse or relapse amongst this 
sub-group.  
Satisfaction with treatment ran through all sections of narratives, and in particular the 
current chapter. For this sample, satisfaction with treatment encompassed the 
following dimensions (the majority of which have been outlined in detail already): 
treatment effectiveness, aspects related to the clinic setting itself, patient control over 
treatment (as previously outlined), relationships with staff (also previously illustrated), 
the holistic nature of the regimen, procedural aspects of treatment delivery, a 
reflective awareness of recovery, and general positive mentions about the treatment 
or care received. Patients spoke favourably about aspects of the treatment 
medication itself, such as the superior bioavailability of this drug, that withdrawal was 
not as unpleasant as oral methadone treatment and that the drug was sufficiently 
reinforcing and thereby they were not tempted by illicit heroin use.  




Chapter 9 – Findings: Impact of IOT 
 
Chapter eight describes patients’ narratives on the impact of IOT. Patients were not 
directly asked what they perceived the impact of IOT was, however this was a theme 
that emerged from narratives overall. The impact of IOT was experienced within a 
number of dimensions of life. Sub-themes within this theme included significant and 
positive impact on the following areas of life: illicit use and the achievement of 
abstinence; improved quality of life; psychological recovery, developing a non-using 
identity, and leaving the drugs subculture; education and courses; improved 
relationships; improved health and harm reduction; improved housing; protective 
factors (arising both as a consequence of IOT and as protective aspects of patients 
life which decreased the likelihood of relapse; likely a two-way relationship); stability; 
and gratitude (again this was likely a two way relationship – both as a consequence 
of IOT, whilst also becoming a factor protecting patients from the likelihood of 




Table 44. Outline of the ‘Impact of Injectable Opiate Treatment’ chapter themes and sub-
themes 
Reference Theme Sub-theme 
9.1. Reducing or ceasing illicit drug 
use 
 
9.1.1  Achieving abstinence-based 
recovery. 
9.2. Improved quality of life  
9.3. Psychological recovery  
9.4. Leaving the drugs sub-culture  
9.5. Developing a non-using 
identity 
 
9.6. Education and courses  
9.7. Improved relationships  
9.8. Improved health and harm 
reduction 
 
9.9. Improved physical appearance  
9.10. Improved housing  
9.11. Achieving and maintaining 
stability 
 
9.12. Reflective awareness of 
recovery 
 
9.13. Feeling grateful  
9.14. Protective factors  
9.14.1.  Service-user involvement 
9.14.2.  Caring for pets 
9.14.3.  Hobbies and passions 
9.14.4.  Relationships with family and 
dependents 





9.1. Reducing or ceasing illicit drug use 
 
The first theme to be outlined and analysed is illicit use. Illicit use was the most 
prominent theme and encompassed a number of different elements of patients’ 
experience. Comments and experiences ranged from the perceived efficacy of the 
substitution drug itself - in relation to reducing craving and the desire to use illicitly - 
through to the impact that IOT had on patients’ psychological processes in relation to 
their illicit drug use and recovery; including increased motivation to make change. For 
some patients, however, there was a continued use of illicit heroin and ongoing 
worries and fears; these will also be outlined.  
In some cases the cessation of illicit drug use was sustained long-term and in other 
cases it was not. Of interest was that for some patients their perception of IOT 
effectiveness (as defined through cessation of use of illicit drugs) also encompassed 
a positive experience of injectable methadone treatment for the duration that they 
received this particular treatment. For whom this was relevant, the complete trajectory 
is illustrated. Two key aspects of importance were the need for a period of adjustment, 
and achieving the right dose. 
“I stopped using heroin for about two years when I was on the RIOTT scheme 
– all the time I was on the RIOTT I did stop using.  
…With heroin I was completely satisfied with the injectable methadone. I didn’t 
use on top at all.” - Daniella (P1), negative discharge (Other); SIM  
Whilst patients may have spent time adjusting at the beginning of IOT - to the new 
way of life - in a number of cases the same patients were those who had abstained 
from illicit heroin use for a number of years. 
“I had got on a comfortable dose, and I did, sort of, stop using street heroin, 
but not straightaway. Quite soon after that, I dunno, probably about six months 
into the programme that I stopped using street heroin… 
There is a need for a period of adjustment to treatment, and for this reason abstinence 
from illicit use was not immediate and took some time. This is useful information for 
policy and practice. 
…I started on the RIOTT, September 2007. I stopped using street heroin 
probably about, I dunno, a maximum six months into the treatment. So, I 
probably stopped using crack sometime in the summer after that, so summer 
288 
 
of 2008. It was, sort of, summer or early autumn, I would say, I stopped using 
crack all together. So it’s been, what, 2008, 2009, 2010; five years.” [Six years 
at time of interview]. - Pam (P19), positive discharge; SIH 
The above quote again illustrates the trajectory of progress; in this case in relation to 
use of other illicit drugs taken in addition to illicit heroin. The following quote illustrates 
the psychological processes of change within the IOT treatment trajectory, and in this 
case, how IOT changed patients’ perception of illicit heroin and its harm. 
“No, I don’t use heroin anymore. If one thing positive came out of the RIOTT 
trial, it made me afraid of the strength of street heroin. My boyfriend always 
used before me, and I was always scared of… and still am. I don’t use 
anymore street heroin because I’m afraid of the potency of it.” - Clara (P7), 
negative discharge (other); SIM   
Additionally, a number of patients specifically mentioned that they ceased illicit use of 
heroin right at the beginning of the treatment programme. Narratives on reducing or 
ceasing illicit heroin use also included the fact that IOT motivated patients to attempt 
to demonstrate IOT’s effectiveness, and the impact of dose stability on eventual 
cessation of illicit heroin use.  
“Oh it was almost instant, Vicky, I was really surprised.  Once it was adjusted 
and I was getting my right dose and I was satisfied, I was just on the right sort 
of buzz and I wasn’t… it was an instant success.” - Harry (P8), positive 
discharge; SIM 
Use of the term ‘instant success’ perhaps illustrates the patient’s level of satisfaction 
with IOT. Connected to this, patients highlighted that illicit heroin (and in some cases 
crack) use occasionally continued at the beginning of treatment – but eventually 
stopped completely, and that it was initially difficult to change the drug using routine. 
This demonstrates, again, that longer-term IOT was necessary for longer-term 
change in some cases, and how significant the initial period of adjustment was.  
“Once I was on my own I think I used twice, and that was, like, just smoking 
some crack, and I had a bit of gear after, then that was it. Done. I never used 
again.” - Charlie (P3), positive discharge; SIH 
The quote demonstrates the long-term effect of IOT on illicit drug (heroin and crack) 
use, and even following a positive discharge status. As also introduced above, a 
number of patients mentioned the implication of dose stability on the cessation of illicit 
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drug use, and this was often the context for continued illicit drug use at the beginning 
of the trial. 
“Certainly the only lapse after I'd been here three months. Because while I 
was still increasing my dose I had to go out sometimes because they weren't 
giving me enough. But once I reached my optimum dose I didn't use at all.” - 
Jerry (P20), long-term IOT; SIH 
Patients also spoke about the reduction in illicit heroin use and that IOT motivated the 
desire to reduce illicit heroin use. Even in the context of reduction rather than 
cessation, patients alluded to a permanent positive change to their level of illicit heroin 
use. 
“Well I was doing that, I thought I was doing pretty well, but since then... Since 
I did that, I haven’t gone back to how I was before, because I was really chaotic 
before I was doing that. I haven’t ever gone back to the amount I was using 
before I went onto that. So I have kept it down.” - Daniella (P1), negative 
discharge (other); SIM 
The above quote specifically illustrates the impact of IOT on long-term illicit (both 
heroin and crack) drug use and lifestyle. One of the main narratives that arose from 
the interviews, in relation to impact, was that IOT served as a positive interruption to 
the cycle of chaos and harm patients were causing to themselves prior to IOT. The 
situation of the individual patient at referral to IOT varied across individuals but in all 
cases the cycle of harm and chaos was broken and improved upon through the 
course of IOT. Effectiveness by means of cessation or reduction of use of illicit drugs 
was pertinent to all typologies and treatment groups.  
 
9.1.1. Achieving abstinence-based recovery 
 
A number of patients mentioned that they had achieved complete abstinence as a 
consequence of IOT. The abstinence theme encompassed various strands including 
complete abstinence (including those abstinent from maintenance medication also), 
narratives on long-term abstinence, and a complete lack of desire to use illicitly. 
Achieving abstinence had clear presence within the data set, and was arguably the 




“When I left RIOTT I was on a methadone script in [name of neighbourhood], 
and then I sort of eased off, and something happened, and then I just never 
went to renew it, and touch wood I haven’t gone back to using; mainly, I think, 
because I don’t want to.” - Harry (P8), positive discharge; SIM 
Through IOT, some patients were able to access a vision for the future that did not 
involve heroin or maintenance medication. 
“This was about two years without using injectables, and then I just cut myself 
down. And just, one day, I hurt my leg and I thought, ‘Oh, well, I’m in so much 
pain with my leg, let’s try and stop using it: MXL,’ and I did.” [VB: So you’re 
not on any treatment drug now?] Patient: “No, no, no, no, no.” - Charlie (P3), 
positive discharge; SIH 
Through the achievement of clear changes during a longitudinal IOT trajectory, 
patients may have cultivated confidence for the ability for abstinence-based recovery 
(i.e., discharge from all maintenance treatments) – as illustrated in the quote above. 
“I got kicked off on to a 50ml methadone. I got down to 2mls and I was gonna 
go away, I think it was a Thursday. Well, I went there and I was given the 
Friday, Saturday and Sunday dosage and I took off to Scotland with a 2ml 
habit. I stuck it four months up there, clean, and I haven’t looked back since, 
but that’s four years now.” [VB: So, you’re not on anything now?] Patient: 
Nothing. [VB: No methadone, nothing?] Patient: No, no, no, nothing. – 
Matthew (P17); negative discharge; SIM 
 
9.2. Improved quality of life 
 
The next theme within the impact of IOT section of the findings was ‘Improved quality 
of life’ – that is, patients made improvements to various dimensions of life as a 
consequence of IOT. This was a large and diverse theme and sub-themes will be 
outlined. Overall this theme encompassed both areas of gain (amassing something 
positive; e.g., achieving education and completing courses) and cessation 
(obliterating something negative; e.g., leaving the drugs subculture).  
Patients specifically illustrated general areas of life where they had experienced 
progress and improved quality. These included: psychological progression; improved 
family and relationships; beginning and engaging with education and courses; 
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improvements to their financial situation; decreased harm reduction and improved 
health; improved housing; the development and progression of goals; reduced or 
ceased criminal justice involvement; significant changes to situation and life, and in 
some cases the perception that IOT saved their life. As previously outlined, a number 
of patients mentioned that they thought IOT had changed their lives and others, that 
without IOT they would be dead. This indicated the strength of the impact interpreted 
by patients. This particular belief was asserted by long-term IOTs and positive 
dischargers. Patients appeared acutely aware of the level of instability and chaos they 
had reached at their referral to IOT, and again, perhaps connecting – through IOT – 
to this awareness of how bad things had got, is linked to the ability to make change 
and recover. 
“Well, it saved my life, basically, because I was in a bad way, and I think if I 
hadn’t have gone on that, and my life was still chaotic, I think I’d be dead now.” 
- Fran (P13), long-term IOT; SIM 
Patients described improvements to the quality of their lives, as a consequence of 
IOT, with particular reference to feeling more integrated into society and their renewed 
connections with (non-drug using) social groups. 
“I’ve got a lot of good friends who run their own businesses and things like 
that and when I see them now, I go to the pub with them, I don’t drink, I get a 
coke, we play pool, we all have a laugh and a joke, but when I was on the 
drugs, they wouldn’t even stop in the car, they’d just keep driving, but now 
they see I’ve made a change and it’s not just a little change, it’s been a five 
year change and they can see it in me. When I went to prison I was 9 stone 
8...I just weighed myself over there, I’m 16 and a half stone. When I went into 
prison, I was all sucked in.” – Nicholas (P14), positive discharge; SIH 
Patients may have felt more connected to society following IOT, they were also able 
to see that people cared for and respected them; that they were worth something, 
and thereby their life was worth something. 
“Like I said there’s two ways I’d be now if I wasn’t in treatment, I’d either be 
dead or totally forgotten about and that’s scary just to think about that.” - Scott 
(P35), long-term IOT; OM 
Within improvements to quality of life was reflective awareness, once again, on the 
harms patients had previously caused to themselves, or at best, risked causing to 
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themselves. Patients expressed that they felt grateful for the awareness of potential 
harm. Patients were also those with long criminal justice histories, and through RIOTT 
became motivated to never return to prison. 
“All that was going to end up happening was I'd end up getting an injection 
and I'd end up dying. Or I'd have ended up back in prison.” - Wayne (P30), 
clinic closure; SIM 
Patients indicated changes to their psychological perceptions. Patients spoke of 
developing their non-using identity, a desire for stability, and that goals (further) 
progressed over time (which applied to all typologies). Sub-themes in improvements 
to quality of life were often cross-cutting themes (previously outlined) and 
encompassed the following areas: health, education and courses, family and 
relationships, harm reduction, housing, psychological adjustment, and illicit use. 
Improved quality of life spanned all typologies and treatment groups. 
 
9.3. Psychological recovery 
 
Connected to quality of life was psychological progression. Patients spoke about 
improvements to self-esteem, and overall, IOT seemed to provide new or increased 
self-belief and self-efficacy (including through the development of a non-using 
identity). This was sometimes in parallel to an overall sense of hope and faith in the 
treatment, mirroring how some patients felt at treatment outset. 
“I felt good and they could see that I was committing to the programme and 
that I was keeping myself together and sort of just coming in, being positive, 
speaking, doing what I done and then saying, right I’ll see you this afternoon, 
bye, I’m going off to college now, I’m going off to…it gave me that sense of 
importance which I’d never had before.”…  
…. And I think it would happen for everybody eventually.” - Ellie (P22); positive 
discharge; SIH 
That IOT led to psychological development, feeling important and of worth - and 
engagement with recovery on this level - was experienced across the sample; 
amongst all typologies and treatment groups. One particular aspect of the drug using 
identity was involvement in the drug using subculture, and consequently leaving this 
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sub-culture was a prominent element of the impact of, and recovery during, IOT. This 
leads on to the next sub-theme. 
 
9.4. Leaving the drugs subculture 
 
Strongly linked to the drug-using routine was involvement with the drugs subculture, 
and as evidenced in the ‘Heroin use history’ chapter, peers within this culture were 
triggers to continued use and lapse/relapse. Similarly, leaving this subculture was 
both a consequence of IOT and also a factor that comprised the trajectory of recovery 
and improved quality of life. 
“And it was only until I got onto the RIOTT, when I moved out of the druggy 
environment, that I, kind of, just worked my script, kind of, thing, and it was 
the only thing that kept my head okay and my sickness away. It, kind of, 
worked both ways.” - Charlie (P3), positive discharge; SIH 
The quote illustrates the patient’s insight in to the two-way nature of the benefit of 
removing one’s self from the drug using environment; whereby this is interpreted as 
both a symptom and cause of making progress and continued recovery. For some 
patients this had been a very deliberate step, i.e., with the awareness that the sub-
culture is a trigger and that IOT provided space and stability for this longer-term 
awareness of relapse prevention strategies. 
“That’s why I’m out in the country and when I come to get my methadone I 
ring them up and my partner drives me in and drops me outside the clinic; 
pharmacy, chemist, pick up my methadone, straight out, straight in the car, I 
don’t want no connections with nobody, I don’t want to sit in there for five 
minutes with people coming in and talk to you, no I don’t want nothing to do 
with them, nothing….Yeah I can’t live in the city any more, I can’t do it, I don’t 
think I’m strong enough, I might be in the future but I’m not at the moment.” - 
Jacob (P4), negative discharge; SIM 
The above quote illustrates how the impact of IOT continues to be experienced, by 
somebody who now receives oral methadone. IOT interrupted the cycle of difficulty 
and the resultant stability led to the development of new healthier patterns of 
engaging effectively with treatment, and an awareness of what triggers to relapse are. 
This awareness was key to ongoing relapse prevention. As indicated above, one 
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prominent aspect of the drugs subculture was the other drug users within these 
circles, including those accessing treatment in clinics and dispensaries. Consequently 
- within this qualitative sample - patients often chose an isolated life, rather than 
risking susceptibility to the influence of peers. 
“I don’t mingle with people. I’m strictly on my own now….I don’t have a phone 
anymore. Because even like if I don’t give them my number they’ll get my 
number somehow. So I don’t have a phone. I’ve got one but I just don’t use it. 
I’ve switched it off. Because that’s why I can’t have any friends round.” - Iain 
(P25), positive discharge; SIM 
“Well I know them [other IOT patients] but I don’t really associate with many. 
I mean I’ve been quite a loner, to be honest, for the past six years.” - Elena 
(P37), positive discharge; SIM 
As previously outlined, patients were consciously aware of this step, and the 
necessity of it, and it was both a symptom and a cause of continued recovery. An 
isolated life was preferable to the chaos and instability that was present before 
patients engaged with IOT. Distancing one’s self from heroin using peers was a highly 
prominent feature of impact and recovery; applying across the dataset, 
encompassing all typologies and treatment groups. 
Included within the impact of recovering from engagement with the drugs sub-culture 
theme were long periods of time not involved in the criminal justice system and 
incarceration. This was in the context of a population who had previously cycled in 
and out of prison, as demonstrated in the heroin use history chapter. 
“It’s the longest I’ve been out of jail. When I was on the street it was, I was in 
trouble, big trouble; in and out of prison.” - Scott (P35), long-term IOT; OM 
“I wasn’t going out thieving for money for drugs every day, and I got out of that 
habit – for two years I never went out thieving – I don’t want to get back into 
that again now.” - Daniella (P1), negative discharge (other); SIM 
What was particularly noticeable here was the strength behind patients’ resolutions 
to remain stable, and, more particularly, never to return to the drugs sub-culture, 
indicating that patients may not have ever had reflective space (i.e., a period of 
abstinence long enough to reflect on their individual recovery) for recovery prior to 
IOT, and this was what was required (and provided through IOT) for recovery in this 
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domain. Following leaving the drug using subculture, patients were able to develop a 
non-drug using identity; outlined below. 
 
9.5. Developing a non-using identity 
 
As was highlighted within the heroin use history chapter, that patients lost their non-
using identity through illicit heroin use and as part of their recovery patients were able 
to re-connect with or develop a non-using identity, during, and as a consequence of 
IOT. 
“I was quite positive of what I was doing and where I was heading. I didn’t 
want that life back again. I’d got so far, that after a year or two of not using, 
and I was, like, volunteering, just into work. I was mixing with some really nice 
people who weren’t using, der, der, der, I didn’t want to go back. I knew from 
then that using wasn’t for me no more, you know what I mean. I just knew I 
weren’t gonna go back.” - Charlie (P3), positive discharge; SIH 
Through the experience of sustained stability patients were able to create a new 
identity, and in some cases with new contacts and friends being completely unaware 
of the patient’s drug-using identity and past. 
“And while you’re here [in IOT] like moments, significant moments, are stuff 
like going out for a drink with one of my lecturers and he had a story about 
somebody he knew who was a bit crazy and it’s like, oh my god, somebody is 
sort of saying it to me like, and they clearly have no idea, and that was 
amazing; that was like ‘yes!’” - Ellie (P22), positive discharge; SIH 
In this instance, the patient is celebrating being viewed as a ‘regular’ person in 
society, and not a drug user or ‘junkie’, or even ‘different’. The patient has first enrolled 
on a university course; and then later celebrates continued success by means of 
being accepted by the relevant cultural and peer group. In this context being accepted 
carries greatest significance. The perception that patients had created, or were 
venturing towards, a non-using identity was expressed by positive dischargers only.  
Also linked to the development of a non-using identity was engagement with 
education, courses and activities. Again, this was a consequence of IOT, and 
facilitated psychological recovery, linking to a more positive self-esteem and self-
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regard. This was likely a factor in patients’ determination to not return to the drug 
using lifestyle and subculture (outlined below). 
 
9.6. Education and courses 
 
As a consequence of IOT some patients engaged or re-engaged with education. This 
ranged from completion of short courses to university degrees. In this context patients 
made reference to their histories, such as education being interrupted at a young age. 
The fact that patients were making such big changes to their lives overall at this point, 
really illustrated the profound effect that IOT had on their recovery trajectories.  
“I started going to college, getting a little bit of education, like, learning how to 
use a computer. A bit of maths, a bit of English, because obviously, I left 
school at 14, so I wasn’t really educated that well. So I went back to college, 
got NVQs and diplomas and stuff like that.” - Charlie (P3), positive discharge; 
SIH 
Within these narratives arose a sense of optimism, hope and motivation to educate 
one’s self, since recovery from entrenched addiction. 
“I can’t read or write very well, but I was going to classes, although I didn’t 
have to because I was getting money sent in, but I still wanted to try and 
educate myself a bit more, you know... And...now...I read books, it might; like 
my father used to read a 600 page book in a day, but it might take me three 
weeks, but at the end of the day...” - Nicholas (P14), positive discharge; SIH 
“I’m doing a degree.” - Pam (P19), positive discharge; SIH 
Engagement with education and courses was a strong sub-theme and was pertinent 
to all typologies and treatment groups. 
 
9.7. Improved relationships 
 
Also connected to development of the non-using identity was the impact that being in 
IOT had on relationships, including interactions and dynamics with family members 
and dependents. Relationships were rekindled and reconnected, and patients stated 
that they became more of a role model to their dependents. Families started to trust 
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patients again, in the context of abstinence and recovery. Patients also mentioned 
cessation or reduction in the context of protecting dependents, and in some cases 
this manifested as a developing awareness which cultivated and progressed by virtue 
of the stability created by IOT. As previously, stability in this regard was progressive 
and further developed over time. Patients also spoke about family support in the 
context of IOT – that their families were supportive of the treatment, and this perhaps 
had a role to play in improving their quality of life. This is especially important given 
that heroin users who are dispensed medication in pharmacies are often judged 
negatively by wider society.  
“I work, his mum doesn't; for money I work and I've always got money, you 
know, so at least he's got the difference to see and he has a father figure in 
his life.” - Reg (P12), long-term IOT; OM  
Not only did the above patient reconnect with his son during IOT, but he is explicitly 
aware of how his stability and drive (career wise) will positively impact his son. Once 
again the progression is evidenced; first the reconnection, and secondly, the impact 
of being a positive role-model following this reconnection. 
“And I’ve got children. I’ve got people that...look up to me, you know. I’ve got 
young people that look up to me, you know.” - Jason (P26), negative 
discharge; SIH 
Once again, what initially arose as a consequence of IOT – the space and stability for 
reconnection with family – then became a protective factor from lapse and relapse 
over time. Critically, patients were recovering their lives, as well as from their 
addiction. 
“My relationships with my family are massively better than they were. I mean, 
they’re talking to me which before I hadn’t seen most of them for going on 
twenty years. …It changed in terms of my family because I was able to prove 
that I wasn’t using. I mean, my dad wanted visible evidence so I got the staff 
to print off my sample sheet and once he saw that I hadn’t actually used 
anything in 18 months he was willing to take sort of baby steps to see where 
it would go.” - Fay (P10), long-term IOT; OM 
Interestingly, the above illustrates how a good relationship with staff and the clinic 
impacted relationships the patient had with wider support networks and their ability to 
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engage with progressive steps through recovery. This theme was relevant to all 
typologies aside from the (smaller sample of) clinic closures. 
 
9.8. Improved health and harm reduction 
 
Patients outlined various ways in which IOT had positively impacted health. Here the 
holistic nature of the programme was particularly illuminated. Patients made changes 
and achieved gains in various aspects of their health, including much wider areas 
such as weight loss and nutrition. 
“Yeah they sent me up to a dietician there and she was great, she trimmed 
over, just over three stone off me.” - Trevor (P24), negative discharge; OM 
Deliberate weight loss for better health is obviously not an aspect directly relevant to 
the impact of IOT per se, nor would it be a goal for all patients (some may be 
underweight). However, it indicates an engagement with wider areas of life and 
health, by virtue of, firstly, the holistic support available through the programme, and 
secondly, increased motivation to make these improvements. Patients specifically 
highlighted improvements to health as a consequence of IOT. 
“Trying to score and running out of veins. It wasn’t good. My health wasn’t 
good when I started. It's much, much better now.” - Gerry (P20), long-term 
IOT; SIH 
Patients highlighted how the clinic engaged with their wider health. In the following 
quote the psychological processes around gratitude for good health and negative test 
results are illustrated. This gratitude motivated patients to be more health conscious 
and health improvements progressed to healthier cognitions about health and new 
goals. 
“They encourage you to go and have an AIDs test and all that stuff. It’s things 
that you wouldn’t do, I wouldn’t do normally. It was good because I thought 
‘right, I’m not gonna do anything now to risk that’ if I’ve got away with it I’m 
lucky and I’m now not gonna gamble, you know. So they encourage you to go 
for these blood tests.” - Shane (P21), long-term IOT; SIM 
Once again, a new – in this case health - consciousness was created by IOT. Harm 
reduction was also highlighted in the context of the requisite for every day clinic 
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attendance. This protected patients from health problems and adverse events that 
might not have otherwise been noticed had the patient not been attending the clinic 
every day. 
“It was one of the nurses at RIOTT that actually probably saved my life; 
Sandra, she used to work here and work in the injection clinic. I came in for 
my afternoon injection one Friday, I think it was, and she said you look like 
you’re going to keel over; you need to go to A&E now.” - Andy (P23), positive 
discharge; OM 
Patients spoke about the impact IOT had on their previously risky or dangerous 
injecting practices. IOT allowed patients to become more health conscious and 
through this process they were able to reassess their perception of risk, and their own 
propensity to engage in risky practices. Once again it appears that the stability that 
arose during the time spent in IOT created space for reflection on previously 
dangerous practices, which allowed and prompted room for further change. 
Patients outlined harm reduction, safe injecting, and also that IOT had specifically 
had an impact on their injecting practices; that these practices became safer. A few 
patients also mentioned the fact that IOT provided space for them to make changes 
to their – problematic - alcohol use. Patients demonstrated a conscious awareness of 
the harm reduction approach that IOT offered. It may be that the stability gained from 
the fact that IOT offered clean, clinically pure heroin, allowed patients to fully 
comprehend the risk of damage street heroin – had been and - could cause, and that 
this awareness is implicated in the motivation to cease use of illicit heroin. 
“After a week or so you get your heroin back, but you'll now get street clean 
heroin, a street-free heroin, you're getting clean heroin, which is not going to 
do the same damage, it's still going to damage you but not anywhere near the 
same, like with street heroin.” - Oliver (P16), long-term IOT; SIH 
Patients highlighted their lack of control over injecting, and thus the uncontrollable 
risk to health. 
 “So keeping you away from the dealers and preventing these kind of health 
problems that could have just become …That I would give myself. Because I 
had to inject, I’m an injecting junkie, you know. I want to inject everything. But 




Illustrated also was the impact on wider health behaviours. For example, since heavy 
alcohol use was forbidden during IOT, patients had the opportunity to make changes 
to problematic drinking patterns. 
“It’s decreased a lot, it was very heavy. Yeah before the IV clinic I drank 15 
cans a day. Strong cans, yeah. The IV clinic they would not let you drink, we’d 
sneak one a day you know because it’d show and they would go ‘Oh no’, they 
wouldn’t let you, no they wouldn’t let you.” - Trevor (P24), negative discharge; 
OM 
Changes to drinking patterns were often significant following IOT. In one highlighted 
case the patient was required to detox from alcohol dependence before he could 
begin IOT – and this detox was successfully achieved, demonstrating the wider – 
indirect - health impact of IOT. 
“I went into the AAU [Acute Assessment Unit – a detoxification unit] at the 
[name of mental health hospital]. Yeah and came off the alcohol there, that 
worked for a while and then just before I was given a date to start the 
injectables and just before that I went onto a five-day detox for the alcohol, 
came off the alcohol and then January 2008; that’s when I started injectables.” 
- Andy (P23), positive discharge; OM 
 
9.9. Improved physical appearance 
 
Another related factor mentioned by several patients was an improvement to one’s 
physical appearance, as a consequence of being in IOT. This is another factor that 
may also feed in to and link to the creation of the new non-using identity; an identity 
which may have inspired patients to continue to cultivate. 
“Everyone was saying how well I looked…And then be well turned out, do you 
know what I mean, instead of, like, looking like a tramp all the time.” - Jason 
(P26), negative discharge; OM 
Here the patient is also getting feedback from the outside world, which may further 
accentuate the desire to maintain the non-using identity. Patients described the 
multiple ways that they looked and felt better. Patients outlined that looking after 
themselves involved washing themselves and wearing clean clothes, and this made 
them more approachable to the people around them.  
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“It’s made us more approachable, made us back to normal, like dressing 
properly, washing every day, cleaning. You know, I didn’t wash my clothes, 
my house, everything. Eating and stuff and the way you dress and all that. 
Looking after yourself basically…but looking after yourself, cooking and stuff 
and washing, cleaning and all that. It makes a difference actually, do you know 
what I mean?” - Patrick (P39), long-term IOT; OM 
Once again the simultaneous benefit of feeling better within one’s self and the fact 
that the patient felt more integrated and accepted into society is emphasised as 
pertinent to long-term recovery. Progression health wise and through harm reduction 
was pertinent to the whole qualitative sample, aside from the smaller sample of clinic 
closures. 
 
9.10. Improved housing 
 
Patients across all typologies identified improvements to their housing situation, and 
a sense of pride in creating a nice home. Some patients highlighted that their housing 
was stable prior to IOT and, for a number of patients, improvements occurred during 
IOT. Patients also highlighted the fact that they had maintained stable housing long-
term, that housing remained stable at the time of interview.  
“My housing situation’s great. I’ve been in the same place for about eight years 
now and that’s the longest I’ve been in one place in my entire life.” – Fay (P10); 
long-term SIH; OM 
“A lot of the chaos was taken out of my life and the need to generate money. 
Once you take that away and you can focus and focus on your house.” – Tom 
(P9); positive discharge; SIH 
As well as acquiring stable accommodation, several patients highlighted the ability to 
create a nice home. Creating a nice home applied to both positive and negative 
dischargers only. 
“Oh I’ve got a lovely flat and I’m really proud of it because the money...I spent 
on heroin I robbed but I save money up, if I want something I save it up.  Like 
I’ve always wanted a plasma television and I saved up for over a year.” – 
Nicholas (P14); positive discharge; SIH 
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However, in context, improvements to housing did not apply across the entire 
qualitative sample; with some patients highlighting current housing difficulties – 
illustrated and discussed later in the chapter. 
 
9.11. Achieving and maintaining stability 
 
An overall theme, and one which ran through all interviews and sections of the 
schedule was stability. This theme was prominent and predominantly contains sub-
themes that have been captured elsewhere in the analysis. Stability was comprised 
of improvements to many areas of patients’ lives, such as family and relationships, 
reintegration and moving away from the drugs subculture, health, housing, illicit use 
and abstinence, harm reduction, cognitions and emotions; and general and specific 
mentions of stability (which were explicitly reported by almost half the sample in this 
context). For some patients stability involved having a nice home, with household 
appliances, and the ability to look after a pet. 
“And I've got everything you need in a flat, I've got fridge, freeze…freezer, 
cooker, washing machine, everything.  Carpets on the floor, the whole, 
everything, sofas, settee, beds, pans, der der der, I've got all of it and I went 
in that flat with nothing, absolutely nothing. As I said I've got four dogs that are 
my babies and I wouldn’t…I wouldn’t even have a dog when I was chaotic 
because I wouldn’t look after it.” - Ron (P27); long-term IOT; SIM 
As is indicated patients were keen to demonstrate their progress and current stability, 
indicating a greater sense of worth, pride, purpose and long-standing belief in IOT for 
recovery. 
“It’s given me a bit of stability…Yeah my life is a lot more organised now. I’m 
not in debt, I’m in front of everything not by a lot, my rent, poll tax, gas, electric, 
I’m in front of all of that so makes me more comfortable. In the respect of it 
like calming everything down, it’s like take a deep breath and I’m in a lot better 
situation now than I was then. I mean I was just about hanging on to my flat 
with the rent and all that and gas, electric, it was like juggling, I’d be on 
emergency one week; it’s not like that now.” - Lee (P36); long-term IOT; SIH 
Once again it appears that a course of IOT was beneficial to help stabilise patients 
by interrupting and reducing the chaos and instability central to their lives prior to IOT. 
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“I feel it’s one of the best things I’ve ever done. Do you know what I mean? In 
so many ways. It’s made my life more stable.” - Patrick (P39); long-term IOT; 
OM 
A general mention of the achievement of stability was prominent across all typologies 
and treatment groups. 
 
9.12. Reflective awareness of recovery 
 
It was clear that a self-reflective mechanism was present through patients’ narratives 
of their journey through recovery. Patients highlighted relevant psychological 
processes, such as the importance of self-belief and the impact of judgement from 
others.  
“Well, I’m pretty straight with people, and I do tell people, even if I’ve only just 
met ‘em, you know, and if they say, ‘Oh, what are you up to?’ ‘I’m just going 
up for my injection.’ ‘Oh, what’s that then?’ And then I’ll just say, it doesn’t 
bother me, you know. ‘I used to be a heroin addict and now I’m in treatment 
and I’ve been in treatment for however long.’ And they say, ‘Well done,’ or 
they’ll say it in a way where they’re looking down their nose. ‘Oh, well done,’ 
but you know the sarcasm, you know, but I don’t let it bother me. Water off a 
duck’s back.” - Fran (ID 13), long-term IOT; SIM 
“And I think when people think it’s wrong to give this treatment it says to me 
that they think that heroin must be the best drug in the world, well they must 
think that addicts are just so shit or humanity is just such a horrible thing that 
you really think that somebody is.” - Ellie (ID 22), positive discharge; SIH 
“But it’s like everything, it will only work if you want it to, won’t it?” - Harry (ID 
8), positive discharge; SIM 
Only a few patients spoke about the importance of self-belief and self-esteem (and 
both were positive dischargers; SIH and SIM treatment groups), however a greater 
number of patients spoke about the impact of judgement from others, and more 
commonly the impact of acceptance by friends and loved ones. The latter was 
highlighted by positive, negative and long-term dischargers in equal measure, but not 
by the clinic closures – this theme spanned all treatment groups, and in particular 
those originally assigned to SIM. Patients held clear perceptions and reflections about 
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their own progress through treatment, with many patients citing that they felt happy 
or pleased with their progress, and a smaller percentage highlighting that they wished 
progress had been quicker or that they had regrets about decisions they made during 
their treatment journey.  
“I think personally I done really well whilst being on it. I had little slips here and 
there and I was warned and you know, but I think that went for a lot of people 
but I also learnt from it. I did respect it, I did appreciate, I didn’t want to be 
thrown off, and I stressed that to them, so all in all it was a positive experience 
for me and I did use it that way. As I say, I think I done really well because 
even though I had slips and relapses, I’d like to always bear in mind that it has 
been a success and that even though I failed in a lot of other tasks trying to 
get my life together and clean up but I could actually say that has been a 
success story for me and I am glad of joining it, no regrets.” - Harry (ID 8), 
positive discharge; SIM 
“I’ve come on massively just even in things like self-esteem. My mental 
health’s better, my physical health’s better, my relationships with my family 
are massively better than they were. I mean, they’re talking to me, which 
before I hadn’t seen most of them for going on twenty years.” - Fay (ID 10), 
long-term IOT; OM 
The fact that family relationships were in some cases so drastically improved seemed 
to validate patients’ trajectories, and contributed to a more positive self-regard. This 
illustrates the two-way and multi-faceted nature of factors contributing to progressive 
recovery. There were a high number of positive dischargers within this theme, as well 
as those in long-term IOT. Less prominent but still present were negative dischargers, 
however there were no positive comments about progress from the clinic closures. 
The theme spanned equally across all treatment groups. 
A number of patients cited perceived regrets about the decisions they made during 
their course of treatment, for example: staying in IOT for too long; coming off IOT 
completely; reducing (dosage) too quickly; and increasing (dosage) too high. 
“I don’t think I was ready to do it [leave IOT], to be honest. I should have 
carried on with the good support that I had here and...  Because I walked out 
of rehab after nine days and ended up on the street and lost my flat so I ended 
up in a bigger mess than before. I was quite stable, I had a flat, I was here at 
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RIOTT, I was doing really well, but then things just went downhill after I left.” - 
Stacy (ID 5), positive discharge; SIM 
Illustrated again later, the above quote reveals the detrimental effect of leaving IOT 
prematurely, and in this case, despite the patient having made the decision to exit 
IOT, voluntarily, with a clear after-care plan. The need for ongoing therapeutic support 
– even when patients are detoxed from maintenance medication - is perhaps 
illustrated. It is also interesting that this patient received SIM treatment only, and 
perhaps highlights again the benefit of the holistic nature of the support gained from 
being in the regimen. Positive dischargers were dominant voices in terms of citing 
regrets over decisions made, with some, but fewer, negative dischargers. There was 
an even split of those assigned to SIM and SIH, with one assigned to OM. There were 
no long-term IOTs within the regrets sub-theme. 
A cross-cutting sub-theme was the idea that whilst on the one hand IOT provided 
space to stabilise and make changes; on the other hand stability took time and 
patience, and was not immediate. 
“Like I said, it gave me time to straighten myself out, you know, it did give me 
that time. I can’t speak badly of RIOTT, you know, because it gave me time to 
sort my life out a little bit, you know.” - Jason (ID 26), negative discharge; OM 
“I think if I tried to rush it, rush the whole programme I don’t think it would work 
for me because I was allowed to do it at my own pace and I was allowed to 
set my own goals, I know it doesn’t work say for everybody, well it isn’t the 
same for everybody; you know, they have to have goals set for them 
sometimes to achieve anything you know.” - Jacob (ID 4), negative discharge 
(other); SIM 
The above quote links to – and fell under – a theme from the previous chapter also; 
‘Person-centred care and autonomy over clinical decision-making’. That stability took 
time was cited by negative dischargers and long-term IOTs. That IOT provided 
psychological space to stabilise and make changes was mentioned predominantly by 
positive dischargers, additionally, several long-term IOTs and a balanced 
combination of SIH and SIM groups – with only one OM – however, it was not cited 




9.13. Feeling grateful 
 
Linked to the psychological process of change, as well as a reflective awareness of 
recovery, was an expression of gratitude by patients. This applied to a smaller 
proportion of the sample. Patients expressed gratitude for the fact that the damage 
caused by heroin was limited, with an acknowledgement of the potential further harm 
they could have suffered, had IOT not become available.  
“I consider myself quite lucky that what I’ve got is limited to a little bit of visual 
damage that you can see as opposed to an open festering wound that some 
people have got, you know.” - Shane (P21), long-term IOT; SIM 
“I’ve got quite a lot of joint pain and I’ve got COPD and asthma, so my health 
isn't great but it’s better than it would have been if I’d kept using, so I mean 
you can't expect to lead the life I have for the last 30 years and be sort of fully 
healthy by the end of it.” - Fay (P10), long-term IOT; OM 
The above quote also demonstrates some level of acceptance of the situation that 
culminated for them. A large number of patients were grateful for IOT on the basis 
that it saved their life. 
“But I do feel like RIOTT is one of the things that saved my life because I was 
injecting massively, doing a huge amount of heroin.” – Stacy (P5), positive 
discharge; SIM 
Linked to the findings in the last chapter, the way that the patient conceived IOT, had 
an impact on how well the patient engaged with and adhered to IOT. Patients also 
illustrated gratitude in the context of the system of care they were involved with 
through IOT, and gratitude for this support. Again this illustrates narratives associated 
with psychological recovery, which was another element of efficacy. 
“You’ve got people who are interested in what you’ve got to talk about. And 
it’s the fact they engage with you like an actual human being and it just felt 
like they were, it wasn’t like going into a clinic and being administered, it was 
like we were a community of people who everybody cared about each other, 
you respect them because they’re here 365 days a year.” - Ellie (P22), positive 
discharge; SIH 
This quote illustrates something fascinating about the nature of the relationship 
between patient and staff and how this links to psychological recovery – ‘you respect 
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them because they’re here 365 days a year’. Once again, gratitude appears to be 
implicated in engagement, sense of self-worth, and thereby overall recovery. This is 
highlighted again below. 
“I've had interferon treatment on my liver, I don't know whether it's worked or 
not, but psychologically it's helped me because they might care a little bit.” - 
Oliver (P16), long-term IOT; SIH 
In the case of the above patient it was clear (and also within an earlier quote – as 
illustrated above) that his interactions with, and perceptions of, those administering 
his care were highly relevant psychological processes involved in perceived efficacy 
and recovery. Gratitude also links back to a reflective awareness of recovery – as 
outlined in experience of IOT – additionally it demonstrates the narratives involved in 
psychological recovery, and was a component of what made the experience of IOT 
so impactful for these patients. Gratitude was mainly declared by those in long-term 
IOT, with one positive discharger also. It was clear that efficacy was a multi-faceted 
theme, encompassing reduced craving; reduction/cessation of illicit use; and 
psychological processes of change. 
 
9.14. Protective factors 
 
Gains which were made as a consequence of being in IOT became protective factors 
to patients remaining in IOT and not using illicit heroin over the long-term. These 
protective factors included dependents, pets, service user involvement, pursuit of 
hobbies and passions, and family support and care. IOT itself was also seen as a 
protective factor, for example, in regards to health and preventing further damage. 
Other factors which protected patients from relapse during their recovery were 
negative experiences with street use, a lack of veins for illicit use (i.e., through IOT 
patients could administer heroin intramuscularly), the perceived lack of effect of illicit 
drug use, and perceived reduced quality of illicit drugs. These factors are not 
necessarily directly consequential of IOT, but are external factors associated with 
recovery, and which protected patients from further illicit use. It was important to 
highlight both factors which arose as a direct consequence of being in IOT, and 





9.14.1. Service-user involvement 
 
As previously outlined in the experience of IOT chapter, some patients took on 
service-user representative roles and these roles became protective factors, both to 
the maintenance of stability, and against relapse. 
“Yeah, because I mean I started doing service user involvement stuff around 
that time as well, so it gave me something else to do, something else to focus 
on, I suppose. … I mean, I did the coffee morning there, so I suppose, for me, 
it was more, maybe, more of a professional thing. …I started getting to know 
people through the service user involvement stuff, really. So, I suppose that’s 
where I got my support, through the service user involvement work.” - Pam 
(P19); positive discharge; SIH 
The sense of empowerment that service user involvement provided was also 
highlighted. The following quote also links back to dissatisfaction with previous 
treatment (pre-IOT), and the sense that IOT was a new and hopeful concept, as 
previously highlighted in earlier chapters. Those who cited service user involvement 
and being service user representatives as pertinent to their recovery were all positive 
dischargers and long-term IOTs. Cause and effect is obviously not known, but this 
activity appeared to serve as a protective factor for respective patients. 
“I didn't see it as being any saviour but I thought that if I joined in I might be 
able to change it from within. Because this was heading in the right direction. 
And they might, if not listen to us, at least tack a course that stayed away from 
the pain and squalor of the treatment that was already available.” - Oliver 
(P16); long-term SIH 
Additionally, service user involvement led to new projects and passions for some 
patients, which are part of the overall picture of recovery.   
“Absolutely because in a way, you know, everything sort of slotted in. One 
thing led to another and it was like a natural thing. It was like a natural process 
and I found my niche.” - Elena (P37); positive discharge; SIM 
The motivation to affect the direction and future for policy and practice on OST 
became a protective factor for those with service user involvement responsibilities. 
This indicated that empowerment and service user involvement was implicated in the 




9.14.2. Caring for pets 
 
Pet ownership was made possible through the stability that IOT offered patients who 
wished – and some had illustrated this as a goal at treatment outset - to own pets. 
Then through the routine and stability provided by owning a pet, and the fact that 
another creature now depended on patients’ stability, pet ownership became a 
protective factor. This applied to a number of patients within the qualitative sample, 
including positive and negative dischargers and long-term IOTs. 
“Yeah, and it sort of…every time I think about using I think well if you start all 
that again they’re gonna suffer, well they wouldn’t suffer 'cos I'd get rid of them, 
I'd find them good homes to go to but…” - Ron (P27); long-term IOT; SIM 
 
9.14.3. Hobbies and passions 
 
A few patients highlighted the ability to pursue hobbies and passions again. These 
patients were all positive dischargers. 
“The first year we started both of us, Andy [another IOT patient, and Ellie’s 
partner] came out of hospital and he looked on, I got him a copy of Floodlight 
and took it up there, the next time I came to visit him. We were looking at 
evening courses and we did some certificate in music technology at adult 
education centre in Westminster so we’d go Tuesday evening and it gave us 
stuff to do and Andy got money from charities so he got a computer, I got my 
equipment from Dorset. So we got the studio back up so we started doing 
music again.” - Ellie (P22); positive discharge; SIH 
In other sections some patients highlighted some degree of struggle with courses 
that they were completing, however, overall they seemed to contribute to the 
overall picture of protection from relapse.  
 
9.14.4. Relationships with family and dependents 
 
In some cases IOT was a factor in patients reconnecting with dependents. The 
maintenance of these relationships then became protective factors. 
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“My youngest child, she had already been in care. Well, she hadn’t been in 
care that long when I started on RIOTT, but it took quite a while for me to – by 
the time I actually re-established contact, it was – well, put it this way – it was 
obvious then, that by the time I would be in any, sort of, situation to get her 
back, it would be pretty much, she would have been away from me for years, 
so it was, sort of, pretty much clear then that she was never gonna come back 
and live with me, even my youngest. But I did re-establish contact with her, 
yeah, which was in itself, I suppose, yeah, really important for me, yeah.” - 
Pam (P19); positive discharge; SIH 
Children and grandchildren were also highlighted by patients as the specific reason 
why they reduced or ceased illicit use. Dependents as protective factors applied to 
long-term IOTs and negative dischargers. Over time, and as they developed, the 
commitment to these relationships became protective factors against relapse. These 
connections and commitments were made possible through the stability offered 
during IOT. 
“I love my son, he’s great, I’d give up methadone tomorrow just to bring up my 
son…I wasn’t injecting when he was born, when he was conceived, I’d been 
clean from needles for just over five years now.” - Trevor (P24); negative 
discharge; OM 
“I live with my partner and my daughter's got her own house and we've got a 
grandson who's one, so that's why I've been trying to knock it on the head 
completely.” - Richard (P34); negative discharge; SIM 
It may be the case that the above situation could not have arisen if the patient was 
still involved in the chaotic situation prior to referral to IOT.  
9.14.5. Reduced quality of illicit drugs 
 
Similarly to family relationships – in the sense that cause and effect was not direct, 
yet still implicated in the overall picture of recovery - the fact that patients perceived 
that street drugs had diminished in quality at the time patients were in IOT, was cited 
as a pertinent factor to cessation of use of illicit drugs by a number of patients. This 
was interesting to uncover. 
“What happened is…by coincidence when I started this treatment the street 
drugs quality went through the floor. It turned to crap. And by coincidence I 
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had already started my RIOTT treatment. So it made it easy… easier to knock 
crack on the head; heroin I knew I could stop if I had a substitute.” - Shane 
(P21); long-term SIH; SIM 
The perceived diminished quality of illicit heroin was cited as one aspect of the overall 
picture that illustrated when and why patients ceased illicit use. Reflections on this 
period were interesting, and sometimes also included the fact that IOT reduced 
craving for illicit opiates; the combination of the two factors led to a natural 
progression to cessation of illicit use. Perceived reduced quality of illicit drugs as part 
of the picture of what led to cessation of use of illicit drugs was cited by positive and 
negative dischargers, and long-term IOTs. 
“Well it’s not that I decided like, consciously, it just … it was a natural 
progression I think, you know, it was like I can’t be bothered, I don’t want it, I 
don’t need it. Because even if I used I couldn’t have felt it. Because I’d already 
had my dose and once your receptors are busy, you know, and also because 
of the quality of what we were being provided there, any street rubbish 
wouldn’t have touched me.” - Elena (P21); positive discharge; SIM 
Overall, IOT provided space for important changes to take place, and for other 
activities to be pursued and enjoyed; it appears that these activities sometimes 
became protective factors deterring patients from returning to illicit use and the 
associated lifestyle and instability. That IOT is delivered in a holistic programme of 




Chapter Summary and Discussion 
 
The impact of IOT was a strong focus of the experience of IOT, across the qualitative 
sample and amongst all typologies. Illicit use was a prominent theme, and whilst at 
first glance may have seemed obvious, the facets of it were quite detailed and 
complex. For some patients reduced or ceased illicit drug use was maintained long-
term (up until the qualitative interview) and for some, cessation of illicit drug use was 
achieved as soon as they began IOT. In contrast, a period of adjustment to the IOT 
process appeared to be key to some patients, as was the importance of finding the 
right dose. The evolving nature of patients’ perceptions of their recovery was 
illustrated, and overall IOT provided means by which the unhealthy cycle of illicit 
heroin use could be interrupted. Related to this concept were narratives on 
achievement of abstinence-based recovery, which were outlined separately. 
Cessation of use of illicit drugs applied across the whole sample. 
The next area of gain was improved quality of life. This encompassed areas of 
expansion (e.g., completing courses and education) and areas of cessation (for 
example, leaving the drug subculture). Areas of improved quality of life involved 
psychological recovery; improved family and relationships; starting and continuing 
education and courses; financial stability; harm reduction; staying out of prison; and 
improvements to both health and housing. Whilst not drawn out directly through a 
qualitative theme, is useful to keep in mind differences across regional locations when 
analysing the improvements to quality of life theme. The three geographical locations 
are very different socio-economically – particularly when contrasting opportunities 
that might have been available to patients in central and south London, to those in 
the small market town Darlington. Indeed, one patient in Darlington commented to 
me that Darlington was ‘rough’, during interviewing. It is particularly important to also 
bear in mind that Darlington was the clinic that had closed earlier than other clinics, 
and in several cases participants were aware that there were other clinics still 
operating in other parts of the country; for example, this was commented on at the 
end of interviewing, during small talk between one participant and interviewer. Whilst 
not overtly communicated, this may have an effect on patients’ motivation and hope 
for the future. 
Patients made clear that they believed IOT had saved their life. Friends and peer 
groups either noticed differences or these groups changed. Patients demonstrated a 
reflective awareness of the harms that had been caused by heroin. Some of the sub-
themes in the quality of life theme were cross-cutting themes to the later theme; 
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protective factors. It appeared that IOT provided enough stability for patients to 
engage in areas and relationships which improved their quality of life, and these 
activities and relationships then served as protective factors to relapse. 
Psychological recovery was clear and key. Patients outlined that they were committed 
to the IOT programme and staff could see this. Patients outlined that they felt positive 
and had a (new) sense of importance through the engagement with IOT, and perhaps 
the requirement for daily attendance. It appeared that engaging with the clinic, staff, 
keyworkers and other patients potentially led to a feeling of self-worth. This linked to 
following subsequent themes; leaving the drug subculture and developing a non-
using identity. Patients engaged with education and courses and relationships 
improved. Within this theme, and all themes within this section, it was clear that this 
arose as a consequence of IOT, and also served as a protective factor from relapse.  
Patients undertook volunteering activities and formed new peer groups. Patients 
described that they did not wish to go back to the old life. Patients chose to lead a 
more isolated life if this was perceived as a factor pertinent to relapse prevention. 
From a health perspective gains were both holistic (e.g., desired weight loss) or 
directly connected to changes to illicit use of drugs (e.g., further vein damage was 
prevented). Patients outlined feeling more stable. Sometimes this was a general 
feeling, and sometimes it connected to something specific such as stability derived 
from the creation of a nice home that patients were proud of. Patients described again 
that stability took time. That stability took time was illustrated by clinic closures and 
long-term IOTs only, and that IOT provided space for recovery and changes, by 
positive dischargers and long-term IOTs. 
Overall IOT seemed to contribute to the development of very reflective patients with 
a lot of insight in to their psyches and psychological recovery. Patients described the 
role of individual motivation, as well as the impact of judgement from other people 
could have on them. Patients described the resilience they had created in response 
to this. Acceptance from others was a strong theme and linked to a previous theme 
around family support, both of which were pertinent factors to recovery, both as a 
consequence and maintainer of stability. Patients outlined that they respected the 
treatment programme, and some patients described that they had regrets about 
leaving IOT when they did. Feeling grateful was a connected theme that arose from 
narratives. Patients were relieved and grateful that damage caused was limited, and 
expressed gratitude for health care professionals and systems. An ongoing theme 
was reflection on how well the patient perceived they had done in IOT.  
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Throughout the interviews areas of importance arose as both a consequence of IOT 
and (later functioned as) an ongoing protective factor. These included service-user 
involvement responsibilities, the responsibility of caring for pets and dependents, and 
undertaking hobbies and passions. Interestingly, the reduced quality of illicit heroin 
was also cited as a protective factor from illicit heroin use. It may well be that patients 
were more attuned to the latter both as a consequence of living a more stable life, 
and obtaining clinically pure heroin. Both of which these factors may have provided 
more attention to the fact that the quality of illicit heroin had diminished. Overall the 
impact of IOT was significant, and for all patients interviewed, some degree of 
recovery was achieved. 




Chapter 10 – Findings: Recovery 
 
The following chapter outlines patients’ conceptions of recovery following IOT. 
The concept of recovery in addictions is a topical discussion. Recovery is introduced 
and explored in the introduction. Laudet (2007) describes that recovery goes well 
beyond simply abstinence; it is experienced as an ongoing process of growth, self-
development, and a reclaiming of identity. It may well be that the individual remains 
in recovery through the life-course. Recovery in the context of IOT is less explored 
and is important. Patient’s’ steps following IOT, and where this treatment fits in to the 
individual’s overall journey of recovery is an ongoing debate and warrants further 
exploration. Patients are unlikely to be prescribed IOT for life, particularly in light of 
recent (March 2015) UK IOT clinic closures, therefore the recovery forecast following 
this treatment is important. It is important to gauge patients’ perspectives on their 
recovery trajectory, and what patients perceive IOT’s role within this is. 
One of the overall aims of the thesis was to examine patients’ concept of recovery in 
the context of IOT. The next chapter specifically (and directly) examines patients’ own 
views about recovery in the context of this unique treatment. Patients were specifically 
asked about their views on recovery, and their views on recovery in the context of 
IOT. Responses match aspects outlined during narratives on experience and impact, 
however specific narratives in response to being directly asked about recovery in this 
context are also detailed. It is useful to view the narratives in the context of patients’ 
goals; both at treatment outset, and goals for the future, which are outlined in the next 
chapter. 
Following interviewing and analysis, perspectives on recovery amongst those who 
had undertaken IOT fell into discrete themes. Overall, there was a clear vision of 
individualised recovery; (reaching a state of) stability and functioning; health and harm 
reduction; employment and financial stability; (for some) abstinence-based recovery; 
cessation of illicit opiates; ongoing maintenance treatment; ongoing support; 
psychological adjustment (including recovering self-esteem); reintegration; making 
progress; protective factors and activities; and barriers to recovery. Barriers to 
recovery encompassed instability; dissatisfaction with treatment; health issues; and 
continued illicit use. The final two themes – protective factors and activities and 
barriers to recovery emerged during the course of interviews, as opposed to in direct 
response to being asked about conceptions of recovery in an IOT context – which 
was the case for the other themes within this chapter.  
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Table 45. Outline of ‘Recovery’ chapter themes and sub-themes 
Reference Theme Sub-theme 
10.1. Individualised recovery  
10.2. Stability and functioning  
10.3. Health and harm-
reduction 
 






10.6. Cessation of use of illicit 
opiates  
 
10.7. Ongoing maintenance 
treatment 
 
10.8. Ongoing support  
10.9. Psychological adjustment  
10.9.1  Recovering self-esteem 
10.10. Reintegration  
10.11. Making progress in 
treatment 
 
10.12. Protective factors and 
activities 
 
10.13. Barriers to recovery  
10.13.1.  Instability 
10.13.2.  Dissatisfaction with 
treatment 
10.13.3.  Health issues 




10.1.  Individualised recovery 
 
On a conceptual level, a number of patients made the point that the recovery journey 
is individualised, therefore to project a goal or vision for the future very much 
depended upon on what point the individual was at in the recovery trajectory or 
journey. Therefore, the case note reviews and typologies provide a useful, additional 
reference point to the following section, so that patients’ perceptions can be viewed 
in light of individual and group treatment trajectory. The individualised nature of 
treatment was emphasised by a number of patients, and this concept is illustrated 
and discussed. 
 “You need to tailor it to suit individuals and I believe that people should be 
profiled when they enter, re-profiled six months later, and then go from there 
to see what's going to go.” - Oliver (P16); long-term IOT; SIH 
Patients underwent reviews with their keyworker on a regular basis, and it is 
interesting that some patients commented on the need for a regular review. That 
recovery was personal and individual was very much emphasised. 
“Well recovery in terms of that approach, well I think it depends on the 
individual, you know. …It’s very personal, absolutely. You can’t stick a label. 
You know, recovery, I think to me that recovery means a positive progression 
for each person’s levels and standards. You know, you just can’t generalise. 
It’s a very personal thing. You can’t put standards on it.” - Elena (P37); positive 
discharge; SIM 
“Well, for me, recovery is very much a personal thing. You can't force a type 
of recovery on one person just because it worked for another person.” – Fay 
(P10); long-term IOT; OM 
Here the need for a personal post-IOT care-plan is emphasised. This was often 
written into a patient’s IOT care plan, however is not always possible in practice, for 
example, when patients drop out of treatment without notice; go to prison; go in to 
hospital; or in the case of clinic closures, where ultimately the majority of patients 
were transferred back to oral methadone. 
At the time of interviewing in Brighton, commissioning changes meant that original 
IOT patients were allocated 18 more months of IOT only, and new patients to IOT 
(i.e., non-RIOTT and therefore not interviewed) were given an 18-month total IOT 
care-plan, and this was made clear to patients entering IOT from this point onwards. 
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When mentioned, patients spoken about this new regime unfavourably, the necessity 
for the individuality of treatment was highlighted again in this particular context. 
“I think they should think about the powers that be into turning this 18-month 
thing into like tailored to people’s individual needs. And just, you know, you 
can’t put everyone in the same box, because everyone’s different.” - Josh 
(P41); long-term IOT; SIH 
Once again this suggests that patients felt that treatment duration could only be 
decided on an individual basis. Across the sample – and as highlighted in earlier 
sections – patients had a tendency to compare their progress to that of other patients, 
and this should also be taken in to account and incorporated in to individual treatment 
care plans. 
“I think that if somebody progresses or really shows signs of stability, you 
know, it depends on where they’re coming from, you know, it depends on their 
journey, you know, if they were very chaotic and then they managed to 
achieve a degree of stability at least, you know, get their housing sorted out, 
you know, and get themselves clean and get themselves, you know, fed and 
watered and washed and stuff, you know; that is recovery.” - Elena (P37); 
positive discharge; SIM 
That recovery was felt to be individualised and personal was expressed across 
positive dischargers and long-term IOTs only. 
 
10.2. Stability and functioning 
 
Almost half the sample cited stability and functioning as a key component of what 
recovery meant to them. Within this, around a quarter of patients specifically cited the 
desire to live ‘a normal life’ or to continue as they were currently. These comments 
mirrored goals patients had on entering treatment, as well as the reported impact and 
effect of IOT, indicating an overall sense that this goal had been both fulfilled through 
IOT, and remained what the patient was striving for within their ongoing recovery. 
“Normality, that’s what recovery to me is, normality - what you do, what that 
person does.” - Charlie (P3); positive discharge; SIH 
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Here the patient seems to be expressing the desire to fit in to ‘normal’ society again; 
the desire to no longer be, or be seen as, an outsider. 
“It’s a case of trying to lead a normal life, whatever normal is, you know. For 
people like me I don’t think I’m ever gonna be normal, but at least I can have 
a better quality of life.” - Fran (P13); long-term IOT; SIM 
There was often a lot of energy and passion around recovery and what this meant for 
patients, including hopes and goals that patients wished to explore – this energy and 
passion is reflected in some of the quotes illustrated here. 
“It means taking control of your life again, and taking control… moving 
forward. Achieving things, doing things that you wanted to do when you were 
16, 18 years old and you missed your chance; to go to uni, say in my case, or 
for some of the other people that are not so academic, they missed the chance 
of a job that they'd really like to do, or just even have a normal home life. 
…That to me is recovery, is when you start having… you have proper friends; 
you don’t just have associates that you hang around with because they do 
drugs and you do drugs and you're in the mix that way, so you're forced 
together. It's to have normal relationships with people and normal friendships 
where it isn't all backstabbing and based on crime or based on being off your 
head. A normal existence.” - Tom (P9); positive discharge; SIH 
Once again the desire to be reintegrated in to society is synonymous with the idea of 
a ‘normal’ life. Socialising with non-drug users is also emphasised. The above quote 
illustrates another commonly cited sub-theme within the recovery theme – recovery 
for life – the idea that recovery must include advancement in areas of life outside of 
drug use and cessation, such as, housing, employment, family, financially, peer 
groups, and lifestyle. Gaining control back over the life previously lost to drugs is 
emphasised. Having control in recovery was a prominent cross-cutting meta-theme – 
for example, having perceived control over clinical decision-making within IOT. That 
this was such a strong feature of treatment and recovery is interesting, and perhaps 
particularly pertinent to a sample of people who had spent so many years completely 
controlled by a drug. 
“But recovery I see that as a functional life and most people think detox, 
abstinence, functional life, whereas this programme is: life starts because you 
let it, because you’re not busy being a drug addict - and life gets more 
interesting because it is, and the drug more boring because it is. And so then 
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you go to functionality and then your sense of who you are changes and the 
drug becomes less important.” - Ellie (P22); positive discharge; SIH 
Here functioning is embroiled within wider aspects of recovery, and the previously 
touched upon consequences of IOT, such as restoration of the non-drug using 
identity, and the role of engagement with life and wider society. The patient makes 
reference to pertinent aspects of the complete trajectory of recovery linking 
functioning to engagement, identity and purpose; and suggests that this is all possible 
due to the stability of the programme and the cessation of chaos. It is clear that the 
programme allowed the patient to access a vision of what recovery meant to her. 
In addition to stability and functioning several patients asserted that for them recovery 
was what they were doing at the present moment; they were currently recovering. 
Several patients said that they would like to continue as they were currently, in terms 
of current treatment received – this applied to those who remained in IOT at the time 
of interview. 
“What recovery means to me is what I'm doing now.” - Reg (P12); long-term 
IOT; OM 
“I'm going to carry on doing what I'm doing, even if they stop the treatment 
tomorrow, I will carry on doing what I am doing.” - Oliver (P16); long-term IOT; 
SIH 
The presence of this sub-theme indicated that some patients had reached a point that 
they were satisfied with within their recovery journey and current situation. This sub-
theme only applied to those in long-term IOT however. One other theme outlined by 
a number of patients was having the psychological headspace to engage with 
recovery. In previous sections patients also saw this as part of the impact of IOT; 
something that IOT allowed for. This was illustrated predominantly by positive 
dischargers, and one long-term IOT. 
Overall, stability and functioning in their various guises and as features of recovery 






10.3. Health and harm reduction 
 
Connected to the overall concept of stability was a vision of good health and harm 
reduction. 
“Recovery, to me, would just mean to get rid of hepatitis, hepatitis C, to go 
through the fibroscan and pegylated interferon without going bald.” - Luke 
(P18); negative discharge; OM 
The following quote is by somebody who was abstinent from both street drugs and 
treatment drugs at the time of interview. This provided support to the idea outlined 
earlier, that recovery is individualised, and that different people will have different 
ideas and needs, based on where on the trajectory they are at that time. Patients may 
have been better able to begin formulating goals for other areas of life once illicit use 
completely ceased. 
“You are recovering from whatever ailments, whatever you’ve, sort of, like, put 
yourself, mentally and physically, through, and you want to change it.” - Jason 
(P26); negative discharge; OM 
Linked to this was the patients’ concept that harm reduction was a sufficient goal or 
aspiration. This may be linked to remaining in IOT long-term; that patients conceived 
IOT as a mechanism by which harm could be reduced. 
“My idea was always harm reduction. Don’t kill yourself, don’t kill other 
people.” - Shane (P21); long-term SIH; SIM 
The goal of health and harm reduction applied mainly to negative dischargers – 
perhaps suggesting some anxiety around the area of health for this particular sub-
sample – and applied to one positive discharger also. Other less prominent aspects 
of stability and functioning (as indicators of recovery) outlined by patients included: 
financial stability and employment; housing stability; having more time available - and 
relatedly - headspace available for recovery; no longer needing to commit crime; an 
improvement to family and romantic relationships; and when the individual stops 
thinking about illicit drugs. That the patient no longer thinks about drugs, and 
perceives this as an indicator or recovery, was also specified in the above comments 
around returning to work, signifying the vision and hope for a complete life change. 
This complete life change was introduced by another patient who stated at the 
beginning of his interview that he had turned his ‘life around 365 degrees’, as a 
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consequence of IOT; a patient who was also in stable employment at the time of 
interview (Reg; P12; long-term IOT; OM). 
 
10.4. Employment and financial stability 
 
Several patients mentioned work as a feature of their recovery vision, sometimes this 
was directly mentioned – such as the goal to find a job - and other times work was a 
mechanism by which patients connected to structure, routine and a reason for living. 
“My idea of recovery includes work.” – Shane (P21); long-term IOT; SIM 
Employment and financial stability were significant to the concept of recovery for both 
those in long-term IOT and positive dischargers. 
“Having something to get up in the morning…the first thing that comes to mind: 
‘What am I gonna do? What’s happening at work and how am I gonna achieve 
that? Am I gonna do that?’” – Charlie (P3); positive discharge; SIH 
The above quote indicates the pertinence of the shift in thinking about something 
other than drugs when one wakes up in the morning – something that the patient is 
motivated and interested in. This was mentioned by several patients in the context of 
what recovery meant to them. Altering one’s mind-set seemed to be key to patients’ 
conception here. 
“Recovery’s beating the drugs, right, and never ever going back; that is when 
you’re recovered.  If you beat it and you’re still thinking about it, you’re not 
recovered as far as I’m concerned.” Scott (P25); long-term IOT; OM 
 
10.5. Abstinence-based recovery 
 
Whilst recovery was viewed as multifaceted (and individual) patients did commonly 
highlight their relationship with, and aspirations for, illicit heroin use, within their 
concept of recovery following IOT. Across this theme sub-themes were varied. For 




“Well, I suppose it would be the eventual not need for any opiates.” - Sammy 
(P11); long-term SIH; SIM 
Being completely detoxed from all opiates as the definition of recovery had high 
emphasis across all typologies. Some patients also highlighted the physical addiction 
to opiates, including OST, and the desire to feel well without having to take 
medication. In this context the frustration around the cycle of dependence and 
associated physical discomfort was highlighted, with strong resolve to make a change 
on this basis. 
“For me, the goal is just abstinence, I just want to be able to get up in the 
morning and not think ‘Oh three hours until I feel well’. I want to feel well the 
minute I wake up. And get home from work and just don’t want to use heroin 
any more, I've had enough.” Gerry (P20); long-term IOT; SIH  
“But recovery would be abstinence and staying clean and having a normal life 
again, do you know what I mean?” - Patrick (P39); long-term SIH; OM 
Within the context of abstinence as recovery, some emphasised (as before) the 
critical point being when the user stops thinking about heroin. Again the lack of power 
or control over dependence on opiates – illicit or prescribed – was highlighted – with 
recovery viewed as a re-gaining of this power and control. 
“But the recovery is just basically being able to live your own life to the extent 
that you can, yeah, without the need for, I mean without being kind of 
constantly dependent on something that has power over you, that you are 
powerless over, if you see what I mean.” - Andy (P23); positive discharge; OM 
There was also quite a high level of ambivalence towards the concept of abstinence 
expressed by the qualitative sample. Ambivalence sometimes arose as a 
consequence of the patient finding recovery a difficult journey, and viewing the heroin 
using lifestyle more positively, since this was the way they had habitually masked 
reality, their emotions, and problems. In this case the awareness and reflection that 
arose through the stability of IOT, had caused the patient pain. This is a really useful 
finding, and provides further weight to the need for ongoing therapeutic support 
through both IOT and OST and beyond. 
“I’d love to be abstinent. I do have a spliff now and again, I’m still having a 
sniff, I’m still having a pipe now and again, but it’s not... I’m waiting for it all to 
collapse one day and I’ll go, ‘Well, fuck it’. I might just go through it again and 
324 
 
go off my nut for a little while. It’s coming, I know it’s coming. I frighten myself. 
There’s two ‘me’s’ up here. I try to get on – do you know what I mean? I was 
happier as a junkie than what I was trying to be – dealing with reality and 
being... The way life is treating me with the benefits and all that now. It’s hard. 
…One angel and one devil really.” - Jack (P2); positive discharge; SIH 
The above quote illustrates the pain and turmoil that can arise during recovery. The 
patient potentially applies the Rule Violation Effect, and all or nothing thinking, 
whereby he is expecting to fail, and thereby potentially legitimising relapse before it 
happens. The patient’s ambivalence is illustrated, and the implication of psychological 
craving. The above quote also demonstrates well the synergic relationship of society’s 
stresses and an individual’s recovery, illustrating the pertinence of wider stresses 
present in patients’ lives through their recovery. In this case the stress caused by 
welfare policy changes is a potential trigger or risk to relapse. Focussing on support 
and resilience in these wider areas of life is beneficial to recovery from entrenched 
addiction, within IOT and treatment generally, as well as more holistic (practical) 
support around housing and benefits. Ambivalence about abstinence arose within all 
typology groups. At first glance detox was viewed as the end point of the patient’s 
IOT trajectory, and as with other forms of treatment, what the patient was working 
towards. However, as has been clearly demonstrated, support following a detox may 
be beneficial, if not vital, for ongoing abstinence. 
[On detox:] I could have it arranged. That’s no worries. It’s thinking – am I 
ready? I’ve been there twice. I’ve kept away from heroin for some years, 
dabbled, hit the drink and ended back in – still come out. Still on drink, so 
yeah, it’s finding that – without anything, just being yourself.” - Jack (P2); 
positive discharge; SIH 
 
10.6. Cessation of use of illicit opiates 
 
Sub-samples of patients focussed on being illicit drug free or completely abstinent; 
leaving IOT; ongoing maintenance (unspecified) treatment; and being maintenance 
treatment free. These themes applied across the sample, and were prominent. For 
some patients, not using illicitly was at the centre of recovery, and their primary goal. 
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“Recovery is about – as long as I don’t use on top of methadone, I suppose 
that will do me for now. So it’s being clean for street drugs. From any street 
drugs, any crack.” - Daniella (P1); negative discharge; SIM 
“I think it was the period of time of not using, because I didn’t see that 
[maintenance treatment] as using, that was treatment.” - Matthew (P17); 
negative discharge; SIM 
Staying illicit drug free was cited by all typologies aside from clinic closures. This may 
be due to the limited number from this sample, or perhaps that this sample could not 
connect with this concept, since they were back on oral methadone treatment, with 
varying degrees of success at remaining abstinent from illicit drugs. A large proportion 
of patients highlighted exiting from IOT as their most pertinent aspiration for recovery. 
This was interesting, and contrasted with earlier, alternative perspectives on the 
desire for IOT for life. This may mean that patients did not always perceive they could 
ever fully recover under this definition, and yet they still applied it to their concept of 
recovery. With this in mind psycho-education on recovery and the potentially 
individualised nature of it could be useful within OST generally. 
 
10.7. Ongoing maintenance treatment 
 
For a proportion of patients, successful recovery involved ongoing maintenance 
treatment and this had relevance to all typologies. For some patients this was seen 
as both realistic and achievable, yet provided enough stability for them to be able to 
function within society. 
“I do very much believe in medically-assisted recovery because for someone 
like me that’s really about as good as it gets. Because of my history, even if I 
came off all the opiates I would be suffering from really chronic pain but I would 
never be given adequate pain relief because I’ll always be seen as drug 
seeking.” - Fay (P10); long-term IOT; OM 
By way of context the above patient was engaged in voluntary work and enrolled on 
a university degree programme at the time of interview. 
“My idea of recovery includes work but does not include having to stop taking 
the prescribed drugs.” - Shane (P21); long-term IOT; SIM 
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Once again the above quote illustrates a realistic expectation of the realities of the 
recovery journey for the individual in question. That firstly, it requires effort and 
strength from the patient, and that in some cases recovery is only possible if it is 
medically-assisted, despite IOT. This is to reduce (and protect from) the chaos, 
instability, ill-health and pain, and other unhealthy dimensions of the drug using 
lifestyle. 
“That doesn’t mean you have to be abstinent, it just means you've got…found 
a treatment that gives you…helps you to be and function normal.” - Ron (P27); 
long-term IOT; SIM 
 
10.8. Ongoing support 
 
A few patients cited receiving support from a treatment service; that engaging with 
support in and of itself was viewed as a component of what recovery was. In this 
situation it may be that the patient associates support with successful recovery, and 
periods without support as linked to the chaotic situation (e.g., pre-IOT). Where 
addiction appeared to be equated to loss of control and no support, recovery 
appeared to equate the regain of control and an ability to access support. The patients 
who reflected on the importance of support often offered a realistic evaluation of the 
recovery journey, and what it was that patients needed to recover – perhaps in view 
of previous unsupported attempts of the past. This also illustrates that ongoing 
support beyond IOT is also important. This arose in other sections of the interviews – 
for example instability in the final chapter on the ‘Current situation and goals for the 
future’. 
“Well, it’s a real hard thing to be honest, especially when you’ve been an 
addict for so long. But it’s massive and you need the support. You just need 
ongoing support; you really do and know what to do. Because you cannot do 
it on your own and you need, like, the people here because you can’t do it on 
your own. I’ve tried it and it doesn’t work.” - Stacy (P5); positive discharge; 
SIM 
In this context – with reference to recovery - the benefit of holistic and person-centred 
treatment is again highlighted. 
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“To me recovery is the ability to engage properly with a service that is sensitive 
and flexible to my needs and will allow me to develop and progress in my own 
time, whilst getting support. Not having unrealistic goals but just allow myself 
to find my own feet again. Which, without pressure, you’d be surprised, it 
happens a lot faster than pushing people to do things that maybe they are not 
ready for, or coercion, or the punishment model.” - Elena (P37); positive 
discharge; SIM 
The two patients directly highlighting the need for ongoing support were both positive 
dischargers originally assigned to SIM treatment. 
 
10.9. Psychological adjustment 
 
Patients often highlighted psychological processes or states pertinent to their 
conception of recovery. Several patients highlighted changes to their sense of self, or 
self-esteem, as being an important component of recovery, and indicative of success. 
A few patients highlighted the benefit of psychological therapy within recovery, and 
one highlighted cognitive improvement as indicative of recovery. The mechanisms of 
change were identified, such as the direct desire to change and having an ability to 
form goals. Patients also highlighted psychological adjustment and again having the 
headspace to engage with recovery. 
 
10.9.1. Recovering self-esteem 
 
Self-esteem and its importance to the recovery journey arose at various points within 
the interviews. In the following quote the belief that those activities which contribute 
to improved self-esteem need to be encouraged was reflected by means of the 
patient’s own experience. The patient highlights the need for activities to motivate a 
desire to stop using illicit drugs, which he links to increased self-esteem; and came 
from his experiences within his own recovery journey. 
“I believe, as well, a lot of people, it should be, we do it at work, with a support 
agreement, there should be parts of it that says you should have to go and do 
voluntary work; you have to go and do college; stuff like that. Because if you 
just come here, go home, come here, go home, you have no reason to stop 
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using, you have no reason. Why do you wanna stop using, do you know what 
I mean, if you’re just gonna stop using and still do the same stuff – nothing. 
You haven’t even got the bonus of coming to get stoned; do you know what I 
mean? So if you’ve got nothing to do during the daytime then it ain’t gonna 
work, and I’m a great believer, if you do something during the daytime, get 
your head into something, it’s gonna work quicker and you’re gonna feel better 
about yourself.” - Charlie (P3); positive discharge; SIH 
As illustrated in the above quote, the majority of references to self-esteem and an 
improved sense of self, came from the patients’ individual recovery experience and 
were part of a multi-faceted journey of progress. Overall the trajectory appeared to be 
necessary for the patients to experience these processes and have the ability to 
reflect on them, and apply them to long-term goals and experiences. 
“I'd find achieving goals gives you self-esteem, because obviously when 
you're using all the time and you're relying on other people to maybe get gear 
for you or bring you money or whatever; it's chaotic again.” - Tom (P9); positive 
discharge; SIH 
The above quote illustrates the synergistic relationship between perceived locus of 
control and self-esteem within recovery through IOT – with perceived lack of control 
linking to chaos. One comment specifically focussed on self-esteem as a 
consequence of having been in IOT. 
“Was good for me self-esteem and I was picking myself up then and I was on 
like a high, natural high with life.” - Rita (P29); negative discharge; SIM 
Self-esteem as a component of what recovery meant to patients was applicable 
mainly to positive dischargers, with one negative discharger. Less prominent was the 
concept of an improvement to cognitive functioning. The quote illustrates a sense of 
hope, or perhaps even an idealised view of recovery and in this case, life without 
opiates. Additionally, the recognition that by being in maintenance treatment one is 
not fulfilling one’s absolute potential, in the arenas of stability and well-being. 
“I’m hoping that when I come off my brain will be better, it’s quite nice to be 
able to think well maybe I’m rubbish because I’m still under an opiate, maybe 
when I come off that then I’ll be able to answer my maths questions in about 
five seconds, maybe I’ll be able to do a Sudoku faster than Andy.” - Ellie (P22); 
positive discharge; SIH 
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Earlier on in the analysis a few patients spoke about benefitting from the 
psychotherapy that was offered to some patients for a finite period as part of their 
recovery during IOT – in some patients’ conception of recovery, undertaking 
psychotherapy was also something they envisaged as beneficial to their ongoing 
journey. 
“Having psychological input. Just finding out why this happened to me. I have 
a fair idea and I would like to investigate that more.” - Clara (P7); positive 
discharge; SIM 
Psychotherapy was mentioned by two positive dischargers (both assigned to SIM). 
Interestingly psychological recovery, and the necessity of the appropriate type of 
support for this, was also contrasted with conventional substitution treatment. 
“But I think the emphasis needs to be taken away from methadone, and more 
on the mental willingness to face life without heroin.” - Oliver (P16); long-term 
IOT; SIH 
Within these narratives were patients’ views about effective recovery. This was further 
supported by other patients, and is corroborated by other comments that arose from 
the conception of psychological recovery. 
“You’ve got to do something at the end of it I think. And it should not only be 
left down to the individual to find that something to do. That’s the one thing I 
would say negative about RIOTT.” - Patrick (P39); long-term IOT; OM  
This taps in to, and leads on to, the next theme – the perception of need for re-





Linked to psychological recovery was the concept of reintegration. That is, 
reintegrating back in to society and communities; commonly expressed as the ability 
to make a contribution. Reintegration was conceptualised as both the gaining of 
something (such as an ability to make a contribution to society) and the cessation of 
something (through the cessation of problematic behaviour that served to ostracise 
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the patient from society and proximal communities – e.g., crime – and subsequent 
negative perceptions of the user from the outside world). 
“Be thought of as a productive member of society. Pay your taxes and what 
have you. Yeah.” - Reg (P12); long-term IOT; OM 
“Get back into society, be a useful, you know.” - Elena (P37); positive 
discharge; SIM 
Patients felt that reintegration and activities were important, but needed to be a part 
of the IOT trajectory. Once again this was contrasted with support offered through 
IOT. 
…. “Reintegrate you back into the community and work wise. Just a little bit 
more support would be better. A lot of people find it difficult moving on to the 
next level. Going getting a job, getting some information, you know, like stuff 
like that. That would really help I feel.” Patrick (P39); long-term IOT; OM 
In wider narratives several patients (both positive and negative dischargers) made 
reference to the making of goals in life as indicative of what recovery meant to them. 
The ability to make goals, and to strive towards them was sometimes viewed as the 
differentiation between a life dominated by heroin, and successfully embracing 
recovery. 
“It means getting better, getting well and getting myself back on my feet. And 
getting something; some goals in life. To me, that's what it means.” - Susie 
(P32); negative discharge; OM 
Patients could state what their goals were within their recovery but it was clear that 
the ability to make goals in and of themselves, and strive towards them, were 
pertinent aspects of how patients conceptualised recovery and the desire to change. 
Stable housing also featured within wider narratives on what the overall picture of 
recovery looked like to patients. Cessation in engagement in criminal activities was a 
consequence of IOT, and patients viewed this as a component of successful recovery. 
This was sometimes in the context of the broader picture of health and stability. 
“Just getting over all the health issues, the trauma, experiences, be it prison, 
on the drugs, street, homelessness, the whole crux of it, it’s all centred and 
geared around heroin, it really is your whole lifestyle. So recovery to me is just 
getting over all that.” - Harry (P8); positive discharge; SIM 
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Once again as also implicated in psychological recovery, several people highlighted 
the change to how they were viewed by the outside world – this was obviously as a 
consequence of changes patients had made that were noticeable and demonstrated 
stability. 
“Not having the name 'smackhead', and mixing with normal people without 
them looking down at you. That's basically recovery but that takes a long time 
because - excuse the French - shit sticks, doesn't it?” - Richard (P34); 
negative discharge; SIM 
Within these narratives several positive and negative dischargers highlighted the role 
of both good friends, and non-using friends as instrumental to, and indicative of, 
successful recovery. Whether by good friends, or wider society, how patients were 
viewed by these groups, was clearly of consequence to how patients engaged with, 
and viewed their recovery. This external validation was important, applying to both 
positive and negative dischargers and long-term IOTs. 
“I’ve got friends who don’t do heroin, I’ve got friends who I go round and see 
in the evening, have a nice time and walk my dogs with, other people.” - Jacob 
(P4); negative discharge; SIM 
“Having good friends.” - Charlie (P3); positive discharge; SIH 
Patients cited the holistic gains that they made within their lives during their time in 
IOT. These gains became highly pertinent to their recovery, and patients cited a 
number of aspects of life that encompassed their concept of successful recovery. 
Whilst components of recovering wider life have been highlighted in other sections, 
patients sometimes explicitly highlighted that recovering their whole life in its multi-
faceted components was what recovery meant for them. The distinction of this 
concept rather than simply recovering from illicit drug use was emphasised. Wider 
components included: employment; being an effective role model (e.g., to 
dependents and grandchildren); family and attachment relationships and their 
influence (e.g., the effect of a non-using partner versus a using partner); non-using 
peers and friends; making goals; stable housing; financial stability; ‘coming out the 
other side’ (of their addiction) and recovering from the heroin using lifestyle. 
Several patients illustrated how employment fitted in to their IOT regimen, and the 
willingness to prioritise work or take a flexible approach to their treatment, with work 
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as a priority – e.g., either through attending the clinic early in the morning or later in 
the evening. 
“Yeah, I'm used to working really, although I've spent a fair bit of my life out of 
work, I've spent a lot of it in work, I worked when I was here, and something I 
didn't mention for the best part of a year I was working down the road at the 
recycling plant and they kept the clinic open for an extra half an hour so that I 
could get here. …It is an aim, yeah.” - Gerry (P20); long-term IOT; SIH  
Here the patient has had the experience of employment during his IOT trajectory and 
wishes to incorporate it again in to the future recovery plan. Within impact of IOT and 
in patients’ conceptions of recovery, several patients alluded to the importance of 
being an adequate role model to children and grandchildren. It was clear that patients 
felt that as their children grew up and had more of a sense of what was going on in 
the lives of their parents and grandparents, the more motivated patients became to 
stay in the maintenance stage of recovery. Having non-using peers and friends was 
highlighted as a positive sign that patients had achieved stability, and was felt to be 
connected to effective recovery and this concept of recovering wider life. This was 
also touched upon within the desires to lead ‘a normal life’ as illustrated earlier. A 
number of patients conceptualised recovery within the frame of making and achieving 
goals. One patient highlighted that it involved a complete shift in their thought process, 
as well as an ability to make goals. 
 
10.11. Making progress in treatment 
 
With particular relevance to the overall treatment and recovery trajectory, patients 
specifically highlighted the ways in which they felt they had made progress through 
IOT and recovery. The main themes within the making progress sub-theme were 
around clinical decisions (intermediate treatment goals and steps), protective factors 
(such as work and activities) and psychological adjustment.  
Patients spoke positively about the fact that they chose to reduce doses, did not wish 
to increase dosage, and reduced the number of days that they received IOT a week. 
Patients also spoke positively about the progression to Slow Release Oral Morphine 
(MXL) treatment, and that dose stability led to the cessation of use of illicit heroin. 
These progressive steps indicate the importance of an individually-paced and flexible 
regimen, which is person-centred and tailored to the individual’s stage of recovery. It 
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also illustrates again how patients’ views about and goals for their treatment 
progressed and changed with time. 
“And, yeah, it was a bit of a drag sometimes, and, yeah, sometimes, I started 
doing a course, for example, and then it would, that finished at, like, 4 o’clock, 
and I had to be there by half four, so it’d be really hectic, you know, and really 
stressful getting there. But that’s when I started thinking, ‘Oh, well maybe I 
don’t need two injections today. Maybe I could just do with one.’ So, like I said, 
it was, sort of, a gradual progress, really.” - Pam (ID 19), positive discharge, 
SIH 
“But now I wanna go back to work for a few reasons. One of them being it will 
make me feel good that I’m back in work. It will give me money to buy the 
things that I’ve always desired….And that will satisfy them, I think. That will 
make people happy. Make me happy as well. And then if, if the treatment 
clashes with the work, then I’ll have to adapt. And I know I can adapt now.” - 
Shane (ID 21), long-term IOT; SIM 
The last sentence of the above quote illustrates quite apparently the dramatic shift in 
attitude and perception following long-term IOT. Patients were typically those who 
had previously prioritised acquiring and taking heroin over everything else, and for 
many years, who were then motivated and excited by IOT – sometimes to receive 
‘free heroin’, and sometimes to attempt to finally make a change that had not 
previously been possible – yet were now reaching a stage where they could imagine 
adjusting their IOT treatment to suit a work schedule. 
“That’s the way I, kind of, thought and then it got to a stage where I didn’t want 
that connection any more with using, so I started just intramuscular. And then 
after that it led onto, like, half intramuscular, tablets, and then tablets only 
when I started working.” - Charlie (ID 3), positive discharge, SIH 
 
10.12. Protective factors and activities 
 
Linked to the making progress theme was the often mentioned role of protective 
factors in maintaining gains made through IOT and recovery. These mostly centred 
around activities – such as service user involvement (as covered previously), 
employment and voluntary work - keeping busy, and the support that was received; 
from the clinic, other organisations, family and partner. Employment, volunteering and 
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other activities became a priority for some patients, and conscious, reflective 
awareness of the fact that these activities had become a priority appeared to motivate 
continued commitment to stability and recovery. This indicates again, the role of a 
reflective and self-aware journey through recovery, so that personal values and 
associated goals could be prioritised and coordinated in to the recovery trajectory. 
“When I started doing volunteering and looking for work, I knew that I couldn’t 
keep using while I was at work, or it wasn’t a long-term thing, so I had to put 
a plan of action in there.” - Charlie (P3), positive discharge; SIH 
“Work - work was supportive, yeah. Yeah, work knew about it. Yeah. They 
were well aware of it. And I was able to - I was able to work the clinic times 
round - do it in my own time, and working times round it, you know.” - Reg 
(P12), long-term IOT; OM 
The above quote indicates both the power of a flexible and supportive treatment 
system and outside support and acceptance, for recovery. Often it was a combination 
– or cycle - of protective factors that contributed to patients’ progress. Work or 
volunteering as a protective factor applied only to those in long-term IOT and positive 
dischargers. 
Family and attachment relationships improved, allowing for support to be 
incorporated in to the experience of IOT and the recovery journey. A number of 
patients highlighted some form of family support throughout treatment. Within these 
narratives, several patients mentioned that whilst family were initially worried or 
sceptical about IOT, in time they specifically noticed the positive effects the treatment 
had on patients. Family support appeared to arise as a consequence of the regimen 
and patients’ stability, however also functioned as a maintaining, or protective factor. 
“My dad wasn’t too pleased about it at first, but when he realised it was 
working he became a lot more tolerant of it, but he’s the only family member 
that knows.” - Fay (ID 10), long-term IOT; OM 







10.13. Barriers to recovery 
 
Across interviews there was sometimes some degree of difficulty in patients’ 
trajectories, as well as the gains that were made during IOT. These arose at various 
points and were overall themes. Whilst the level of difficulty and struggle during IOT 
treatment was less prominent than the positive impact that IOT had on many and 
varied aspects of patients’ lives, it is important to highlight these difficulties when, 
where and how, they manifested. Overall, regression and difficulties could be 
categorised into two main sub-themes: instability and dissatisfaction with treatment. 
Other specific themes included health problems during IOT. However in all cases 
these were entirely separate from IOT treatment, and often patients found IOT 
particularly helpful and supportive in these contexts – for example, housing, illicit use, 
difficult cognitions and emotions, and difficulty in relationships. It was proposed that 
the exploration of these attitudes and difficulties may provide a useful guide for the 
development of future policy and practice and the ability to pre-empt areas of potential 





A prominent aspect of the negative and difficult experiences patients illustrated was 
some form of ongoing area of perceived instability. This also encompassed trust and 
faith in the treatment, clinic and staff. Outside factors were sometimes unstable for 
patients and these were cited too. Overall instability encompassed clinical aspects of 
treatment trajectory, interpersonal aspects of the lives of this recovering sample, as 
well as the social and psychological aspects. Adverse events, continued alcohol use, 
withdrawal experiences and having to leave IOT against one’s will or preference (for 
example, in the case of IOT clinic rule violations or hospital admissions respectively) 
all undermined the feeling of stability for patients. Some patients cited anxiety around 
the fear of IOT ending, and judgement from other people (a cross-cutting sub-theme). 
On a social level, having no social support was an unstable factor for patients, as was 
being unemployed and on state benefits. The rupture to, or breakdown of, 
interpersonal relationships was also pertinent. 
“I did have three overdoses whilst on the way down [SIH dose reduction], 
which were a little bit surprising and Dr. Smith had to step in when I did 
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overdose and just hold me for a day or two. I overdosed three times coming 
down in dose, which couldn’t really be explained.” - Tom (P9), positive 
discharge; SIH 
“Once I got a dirty hit in there, but I didn’t tell anyone. I couldn’t wait to get out. 
You know if you inject something and you’ve got a bit of dust or dirt in it, I don’t 
know how that happened in a clinical setting, but I couldn’t wait – and I’m to 
go, like, you know, put my feet really to the floor to stop myself. I just couldn’t 
wait to get out and bought some paracetamol in a convenience shop.” - Luke 
(P18), negative discharge; OM 
Patients cited their lack of support during IOT, as a cause of instability. 
“As you know, once you’re tarred a junkie, it doesn’t matter where you get it 
from.” - Jack (P2), positive discharge; SIH 
Patients also cited their ongoing worry about SIH ending. This led to ongoing feelings 
of instability. 
“'Cos when you've found something that works and makes such a dramatic 
impact in your life, has such a dramatic impact for the good on yourself, it 
becomes a worry if you think it’s gonna be taken away. And I don't know 
whether they quite understand that bit of it.” - Ron (P27), long-term IOT; SIM 
That patients previously used heroin to cope with difficult life events and feelings of 
loss, and then recovered through a treatment programme that they appreciated and 
respected, brought grave feelings of fear about it being withdrawn and a return to the 
chaotic and unstable situation of their pasts, for those still in IOT at the time of 
interview. It was clear that the threat of treatment ending was a very emotive topic for 
patients, and the sense of hurt felt by patients at the potentiality of this not being 
understood by staff and management was apparent. 
Instability encompassed pertinent sub-themes, such as fears about IOT ending, 
having to leave IOT against their preference, and adverse events, and as such ran 
across all discharge statuses and treatment conditions. Withdrawal experiences 
applied to all, aside from long-term IOTs. Fears about IOT ending were pertinent to 
positive dischargers and long-term IOTs; and both adverse events and having to 
leave IOT against one’s will applied to all typologies. On an interpersonal and social 
level, aspects such as relationships, judgement from others, benefits and 
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unemployment and, in particular, a lack of social support, applied across all treatment 




Some patients expressed dissatisfaction with aspects of the treatment. The themes 
under patient dissatisfaction have been outlined in other sections of the analysis and 
will be summarised here. Dissatisfaction as a theme encompassed dissatisfaction 
with clinical decision-making - such as the burden of twice a day clinic attendance - 
dissatisfaction with dosage (both too high and too low), dissatisfaction with having to 
reduce the number of injecting days, the requirement for daily clinic attendance, 
negative perceptions of both the IM and IV route of administration, negative 
perceptions of staff, and clinical procedures; including the change from RIOTT to IOT, 
where it was perceived that rules tightened or changed unfairly. Dissatisfaction also 
encompassed patient regrets and the perception that the IOT regimen did not live up 
to patients’ expectations. Regrets were relatively prevalent though only applied to 
those with positive and negative discharge statuses. Patients expressed regrets over 
decisions they had made themselves for their treatment, with complicity from the 
clinic; which the patient then later reflected on in a negative light. 
“Not being so greedy. I wish I wasn’t so greedy. Because you seem to give 
out much more than what people actually need.” - Jack (P2), positive 
discharge; SIH 
 
10.13.3. Health issues 
 
Health problems were not usually connected to treatment, and in fact treatment was 
found to be helpful and supportive in this context. However, they were distressing to 
patients during treatment. Health problems during IOT applied to negative and 
positive dischargers as well as clinic closures. Additionally, these narratives outlining 
difficulties sometimes illustrated the patient’s exit route from IOT, which was 
interesting information to uncover. 
“The health issues I had at the time, so I had operations, my health 
deteriorated, I got major illnesses, so there was all that and then having to 
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recover from all that and get healed and at times I was like anxious and a bit 
apprehensive that they might not want to know no more and that was the end 
of it but it weren’t like that, they were still there for me.” - Harry (P8); positive 
discharge; SIM 
“But I went into hospital one day – this is how I stopped using the RIOTT...  I 
went into hospital because I had a blood clot in my leg.” - Daniella (P1); 
negative discharge (other); SIM 
Within this theme patients also referred to recent or current health problems. These 
were low in number and were all from positive dischargers.  
 
10.13.4. Continued use of illicit drugs 
 
Another prominent sub-theme within the barriers to recovery theme was continued 
illicit heroin and crack use. Here, exit route from treatment is also highlighted. 
“There was crack use throughout, yeah. That’s why I finally came off of the 
RIOTT, because they were saying to me that, ‘Look, yeah, we know that 
you’re stabilised off of street heroin, yeah, but your crack use; it’s gone up.” - 
Jason (P26); negative discharge; OM 
Overall, an increase in crack use applied to negative and positive dischargers. 
Jason’s quote continued –  
“Crack is my drug of choice. Do you know what I mean? So, that’s what I 
would prefer. Heroin: I can take it or leave it. Do you know what I mean? There 
was a time when I couldn’t, but now I can take it or leave it. It doesn’t bother 
me at all.” - Jason (P26); negative discharge; OM 
In this case IOT interrupted the cycle of chaos and instability caused by entrenched 
heroin use. Therefore, if illicit use does not stop completely, the entrenched nature of 
this addiction may be interrupted, and at least in the case of heroin use.  
“I had a bad day, come out with a silly remark, and I just said to them, basically, 
‘What you’ve done is take the place of my dealer.’ You can’t have no… none 
of that. [VB: Is that how you feel?] No, no, no. I mean, if I hadn’t have come 
out with that stupid remark I’d have still probably been doing it.” - Matthew 
(P17); negative discharge; SIM 
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The above patient was completely abstinent (including from maintenance treatment) 
at the time of interview however. The cycle of ongoing illicit drug use use was also 
demonstrated by one patient, but once again the unhealthy cycle of use was 
interrupted by IOT, at least for a period of time. 
“Well normally now it’s once a week, once a week. But I have to like cut that 
down now because I kind of promised Paul [current keyworker], because he’s 
been really good to me, I mean I used to be long term before, I mean we’re 
talking like four years ago/five years ago I was like injecting it three/four times 
a day. And my house was full of people all the time. And I was like that. …That 
came after the RIOTT as well. I kind of went back downhill again.” - Iain (P25); 
positive discharge; SIM 
The following quote illustrates a despondency towards the patient’s continued illicit 
use.  
“You know, especially having hepatitis now, I just think, ‘Well, that’s it,’ and it’s 
not gonna do me any harm.” - Luke (P18); negative discharge; OM 
The patient expresses a sense of fatality that was also a theme that arose from the 
heroin use history chapter; this sense of helplessness and fatality is clearly a factor 
affecting ongoing illicit use for some of the qualitative sample. Continued illicit use of 
heroin in this instance applied across all typologies, though overall numbers were low. 
Continued use of other drugs (benzodiazepines, crack and unspecified drug use) also 
applied across all typologies in low numbers. Overall illicit use varied in presentation 
– one negative discharger had periods of illicit use; one positive discharger had 
relapsed at some point; and one long-term SIH spoke about experiencing the 
occasional temptation to use. As touched on above, (negative) cognitions and 
emotions encompassed a resignation to one’s fate and feelings that IOT had come 
too late; the damage had already been done (a negative discharger) and that goals 
were not met (two positive dischargers). 
Housing problems were an aspect of this sub-theme and included comments that 
accommodation was unstable or patients were in, and remained in, temporary 
accommodation (three long-term IOTs and one negative discharger); or that current, 
stable, and more permanent, accommodation had issues (one positive discharger 
and one long-term IOT). These issues encompassed both damp and overcrowding 
for families in social housing properties. 
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Chapter summary and discussion 
 
That recovery was individualised was one of the most prominent themes to arise from 
the analysis on patients’ conceptions of recovery. Within the view that recovery was 
an individualised journey or approach was also the perspective that treatment 
duration should be decided on an individual basis. Patients also emphasised the 
viewing of patient progress in light of their heroin use history and situation at referral 
to IOT; that “progress” is relative in this sense. 
One of the main conceptions, and indicators, of recovery from the patients’ 
perspective was stability and functioning, again mirroring one of the main themes 
arising from the ‘impact of IOT’ analysis. This indicated congruence between goals 
within, and expectations of, IOT, and expectations and goals for the future. This also 
linked to the next sub-theme, which was the desire to feel ‘normal’ or fit in to ‘normal’ 
society again; reintegration back in to society was a prominent theme. It was clear 
that functioning and stability was a bridge to reintegration back in to society for 
patients. Once again, whilst not overtly communicated (and perhaps in part due to 
the smaller sample size of the Darlington qualitative cohort) there may be 
geographical variations to the process of reintegration patients may have experienced 
in their prospective locations – with Brighton a seaside town, London a busy inner 
city, and Darlington a small - and in some places quite deprived - market town with 
perhaps not a great deal of opportunity available to patients. Arguably, all three clinic 
locations have relative levels of deprivation and crime, though London invariably has 
more opportunity available to patients, such as volunteering opportunities and a wider 
range of adult education provision. 
A recurring theme, applicable to these data, was the desire or ability to regain control. 
Reclaiming the power and control lost to patients through heroin addiction was at the 
centre of the recovery picture for these patients. Importantly, IOT allowed patients to 
access a vision of what recovery meant to them, and this may have been a key 
component of success. Some patients indicated satisfaction with the current level of 
stability and functioning; explicitly stating that recovery is what they are currently 
doing. That this applied to long-term IOTs only, demonstrates the need for ongoing 
support for patients to stay motivated to keep striving. 
A vision of good health and harm reduction was pertinent to patients’ vision of 
recovery. The stages of recovery are illustrated within this, for example the 
importance of cessation of illicit use of heroin, in order to access a clearer perception 
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of goals health wise. The conception of stability and functioning encompassed a 
number of wider factors for patients, including eventually reaching the point where 
the user no longer thinks about drugs. Overall patients envisaged a completely new 
outlook as significant to the vision of successful recovery. Employment and financial 
stability were implicated within the recovery vision. Sometimes employment was a 
stand-alone aspiration and sometimes it was mentioned as part of the overall picture 
of routine, stability and functioning patients desired. Once again this was only 
pertinent to the long-term IOTs and positive dischargers, though the achievement of 
stability overall had relevance to all participants. 
Whilst the holistic nature of recovery was emphasised, illicit use and maintenance 
treatment was a strong feature of the recovery trajectory for patients. There was a 
divide across the sample between those who saw IOT or OST maintenance as 
appropriate for ongoing recovery, and others who viewed complete abstinence as the 
epitome of recovery. Both camps comprised all typologies. In this context no longer 
thinking about heroin was again highlighted and viewed as the ultimate indicator of 
recovery. Within these narratives, some patients highlighted how difficult recovery 
was, and the need for ongoing support. As well as regaining control, another 
important theme appeared to be continuing to access support. 
Ambivalence about abstinence was a feature of patients’ experience when describing 
about concepts of recovery. Some degree of current mental anguish was experienced 
by some patients, and the synergistic role of stressors caused by wider society – for 
example, welfare policy changes. These were potential risks to relapse, and included 
associated stress about this risk. Patients emphasised their psychological recovery 
and the importance of this dimension. This encompassed recovering self-esteem; 
once again, changes to sense of self and self-identity; the role of psychological 
therapy in recovery support; and improvements to cognitive functioning. 
Psychological adjustment and the benefit of reflective space was also referenced. 
The progression of experiences and associated psychological processes preceded 
an ability to self-reflect in the context of mapping out goals for the future. Achieving 
goals in and of themselves also contributed to a picture of improved self-esteem. 
Once again perceived control was implicated in the picture here also. Self-esteem as 
a definition of recovery was mostly illustrated by positive dischargers. 
Throughout overall narratives, arose the view that recovery needed to be supportive, 
and that this support needed to be holistic across a number of life domains. This 
introduced another theme; the need for re-integrative recovery – where patients gain 
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support to integrate back in to regular society. Here patients emphasised the 
importance of their having an ability to make a contribution. Adjectives such as 
‘productive’ and ‘useful’ were highlighted, and the need for support which would allow 
for this area of life to flourish was emphasised. Psychologically, having the ability to 
make goals was linked and highlighted. Other areas of importance to the recovery 
picture were stable housing and cessation of engagement in criminal activities. These 
matched goals at treatment outset. Finally, patients illustrated the role of good, stable 
(non-drug-using) friendships, and the pertinence of how patients were perceived by 
the outside world. External validation was important to a conception of effective 
recovery. 
Patients conceived the relevance of recovery for wider (aspects of) life. Many of the 
sub-themes encompassed within this idea have been illustrated and described 
already; concepts included an ability to engage with employment; the role and impact 
of children, grandchildren and friends. Additionally, an ability and motivation to make 
new goals, and notably, a shift in how they perceived their life and in turn their 
recovery within it. Cognitions and emotions in relation to how patients viewed 
recovery was relevant overall. Overall there were strong links between two themes – 
reintegration and the need for ongoing support post-IOT. Support needed to 
encompass wider recovery, and in a number of cases needed to be ongoing, and 
perhaps even lifelong, to protect against the cycle of relapse that was most feared by 
IOT patients. 
The final themes were not outlined in direct response to the questions on how patients 
conceived recovery, but were themes about recovery that arose at various points 
during interviews. Linked to reintegration, was the next theme – making progress in 
treatment. Patients highlighted progressive steps, such as dose and day reductions 
and switching to IM administration. Patients also highlighted a shift in perspective 
including the eventual desire to find employment. This – amongst other concepts and 
activities – also served as a protective factor. Overall, psychological adjustment 
during the trajectory, and to treatment changes, were highlighted within this theme. 
The final section outlined barriers to recovery. These arose at various points across 
interviews. Negative experiences and dissatisfaction encompassed occasional 
mistrust between patient and staff; perceived regressive steps; the negative impact 
of unwanted or mishandled clinical decision-making; difficult exit strategies; relapse 
experiences; perceived instability (within both life in and out of the clinic); worries and 
fears; continued illicit drug use; disliking effects of medication; perceived lack of 
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autonomy, and - aspects of worry unrelated to treatment such as – health issues and 
housing. 
On a final note several patients included the phrase ‘coming out the other side’ of 
their addiction, and others still spoke about recovering from the heroin using lifestyle. 
Narratives (from positive dischargers and long-term IOTs) indicated a change in the 
perception of one’s identity. This may lead to changes to self-esteem and self-worth, 
all contributing to a more stable perception of one’s own recovery. All or nothing 
thinking is common in relapse to addiction and in this case, perceiving one’s self as 
a ‘junkie’ may have previously undermined recovery efforts. Through IOT patients 
were able to change these cognitions. It appeared that the cognitions and emotions 
patients had in relation to how they conceived recovery was an important factor in the 
effectiveness of, and motivation for, engagement with effective recovery. Patients 
were brave enough to begin conceiving a life without heroin, and it may have been 
these conceptions and psychological processes that facilitated success. Once again, 
the right steps at the right time were key, and the trajectory itself was vitally important 
for patients to arrive at a more reflective and self-aware point. Importance is placed 
on where patients go beyond IOT, the need for ongoing support, perhaps in the form 
of ongoing work with, and cultivation of, those conceptions, beliefs and ideas. 
“I’ve recovered from being a ‘junkie’. Now I’m an ‘addict’. And an ‘addict’s’ 




Chapter 11 – Findings: The current situation and goals for the 
future 
 
The final section of findings describes patients’ current situation and goals for the 
future. The chapter completes the examination and description of the trajectory and 
allows interpretation of the findings in light of patients’ goals at treatment outset, and 
experiences of treatment. There are two sections to the chapter; the current situation 
– which encompasses issues and experiences outlined during interviews – and then 
a section of patients’ goals. Patients were specifically asked about their goals for the 
future. 
 
Table 46. Outline of ‘The current situation and goals for the future’ chapter themes 
and sub-themes 
Reference Theme Sub-theme 
11.1. The current situation  
11.1.1.  Instability and difficulties 
11.1.2.  Stability and 
improvements 
11.1.3.  Current drug use 
11.2. Goals for the future  
11.2.1.  Abstinence from illicit 
heroin use 
11.2.2.  Reducing illicit drug use 
11.2.3.  Subutex maintenance 
treatment 
11.2.4.  Employment, voluntary 
work, and other activities 
11.2.5.  Education and courses 





11.1. The current situation 
 
Patients’ current situation was a significant topic of discussion across the sample. 
This was a useful focus within interviews as patients were able to illustrate how much 
of an effect – and whether this effect was temporary or long-lasting in light of the 
current situation – IOT had had on their lives longer-term. Across the sample patients’ 
narratives on the current situation were dichotomised by stability, or a stable situation, 
and instability and difficulties. Patients’ accounts of their current situation could also 
be dichotomised by illicit drug use versus non-use. Additionally, narratives focussed 
on experiences and perceptions of OST following IOT, as this was the post-IOT 
trajectory for a number of qualitative patients. 
 
11.1.1. Instability and difficulties 
 
Difficulties were apparent for a number of patients, though at this point these 
difficulties were not as a consequence of heroin dependence. A large number of 
patients illustrated present day difficulties. Overall, difficulties centred around physical 
health, housing, domestic violence, psychological health, family and relationship 
difficulties – including children involved in the care system – financial difficulties, 
difficulties with university work, and criminal justice involvement. Patients’ for whom 
these themes were relevant illustrate clear areas of ongoing instability and 
vulnerability in their lives. In some cases, the stability that arose through IOT created 
new (positive) ventures and responsibilities (for example, university study, and 
reconnection with dependents and family), which were then cited as a source of 
current worry and concern for patients. In some cases, it was a new area of concern. 
“I’m in a property by St. Mungo’s waiting to be evicted. I stay at my boyfriend’s 
a lot, but I suffer a lot of domestic violence with him at the moment. …I’m in 
supported accommodation now, but they’ve taken my support and I’m being 
evicted, so I don’t know where I’m ending up. I’m just waiting for an eviction.” 
- Daniella (P1); negative discharge; SIM 
Whilst obvious areas of patients’ lives may have been more stable, patients cited 
emotional or psychological difficulties. For some it appeared that a more reflective 
consciousness created through the stability provided by IOT opened up areas of 
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psychological difficulty for patients, which had previously been masked with drugs 
and the associated chaotic lifestyle. 
“I’m on trazodone, I’m on atarax, I’m on – by my psychiatrist - and all these 
chemicals going through my body. You know what I mean? It’s going to give 
way sooner or later. I’m having nightmares upon nightmares. It’s too surreal 
for me now. I’ve only been on them since August last year, but yeah, it’s all 
getting a bit much. Six hundred milligrams of trazodone at night, which is a 
very heavy dose.” - Jack (P2); positive discharge; SIH 
As well as psychological difficulty it appeared that health problems also came to the 
fore, and which appeared to arise out of the health consciousness that stability 
through IOT had provided space for. 
“I have been advised it would be the right thing to get support or maybe to get 
a script or at least have some contact with a counsellor or something maybe 
which I think I might need to do because I’m starting to feel vulnerable.  
…I’m staying on top of it but every now and then I get struck down with a bad, 
it seems to be chest illness, TB was my last one. I had severe pneumonia a 
few years back and it very nearly killed me. I had two chest drains, intensive 
care for three weeks. I’ve had DVT in my legs due to injecting but I’ve come 
through all that and so that bothers me a bit and concerns me, I think as I’ve 
got older I am a lot more health conscious, or try to be but financial reasons 
dictate otherwise as you know. …I’m not in a great position at the moment, 
Vicky, financially, support wise, I’m on my own, so I am a bit lost again at the 
moment.” - Harry (P8); positive discharge; SIM 
The following quote particularly demonstrates that the situation was mixed for patients 
post RIOTT. The above patient was detoxed from OST completely, and not using illicit 
drugs at all, however, difficulties and triggers to relapse were highlighted and the 
interview seemed to allow reflective space for this awareness. The majority of patients 
seemed to trust me as interviewer and this led to an open discussion – I thought this 
was particularly illustrated with the fact that the above patient often used my first name 
when he responded to my questions. The above patient was one of a number where 
I got a sense that they had reflected a lot prior to the interview, in preparation for the 
interview, indicating again the reflective ability that patients had cultivated since – and 
perhaps as a consequence of – being in IOT long-term. Once again more conscious 
awareness around health was also highlighted. Whilst worrisome for patients, 
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indirectly this may have led to better health and well-being overall; awareness being 
key for intervention and involvement with medical services. 
“Unfortunately I suffered some sort of mental breakdown where I was a bit 
able to remember things from very, very young. It grew into a manic episode 
and I'm still being treated for that now, with - I'm up to 800mls of quetiapine, 
or I was at the time and lorazepam to get me to sleep.  
…It was just all very unexpected, because I'd been planning this detox for 
about the past three years.”  - Tom (P9); positive discharge; SIH 
The above quote illustrates clearly the difficulty and turmoil that could arise for 
patients following IOT. More particularly, that the recovery trajectory overall also 
encompassed pain and suffering that patients may have previously been able to 
shield themselves from by using heroin and its associated lifestyle, evidenced in the 
heroin use history chapter. 
“I’ve got quite a lot of joint pain and I’ve got COPD and asthma, so my health 
isn't great but it’s better than it would have been if I’d kept using, so I mean 
you can't expect to lead the life I have for the last thirty years and be sort of 
fully healthy by the end of it.” - Fay (P10); long-term IOT; OM 
The above quote illustrates, again, knowledge of the harm caused by heroin use, and 
that IOT had had a positive impact, even in the context of current difficulties. It was 
very interesting to discover that stability may have led to anxiety about areas that 
patients may not have previously been able to reflect on. Within the instability theme 
several patients also alluded, once again, to a sense of resignation or fatality about 
their situation – a feature of the transition to heroin use within heroin use history. In 
the following case this resignation was in the context of a relatively stable current 
situation, however. 
“So I keep saying I’ll do some voluntary work or go to college but I know, as 
is always the case with me, it never happens and so I think I do need a bit of 
support somewhere in there but, you know wouldn’t hurt, would it?” - Harry 
(P8); positive discharge; SIM 





11.1.2. Stability and improvements 
 
In contrast, a large proportion of the sample cited stability within their current situation, 
or a qualitative improvement to their situation. Stability also applied across all 
typologies and treatment groups. Patients highlighted improved health, abstinence, 
successful detoxes, more stable housing, non-using partners, support groups, 
dependents as protective factors and improved family dynamics as areas 
encompassed by current stability. 
“My housing’s fine at the moment. I’m in temporary accommodation; it’s not 
great but it’s better than a hostel. I’m in a one-bedroomed flat but that’s only 
because I've recently had my child, I think they gave me that. But before I’ve 
been homeless and it hasn’t been too good.” - Stacy (P5); positive discharge; 
SIM 
Patients sometimes cited current difficulty in the context of their perception that things 
could be worse. 
“I'm cushtie housing-wise, I bought a house in [street name] Street. I live with 
my partner and my daughter's got her own house and we've got a grandson 
who's one, so that's why I've been trying to knock it on the head completely.” 
- Richard (P34); negative discharge; SIM 
Here again dependents are highlighted as a protective factor embroiled within the 
recovery journey. 
“Although Jemima [patient’s step-daughter] is very ill, things are pretty stable. 
We haven't had social service intrusion or anything, there's been no 
complaints made or we haven't had to ask for help from anyone. We're pretty 
self-sufficient.” - Gerry (P20); long-term IOT; SIH 
Once again there is an overall sense of the patient feeling that things could be worse. 
In many cases instability was separate to that which would arise from using illicit 
drugs. 
“I’ve tried, I sell the Big Issue, that’s more to keep me occupied as well as a 
little income that just keeps me ticking over as well.  What I like is, I like to 
think I’m a sociable, talkative bloke and I chat to a lot of people every day and 
it’s nice, I get satisfaction from that.” - Harry (P8); positive discharge; SIM 
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11.1.3. Current drug use 
 
Within mentions of current instability included patients’ accounts of their current drug 
use including accounts of non-use. A significant proportion of the qualitative sample 
highlighted incidences of current drug use – for example from occasional heroin or 
crack use through to more regular - though purportedly not problematic - use of 
cannabis. Patients highlighted current heroin use, however there were more 
occurrences of other drug use. Patients most often made reference to the fact that 
current drug use was sporadic or much less problematic than at referral to IOT. 
Overall there was less sense of chaos or lack of control within these narratives. 
“Carried on using – I haven’t really stopped. I was on the RIOTT for a while. I 
didn’t use heroin, but I was still injecting crack. Now it’s – once a week I’m 
injecting heroin and maybe twice a week crack and I’m on methadone as well 
now. I’m on methadone 50mgs. …I have been offered to go back to the 
RIOTT, but I don’t want to because of having to go there every day. Your life 
is just tied into that and I’m not injecting every day anyway. …Crack’s my 
problem more now.” - Daniella (P1); negative (other); SIM 
Patients also revealed the trajectory that led to lapse and relapse following the end of 
IOT. 
“I’m dabbling, but not to the extent of getting myself in trouble. But boredom 
set in about a year later and I started dabbling again.” - Jack (P2); positive 
discharge; SIH 
“I’ve only really started having a problem again with it as my dose has been 
reduced. …Since I’ve been subject to the court order my usage of illicit heroin 
has dropped and I’m quite pleased at the moment; I’ve gone quite a spell 
without using. So long in fact that I can't remember when I last used. You 
know, it’s not years but it’s weeks at least, and with the court order and that, 
I’m confident I can keep that to a nothing; no usage.” - Sammy (P11); long-
term IOT; SIM 
Some patients were currently abstinent from illicit heroin, but alluded to relapse post-
IOT. 
“I relapsed a little while ago but it was only a one off.” - Jacob (P4); negative 
discharge (other); SIM 
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Mental health difficulties were implicated in relapse. 
“Unfortunately with the breakdown, a month and a half after I detoxed I started 
using again. I used for two weeks and then came back in here, where I was 
put back onto subutex. …I'm under three different doctors I think and they 
want me on a steady intake of subutex while they work out what's going on 
head-wise, psychiatric-wise and body-wise, because I've also lost something 
like two and a half stone. In the five years I was on RIOTT I don’t think I had 
a dirty heroin sample, but now I've started to play around.” - Tom (P9); positive 
discharge; SIH 
Often drug use was minimal, not habitual, and involved other drugs, as opposed to 
heroin. 
“I smoke cannabis, but other than that, no.” - Fay (P10); long-term IOT; OM 
Several patients highlighted fear of returning to an unstable or chaotic situation. 
Patients mentioned that they wished to make a change to their current situation before 
it got out of control. Here again, the awareness gained through RIOTT might have 
been the mechanism which prevented a full relapse, and once again the trajectory of 
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“I’ve had a little relapse, a little setback, where I’ve been dabbling. I’ve ended 
up making new friends and dealers and it’s such a small area where I live, 
they all seem to know me, like, I just go to the shop and you’ve got someone 
hailing you, and then it becomes too easy to score again. I mean, there’s no 
point in me buying heroin because it doesn’t do anything, but it’s the thought, 
that, I don’t know what it is. … It got to the point, when I was on my own and 
I had a bit of money, and I was depressed, or whatever, I ended up buying a 
bit for myself, but then regretting it once I’d done it. Once it was gone I was 
regretting it straightaway. ‘Why did I do that? Why did I do that? I hate myself 
for doing that.’ So I’m trying to stay away from it now, because I wanna sort 
my life out, because things have started getting chaotic again for me. I’ve got 
all these debts, you know.” - Fran (P13); long-term IOT; SIM 
A number of patients highlighted abstinence from illicit drugs in the current situation 
– including abstinence from any substitution drug - however sometimes abstinence 
was motivated by reasons other than commitment to recovery. 
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“So, yeah, I just think the heroin’s too shit to bother buying and I can’t afford it 
anyway.” - Luke (P18); negative discharge; OM 
The quote indicates the lack of sole drive towards acquiring and taking heroin, 
however, which again may have involved a drastic change to the patient’s way of life 
and identity, both contributing to and culminating in greater stability. Current use of 
illicit substances, albeit in reduced amounts and frequency, was prominent across all 
typologies and treatment groups. 
 
11.2. Goals for the future 
 
As illustrated and analysed in the referral to IOT chapter, patients were asked to 
reflect back on goals that were formed at treatment outset. Patients were also later 
asked to talk about their goals for the future – following the IOT regimen. 
There were clear and specific sub-themes within patients’ narratives. The main 
themes that arose from this inquiry were: abstinence; to reduce illicit drug use; 
subutex; artistic aspirations; education; work, activities and voluntary work. To some 
degree these matched those made at treatment outset, though some new themes 
also emerged. It was interesting to discover new themes, as a further indication of the 
impact of IOT, and the progressive nature of goals in this context. 
 
11.2.1. Abstinence from illicit heroin use 
 
A number of patients cited abstinence as their primary goal going forward, and 
following the IOT regimen. For some this simply involved maintaining abstinence 
already achieved. 
“Just stay clean and stay away from it.” - Jacob (P4), negative discharge 
(other); SIM 
Once again patients expressed anxiety around the ability to achieve this goal. 
“Absolutely terrified, because it’s the only time in my entire life that I’ve 
managed abstinence for any prolonged periods of time.” - Fay (P10), long-
term IOT; OM 
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Sometimes the goal of abstinence was in the context of other goals, such as 
interpersonal goals. 
“Yeah, to get clean and to visit my family. Because they wouldn’t tolerate me 
for very long if I was using. They wouldn’t see me.” - Clara (P7), negative 
discharge (other); SIM 
A number of patients cited abstinence from all maintenance medication, including 
methadone, and the desire to eventually leave IOT treatment completely. 
“Actually I’d like it. I’d like it. Yes, yes, definitely. I mean, I’m nowhere near a 
point where I’m going to absolutely drop my methadone use. That’s a future 
goal, but me not coming here and injecting once a day I think would help me 
to not use period because it takes the injection out of the equation, which I 
think you understand.” - Sammy (P11), long-term IOT; SIM 
There was a clear sense that some patients had reached the end of the drug taking 
and treatment line – as also expressed earlier by one patient (e.g., with the proposal 
that users eventually naturally stop). 
“For me, the goal is just abstinence, I just want to be able to get up in the 
morning and not think ‘Oh three hours until I feel well’. I want to feel well the 
minute I wake up. And get home from work and just don’t want to use heroin 
any more, I've had enough.” - Gerry (P20), long-term IOT; SIH 
Whilst initially some patients had reached a point where they had had enough of the 
instability and chaos associated with taking illicit drugs, so too did some come to feel 
this way about attending the clinic every day for IOT, and the progression to 
abstinence as the goal. Some patients had made a plan, and this was in the context 
of a resolutely determined desire to never return to street heroin use. 
“I'm not happy about being on it [IOT]. I do want to leave, I do want to get 
clean. And I do believe that my route is best, I want to get off, and I will do and 
the thing is I want to - now I've got it sorted, I'm going to carry on doing what 
I'm doing even if they stop the treatment tomorrow, I will carry on doing what 
I am doing, I do not want to use street drugs ever again.” - Oliver (P16), long-
term IOT; SIH 
For other patients the goal was abstinence from illicit heroin, in the context of current 
continued illicit use. The range of responses within the abstinence goal reflects the 
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different stages that patients were at following differing lengths of the IOT trajectory. 
Abstinence was prominent across all typologies, with less representation within clinic 
closures, however, again, this could have also been due to the smaller overall sample. 
 
11.2.2. Reducing illicit drug use 
 
Patients spoke about their current reduction plans – e.g., reductions from oral 
methadone - and the fears and anxieties around this. Often the goal was conflicted 
with fear, for example the following patient who was currently (at the time of interview) 
on oral methadone. 
“I do want to cut down but it’s just so – coming off that last bit of methadone - 
it’s just so horrible.” - Daniella (P1), negative discharge (Other); SIM 
Patients were often determined yet unspecific with their goal, such as the narrative 
below, from another patient on oral methadone (at the time of interview). 
“I don’t want to be on it for the rest of my life. Sooner or later I want to come 
off of it, you know, because I don’t want to be 60 and still going to these places, 
sooner or later; I was talking to Joe [keyworker] before, sooner or later I’m 
going to get it, start reducing, reducing and reducing and my body will tell me 
if I’m reducing too quickly, you know.” - Nicholas (P14), positive discharge; 
SIH 
As before the overall goal (to reduce) was in the context of a longer-term treatment 
reduction plan, and in the context of other hopes and aspirations patients had for their 
lives. The quote below (patient currently on MXL) – and above - illustrates the 
collaborative nature of the plan – between patient and clinic/keyworker.  
“Reducing until I’m off. I wanted ideally to be off it by the time I do my final 
year [of university degree] so I’m a bit disappointed. …Slowly, they know that 
I want to have a child but they know that I wouldn’t want to have a child while 
I’m on benefits so they know that if I go off too quickly it would be a bit risky 
and they know that I’m quite old so I haven’t got that big a window really.” - 
Ellie (P22), positive discharge; SIH 
The quote indicates how collaborative, and key, the relationship with the clinic and 
keyworker was in forming individualised and meaningful goals for the future for this 
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patient. The following quote is by a patient currently (at the time of interview) on MXL 
and who was referring to MXL as her treatment drug of choice, however refers to a 
‘cup’ which would relate to oral methadone, however she did seem to be referring to 
MXL. 
“I just want to go down to the minimum possible. You know, like the therapeutic 
dose, let’s say 30mgs, which is the smallest tiny little cup that they make. You 
know, just … yeah, yeah, just to keep it … because there is a theory that, you 
know, goes around, that less is more. And it’s actually true. I mean I’ve found 
that the less I take…You know, the less I want and the more… it seems to 
work.” – Elena (P37), positive discharge; SIM 
Once again reduction as a goal had strong prominence amongst positive and 
negative dischargers, and apparent but less prominent presence amongst long-term 
IOTs and clinic closures. 
 
11.2.3. Subutex maintenance treatment 
 
A handful of patients mentioned subutex (or buprenorphine) as the substitution 
programme that they were working towards, or that they considered to be their goal. 
This was an interesting finding in the context of an IOT trajectory. In the following 
case buprenorphine was viewed as progression pertinent to the patient’s stage of 
recovery. 
“To be honest, that’s what I want to go over to now. That’s why I’ve stayed on 
such a low dose because I think that’s such a fantastic drug and I think more 
people should go Subutex rather than methadone. I need to change over to 
Subutex and stay on a low dose because I don’t want to be... I’m 35; I don’t 
want to be stuck in this. I’ve gone backwards too many times.” - Stacy (P5), 
positive discharge; SIM 
Once again the sense of desperation over the cycle of addiction, and determination 
to make lasting change is apparent. This was a goal for several positive dischargers 





11.2.4. Employment, voluntary work, and other activities 
 
As was also the case at treatment outset, aspirations in the area of work, voluntary 
work and other activities was a prominent goal. 
 
“Yes, very much so. I mean, working in hostels for the homeless it kind of hits 
all the things I’ve been studying for the last five years because I’m part way 
through an open degree with the Open University. I’ve only got one more little 
level three course and I’ve got an open degree and I’ve just finished a 
foundation at [university name] University in substance misuse.” - Fay (P10), 
long-term IOT; OM 
“I’d rather be getting out and going to work like and then, you know, coming 
home in the evening and, you know, that’s my goals now, like, just to get a 
job. Well I suppose, yeah. Yeah recover I suppose is me in my council flat with 
a job and that’s it and I can go from there like, you know. That was my goal. 
That’s all I want out of life at the moment.” - Josh (P41), long-term IOT; SIH  
On several occasions patients alluded to the desire for simplicity and stability; home 
comforts and a quiet life – presumably wanting a complete change from the chaos of 
the past. Work, activities and voluntary work was a goal for those in long-Term IOT 
and positive dischargers only. 
 
11.2.5. Education and courses 
 
A number of patients mentioned the desire to complete, reengage or engage with 
education or courses. Often aspirations were quite high – the completion of university 
level degrees – and feasible – i.e., patients were part way through courses, and the 
goal was to complete them. A number of patients mentioned courses in substance 
misuse or mental health, and the desire to work in these fields, corroborating the need 
for activities that are significantly meaningful to patients. 
“I wanted to go to uni last September and do a degree in drug misuse and 
intervention, but unfortunately I didn’t feel comfortable enough with the state 
my mind was in. With the loss of confidence after doing the detox, I said I'd 
defer for a year and do the voluntary work wherever I can and then start again, 
356 
 
sort of thing, and hopefully go in in September next year.” - Tom (P9), positive 
discharge; SIH  
The quote above illustrates how a recent relapse affected pursuit of an aspiration. 
Similarly, the quote below highlights an aspiration, yet perhaps suggests some 
hesitancy around complete faith in the ability to achieve it. That the holistic aspects 
of recovery do not progress at rates that are unmanageable for patients is perhaps 
important. 
“I mean I ideally would like to finish university”. - Ellie (P22), positive 
discharge; SIH 
“I want to finish my degree.” - Pam (P19), positive discharge; SIH 
Overall, whilst goals were sometimes not achieved, the fact that such aspirations 
were created and goals attempted was a starkly different situation to those who had 
reached breaking point upon entering IOT. Education as a goal was mostly expressed 
by positive dischargers, as well as one person in long-term IOT. 
 
11.2.6. Artistic aspirations 
 
A number of patients spoke about artistic tendencies and artistic aspirations in the 
context of narratives around future goals. Several patients mentioned that they had 
previously been artistic, ‘until the drugs came along’. This demonstrated the ability to 
reconnect with a previous self-identity, and find space to think creatively about goals, 
following the IOT trajectory. 
Sometimes aspirations were specific or about to be realised. 
“Well I’m about to do a documentary thing called Addicts Orchestra, I don’t 
know if you’ve heard of it, it starts on Monday, I’ve still got time to pull out, it’s 
a really powerful idea; addicts with music, for a violinist, it completely, to make 
a piece of music, and if I was to think of this as completely self-interest I 
definitely couldn’t do it.” - Ellie (P22), positive discharge; SIH 
As above, and also below, aspirations were sometimes based on skills patients were 




“I think I’m really good at art as well. I’ve been in and out of it but I’ve never 
held that down. I’ve got another hobby which I do, model making, but I do want 
to get back into my art.” - Harry (P8), positive discharge; SIM 
Aspirations were also more abstract or unspecific. 
“If you go down by the Thames and all these stones, you know, you polish 
them up and there’s bit of jewellery that someone could buy. You know, there’s 
loads of different things you can do like that.” - Cheryl (P40), positive 
discharge; SIM 
Aspirations were also grand and specific. 
“I want to write a book. I know it sounds a long way off, but I’m desperate to 
write a book about all my experiences, my whole life…I’ve got a lot to tell, you 
know, but I don’t think it’s ever gonna happen.” - Fran (P13), long-term IOT; 
SIM 
The above quote illustrates an aspiration coupled with a sense of negative resignation 
– or fatalism, which was a theme that ran through a number of narratives – both 
reflecting on one’s past, and heroin use history, in the context of leaving OST, and 
aspirations for the future. This is also reflected in the first quote – ‘I’ve still got time to 
pull out’. These automatic negative thoughts may be identified during treatment and 
worked with therapeutically to facilitate a more holistic recovery, something which 
may have sometimes taken place in key-work sessions. Once again artistic 




Some patients highlighted the benefit of IOT in the context of current difficulties 
indicating that the path to well-being is not linear, despite a holistic, efficacious 
treatment programme. Stability also had strong prominence in narratives on patients’ 
current situation, though some patients highlighted unfulfilled goals and dreams in 
this context. Current drug use had surprisingly strong prominence, however drug use 
was usually occasional and heroin use more sporadic. Regular, yet purportedly not 
problematic, cannabis use was also highlighted, and a small number of patients 
illustrated post-IOT lapses and relapses. This indicates that a course of IOT does not 
lead to permanent abstinence for all patients, and situations – such as boredom, new 
358 
 
connections, depression and psychological breakdown - were highlighted as triggers 
to lapse and relapse in these cases. 
Goals involved change and stability as well as more specific goals. Goals sometimes 
matched those at treatment outset (such as abstinence and reduction from illicit drug 
use), however other new goals also emerged (such as artistic aspirations). Goals 
were often outlined in the context of maintaining current stability or completing a 
current project, such as a university degree. It was notable that all patients currently 
completing university degrees were either in London or Brighton (where there are 
universities, and in particular London, where opportunities for adult education are 
ample) as opposed to Darlington. Once again, a regional variation in terms of 
available opportunities for reintegration for patients, might be pertinent to recovery. 
The final more unique goal was the pursuit of artistic aspirations. These were 
sometimes highlighted in the context of the fact that they had been unfulfilled in earlier 
life due to dependent drug use. It was clear that goals were more prominent and 





Chapter 12 – Discussion 
 
The research aimed to describe the patients’ experience of injectable opiate 
treatment; and determine the role of IOT in the patient’s overall journey of recovery. 
In so doing the thesis contributes to the scientific understanding of IOT. The thesis 
achieves these aims through quantitative descriptive analysis of long-term outcomes, 
and a description of patients’ experience of treatment through qualitative interviewing. 
The thesis gained rich and in-depth information about patients’ experience, which is 
of use to future IOT and OST research, clinical practice and policy. The following 
chapter outlines the researcher’s reflections that were made both during and after 
data collection and write-up; a summary and discussion of the main findings from 
each chapter; and makes recommendations for future research, policy and clinical 
practice. The chapter considers methodological strengths and limitations and results 
are discussed with reference to previous research literature explored in chapter two 
(the literature review). 
 
12.1. Researcher’s reflections 
 
The researcher made notes both during data collection and in the write-up stages 
regarding her own personal reflections during interviewing and data analysis. The 
researcher observed thoughtful and reflective responses from patients during 
interviews. In some cases it was clear that patients had spent some time reflecting on 
their experiences prior to sharing their stories on the day of the interview – in several 
cases patients mentioned that they had spent some time thinking about the 
experience and the interview prior to undertaking it. The researcher subsequently 
reflected that there may been some degree of rosy retrospection bias in patients’ 
accounts, particularly if patients wished, either consciously or unconsciously, to 
present IOT in a positive light – not least in the context of potential clinic closures. 
Patients appeared to be aware that this was a possibility, or that the funding for the 
treatment may not be reinstated. That said, wishing to present IOT in a positive light 
is a valid lived experience on the part of the patients and the qualitative interviews 
aimed to represent the experience and perspective of IOT service users. The 
researcher – and academic supervisors who triangulated sections of the analyses – 
reflected that patients appeared candid and open in the accounts that they shared. 
The researcher reflected that this appeared to be facilitated by the first question where 
the researcher asked patients about their heroin use and treatment histories. This 
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question appeared to allow patients to relax in to the experience of sharing their 
experiences, and appreciate being listened to. It is also the case that patients who 
have spent large amounts of time in drug treatment are likely used to, and practiced 
at sharing their stories. 
Whilst the researcher was separate to the clinical team and the RIOTT research team 
– an aspect that was outlined to patients during recruitment in an attempt to yield 
more honest and open responses – it was clear that she was from a very different 
background and culture to the patients in the qualitative interview study. With this in 
mind it is important to remember that a power dynamic would have still likely been 
present. Patients may have made assumptions about the researcher and this may 
have affected how they presented their narratives and experiences. This effect may 
have been more pertinent in some interviews than others. Patients may have wished 
to say the ‘right’ thing, or to impress the researcher – e.g., when reporting their 
progress through recovery during IOT; this could have perhaps occurred again, 
because the patient wished to present IOT in a positive light in order to add strength 
IOT’s perceived efficacy. Additionally, rosy reporting biases may have occurred 
simply because patients wished to frame their own progress in a positive light. There 
was clearly some degree of competition between patients, with comparisons to the 
progress of other patients a common feature of interviews. Once again, whilst these 
are potential biases, they also represent the lived experience on the part of this cohort 
of patients. That patients’ narratives were positive, and that they really appeared to 
want to communicate a positive experience of IOT, is worth taking in to consideration 
when interpreting the findings however. 
The motivation to affect the direction and future for policy and practice on OST was a 
meta-theme which emerged during analysis of narratives, particularly amongst those 
with service-user involvement responsibilities. This indicated that empowerment and 
service-user involvement was implicated in the success of IOT, as well as an 
important area of patients’ recovery. This aspect is also indicated by the willingness 
of patients to take part in the qualitative interviews, with no direct refusals during 
recruitment. Two patients asked that they be asked to participate another time, and 
the researcher did not push these individuals to participate, since a reluctance at that 
time may have been indicative of an overall reluctance to participate. The researcher 
did not wish to persuade patients to partake; that participation was completely 
voluntary was important ethically and methodologically to the study.  
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During recruitment (in the waiting room of a treatment clinic) one patient stated that 
she thought it would not be difficult for the researcher to recruit patients to the 
qualitative study, as RIOTT was ‘close to patients’ hearts’. That patients appeared 
thankful for being given a voice to share their experiences through qualitative 
interviews was something that the researcher noticed and interpreted during data 
collection. That patients were reimbursed for their time was also a factor to consider 
in motivation for participation, and once again this may have led to response biases 
during interviews.  
The researcher spent a week in the Darlington location during data collection, 
whereas for interviewing in London and Brighton this was unnecessary, as trips to 
Brighton could be completed in a day, and the London clinics were close to the 
researcher’s workplace. The researcher reflected on the stark differences across 
regional locations, socio-economically, and in terms of provision of opportunity. 
Brighton is a pleasant, busy seaside city locality within the city of Brighton and Hove. 
There is a lot of green space and patients are close to the sea. The area is also quite 
densely populated. In London, patients clearly had a lot more opportunity for 
volunteering and completing courses and education, however. Patients in London 
seemed busy; their lives operating at a faster pace than those in the other locations 
(and in particular Darlington). In Darlington, the clinic was located in quite a deprived 
location with not much around for people to do. The town centre itself was a little 
busier, but it was clear that there were far fewer opportunities for patients to engage 
with education, activities and volunteering. It was notable that these opportunities 
were not present in the lives of the Darlington cohort. Whilst it was not specifically 
commented upon during interviews, the researcher felt that the size and lack of 
opportunity in Darlington was present in participants’ narratives, compared to the 
experiences of those in London, and to some degree, Brighton. Overall, the 
researcher felt that location, surroundings, and geographical opportunity could be 
very pertinent to successful, long-lasting, and meaningful recovery. 
The researcher would like to state that she was very much in favour of IOT on a 
conceptual level throughout data collection and write-up, and kept this bias in mind at 
all stages of her work. Additionally, the researcher is a psychologist (in both research 
and clinical practice) with previous experience of working in addictions treatment 
services, and tried to remain mindful of these potential biases during data collection 
and analysis. Most importantly the researcher wished to present a balanced picture 
of patients’ experiences through IOT; both positive and negative. 
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12.2. Methodological considerations 
 
The thesis benefits from a retrospective account of individual patients’ reflections on 
their heroin use and treatment history and trajectory of experiences during IOT. This 
differs from previous qualitative research - e.g., Romo et al. (2009) and Oviedo-
Joekes et al. (2014) - in this area where patients were interviewed either during or 
shortly after the IOT RCT. Patients in the current thesis were interviewed a number 
of years following the IOT trial. Some patients remained in IOT at the time of the 
interview, however in all cases patients were being asked to recall events from at 
least several years previously – in some cases up to seven years previously. It is 
important to consider that patients’ memories may not have always been accurate. It 
may have been the case that a rosy retrospection bias occurred particularly amongst 
those who had finished IOT and wished to return, or those who remained in IOT, and 
were aware that the future of IOT was under threat, or that they were on a new time-
limited programme. In contrast, those with negative discharge statuses may have 
been more likely to present the less positive picture. However, the research aimed to 
represent the retrospective, views and perspectives from this cohort, rather than a 
factually correct description of patients’ trajectory. 
 
12.3. Summary of findings 
 
The thesis illustrates in great detail the process of recovery and response to treatment 
for this sample of IOT service-users. Generalisability of findings in the preceding 
chapters are not always peculiar to an IOT trajectory, and in a number of cases are 
congruent to literature on wider Opiate Substitution Treatment research, policy and 
clinical practice. It was clear that there were a number of factors implicated in change 
and recovery for this sample and these will be outlined and discussed in the context 
of their particular chapter. At the end of each chapter’s summary of main findings, 
and respective discussion of these, is a summary table detailing the implication of the 





12.3.1. Summary and discussion of findings:  A description of Injectable 
Opiate Heroin treatment process and the effect of treatment duration on 
outcome 
                                                                                                                                                                                                                                                                                
Overall the chapter illustrated the complexity of movement amongst participants 
assigned to the three treatment groups in the IOT trial. In line with Haasen et al. (2007) 
there were a greater number of treatment drop-outs in the control conditions (in this 
case OOM and SIM) following randomisation than there were in the SIH condition. 
The trends demonstrate that those assigned to SIH treatment tended to stay in this 
treatment programme long-term. For those who remained in SIH treatment longer-
term initial gains made were sustained, and in some cases (such as social functioning 
status) improved, the longer the participants remained in SIH. This is beneficial, 
particularly in light of the fact that van den Brink et al. (2003) find that an interruption 
to SIH treatment for even two months had a substantial negative impact. Additionally, 
in van den Brink et al. (2003), the longer participants remained in treatment the less 
they required the use of ancillary services. This may also explain any subsequent 
decrease in outcome status longer-term, and is also important to view in context of 
the later qualitative finding that ongoing support, post-IOT – and despite achieving 
abstinence - may be required. 
In contrast, however, some participants discharged from treatment, and some much 
earlier. This provided the context to explore treatment experience and discharge 
trajectory in greater detail with a substantial sample, through qualitative interviewing. 
A striking finding from the chapter four (and the RIOTT trial data) was that in the main, 
patients who were assigned to non-preferred (SIM or OOM) treatment groups at 
treatment outset remained in these groups for six months, until they could be 
transferred over to SIH. It is striking that the promise of SIH was enough to keep these 
patients retained to treatment that (in the case of OM) had historically failed for 
patients. Additionally, it was notable (from figures 2-4 on pages 139-141 of chapter 
four) that a great number of patients moved across when they were able to. The 
chapter also describes some of the different clinical trajectories, such as mean 
dosage, and numbers receiving once a day, versus twice a day, injectable, treatment. 
The basic outcomes are described, and the context is set for the exploration of 
participant trajectories in greater detail. Further research may wish to conduct 
longitudinal regression analyses on the data set as a whole, in order to more reliably 
examine individual rates of change over time. These analyses were outside the scope 
of the thesis. 
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12.3.2. Summary and discussion of findings: Heroin use history 
 
Chapter six addressed objective seven; to describe patients’ drug use and treatment 
history. A number of interesting areas arose from this work, and it generated a number 
of areas for further exploration or of use to clinical practice and policy. The main 
findings are outlined and the areas of further exploration for research, clinical practice 
and policy are outlined in table 42.  
Patients were those for whom addiction had clearly taken over their lives, and for 
which there had been serious consequences. Patients’ lives prior to initiation in to 
heroin use and developing an addiction was often implicated in the drug using 
trajectory. One example was the implication of peer group and family members who 
used addictive substances. A large proportion of patients were clearly influenced by 
others in their initiation to heroin use – including romantic partners and peer groups. 
This was a factor implicated in later lapse and relapse, with patients in the goals and 
current situation section (chapter 11) citing the need for a more isolated and solitary 
life in ongoing recovery. Ascertaining this information at treatment outset is useful for 
an individualised programme of relapse prevention. Peer groups also had an 
influence; and getting in with the wrong crowd – this sometimes took place whilst the 
patient was in prison – was commonly reported. Patients cite that they did not have 
friends who did not use illicit drugs. Without role models and peer groups in other, 
healthier circles, the need for acceptance in to a community may have played a role 
in these early initiation experiences. Once again this links to later findings – such as 
in the impact of IOT, and the importance of the community and social side of coming 
to clinic - with some patients highlighting friendships with other patients, and others 
citing the impact of having a community of people they saw every day, who they had 
positive interactions with (including staff). In the ‘heroin use history’ chapter, the 
desire for a community was specifically cited. This was also in the context of broken 
homes and losing family members. Community is clearly important, in order to feel 
accepted and as a source of support. Best and Laudet (2011) outline the idea of 
recovery champions in recovery communities, and this may be of value in an IOT 
context. 
Equally pertinent (and often simultaneous) were the experiences of patients who took 
heroin to escape the reality of their lived situation – this was also evidenced by a 
sample of patients who stated that they always took drugs alone. Patients also 
highlighted negative role models – such as family members who either used drugs or 
encouraged drug use by supplying drugs to patients – as normalising factors in 
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initiation and continuation. The effect of these significant individuals and a culture of 
drug use being acceptable (and normalised) may be implicated in the fact that drug 
use became so entrenched for this sample. It may be that only a treatment as 
intensive (every day attendance amongst a community of other similarly entrenched 
users and staff available all day every day) as IOT was able to break such entrenched 
patterns of use, through a social and cultural impact, as well as stability derived 
through sufficiently reinforcing medication and a holistic programme of care.  
Clearly the community and social side of illicit drug use, and subsequent treatment, 
was of pertinence to some patients in this sample. This is in congruence with Best 
and Lubman (2012) who outline that the key predictors of recovery are active 
engagement in community and recovery groups. This also demonstrates the value of 
obtaining a heroin use history from patients in research and treatment or clinical 
practice in order to ascertain patterns of use and vulnerabilities, and equally where 
these could serve as protective factors (for example, isolation imperative for one 
patient’s ongoing recovery, whereas a vulnerability for another). Patients highlight 
keeping illicit drug use a secret, particularly from family, with links to later findings that 
patients’ goals at various stages were to repair fractured familial relationships. In so 
doing patients would demonstrate to family members that they had changed, and 
were no longer using illicit heroin. Family approval was clearly important for a sample 
of patients, at various stages of the trajectory. 
Patients also highlighted negative life events that occurred at the time that use began. 
Patients’ vulnerability was clear – with very difficult and unstable home environments 
– and these were again normalised experiences for patients. A sense of loss was 
clear with the implication that heroin use filled a void. Patients also outlined the 
continued chasing of an initial high and patients clearly highlighted how positive their 
– first and (sometimes) continued - experiences with heroin were. In contrast a 
proportion cited being fed up with illicit drug use, and the drug using lifestyle at 
initiation to IOT. A transition to injecting – through lack of availability of other modes 
of administration, or an increased tolerance and the realisation that more went further 
through the injected route – often preceded transition to addiction or dependence. 
Some patients outlined almost immediate dependence, and this may be a 
consequence of such difficult and unstable backgrounds and environments; the wish 
to escape these, and the very quick realisation that heroin achieved this. One patient 




Consequences of use were prominent themes and in some cases illustrated the 
trajectory preceding referral to IOT. Loss was a prominent theme here, with job loss 
and homelessness as key features of this period. Job loss was viewed as a pivotal 
point for some patients – and perhaps where the loss of the non-drug using identity 
is particularly experienced. Narratives suggested that the more a patient lost, the 
more entrenched their addiction became; in a catch-22 cycle. The loss of the non-
using identity (perhaps as a consequence of loss of home and employment) was 
emphasised, particularly with the transition towards an involvement in crime. This may 
have become a new identity and way of life, once again indicating the significance 
and pertinence of holistic programmes of treatment. If wider aspects of life are not 
recovered and either the old identity restored, or a new identity created, patients are 
likely more prone to relapse, particularly in the context of a difficult and unstable 
situation, and the desire to escape or fill a void. Once again, this links to the 
effectiveness of the structure and intensity of IOT.  
Some patients spoke about the previous lack of regard for victims of crime and 
consequence of crimes they had committed, illustrating how this developed into 
remorse following IOT. It may be that patients felt cared for through IOT and thus 
were able to connect more meaningfully to care for others, which had been absent 
during the chaos of a dependent heroin using trajectory and difficult life events and 
backgrounds. Patients found it difficult to disentangle themselves from the heroin 
using lifestyle they were involved in, when they felt particularly resigned to this fate. 
The necessity for the intensity of IOT; for creating new cultures and systems of 
support is emphasised. 
Whilst going to prison was often the consequence of drug using and the associated 
lifestyle, for some it was also a place where treatment began. Going to prison was 
also highlighted later in interviews – in referral to IOT – as one of the reasons why 
patients felt motivated to make a significant change at that point; that they wished to 
stop cycling in and out of prison. This links to Winick’s (1962) maturing out hypothesis, 
however for this entrenched cohort of users, success may not have been possible 
without the intensity of care provided by IOT and the referral trajectory may be 
pertinent to engagement with long-term recovery. Whilst health was clearly negatively 
impacted by entrenched heroin use, it was also restored and recovered to some 
degree as a consequence of being in IOT; once again themes at this initial stage 
connected to later narratives on the impact of IOT.  
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Similarly, patients were able to identify triggers to relapse (e.g., peer group) and 
protective factors (for example, dependents) at this initial stage of the trajectory, which 
were later supported in terms of identified triggers and protective factors, both during 
and beyond IOT. By the same token, patients were also able to identify periods of 
abstinence in their pre-IOT trajectories, such as during pregnancy or residential detox, 
indicating the necessity for ongoing support in order to maintain abstinence beyond 
these periods. It is noteworthy that for these patients residential detoxification and 
rehabilitation provided space for abstinence, whereas day treatment (usually 
methadone) did not, indicating the need for the intensity of support that IOT (and 
rehabilitation) provides.  
An exploration of use of other drugs and alcohol revealed typologies whereby some 
patients used other drugs and/or alcohol – in some cases this was a gateway to heroin 
use – and others did not – in some cases other drugs did not achieve the desired 
effect provided by heroin. Throughout these narratives was a clear sense of self 
reflection and insight in to patients’ addictive patterns. These levels of insight were 
likely made possible through IOT. This was an interesting element to the methodology 
of the thesis, whereby patients could explore their pre-IOT trajectories, with insight 
made possible through stability derived through IOT. Through the heroin use history 
chapter, the full trajectory and its sequence is clearly illustrated; from the influence of 
others, to consequences of use, to habitual drug use, to the loss of the non-using 
identity, to accessing treatment, and then the failure of conventional treatments, 
further consequences of illicit use, right through to referral to IOT. 
Many patients highlighted that methadone was ineffective for them, with other 
perspectives that it was imperative to their heroin using trajectory and that without it 
life would be a lot more painful and difficult. One perspective was that methadone 
was not holistic enough and did not address the underlying cause of the addiction. 
This point is further supported in the impact of IOT chapter, whereby the psychological 
and holistic nature of IOT is illustrated by a large number of patients, as a large part 
of what made IOT effective. Patients appeared to have great awareness of what 
would successfully facilitate recovery, and the common narrative was that methadone 
regimens could not provide this. This may have contributed to not feeling important 
or valued by treatment providers. Perhaps there was a self-fulfilling prophecy at play 
for some patients – whereby an expectation of failure with methadone led to it 
becoming a reality. Belief in treatment appears to be an important dimension of 
subsequent success with the treatment – and this was also indicated through the 
expectation of success with IOT.  
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Patients highlighted that methadone was insufficient at filling the void, yet heroin use 
did fill this void. This void appeared to be psychological as well as physical and this 
demonstrated why an intensive, holistic, supportive, community-based (perhaps 
social), treatment programme was required for the recovery amongst this entrenched 
group of heroin users. By highlighting what was missing from patients’ lives, how 
heroin filled these voids, and how methadone did not, illustrated what was required 
from treatment for this group, and perhaps why IOT was more effective. 
Overall the heroin use history chapter was very useful on multiple levels. Firstly, it 
served as a warm up question and may have helped create rapport and trust between 
interviewer and respondent. Patients may have felt that their individual stories were 
valuable and important. Patients may have felt listened to, and not forgotten – 
particularly in the cases where clinics had closed or they had been discharged 
involuntarily from IOT. The chapter provided very valuable information on initiation to 
heroin use and highlighted individual vulnerabilities, these linked to later findings and 
narratives, and information on what facilitated abstinence. The chapter also explored 
the unexplored question; why methadone had historically failed for this group, directly 
through failings of conventional treatment, and indirectly through providing a clear 
picture of why use had begun, and the multiple factors which had maintained it. 
Understanding why previous treatment has failed is important for recovery, as is 
providing a space for patients to reflect upon and analyse their trajectory. The latter 
is also useful information for clinical practice.  
Table 47 outlines the main findings from the chapter of use and relevance to 
research, clinical practice and policy.
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Table 47. Heroin use history: Main findings of relevance to research, clinical practice and policy 
Reference Chapter 
title 
Finding Recommendation Implication:  
Research (R); Clinical 
Practice (CP); Policy (P) 
1 Heroin use 
history 
Use of other drugs in initiation to heroin use To explore the role of and use of other drugs, 
including potential gateway drugs, in drug 
treatment 
R, CP 
2  The role of motivation; motivation to change 
was a significant factor at treatment outset 
To explore the individual’s level of motivation prior 
to referral to IOT 
CP, P 
3  The relevance of heroin use history in 
subsequent treatment engagement and 
abstinence 
To investigate the role of the heroin use history of 
those former entrenched heroin users who are now 
abstinent 
R 
4  The role of peers at treatment outset To investigate the situation and role of peers at 
treatment outset 
R, CP 
  The importance of building a recovery 
community within treatment programmes 
and services 
To build recovery communities within treatment 
programmes and services 
P, CP 
6  The importance of positive role models As above, and the creation of buddies in OST/IOT P, CP 
7  The need for intensive treatment for those 
with entrenched heroin use histories and 
methadone failures 
IOT made available for those with entrenched 
heroin using histories and methadone failures 
P, CP 
8  The importance of family relationships on 
drug use and maintenance 
To incorporate (perhaps just individual level) family 
therapy into individual treatment where appropriate 
R, P, CP 
9  Methadone treatment was not holistic 
enough / The importance of holistic 
treatment programmes 
The provision of individualised and holistic OST 
treatment programmes 
P, CP 
10  The need for ongoing support post-OST/IOT The importance of relapse prevention programmes: 
The availability of a mechanism of support post-
OST/IOT 
P, CP 
11  The usefulness of reflective space for 
patients to explore and analyse their 
trajectory and recovery 
The importance of relapse prevention programmes: 
The availability of a mechanism of support post-
OST/IOT 
P, CP 
12  The role of other drugs in ongoing recovery Relapse prevention focus on the use of other 




12.3.4. Summary and discussion of findings: Referral to Injectable Opiate 
Treatment 
 
Chapter seven addressed objective eight; to determine patients’ goals for, 
motivations, and expectations of IOT. A number of interesting areas arose from this 
work, and it generated a number of areas for further exploration or of use to clinical 
practice and policy. The main findings are outlined below and the areas of further 
exploration for research, clinical practice and policy follow, in table 48.  
Referral to IOT was important for understanding how patients came to arrive at the 
point where they entered IOT, what motivated them, and to view this in the context of 
their journeys thus far; how they had come to need IOT. Motivations was the initial 
theme identified in the referral to IOT chapter. Patients strongly emphasised the failing 
of conventional treatment and the role this had in the progression towards IOT. 
Patients were fed up with using illicit heroin, however they were also fed up with the 
treatment system that they perceived had failed them to date. Motivation to recover 
had likely declined within conventional systems, and patients perceived that they had 
already tried everything available with little success. Patients felt that IOT stood out 
from these previous treatment experiences and perhaps crucially that they finally felt 
listened to, respected and had a sense of belief in the programme offered to them. 
Participants had a new sense of hope – and Hartnoll et al. (1998) outlined the potential 
role of hope and expectations on outcomes.  
These are all strong psychological processes, and represent a clear shift in the 
trajectory of treatment and support experienced and perceived up to that point. It may 
be argued that this was a particularly motivated and even desperate cohort of 
patients, which impacted the level of engagement and determination for success with 
IOT. Patients previously felt misunderstood, and through being introduced to IOT 
perhaps felt more understood; this may have led to a positive referral process and 
start to treatment. 
Some patients were honest about the fact that they were initially motivated by ‘free 
heroin’. This was a crucial motivator, and trajectories illustrate - indeed in this section 
patients outlined – the fact that these motivations developed into a desire to make 
change and in some cases cease use of illicit heroin or to become completely 
abstinent from all opiates. One participant outlined initial reticence about IOT by virtue 
of the fact that it removed the hard work associated with acquiring heroin. Hartnoll et 
al (1980) had also proposed that users may be initially reluctant to contact a clinic. 
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Importantly this motivation should not be judged, and patients not labelled, at 
treatment outset, as the likelihood of change occurring appears to be high. It may also 
be that patients need to progress through particular and important stages of change 
before progress can take place. That ‘free heroin’ can serve as a strong motivating 
pull for getting individuals into treatment is advantageous, particularly in the context 
of these motivations expanding and developing over time. That IOT is viewed 
positively may attract a sample of those who would otherwise not engage in treatment 
(/again), and this is useful for policy; IOT may serve as a mechanism of initial 
attraction, that leads to a later programme of recovery, and perhaps abstinence. A 
number of patients described that they were still in a ‘street drug mentality’, and 
therefore could not make goals. This capacity for ongoing reflection is likely a very 
powerful force in patients’ current recovery journey, commitment to illicit abstinence, 
and perhaps ongoing maintenance. 
Within the motivations theme was the relevance of significant others. Other people 
were an influential factor during patients’ first encounters with heroin and treatment. 
The peer group had a role in relapse experiences, as illustrated within the ‘heroin use 
history’ chapter, and similarly, patients were also initially introduced to IOT by others. 
An example includes the impact of seeing how well a partner or associate was doing 
in IOT. As indicated, this may also be interpreted in the context of later reports on the 
significance and importance of the community dimension of IOT for recovery. Clearly 
the social and cultural environments have a strong role in illicit drug use and indeed 
successful recovery. Other people had great impact at a number of stages; initiation, 
continuation, initiation in to treatment, and maintenance. 
The IOT recovery community and other patients were a prominent feature throughout. 
Some patients had goals around the desire to disengage with the drugs subculture 
through IOT. Perhaps this was easier to conceive and accomplish within a new 
recovery community of individuals working towards the same goal. Perhaps the fact 
that staff were particularly dedicated to IOT specifically, allowed patients to feel 
understood, as well as a sense of belonging. Also evidenced was the impact of a 
perceived incongruence between the individual’s goals and the perception of other 
patients’ goals. In the cases where patients perceived that their peers were motivated 
only by ‘free heroin’, patients expressed annoyance. This criticism of others was 
pertinent throughout interviews, and this was perhaps very challenging to patients. 
The perception of a community of people all working towards the same goal may be 
disrupted by a perception of those who are not, threatening the equilibrium and 
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generating fear. This fear is understandable in the context of such difficulty and chaos 
that had arisen in the lives of this cohort prior to and because of their addiction. 
Patients are motivated by a desire for change; perhaps for the first time. In a number 
of cases, IOT appeared to come along at the right time; patients had reached the end 
of their ability to cope with the heroin using lifestyle, and desired radical change. This 
illustrates the importance of timing, for greatest impact. That patients were a 
particularly motivated cohort may be implicated in IOT’s success for this cohort. 
Beginning IOT before the patient is sufficiently motivated to make change may not 
have such a great impact, or achieve the same degree of success. Doing so could 
lead to a negative association with the process. Some patients had negative 
perceptions of IOT and it appears that it is important for these not to be judged; 
patients’ initial perceptions are liable to change. This was illustrated through the initial 
desire for maintenance evolving into a desire for abstinence for a number of patients. 
For some patients the desire for stability and normality was very apparent. Linked to 
this was the desire to leave the drugs subculture and re-enter ‘normal’ society. 
Patients wished to achieve stability in wider areas of life such as stability within their 
family relationships. As in Oviedo-Joekes et al. (2009) participants used their time in 
IOT to recover more widely. 
Some patients expressed fears over the removal of IOT. This was further emphasised 
through narratives on perceptions that IOT would be a maintenance treatment. Other 
patients highlighted initial fears upon referral to IOT, such as the fear of the structure 
of the programme. This is useful to gauge and highlights the importance and potential 
impact of conversations patients have at the referral stage. Whilst some patients 
clearly wanted to move away from the heroin using lifestyle, others were initially put 
off precisely because IOT removed the lifestyle aspects (such as effort put in to 
obtaining it) associated with acquiring heroin. At this early stage this perhaps 
detrimentally affected the heroin using identity which the patient had been attached 
to for so long. For these patients, as well as for those who wished to move away from 
the heroin using lifestyle, IOT offers a subtle, private treatment, without the judgement 
from wider society (such as that which may be apparent in a GP surgery or pharmacy 
for methadone prescription and consumption). Table 48 outlines the main findings 




Table 48. Referral to Injectable Opiate Treatment: Main findings of relevance to research, clinical practice and policy 
Reference Chapter 
title 
Finding Recommendation Implication:  
Research (R); Clinical 
Practice (CP); Policy (P) 
1 Referral to 
IOT 
The complexity of initial 
motivations and goals 
Motivations, goals and fears explored at treatment outset, 
and throughout treatment 
CP 
2  ‘Free heroin’ may be an initial 
attraction to patients entering IOT 
A non-judgemental treatment ethos/service that allows for 
changing and evolving motivations and goals 
CP, P 
3  Entrenched heroin users may 
require long-term IOT 
Provisions for long-term (yet finite) IOT for those with 
entrenched histories 
P 
4  Confidence levels may be low at 
treatment outset 
Therapeutic work on confidence at treatment outset and 
throughout IOT 
CP, P 
5  A sense of hope was linked to 
change 
Exploring and developing hope at treatment outset, and 
throughout IOT 
CP 
6  The power and strength of 
reflective space 
Provision of space and opportunity for ongoing reflection 
about the recovery process, during and post-IOT 
CP, P 
7  The desire for re-integrative, 
holistic recovery 
Provision of IOT and OST recovery programmes that 




12.3.5. Summary and discussion of findings: Experience of IOT 
 
Chapter eight addressed objectives nine and ten; to explore patients’ experience with 
IOT; and to explore patients’ satisfaction with IOT. A number of interesting areas 
arose from this work, and it generated a number of areas for further exploration or of 
use to clinical practice and policy. The main findings are outlined below and the areas 
identified for further exploration for research, clinical practice and policy follow, in 
table 49.  
Medical and clinical aspects of receiving IOT were important, encompassing the fact 
that SIH was satisfactory, and that it was very different to illicit heroin. Overall there 
were very mixed perceptions about this. It was interesting to find that whilst patients 
stated that they would not actively purchase medicinal diamorphine for recreational 
purposes, it was perceived as satisfactory enough that they did not need to use illicit 
heroin. Other perspectives were that it was superior to illicit heroin, and one of the 
particularly positive dimensions of this treatment was the security of knowing that the 
drug was clinically pure; patients highlighted that illicit heroin was often mixed with 
other substances. A few patients outlined that initially they continued to use illicit 
heroin and described that they submitted false urine samples. Furthermore, additional 
doses of methadone that patients were prescribed received a very mixed response. 
Overall, patients’ negative association with oral methadone endured. 
In terms of future policy and practice it was very useful to discover that patients who 
undertook SIM treatment were generally in favour of this treatment. Several patients 
were unsatisfied with SIM because it did not stop the desire to use illicit heroin, or that 
the ‘buzz’ achieved was different to illicit heroin, and in some cases disappointing. It 
was of further use to discover that some patients on SIM did not wish to reach the 
level of intoxication they perceived their SIH treatment peers were reaching. This may 
also be linked to findings from the ‘heroin use history’ chapter whereby patients 
demonstrated that they were very motivated to make change upon entering IOT. One 
patient stated that the doctor had said that she was doing well on SIM, and it may be 
that encouragement and praise are beneficial to progress. 
For policy and practice it was very useful to discover that SIM had a significant impact 
on a number of patients’ injecting behaviours; that the fact that the treatment was 
injectable controlled patients’ desire to inject using illicit heroin. SIM was also 
perceived favourably in light of the fact that, for some, SIH was not ‘all that it was 
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hyped up to be’. It may be that this illustrated that heroin itself was also not worth 
chasing, acquiring, and consuming, in later stages of recovery. A number of patients 
outlined negative aspects of SIM treatment such as physical reactions and 
complications. Like SIH, SIM requires close medical scrutiny, though perhaps is not 
the right treatment for everyone. SIM may be better administered as a short-term 
treatment, with the aim of altering patients’ illicit injecting behaviours. Oviedo-Joekes 
(2009) suggest that the promise of heroin following six months of a control condition 
may have kept people in the trial. This may be the case for some of those retained to 
SIM – and in some cases these individuals came to prefer it over SIH. Relatedly, 
some participants in Blanken et al. (2010) stated that they felt overly lethargic on SIH. 
Achieving the right dose was unsurprisingly instrumental to a positive perception and 
ongoing engagement. Ease and flexibility around dose change appeared to be an 
illustration of something particularly meaningful to patients, such as autonomy and a 
good, respectful relationship with staff. Patient autonomy over dose adjustments is 
key in clinical practice. Patients outlined fears about clinical flexibility getting lost in 
clinical practice (that is, outside of a pragmatic based research trial), and therefore 
this flexibility and autonomy should be woven in to treatment philosophy in prescribing 
clinics. That patients compared routinely provided IOT to IOT that was provided as 
part of a research trial (RIOTT) was a common comparison throughout interviews. As 
highlighted in the introduction – and by Uchtenhagen (2015) - effectiveness of 
treatment in real-world conditions may differ from efficacy under experimental 
conditions.  
Some patients began using illicit heroin again when their dose was reduced. 
Progressing to IM administration appears to be important, with some patients outlining 
the resultant psychological move away from attachment to illicit injecting. The need 
for a patient, individually-paced regimen is illustrated. It took time for the IOT 
experience to become the patients’ new culture, and ultimately the development of a 
stable life outside of both cultures. Sufficient time for this period of adjustment is key. 
In support, Oviedo-Joekes et al. (2009) outline a new culture of law abiding created 
by participants in their clinic. 
The clinical injecting environment was important, and a source of stability and security 
for patients. Oviedo-Joekes et al. (2014) find that participants found the supervised 
model stringent but provided valuable stability to their lives. This encompassed having 
caring staff, and prevented worries about overdose. It also removed the association 
with heroin as a ‘way of life’; which was useful. Attending the clinic for doses in the 
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longer-term received mixed responses, with some patients happy with it, and others 
coming to find it burdensome. This is in congruence with Allsop (1997) who proposes 
the pertinence of context and environment to recovery. 
Trust and support from staff and keyworker was vital. When this was perceived it was 
healing and satisfactory to patients and when not present patients perceived that this 
undermined their recovery efforts and even led to a desire to use illicit heroin. 
Therapeutic alliance and good relationships between staff and service-users should 
be key in IOT delivery, and woven into policy and clinic ethos. Community dynamics 
were key for some patients, indicating the value of efforts to cultivate a supportive 
peer environment in clinics. The cultivation of gratitude for staff, support and help 
through IOT was of pertinence. Gratitude may be a concept that could be usefully 
worked with and drawn out through therapeutic involvement and groups. 
The person-centred nature of the treatment was key. It is important that this ethos is 
maintained through future practice. Patients were able to examine their relationship 
with heroin and feel that they were the ones driving decisions about change. This had 
a profound level of impact on engagement with recovery and continued goals and 
changes. That service-users are given a voice through service-user involvement is a 
really important practice. It should be a genuine role whereby service users can see 
changes that are taking place; otherwise service-user autonomy may be perceived 
as illusory. Being coerced into making changes was sometimes detrimental to patient 
satisfaction and progress. This accords with Ward et al.’s (1999) guidance that 
problems arise if OST dosage is reduced or premature abstinence encouraged. In 
practice patients should never be coerced into progressing before they are ready. 
Patients came to realise that treatment trajectories had to be individualised, however 
at some stage this caused confusion; therefore, future practice should make this more 
explicit. This finding aligns with Edwards’ (1987) description of the pertinence of 
individual idiosyncrasies, and thus the need for the conception of recovery as a 
personal and individual journey. 
There was a high degree of anxiety about detoxing. Perhaps a clear timeline that was 
open to changes during the treatment trajectory may go some way towards alleviating 
these anxieties. If the conversations about detox are introduced gently, but earlier, 
patients may not feel so anxious about the idea of it. However this would need to take 
in to account both the flexibility of pace relevant to individual patients, and patient 
autonomy over treatment decisions. Both of these concepts should be made explicit 
to patients in the course of their treatment. Treatment exit may be a particularly 
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difficult or unstable time for service-users, and this should be monitored both at the 
time of discharge and beyond. Increased support during these processes may be 
beneficial. 
Overall, patient satisfaction was one of the main themes across the sample as a 
whole. Ultimately, it was satisfaction with treatment that kept service-users engaged 
with and enthusiastic about their recovery; and this must be prioritised in clinical 
practice. Patients were grateful for the injectable and holistic nature of the regimen 
and demonstrated the pertinence of the link between pharmacological and 
psychological recovery – whereby the pharmacological treatment provided space for 
patients to stabilise and make psychological changes. This was an overall theme 
across the research. The underlying narrative was the synergy between 
pharmacological treatment and the more holistic aspects of recovery, such as 
engaging with psychotherapies and stabilising housing, through the various support 
mechanisms. By reducing the chaos associated with acquiring and taking illicit drugs, 
there was room for more long-term, psychological and holistic engagement with 
recovery, across various aspects of life. Table 49 outlines the main findings and their 




Table 49. Experience of Injectable Opiate Treatment: Main findings of relevance to research, clinical practice and policy 
Reference Chapter title Finding Recommendation Implication:  
Research (R); 
Clinical Practice 
(CP); Policy (P) 
1 Experience 
of IOT 
SIM may be an acceptable 
substitute to SIH, which is 
more effective than OM 
SIM may usefully be employed in clinical practice CP, P 
2  SIM was acceptable and 
severed the connection to illicit 
heroin injecting 
SIM may be prescribed as a short-term maintenance treatment with 
the aim of altering users’ relationship with illicit injecting 
R, CP, P 
3  IM injecting was an acceptable 
route of administration that 
patients came to prefer over IV 
injecting 
Research to determine if there are differences in outcome across the 
two routes of administration 
R, CP, P 
4  The importance of dose 
alterations until stabilised 
Dose alterations must always be possible CP, P 
5  The importance of service-user 
autonomy over dose change 
decisions 
Dose adjustments must be service-user led, and decisions never 
coercive 
CP. P 
6  Unwanted dose reductions 
may lead to relapse 
Dosage should not be reduced against service-user’s wishes CP, P 
7  Once a day dosing is 
acceptable for a number of 
patients 
Once a day dosing may be sufficient in clinical practice CP. P 
8  The psychosocial dimension of 
IOT is crucial to effectiveness 
and outcomes 
The psychosocial dimension of treatment must be employed in IOT 
practice 
CP, P 
9  Therapeutic alliance and 
rapport with keyworker and 
staff is key 
Therapeutic alliance and good relationships with service users must be 
prioritised in clinical practice 
CP, P 
10  Ruptures to service-user/staff 
relationship can lead to 
lapse/relapse 
Service user/staff relationship ruptures must be repaired as a priority CP, P 
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11  Community dynamics and 
support from other service-
users are key 
Services should encourage, and provide resources for, mutual aid CP, P 
12  Service-user autonomy and 
control over treatment 
decisions is key 
An ethos of service-user autonomy and control over treatment 
decisions must be employed in policy and clinical practice 
CP, P 
13  Service-user involvement is 
important 
Service-user involvement or mechanisms by which service-users can 
feed-in and contribute to service delivery should be in operation 
CP, P 
14  Patients fear relapse Fears should be explored on an ongoing basis with service-users in 
key-work sessions or psychotherapy 
CP, P 
15  Patients experience 
ambivalence about abstinence 
Ambivalence should be explored on an ongoing basis, through relapse 
prevention groups and/or individual therapy and key-work sessions 
CP, P 
16  Patients experience anxiety 
about leaving IOT 
Anxiety about leaving IOT should be explored and appropriate 
psychological interventions incorporated into treatment. Time-limited 
IOT with a clearly planned trajectory and stipulated end date may 
reduce anxieties about leaving IOT for some service-users. 
Trajectories must be flexible to change in accordance with individual 
need. 
CP, P 
17  Patients appreciated the 
receipt of clinically pure heroin 
Continued provision of medicinal heroin treatment CP 
18  Patients needed time to adapt 
to the IOT regimen 
Regimens should allow time for a period of adjustment CP 
19  Some patients ultimately found 
the need for clinic attendance 
for IOT doses burdensome to 
their schedule 
Shorter-term IOT may be appropriate for some service-users, 
particularly where holistic gains are made quickly, in wider areas of life. 
CP, P 
20  An overall theme was synergy 
between pharmacological and 
psychosocial treatment 
provisions 
The ethos of multidisciplinary service-delivery should apply to all IOT 




12.3.6. Summary and discussion of findings: Impact of IOT 
 
Chapter nine addressed objectives ten and eleven; to explore patients’ satisfaction 
with IOT; and to explore patients’ views on impact of IOT. A number of interesting 
areas arose from this work, and it generated a number of areas for further exploration, 
or use to clinical practice and policy. The main findings are outlined below and the 
areas identified for further exploration for research, clinical practice and policy follow, 
in table 50.  
The cessation or reduction of use of illicit heroin was a prominent theme. Patients 
stopped using heroin at differing points in the trajectory. For some patients this was 
almost immediate, for others a period of adjusting to IOT and the routine was 
necessary. For some patients this was maintained over time, and in a number of 
cases up until the point of interview - with the firm resolution that the patient would 
not go back to using illicit heroin. Several patients had achieved abstinence-based 
recovery, and were no longer receiving maintenance treatment of any kind. 
Interestingly this applied to one negative discharger. Overall, the trajectory of harm 
caused by illicit heroin use and the associated lifestyle was interrupted by IOT. This 
accords with quantitative findings (such as van den Brink et al.’s, 2003 finding that 
harm reduction and crime reduced in the SIH group. Therefore, even though all 
patients did not achieve complete abstinence, their patterns of illicit heroin use were 
significantly and positively altered through undertaking IOT, which allowed for drastic 
(positive and healthy) changes to their lives. These findings should also be 
considered in the context of the idea that recovery is more than just abstinence (e.g., 
Neale, 2012). 
Family relationships improved as a consequence of IOT, and like a number of other 
areas of improvement, this new and enriched relationship then became a protective 
factor from subsequent lapse and relapse. The same process was in operation with 
courses and education – these were achievable due to the stability provided by IOT, 
and subsequently became protective factors against lapse and relapse. That 
participants highlighted striving towards, engaging with, and enjoying education and 
courses accords with the NTA (2012) illustration of the pertinence of those in recovery 
continuing to learn. Patients found enjoyment and motivation from these 
relationships, activities and new peer groups, and did not want to jeopardise them. 
These activities may have also filled the void left by the removal of illicit drug taking. 
Peer groups had a role to play, and these were often made through hobbies, activities, 
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education and courses and work. These connections became important, healthy 
bonds were formed, and crucially, patients were accepted by these new groups, 
which was a particularly positive experience for patients. This accords with Best and 
Laudet (2011) who state that recovery is contagious – that there is a positive impact 
on both families and communities - and also Romo et al.’s (2009) qualitative work 
illustrating the impact on families and their altered perception of the heroin using 
relative following their benefitting from the medicinal treatment programme. 
Patients developed a new level of consciousness around harm reduction and health. 
Patients were more aware of the potential for harm, whereas in the past this 
awareness was masked by the chaos and instability that marked patients’ lives 
through illicit heroin use. Patients were no longer cycling in and out of prison, and 
developed a strong commitment to stay out of prison; again a new awareness 
appeared to develop, whereby patients had time and space to reflect on the fact that 
life outside of prison was better, and that life had something to offer them. Additionally, 
patients took pride in creating and maintaining a nice home that they were proud of. 
Patients were also proud of the progress they had made through IOT. Patients 
expressed that they were committed to the programme. Like the participants in 
Oviedo-Joekes et al.’s (2014) qualitative research, participants were happy to be able 
to contribute to IOT’s evidence base. Participants were amongst a community of 
others – as well as caring staff looking after them – who were all working towards the 
same goal. For these reasons, patients became irritated when confronted with others 
in their IOT community who were not engaging appropriately. Patients perceived that 
their health was protected by the system of care offered by IOT – sometimes in the 
here and now, for example patients who were sent to A&E upon presentation at the 
IOT clinic; sometimes more holistically, for example, working with a dietician for 
weight loss; and sometimes directly such as through reducing the harms cause by 
illicit injecting. 
Patients perceived great stability and did not want to return to their old lives. Patients 
outlined general feelings of stability as well as stability that had been created over 
time, such as through the creation of a nice home. Patients also made improvements 
to their physical appearance, and all of these aspects served to make patients feel 
accepted by, and integrated back in to, society. IOT was clearly a process of progress, 
with various dimensions of improvement contributing to, and maintaining, others. 
Overall patients either were, or became, an extremely reflective and self-aware 
population. Drug users in recovery per se are likely to be a reflective population, since 
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they have to think about and share their story every time they enter treatment, and 
throughout treatment either with keyworkers, therapists or in mutual aid groups. That 
said, the IOT sample interviewed appeared to have really thought about their 
responses to questions in qualitative interviews. IOT was close to patients’ hearts and 
it very much felt like patients wished to show both IOT and their individual progress 
in a positive light. The process of IOT likely contributes to this wish; patients are cared 
for 365 days a year, in some cases, for up to seven years. The intensity of this 
treatment, and the impact of this, has been starkly illustrated. Reflection was not 
always positive for patients – for example, the awareness that they might still be 
judged by others, but it was clear that patients had some degree of resilience to this. 
Patients expressed gratitude for the programme, the care that they had received, and 
were grateful that the damage they had caused themselves was not worse than it 
was. 
The symbiotic nature of the impact of IOT and protective factors – i.e., that the 
achievements that arose as a consequence of IOT later became protective factors to 
relapse, was a key finding. Additionally, that IOT interrupted the cycle of chaos and 
harm and altered patients drug taking behaviours, and perceptions of what was 
important to them. A new or increased awareness of the potential harm caused by 
illicit heroin use was created, and the opportunity to engage in activities which 
subsequently became more important than taking illicit heroin. Table 50 outlines the 








Finding Recommendation Implication:  
Research (R); Clinical 
Practice (CP); Policy 
(P) 
1 Impact of 
IOT 
Cessation of use of illicit heroin occurred 
at different points for different patients 
There is a need for ongoing person-centred, flexible, 
individualised IOT programmes 
CP, P 
2  The routine created by the requirement 
for daily attendance gave patients a new 
sense of importance 
There is a need for the provision of intensive treatment 
programmes requiring a high level of engagement and 
involvement 
CP, P 
3  Areas of gain through the impact of IOT 
became protective factors from relapse 
The collaborative identification of protective factors during 
OST and IOT, and a celebration of any successes 
achieved through OST and IOT. 
CP, P 
4  Intensive treatment was necessary for 
self-awareness and ongoing recovery 





12.3.7. Summary and discussion of findings: Recovery 
 
Chapter ten addressed objective twelve; to explore patients’ views of, and goals for, 
their recovery. A number of interesting areas arose from this work, and it generated 
several areas for further exploration or of use to clinical practice and policy. The main 
findings are outlined below and the areas identified for further exploration for 
research, clinical practice and policy follow, in table 51.  
Recovery was most prominently conceived as an individualised process. Specific 
ideas of relevance to policy and clinical practice was the conception that patients 
should be profiled at treatment outset and then again during treatment in order to map 
out an individual trajectory that the patient can work towards. This was an interesting 
idea, particularly since patients overall tended to celebrate the holistic and 
individualised nature of the care they received through IOT. It perhaps suggests the 
benefit of a time-limited regimen, with treatment length and exit strategy made explicit 
to patients at treatment outset. This would need to encompass important dimensions 
of care such as therapeutic alliance and unconditional positive regard, to ensure 
patients feel sufficiently supported and not coerced through the regimen. That 
recovery was conceptualised by patients as an individualised process was in 
congruence with Moos (2003) who argued for a specific focus on recovery, with 
specific and individualised treatment goals. 
Patients expressed much anxiety at the prospect of IOT ending, and this applied in 
the main, to long-term IOTs. Perhaps if treatment was explicitly time limited from the 
outset, this would help reduce anxiety about treatment ending. One must also 
consider earlier findings that suggested that a long-term regimen was required, by 
virtue of the fact that the addiction had been long-term. Overall, patients greatly 
emphasised that recovery is individualised, and outlined the necessity for 
individualised areas of holistic focus. 
Patients particularly emphasised stability and functioning as overall components of 
what recovery meant to them. The desire to be and feel normal was really important 
to patients. This appeared to reflect the overarching desire to reintegrate into society. 
Patients conceived, and wanted, to function as part of society. Patients’ emphasised 
the point at which the sense of self begins to change. One patient identified that in 
recovery life becomes more interesting as the drug becomes more boring. The IOT 
programme allowed patients to ask themselves what recovery meant to them – and 
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this reflection was perhaps given more attention by virtue of the process of taking part 
in the qualitative interview. In the previous chapter; impact of IOT, some patients 
outlined a renewed sense of ‘self-importance’ which they had never experienced 
before.  
Work and employment was an aspect that carried great weight in the overall 
perception of recovery for patients. It emphasised the change to patients’ priorities, 
and focussing on and thinking about something important – that was not heroin – was 
an important component of recovery for patients. This is corroborated by Verthein et 
al. (2013) who propose that the main influencing factor for social integration was the 
ability to work. Linked to this idea was a reclaiming of power; no longer being 
dependent on a substance that controlled and dominated their lives. 
Patients emphasised the present moment focus to their conceptions of recovery. 
Patients viewed recovery as an ongoing journey, and were committed to the journey. 
Similarly, Best and Laudet (2011) outline that recovery is an ongoing journey rather 
than an end state. Recovery also involved the examination of the harm they had 
caused to themselves through illicit drug use, to date, and an ability to consciously 
halt this trajectory of harm and change direction. It was interesting that the conception 
of health and harm reduction as a sufficient recovery goal was expressed mainly by 
negative dischargers. Several patients outlined the individualised nature of the 
programme, and the point at which they had conscious awareness that patients may 
appear to receive differential treatment on the basis that they were not at the same 
stage in the treatment trajectory. It may be that health and harm reduction were earlier 
stages of importance for patients who had already achieved some degree of stability 
in these areas. It may also be that discharging from IOT prematurely had a negative 
impact on patients’ health, hence this being an area of importance for this group. 
In terms of illicit drug use there were mixed ideas about what constituted recovery; 
with some patients perceiving that ongoing maintenance treatment was appropriate 
and others who viewed total abstinence from all opiates as recovery. It was 
fascinating to hear from those who conceived work as a component of being 
recovered, in the context of ongoing maintenance (and specifically IOT). These 
patients conceived reintegration and functioning as the most important dimensions of 
recovery, but that IOT enabled this functioning. 
The process of recovery involved some degree of pain for some patients, specifically 
the awareness of one’s psychology. This led to another important idea, which was 
the need for ongoing support (perhaps even once patients had detoxed and left 
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treatment centres). Other patients outlined that ongoing support was their vision of 
recovery, however this support needed to comprise the person-centred elements that 
characterised IOT for these patients – encompassing realistic, non-coercive goal-
setting. Some patients perceived that ongoing psychological input was important. In 
clinical practice this may comprise the provision of ongoing therapy for those who 
have discharged from IOT or other maintenance treatment. Acceptance and 
Commitment Therapy (ACT) might be an appropriate therapeutic modality for those 
who have achieved stability in wider areas of life, and who have ceased use of illicit 
drugs. Related to this was a fairly prominent conception of self-esteem and the role 
this had in patients’ ideas about what recovery constituted. Here again the relevance 
of psychological or therapeutic input is highlighted. At a certain stage in the recovery 
trajectory therapeutic programmes that aim to work with self-esteem may be useful. 
Encompassed within this – and outlined by patients – was the value and relevance of 
making goals; and reaching a stage where making and achieving goals is possible. 
Therapies that focus on goal setting, and exploring and enhancing self-esteem – such 
as Cognitive Behavioural Therapeutic (CBT) modalities - may be beneficial at this 
more advanced stage of recovery for service-users. 
Finally, patients outlined the pertinence of social contacts and the relevance of how 
they were perceived by the outside world (e.g., similar to Romo et al., 2009 and 
Laudet’s, 2007 description of the pertinence of how the user perceives wider society 
perceive him/her). The overall vision involved a complete transformation of one’s life, 
which resulted in both a change to how patients viewed themselves, as well as a 
change to how they perceived they were viewed by the world around them. 
At various stages of interviews – i.e., not necessarily in direct response to questions 
asking patients about their views on what recovery was in an IOT context – patients 
outlined various barriers to recovery. Various difficulties arose for patients despite the 
enormous gains that were made overall. Difficult interpersonal relationships 
continued, housing issues arose, and illicit drug use continued – albeit on a smaller 
scale – for some patients. It is useful to have this information in order to pre-empt 
areas of difficulty in clinical practice and continue to focus on these areas where 
necessary. Once again, the need for ongoing support (in some cases) is 
demonstrated. Given how much patients benefitted from the community of other 
patients undertaking IOT, mutual aid groups for these cohorts may be a beneficial 
and cost effective way to implement ongoing support programmes within services. 
Patients may benefit from continued support from those working towards the same 
goal, and who share some of their experiences. 
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Finally, the fear of IOT ending was highlighted as a prominent and pertinent difficulty 
for patients. This perhaps provides evidence for the benefit of a time-limited 
programme of IOT, with the end date clearly communicated to patients at treatment 
outset. Thereby goals could be collaboratively devised at appropriate junctures of 
treatment, with a mechanism for ongoing support once the IOT aspect of the 
treatment trajectory had been completed by patients. Table 51 outlines the main 








Finding Recommendation Implication:  
Research (R); 
Clinical Practice 
(CP); Policy (P) 
 Recovery    
1  Patients made several mentions to 
the need for ongoing support 
during recovery, and post-IOT 
Ongoing programmes of therapeutic and mutual aid support 
(programmes to incorporate an exploration of the individual’s 
conception of recovery; reintegration programmes; goal-setting; 
opportunities for reflective space; work on self-esteem and other 
cognitions; and which celebrate successes). 
CP, P 
2  Recovery is individualised and 
patients should be profiled at 
treatment outset and at various 
junctures for the duration of 
treatment 
An individualised mapping of the recovery trajectory at treatment 





12.3.8. Summary and discussion of findings: Current situation and goals for 
the future 
 
Chapter eleven addressed objective twelve; to explore patients’ views of, and goals 
for, their recovery. A number of interesting areas arose from this work, and it 
generated several areas for further exploration or of use to clinical practice and policy. 
The main findings are outlined below and the areas identified for further exploration 
for research, clinical practice and policy follow, in table 52.  
The chapter outlining the current situation for patients illustrated in further detail the 
impact of IOT longer term, however, what the situation is for patients following the 
closure of IOT clinics is at present unknown. The current situation chapter highlighted 
that patients experienced instability and difficulty in their lives despite, and since, IOT, 
but that the extent of difficulty and instability was less impactful than the situation prior 
to, and upon, referral to IOT. It was interesting to discover that for some patients, 
current worry and difficulty arose from ventures and responsibilities that were perhaps 
made possible by the stability created during IOT. For example, worries about unwell 
children and university courses. Other issues of worry and instability included 
domestic violence and psychological disorders and distress.  
The need for a service of current and ongoing support is identified. Despite stability, 
and in some cases abstinence-based recovery, the UK IOT sample were a particularly 
vulnerable population with incredibly unstable and difficult pasts. Therefore, the focus 
on reducing or ceasing illicit drug use, obtaining stable housing, and undertaking 
voluntary or paid work may not be as beneficial without the provision of ongoing 
support. Uchtenhagen (2015) made the worthwhile and pertinent point that by 
discharging a patient once they achieve abstinence may be just at the point when the 
individual needs help the most. The chapter illustrated unforeseen difficulties such as 
psychological difficulties experienced during the detox process. This is also in 
congruence with Neale et al.’s (2012) exploration of recovery, which details the 
experience of emotional changes as a prominent overall theme. 
Arising within some narratives was a sense of resignation over unfulfilled aspirations 
and goals. The feeling that these goals would likely remain unfulfilled was described. 
Once again ongoing therapeutic support encompassing self-esteem work may be a 
suitable intervention with this sample. A prominent theme was that whilst there were 
ongoing areas of difficulty, patients asserted that their situation could be much worse. 
Whilst illicit drug use was a feature of patients’ current situation, in a number of cases 
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this was described as unproblematic, less frequent or involved drugs other than 
heroin, such as cannabis. It is clear that IOT altered this sample’s pattern of illicit drug 
use in the longer-term. Other patients describe that the period of IOT temporarily 
altered their pattern of illicit drug use, however in the present day illicit drug use 
persisted to some extent. This applied across all typologies. Table 52 outlines the 
main findings and their implication for research, clinical practice and policy.  
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Table 52. Current situation and goals for the future: Main findings of relevance to research, clinical practice and policy 
Reference Chapter title Finding Recommendation Implication:  
Research (R); Clinical 
Practice (CP); Policy 
(P) 
 Current situation 
and goals for the 
future 
   
1  Patients described unfulfilled 
dreams and goals 
Ongoing support for service-users, following IOT/OST 
(as previously described) 
CP, P 
2  Patients described being resigned 
to the fact that they would not 
achieve current goals 
Support programmes to concentrate on working with 
service-users’ self-esteem 
CP, P 
3  Patients’ current situation – 
following IOT clinic closures – is 
unknown 
Follow-up research (or audit) with former UK IOT 
patients to ascertain current situation, drug use 




12.4. Implication for future research 
 
Some of the qualitative patients had been in IOT for a period of seven years by the 
time of the qualitative interviews. At the time of interview other patients had eighteen 
months of treatment left (i.e., in Brighton), others had been discharged from treatment 
(e.g., Darlington), and others were aware that the end of IOT was imminent but they 
did not know exactly when this would be (i.e., London – in this case the clinics did 
close 14 months after the end of qualitative interviewing). Of particular interest and 
usefulness would be to follow-up with this pool of patients and monitor outcomes – 
both quantitative and qualitative – following the closure of IOT clinics and the end of 
this treatment. It would be useful and interesting to gauge if patients were currently 
retained in maintenance treatments and if so, which. It would be useful to gauge levels 
of current illicit drug use, and how patients perceived their situation post-IOT. For 
patients who had achieved goals and dreams – such as relationship goals, housing 
goals, employment goals, and enrolment in education and courses – it would be 
useful to ascertain whether these goals had been achieved (for example, had courses 
been completed, and were patients still in employment?) - and what effect the ending 
of IOT had had on patients.  
The stage at which patients were discharged from IOT may have had a role to play in 
whether illicit drug cessation would be maintained longer-term. There was a lot of 
motivation to remain abstinent from illicit heroin, and to maintain stability across the 
sample. In light of these aspirations it would be useful and interesting to conduct 
follow-up research with the UK IOT sample to ascertain whether these goals were 
achieved following discharge from IOT and IOT clinic closures. NTA (2012) describe 
that it is difficult to answer the question of how many people recover, without a much 
longer follow-up. The next stage of research might be a specific time-limited IOT trial 
with clear person-centred exit strategies in place from the beginning, and scope to 
follow individuals up for a great number of years during and following IOT. 
Additionally, the quantitative findings - and perhaps those of others studies (such as 
van den Brink, 2003) – may suggest that generic quality of life measures may not be 
sensitive or appropriate enough for an injecting drug using population. Efforts may be 
focussed on designing and validating specific quality of life measures for these 
samples. Future work may also wish to explore operational differences across 
treatment clinics, with larger, more balanced (per site) samples. 
There are a number of useful findings, not just for the IOT field, but for the field of 
addiction treatment more generally, such as the need for individually tailored 
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12.5. Overall summary 
 
As outlined by Strang et al. (2012) IOT by its very nature attracts attention and 
controversy (e.g., appendix 3), therefore a more complex picture of what we know 
about it is required. The thesis goes some way to achieve this. Patients were those 
with very difficult backgrounds and pasts. Addiction took over the lives of these 
patients due to difficult pasts and life events. The lives of this group of heroin users 
was strongly impacted by habitual heroin dependence, and patients did not have 
access to positive role models or non-heroin using peers. The impact of social 
connections and support was illustrated at every stage of the trajectory by patients. 
Drug use was normalised and use became entrenched. Patients suffered a great deal 
of loss as a result of their illicit heroin use, and did not respond to conventional 
treatment programmes such as methadone. Patients eventually reached the end of 
the line with the trajectory of harm caused by illicit drug use and health and criminal 
consequences. Overall the heroin use history chapter was a positive mechanism for 
patients to relax in to the task of sharing their story. 
At referral to IOT the failings of conventional treatment were strong motivators to 
patients to enter IOT. Patients were very unhappy with both illicit heroin use and 
conventional opiate substitution treatments which had not been successful for them. 
As illustrated by the NTA (2003) there was a need to probe what causes treatment 
failure. IOT was perceived as a treatment which addressed the needs of individuals. 
Patients were particularly motivated to make change. Sometimes free heroin drew 
patients to IOT. In light of these motivations evolving and changing, this is a positive 
finding as it serves as an effective mechanism by which patients may engage with 
effective treatment. The social and cultural environment is important at every stage 
of recovery for patients, and patients were motivated to enter IOT by other individuals. 
Some patients initially feared the structure of IOT, and this evolved to become one of 
the aspects of IOT that made it so effective for patients. 
The SIH medication received mixed responses. Patients stated that they would not 
purchase SIH for recreational use, however it was most often interpreted more 
favourably than both oral methadone and illicit heroin. Overall it alleviated the desire 
to consume illicit heroin. Responses to SIM treatment were also mixed, with some 
reporting adverse reactions to the medication, and others who preferred it to SIH. In 
the latter cases the effect was not as intense as SIH and this was preferred. On a 
psychosocial level, autonomy over treatment decisions was key for patients. That 
treatment was person-centred was also imperative. Much emphasis was placed on 
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delivery of a patient, individually-paced regimen. Trust and support from staff was 
also vital for patients’ progress. Community dynamics were also key – illustrating the 
importance of the social dimension of treatment and care patients received. Increased 
support during stages of detox may be important. Overall, time-limited programmes 
may be beneficial, with sufficient flexibility to meet the needs of individuals, and 
treatment exit mapped out at treatment outset. Treatment satisfaction was key to 
recovery and encompassed many areas of importance. Overall the synergy between 
pharmacology and the psychosocial is illustrated through IOT, and patients’ 
perceptions of what made IOT effective. Perneger et al. (1998) outline differentiation 
between specific effects of heroin administration and those of ancillary services; the 
thesis goes some way in differentiating these individual processes, concluding that 
both are fundamental but the psychosocial much more instrumental than might be 
first thought. 
Overall, there was a need for a period of adjustment to IOT. Some patients became 
completely abstinent, and some maintained low levels of illicit drug use. Some 
patients achieved cessation from illicit drugs immediately, and others took some time 
to completely stop illicit drug use. Overall, the trajectory of harm was interrupted for 
individuals. Areas of improvement obtained through the stability IOT provided later 
became protective factors from lapse and relapse. Peer group was important again; 
for both maintenance (by virtue of new healthy connections) and relapse prevention 
(by avoiding old connections). Patients had pride in their progress, and in specific 
areas of individual success. Overall, patients were very reflective respondents, 
though this reflective capacity sometimes uncovered new areas of pain for patients. 
Recovery was a distinctly individualised process, and encompassed stability and 
functioning; reintegration; a new self-identity; a new sense of self; reflective space; 
and was an ongoing journey. In congruence, Laudet (2007) outlines that recovery is 
an ongoing process of change and of reclaiming the self. Patients had mixed ideas 
about the role of abstinence and maintenance treatment in the recovery journey, and 
this again links to recovery viewed as an individualised process. The need for ongoing 
support, even when IOT has ended, was made apparent; but that which 
encompasses the factors that made IOT a success for patients. Particularly, that it is 
person-centred; flexible; individualised; patient; and emphasises therapeutic alliance. 
Mutual aid may be beneficial in support programmes, given how prominent the social 
and cultural impact was at various stages of the trajectory: i.e., initiation in to drug 
use; referral to IOT; maintenance; lapse/relapse; and recovery. Patients need to feel, 
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and be encouraged to make and achieve goals, and recovery involves a change to 
how they - and others - perceive themselves. 
Areas of difficulty continued for patients, despite the stability and gains achieved 
through IOT. This demonstrates that the road to well-being is rarely linear and 
ongoing support is appropriate. Current difficulty included interpersonal and 
relationships; housing; psychological; low level illicit drug use; and the need for 
ongoing support. Current worries arose from new ventures and relationships, 
however, overall, IOT altered the pattern of problematic drug use for all patients. For 
some this involved abstinence and others occasional illicit drug use. Once again the 
need for individualised programmes of support is emphasised, as well as research 
methodologies which are able to capture individual areas of gain and difficulty. 
Finally, the typologies were not utilised as a means by which to structure the 
qualitative findings, however, they did indicate to some degree that clinic closures 
and negative dischargers had slightly less to reflect upon about their experience of 
IOT, compared to the long-term IOTs and the positive dischargers. In terms of 
implication for policy and research, it may be that treatment discharge status is 
relevant for ongoing recovery, linking to the findings that patient autonomy and control 
over treatment decisions are important for the recovery trajectory. Perhaps being able 
to reflect, and reflect positively, on the experience of treatment may be an important 
factor for ongoing wellbeing and stability. Negative dischargers and clinic closures 
are not represented in the section on developing goals for the future. On the other 
hand, long-term IOTs did not mention recovery as constituting the development of a 
‘non-using identity’, both of which are useful to work in clinical practice with patients 
in recovery. 
 
12.6. Strengths of the thesis 
 
The quantitative data demonstrated trends of improvement; overall, patients in long-
term IOT were able to sustain gains made following six months of IOT. The flowcharts 
and description of movement illustrated the complexity of movement by patients 
through IOT, and the basic statistical analyses indicated that gains made within the 
first six months of treatment were maintained or improved upon through longer-term 
treatment episodes. The thesis identified that additional research may wish to expand 
on these analyses with longitudinal regression analyses. Overall, the context for the 
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qualitative work was provided through the quantitative work. The qualitative research 
allowed description and analyses of retrospective accounts of the entire IOT trajectory 
from referral to IOT, to the post-IOT situation. The thesis includes accounts from both 
those who were in short-term IOT (six months), long-term IOT (up to seven years), 
those who chose to discharge from IOT, and those who were compulsorily discharged 
from treatment. The researcher was independent to the original RIOTT team and 
thereby captured honest and candid accounts of patients’ experiences. The research 
is the first in its field to complete such a large and comprehensive account of treatment 
experience and recovery in a UK IOT population. The thesis benefits from a large 
qualitative sample, enabling the elicitation of rich and detailed data. Findings are 
beneficial for both IOT research, policy and practice, and OST research, policy and 
practice more generally. 
12.7. Operational and design limitations 
 
The pragmatic nature of the UK IOT trial made complex quantitative analyses of 
outcome over time difficult, and this methodological difficulty is illustrated in the 
quantitative chapter. However, suggestions are made for longitudinal regression 
analyses of long-term IOT data in further research. These were beyond the scope 
and aims of the current thesis. More appropriate to the aims of the thesis was 
qualitative data to explore the perception and experience of IOT from the service-
users’ perspective. Some patients were interviewed a number of years since they had 
completed IOT, and for all patients interviews were conducted a number of years 
following their referral to IOT. For this reason, patients’ memories may not be 
completely accurate and this should be considered when interpreting results. Case 
note reviews conducted prior to interviews allowed reference to these information 
sources during interviews and generally there was good accordance with patients’ 
accounts of specific steps in the treatment trajectory; this was not formally analysed 
however. One of the original aims was to complete and analyse qualitative interviews 
with clinicians and nurses involved in the RIOTT trial and IOT beyond this point, yet 
this project was too large for inclusion in the current thesis. These data should be 






12.8. Generalisabilty of the results 
 
The sample were a niche group of patients who had completed IOT in the UK. 
Therefore, the findings may not be generalisable to other populations and samples of 
drug users in treatment. However, the findings clearly have wider applicability for OST 
research, policy and clinical practice. The sample were a self-selecting sample and 
may particularly represent those with a positive perception of IOT. A large proportion 
of Darlington patients were not included in the recruitment, as these patients could 
not be located. This sample comprised those who had been involuntarily discharged 
from IOT, and therefore greater inclusion of this sub-sample may yield slightly 
different findings. As previously commented upon, there were also quite apparent 
geographical differences across the three locations, which may limit generalisability 
to other locations. Overall, those no longer in treatment were harder – in some cases 
impossible – to contact for recruitment. It may be the case that satisfied patients are 
those most likely to take part.  
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12.9. Final conclusions 
 
This thesis demonstrates that in order to illustrate the complex nature of an IOT 
trajectory, qualitative methods in conjunction with quantitative analyses are required. 
The UK IOT programme was particularly complex by virtue of the fact that the trial 
was pragmatic and as such involved a great deal of movement through different 
treatment types. The thesis illustrates the complexity of movement for the UK IOT 
cohort and describes the treatment journey using both descriptive statistics and a very 
large and comprehensive qualitative project examining treatment experience and 
recovery. A number of important themes emerged from the qualitative interview work 
and these have been outlined in the discussion, with their respective implication for 
research, policy and clinical practice. Next steps may wish to examine post-IOT 
outcomes some years following patient discharge from IOT. Future policy and clinical 
practice should employ the ethos of good practice outlined by patients in the thesis. 
IOT is best delivered as an individualised treatment programme. Overall IOT should 
be a time-limited continued provision for those entrenched users with long-term, 
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Appendix 1 – Description of Injectable Opiate Treatment utilised in the RIOTT 
trial 
 
The following information is taken from the Lintzeris et al. (2006, p. 3-28) paper and 
describes the details of injectable treatment received. 
‘High doses of injectable methadone or diamorphine.  
For the Injectable Methadone group, initial doses are converted from oral to injectable 
methadone. Whilst there is limited evidence regarding conversions between injected 
and oral methadone in this population, the available data suggests that oral 
methadone has a mean bioavailability of approximately 80%, with large individual 
variation (ranging from 40 to 100% in previous research)]. Hence, the study uses a 
conversion formula of injected methadone dose = 0.8 × oral methadone dose 
(separate research underway at the National Addiction Centre is examining the bio-
availaibility of injectable methadone (IM and IV) in long term oral methadone patients). 
Doses are subsequently titrated (generally upwards) and individualised with the aim 
of reducing illicit opiate use. Patients can also choose to have oral methadone 
supplements. Maximum doses of injectable methadone are 200 mg per day (plus up 
to 100 mg oral methadone), to a total dose of 300 mg per day. Injectable Diamorphine 
group: the dose conversions between oral methadone and injected diamorphine are 
based upon the work of Seidenberg et al. (1998 cited in Lintzeris et al., 2006), 
developed for the Swiss, and more recently used by the German and Canadian heroin 
trials. The dose equivalence between oral methadone and diamorphine is not linear. 
At low doses, the conversion rate from oral methadone (total daily dose) to injected 
heroin (total daily dose) is approximately 1:3; whilst at higher doses, the conversion 
rate approximates 1:5. Other factors that impact upon methadone metabolism (e.g. 
concomitant medications, medical conditions) are taken into consideration at transfer. 
Doses are subsequently titrated and individualised with the aim of reducing illicit 
opiate use. Patients are encouraged to retain a small oral methadone dose (e.g. 20 
to 40% of their initial dose) in order to prevent opiate withdrawal between injecting 
sessions, and to facilitate any transitions between oral methadone and injected 
diamorphine (effectively having a 'loading dose' of methadone). It is expected that 
most patients will use injected diamorphine doses in the range of 300 to 600 mg per 
day, with an upper total daily dose of 900 mg (450 mg per injection).  
Patients can also have up to 100 mg oral methadone supplementary to diamorphine, 
making their total oral methadone equivalent dose approximately 300 mg. - 
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Supervised dosing. All doses of prescribed injectable opioids are supervised 
throughout the 6-month study period. Treatment typically involves once-a-day 
injection of methadone, or twice-a-day injection of diamorphine. Patients have a 
degree of autonomy in the frequency of attendance for dosing and the mix of injected 
opioids/oral methadone – patients unable or unwilling to attend for injectable opioid 
treatment have access to oral methadone doses. This flexibility of attendance for on-
site injecting aims to minimize the inconvenience of IOT, and reflects that many 
patients entering RIOTT may not be injecting every day, and hence, it may not be 
therapeutically necessary for patients to increase their frequency of injecting. An 
example of this dosing flexibility is provided in Table 1. Patients must attend a 
minimum of 4-days-a-week for onsite IOT (to ensure integrity of the treatment 
condition). The principles of IOT used in RIOTT are consistent with recent national 
guidance (NTA, 2003). All doses of injectable opioids are supervised onsite in the 
participating clinics. Two injecting sessions operate each day, 7-days a week. 
Patients self-administer their injections, with the choice of intravenous, intramuscular 
or subcutaneous routes.  
Injecting sites and routes are recorded daily, and routinely assessed throughout the 
trial. Medications Trial medications include (i) oral methadone solution (1 mg in 1 ml) 
or concentrate (10 mg in 1 ml); (ii) injected methadone ampoules (50 mg in 1 ml, 50 
mg in 2 mls, 10 mg in 1 ml ampoules licensed in the UK for IM or IV injection); and 
(iii) diamorphine: the trial uses 10 gram freeze-dried diamorphine ampoules licensed 
and imported from Switzerland (Diaphin®), which are reconstituted by a trial 
pharmacist under aseptic conditions to a concentration of 100 mg/1 ml. Each injection 
of diamorphine is dispensed as a 'loaded' syringe by the pharmacist, and self-injected 
by the patient. The trial has a Clinical Trial Authorisation from the UK Medicine and 
Health Regulatory Authority for importation and use of Diaphin® ampoules. 
Treatment post-trial As injectable methadone and injectable diamorphine are licensed 
and available in Britain, the trial does not need to consider issues of 'compassionate 
grounds' for continuation of treatment. At the end of the 6-month study period, the 
nature of ongoing treatment is decided on an individual basis by clinicians in 
consultation with each patient, in keeping with the recent NTA Guidance Report (NTA, 
2003), and subject to available clinical resources. The basis of this decision will be 
the extent to which each patient has demonstrated a positive clinical response and 





Appendix 2: The step-by-step approach to conducting thematic analysis 
 
The following approach to thematic analysis, replicates the approach outlined in 
Braun and Clark (2006, p. 77-101). 
The research utilised as many leads as were available in making contact with patients 
on the IOT trial, with the aim of stopping at around N=40 interviews or when the point 
of data saturation was reached. In reality the pool of available patients to contact 
during recruitment was almost exhausted by the 41st patient and the researcher 
stopped at this point, also, for reasons of pragmatism; time constraints; and budgetary 
constraints – specifically on further travel. The entire process of analysing the data 
was conducted following Braun and Clark’s (2006) guide – the specific steps will be 
reiterated here but in the context of the current study. 
Stage one – Becoming familiar with the data 
The data was collected and managed by a single researcher (VB). Interviews were 
recorded on to a digital dictaphone and were transcribed by a professional 
transcription company previously used by the research team. A number of interviews 
were spot checked for accuracy by the researcher as interviews were transcribed by 
an outside source. To stay familiar with the data, and prior to transcription, the 
researcher would first replay the interviews once they had been conducted. A 
verbatim account of all verbal utterances were transcribed – including words and 
laughter by both researcher and patient. 
Thematic analysis began with the reading and re-reading of all qualitative transcripts 
to ensure that the researcher was immersed in the data and familiar with the depth 
and breadth of content. Reading was conducted in an active way, and notes were 
taken in margins of transcripts, on patterns and meanings. This initial reading was by 
means of Microsoft Word-based transcripts of the qualitative interview recordings. 
This initial reading served to provide the foundation for the subsequent thematic 
analysis. At this stage the researcher’s academic supervisors also read a number of 
the transcripts and provisional themes and sub-themes were derived from this small 
sub-sample of qualitative transcripts. These initial interviews also served as pilot 





Stage two – Initial code generation 
Once all transcripts had been read at least once and an initial list of codes were 
generated by the researcher – with input from academic supervisors - the initial codes 
were transferred to the qualitative data analysis computer software package 
produced by QSR International; NVivo. The researcher received training prior to this 
stage by QSR on using NVivo for qualitative research. Following this, all subsequent, 
and exhaustive, coding was conducted using NVivo. All transcripts were uploaded 
and the researcher coded every segment of text from each transcript. Identified codes 
were relevant features of the data that were interesting. These were sometimes basic 
segments, and always raw segments, that could be analysed meaningfully. Examples 
of coding segments of text are as follows. 
Table 53. Examples of data coding for study two 
Data extract Coded for 
“Well, I started when I was about 26, 
something like that, not knowing what I 
was getting into. I was just having a little 
toot when I finished work.” 
1. Initial naïveté about effects; 
2. Initial sporadic use; 
3. Initially smoked it; 
4. Initially maintained employment. 
“With foresight I wouldn’t have done 
what I’ve done and I’d have stayed on 
it.” 
1. Regrets breaking rule; 
2. Desire to remain in IOT for longer. 
 
Usually this coded data differed from the units of analysis – the themes, which in 
many cases became broader, though in some cases coding directly translated in to 
an overall theme – at a later stage of the analysis. The data was coded from a data-
driven rather than theory-driven approach, since the treatment and experience of 
treatment was novel and qualitative research in this area occupying a very small 
existing evidence base. The researcher worked systematically through all transcripts, 
giving equal attention to each item. On a practical level, through use of NVivo, 
segments of text are highlighted, tagged and named within each data item. Once a 
segment of text has been tagged and named, it appears as highlighted text in the 
transcript so that the researcher knows and can see that this segment of text has 
been coded. Therefore no text can be left out or ignored. As illustrated above in table 
53, one segment of text may be tagged and named (i.e., coded) using multiple codes. 
The advice in Braun and Clark’s (2006) paper, which the researcher adhered to, was 
417 
 
to code as many potential themes and patterns as possible, and to code extracts of 
text inclusively – i.e., by keeping a little of the surrounding data if relevant, to ensure 
that meaning or context is not lost (Bryman, 2001). In any case all codes and text 
could be linked back to patients through NVivo by means of the patient identification 
number. Since the research was on the individual patient’s trajectory, the researcher 
kept in mind to retain accounts which departed from the dominant narrative in the 
analysis at this earlier stage also. 
Stage three – Searching for themes 
Phase three began when all data had been coded and there was a long list of codes 
in NVivo that had been identified across the dataset. This phase re-focussed the 
analysis at the broader level of themes, rather than codes, and involved sorting the 
codes in to themes, bycollating all relevant data extracts within identified themes. 
Here the researcher began analysing codes and considered how the different codes 
combined to form overarching themes. At this stage the researcher copied the list of 
themes over to Excel so that they could be sorted, arranged and rearranged easily. 
Through Excel the researcher sorted all codes in to relevant themes. Excel was 
extremely useful at this point – in particular the ‘filter’ function, whereby all grouped 
codes could be viewed through the filter of their respective theme. In so doing, the 
researcher could constantly check for coherence and logic of the group of codes to 
their assigned theme. The researcher also found it helpful to write the codes on paper 
and create mind maps of the codes to categorise them in to their relevant theme – 
ultimately the final list of themes, with associated code, was viewed through Excel; 
with each section (e.g., ‘Heroin use history’, ‘Experience of IOT’, etc.), having its own 
sheet in Excel. At this stage codes were organised into both main overarching themes 
and sub-themes. 




Table 54. An example of data coding and thematic analysis 
Code Sub-theme Theme Section/chapter 
code pertains to 



















Treatment Heroin use history 
 
As illustrated above, some initial codes went on to form main themes and some 
formed sub-themes. This phase culminated in a collection of themes and sub-themes, 
and all extracts of data which had been coded in relation to them. At this stage the 
researcher had a strong sense of the significance of individual themes and received 
guidance from academic supervisors. Also at this stage, the researcher went back to 
the original transcripts and checked that the sub-themes and themes that had been 
created were congruous with narratives within the transcripts. 
Stage four – Reviewing themes 
At this stage themes were refined; this involved, for example, collapsing themes 
where relevant and breaking themes down in to two separate themes when this made 
more sense. Data within themes and sub-themes were checked for logical and 
meaningful coherence, and also identifiable distinction from other themes and sub-
themes. At this stage another Excel document was created and themes and sub-
themes with respective section headings (e.g., heroin use history, experience of IOT, 
etc.) were entered into a visually facilitative table. 
At this stage the researcher worked from both the codes – and associated segment 
of text – in NVivo, the list of codes – and associated theme/sub-theme in Excel - and 
final list of themes and sub-themes in the Excel table. This was in order to review and 
refine themes. Collated codes were also read and considered in terms of whether 
they formed a coherent pattern. Where there was a question over this, the researcher 
considered whether the theme itself was problematic or whether the coded extract 
had been assigned to the wrong theme. In some cases, a new theme was created. 
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The second stage of refinement was similar but applied to the dataset as a whole. 
The dataset was re-read to check that the themes and relevant sub-themes 
accurately represented meanings evident in the dataset as a whole. At this stage the 
researcher also checked whether any additional data within themes had been missed 
in earlier coding stages, in light of coding being viewed as an ongoing organic process 
(Braun and Clark, 2006). This process was completed when refinement stopped 
adding anything substantial. This stage culminated in a good understanding of what 
the different themes were, how they fitted together and the overall story they told 
about the patients’ experience of IOT. 
Stage five – Defining and labelling themes 
At this stage the data within the themes were analysed and write-up began. The 
researcher referred back to collated data extracts (codes) for each theme and 
organised them in to a coherent and internally consistent account with the associated 
narrative – this also began the stage of writing up chapters. As well as presenting the 
data, the analysis aimed to identify what was interesting about the extract and why 
(Braun and Clark, 2006). For each individual theme, a detailed analysis was created, 
with reference to the broader overall story or narrative, and with pertinence to the 
research questions. In final write up and analysis, patient typology was also 
incorporated into the discussion of the analysis. At stage five sub-themes were refined 
and clarified. For example, within the ‘Heroin use history’ chapter, the theme ‘Initiation 
and exposure’ encompassed both sub-themes ‘The influence of others’ and 
‘Vulnerability, exposure and fatalism’. Here the researcher ensured that each theme 
could have its scope and content described in a few sentences, and where this was 
not the case further refinement was employed. All themes already had working titles, 
and in consultation with supervisors these were refined and clarified at various stages 
of drafting. 
Phase 6 – Producing the report 
Phase six involved writing up the chapters, as has been presented herewith. This was 
carried out with guidance, comments and editing by academic supervisors. Vivid 
examples were chosen, maintaining sufficient evidence of the themes, whilst not 
neglecting to illustrate and discuss the less common narratives. The researcher 
presented both converging and diverging accounts using quotes, description of 
findings and narratives, and analysis. The final discussion and chapter summaries 
incorporated the research question and relevant objectives. The final themes were as 
follows (elaborated on in the relevant chapters): Heroin use history; Referral to IOT; 
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Experience of IOT; Impact of IOT; Recovery; and Current situation and goals for the 
future. 
Since the process of analysis involved a relatively large sample size (N=41) of 
relatively long interviews (on average 45 minutes) the coding and analysis for this 













Appendix 4 - Full participant topic guide 
 
1. Background 
-Can you start by briefly describing your heroin use history?  
-Can you briefly describe your treatment history? 
-Can you tell me about your current situation:  
Probe: 
in relation to employment; 
living/housing situation; 
health. 
-Do you use street heroin and/or other drugs currently? Can you tell me about your 
current use? 
If no, when was the last time you used street drugs? Can you tell me about this 
situation? 
2. Motivations and goals 
-What prompted you to get injectable treatment? 
-What were your expectations of this treatment? 
-What were your goals upon entering treatment? 
Additional clarification probe: what did you want / hope from this treatment? 
4. Experience of treatment 
-How do you feel about your experience of the treatment overall?  
-How do you feel about your personal progress through this treatment? 
5. Treatment medication: 
-What are your views on the medication you received during IOT?  
Probe: what are your views about -  
1. dosage; 
2. injecting site; 
3. route of administration. 
-Were there any changes to 1. drug, 2. dose, 3. route (of administration), or 4. 
(injecting) site? Addition: What were these, & when? 
How did you feel about these changes? 
-Did you receive supplementary methadone? What impact did this have? 
-How do you feel about the length of time you were in injectable treatment? 
-How did you feel about the idea of switching back to oral methadone? 
6. The Clinic: 
-Can you tell me about your experience of the clinic, and attending the clinic for your 
treatment during the injectable treatment trial? 
-What was your experience of having your heroin treatment supervised at the clinic?  
-Did you receive any other support from the clinic during treatment? What was your 
experience of this? 
-How did you feel about the process of coming to the clinic for treatment? 
Probe: Were there any positive / negative experiences – how, why. 
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-Were you involved in making decisions about your treatment? Tell me more about 
this - how was this? 
-Did you form any social connections with people from the treatment trial? Tell me 
more about this? Did you see people outside the clinic?  
-What was participants’ behaviour like in and around the clinic? 
7. Social support and social interaction: 
-Did you receive any professional psychological or social help during the treatment 
trial? What was your experience of this? 
-Did you have outside support whilst you were in treatment – tell me about this? 
What did other people think of you being in injectable treatment? (Family, friends, 
people you know – users and non-users). 
8. Effect of treatment 
-Were there any significant changes to your personal situation while you were in 
treatment (e.g., employment, family, housing, friends)? Why do you think this was? 
Probe: What impact did IOT have on your life? 
Were any of these changes connected to treatment, do you think? In what 
way/how?  
-Did you reduce your use of street heroin whilst you were in treatment? (Why do you 
think this was?)-Was there anything that specifically triggered lapse or relapse back 
to street heroin use? 
-Did you use other drugs while in treatment? (Which, when? And why this drug?) 
-Were there any physical or medical complications for you during the trial? Can you 
tell me about them? 
-Would you change anything about your treatment decisions, or journey through this 
treatment? 
9. The future (including goals) 
-How long would you like to stay (/ would you have liked to stay) on injectable 
treatment? 
-How do you feel about your current treatment? 
-How do you feel about leaving treatment? -How do you feel about abstinence? 
-Were your goals met during the course of this treatment? 
10. Personal goals 
-Do you have any treatment goals (for the future)? If yes, what are they? 
-What would be your first choice of treatment now? Why is this? 
11. Recovery 
-The concept of ‘Recovery’ is often discussed, what are your thoughts on recovery? 
What is recovery? What does recovery mean to you personally? What is recovery in 
the context of injectable opiate treatment? 
12. Conclusions and additions 




Appendix 5 – Qualitative patient case note reviews 
 
Appendix - Case note reviews; qualitative participants 
Data was collected through the research trial at regular intervals. In addition, some clinics 
completed monthly medical reviews. Data was extracted from both of these sources, and 
where available and possible (accepting time and monetary/travel constraints) – the 
electronic participant journey system was also consulted for validation of this data. Some 
participants have more complete reviews than others, as data completeness varied across 
sites and participants (accepting staff shortages and participant DNAs at various points 
during the trial). 
Periods of abstinence as reflected within these case note reviews refers to periods of 
abstinence whilst in OST, as this was more pertinent to this sample; those who had 
historically ‘failed’ in OST. 
Case note review 1 – ID 1, participant Daniella 
File item Response 
RIOTT ID 50 
Qualitative ID 1 
Clinic locality London 
Gender Female 
DoB 02/01/1967 
Age at qualitative interview 47 
Employment status 
Baseline: Unemployed / sickness 
benefit 
Parental status 3 (live elsewhere) 
Treatment allocation condition SIM 
Treatment trajectory SIM=24 months; OM=12 months 
Treatment discharge status Negative (other): hospitalised (other) 
Responder status (6 months) Unknown (clinical error) 
Ethnic origin WB 
Accommodation status (baseline) Other (unspecified) 
Treatment drug on trial entry OM 
Treatment episode length (baseline) 18 months + 
Dose on trial entry 65mls 
How many days injected in the last month 
(baseline) 30 
Injecting heroin (baseline) Yes 
Other regular use (baseline) Crack/cocaine 
Age of first use (heroin) 18 
Age regular use 18 
Age first injected 28 
Age at first treatment episode 25 
Number of previous treatment episodes 10 
Number of periods of abstinence (from illicit, 
during treatment) 1 
Date participant entered trial 21/05/2007 
Date of qualitative interview 06/01/2014 
Current treatment status (including drug and 
dose at qualitative interview) OM / 50mg 
Treatment preferences at baseline 1. SIH; 2. SIM; 3. OM 
Treatment preferences at 3 years Missing 
Date participant left IOT Last data collected: 17/03/2010 
Treatment at 3 months IM 
Treatment at 5 months IM 
Treatment at 6 months IM 
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Drug at 12 months IM 
Dose at 12 months 50mg 
Additional OM at 12 months 40mg 
Drug at 18 months IM 
Dose at 18 months 100mg 
Additional OM at 18 months 20 
Additional OM at 24 months 30mg 
Illicit use through Treatment Yes 
Use of other drugs through Treatment Yes 
Groin injecting Yes 
IV or IM Both 
Drug use at baseline Heroin=30; crack=30; cannabis=1. 
Drug use at 1 month (no. of days in last 30) 
Heroin=16; crack/cocaine=16; 
cannabis=30; alcohol=10 
Drug use at 2 months 
Heroin=14; crack=14; cannabis=3; 
alcohol=3 
Drug use at 3 months 
Heroin=15; crack/cocaine=15; 
cannabis=4; alcohol=30 
Drug use at 4 months 
Heroin=25; crack/cocaine=25; 
cannabis=6; alcohol=30 
Drug use at 5 months 
Heroin=16; crack/cocaine=16; 
cannabis=0; alcohol=30 
Drug use at 6 months 
Heroin=5; crack/cocaine=5; 
cannabis=0; alcohol=28 
Drug use at 9 months 
Heroin=2; crack/cocaine=30; 
cannabis=5 
Drug use at 15 months 
Heroin=4; Crack/cocaine=30; 
Alcohol=20 
Drug use at 24 months Heroin=0; crack/cocaine=8; alcohol=4 








Case note review 2 – ID 2, participant Jack 
File item Response 
RIOTT ID 310 
Qualitative ID 2 
Gender Male 
Clinic locality Brighton 
DoB 17/04/1973 
Employment status Unemployed/sickness benefit 
Parental status 1 (live elsewhere) 
Treatment allocation condition SIH 
Treatment trajectory SIH=9 months; OM=6 months 
Treatment discharge status Positive: voluntary detox 
Responder status (6 months) Responder 
Age at interview 41 
Ethnic origin WB 
Accommodation status (baseline) Rented (LA/HA) 
Treatment drug on trial entry OM  
Treatment episode length 3-4 years 
Dose on trial entry 50mls 
How many days injected in the last month 
(baseline) 28 
Injecting heroin Yes 
Other regular use Cannabis and benzodiazepines 
Age of first use (heroin) 22 
Age regular use 22 
Age first injected 26 
Age at first treatment episode 30 
Number of previous treatment episodes 1 
Number of periods of abstinence 0 
Date participant entered trial 23/11/2007 
Date of qualitative interview 07/01/2014 
Current treatment status Out of treatment (abstinent) 
Treatment preferences at baseline 1. SIH; 2. SIM; 3. OM 
Treatment preferences at 45 months 1. SIH; 2. None; 3. None 
Date participant left IOT 01/09/2008 
Treatment at 3 months SIH 
Treatment at 5 months SIH 
Treatment at 6 months SIH 
Treatment at 12 months OM 
Dose at 12 months 60 
Drug at 24 months Treatment free (abstinent) 
Illicit use through Treatment No 
Use of other drugs through Treatment Yes 
IV or IM IV 
Other clinical info Diagnosis of depression 
Drug use at 3 months 
Heroin=0; Cannabis=30; Alcohol=0; 
Crack/cocaine=0 
Drug use at 6 months 
Heroin=0; Cannabis=30; Alcohol=0; 
Crack/cocaine=0 
Drug use at 12 months None 
Drug use at 24 months Cannabis=30; alcohol=14 





Case note review 3 – ID 3, participant Charlie  
File item Response 
RIOTT ID 24 
Qualitative ID 3 
Gender Male 





Parental status 0 
Treatment allocation condition SIH 
Treatment trajectory SIH: 36 months 
Treatment discharge status Positive (voluntary move to MXL) 
Responder status (6 months) Non-responder 
Age at interview 49 
Ethnic origin WB 
Drug on trial entry OM supervised 
Treatment episode length 24 months 
Dose on trial entry 80mg 
How many days injected in the last month 
(baseline) 30 
Injecting heroin Yes 
Other regular use Crack and benzodiazepines 
Age of first use (heroin) 14 
Age first regular use 15 
Age first injected 18 
Age at first treatment episode 17.5 
Number of previous treatment episodes 30 
Number of periods of abstinence 2 
Date participant entered trial 27/04/2006 
Date of qualitative interview 04/01/2014 
Current treatment status Treatment free (abstinent) 
Treatment preferences at baseline 1.SIH; 2.SIM; 3.OOM 
Treatment preferences at 3 years Missing 
Date participant left IOT 
Last data collected at 36 months: 
05/02/2010 
Treatment at one month SIH 
Dose at 1 month 170mg (twice per day) 
Additional OM at 1 month 40mg 
Treatment at 2 months SIH 
Dose at 2 months 190 (twice per day) 
Additional OM at 2 months 40mg 
Treatment at 3 months SIH 
Dose at 3 months 210mg (twice per day) 
Additional OM at 3 months 40mg 
Treatment at 4 months SIH 
Dose at 4 months 210mg (twice per day) 
Additional OM at 4 months 40mg 
Treatment at 5 months SIH 
Dose at 5 months 230mg (twice per day) 
Additional OM at 5 months 40mg 
Treatment at 6 months SIH 
Dose at 6 months 230mg (twice per day) 
Additional OM at 6 months 40mg 
Treatment at 9 months SIH 
Dose at 9 months 1.240mg; 2. 250mg 
Additional OM at 9 months 40mg 
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Drug at 12 months SIH 
Dose at 12 months 1.300mg; 2.260mg 
Additional OM at 12 months 40mg 
Drug at 15 months SIH 
Dose at 15 months 300mg (twice per day) 
Additional OM at 15 months 40mg 
Drug at 18 months SIH 
Dose at 18 months 1.300mg; 2.350mg 
Additional OM at 18 months Missing 
Drug at 21 months SIH 
Dose at 21 months 1.300mg; 2.340mg 
Additional OM at 21 months 30ml 
Drug at 24 months SIH 
Dose at 24 months 1.310mg; 2.340mg 
Additional OM at 24 months 30mg 
Drug at 30 months SIH 
Dose at 30 months 1.320mg; 2.340mg 
Additional MXL at 30 months 180mg 
Drug at 36 months SIH 
Dose at 36 months 180mg 
Additional MXL at 36 months 480mg 
Illicit use through Treatment Yes 
Use of other drugs through Treatment Yes 
IV or IM IV 
























Drug use at 9 months 
Heroin=1; crack/cocaine=1; alcohol=1; 
cannabis=3; benzodiazepines=0              
Drug use at 12 months Missing 
Drug use at 15 months 0 
Drug use at 18 months Alcohol=2 
Drug use at 21 months 0 
Drug use at 24 months 0 
Drug use at 30 months 0 





Case note review 4 – ID 4, participant Jacob 
File item  
Response 
RIOTT ID 351 
Qualitative ID 4 
Gender Male 
Clinic locality Brighton 
DoB 09/03/1967 
Employment status Unemployed/sickness (baseline) 
Parental status 0 
Accommodation status Rented privately (lives alone) 
Treatment allocation condition SIM 
Treatment trajectory SIM: 24 months; OM at 36 months 
Treatment discharge status Negative (Other): skin reaction to SIM 
Responder status (6 months) Non-responder 
Age at interview 46 
Ethnic origin WB 
Drug on trial entry OM  
Treatment episode length 12 months 
Dose on trial entry 110mg 
How many days injected in the last month 
(baseline) 10 
Injecting heroin Yes 
Other regular use Cannabis 
Age of first use (heroin) 25 
Age regular use 25 
Age first injected 33 
Age at first treatment episode 40 
Number of previous treatment episodes 0 
Number of periods of abstinence 0 
Date participant entered trial 22/08/2008 
Date of qualitative interview 19/12/2013 
Current treatment status OM 
Treatment preferences at baseline 1.SIH; 2.SIM; 3. OM 
Treatment preferences at 3 years 1.SIH; 2.SIM; 3. OM 
Date participant left IOT 
Last data collected at 36 months 
(31/08/2011) 
Treatment at 3 months SIM 
Dose at 3 months 100mg 
OM dose 235mg 
Dose at 6 months 100mg 
Additional OM at 6 months 50mg 
Dose at 24 months 150mg 
Additional OM at 24 months 110mg 
Drug at 36 months OM 
Dose at 36 months 70mg 
IV or IM IM 
Drug use at 3 months 
Heroin=26; crack/cocaine=2; 
cannabis=30 
Drug use at 6 months 
Heroin=30; crack/cocaine=2; 
cannabis=30 
Drug use at 12 months 
Heroin=28; crack/cocaine=2; 
cannabis=30 
Drug use at 24 months 
Heroin=5; illicit 
methadone=1;cannabis=30 




Case note review 5 – ID 5, participant Stacy 
File item  
Response 
RIOTT ID 335 
Qualitative ID 5 
Gender Female 





Parental status 1 (lives elsewhere) 
Treatment allocation condition SIM 
Treatment trajectory SIM: 24 months 
Treatment discharge status Positive: voluntary detox 
Responder status (6 months) Non-responder 
Age at interview 35 
Ethnic origin WB 
Drug on trial entry OM 
Treatment episode length 3 months 
Dose on trial entry 60mg 
How many days injected in the last month 
(baseline) 30 
Injecting heroin Yes 
Other regular use Alcohol 
Age of first use (heroin) 17 
Age regular use 18 
Age first injected 17 
Age at first treatment episode 25 
Number of previous treatment episodes 3 
Number of periods of abstinence 0 
Date participant entered trial 18/01/2008 
Date of qualitative interview 07/12/2013 
Current treatment status OM 
Treatment preferences at baseline 1.SIH; 2. SIM; 3. OOM 
Treatment preferences at 2 years 1.SIH; 2. SIM; 3. OOM 
Date participant left IOT 22/07/2008 
Treatment at 3 months IM 
Treatment at 6 months IM 
Dose at 6 months 100mg 
Drug at 18 months IM 
Dose at 18 months 100mg 
Drug at 24 months IM 
Dose at 24 months 100mg 
Illicit use through Treatment Yes 
Use of other drugs through Treatment Yes 
IV or IM IM 
Other clinical info 
Drank heavily throughout the trial. 
Attendance an issue. Left early for an 
alcohol detox. 
Drug use at baseline Heroin=20; alcohol=27 
Drug use at 3 months 
Heroin=20; crack/cocaine=4; 
alcohol=30 
Drug use at 6 months Heroin=4; cannabis=2; alcohol=23 
Drug use at 12 months 
Heroin=15; benzodiazepines=1; 
cannabis=2; alcohol=21       
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Case note review 6 – ID 6, participant Serina 
File item  
Response 
RIOTT ID 344 
Qualitative ID 6 
Gender Female 
Clinic locality Brighton 
DoB 02/12/1977 
Employment status Unemployed/sickness benefit 
Parental status 0 
Responder status (6 months) Responder 
Treatment allocation condition SIH 
Treatment trajectory SIH: 6 months; OOM: 12 months 
Treatment discharge status Positive: voluntary move to OM 
Age at interview 37 
Ethnic origin WB 
Drug on trial entry OM 
Treatment episode length >6 months 
Dose on trial entry 80mg 
How many days injected in the last month 
(baseline) 30 
Injecting heroin Yes 
Other regular use 
Alcohol, crack/cocaine, 
benzodiazepines 
Age of first use (heroin) 17 
Age regular use 18 
Age first injected 18 
Age at first treatment episode 24 
Number of previous treatment episodes 6 
Number of periods of abstinence 1 
Date participant entered trial 09/05/2008 
Date of qualitative interview 03/01/2014 
Current treatment status OM 
Treatment preferences at baseline 1.SIH; 2. SIM; 3. OOM 
Treatment preferences at 12 months 1.SIH; 2. SIM; 3. OOM 
Date participant left IOT 
Last data collected at 12 months 
(05/06/2009) 
Dose at baseline 160mg 
Additional OM at baseline 30mg 
Treatment at 3 months SIH 
Dose at 6 months 240mg 
Additional OM at 6 months 50mg 
Dose at 12 months 120mg 
Additional OM at 12 months 50mg 
Illicit use through Treatment Yes 
Use of other drugs through Treatment Yes 
IV or IM IV 
Other clinical info 
Diagnosed with bipolar disorder; 
diagnosed with schizophrenia (last 
episode >3 years ago at baseline). 
Drug use at baseline 
Heroin=30; crack/cocaine=28; 
cannabis=1; alcohol=14 
Drug use at 3 months 
Heroin=0; crack/cocaine=2; 
cannabis=30 






Drug use at 12 months 
Heroin=2; crack=yes (no. of days not 




Case note review 7 – ID 7, participant Clara 
File item  
Response 
RIOTT ID 17 
Qualitative ID 7 
Gender Female 
Clinic locality London 
DoB 10/08/1969 
Employment status Unemployed/sickness benefit 
Parental status 0 
Accommodation status B&B/hotel 
Treatment allocation condition SIM 
Treatment trajectory SIM: 6 months; OM: 12 
Treatment discharge status Negative (Other): prison 
Responder status (6 months) Unknown (DNA) 
Age at interview 45 
Ethnic origin WB 
Drug on trial entry OM 
Treatment episode length 8 years 
Dose on trial entry 50mg 
How many days injected in the last month 
(baseline) 30 
Injecting heroin Yes 
Other regular use Yes 
Age of first use (heroin) 25 
Age regular use 26 
Age first injected 25 
Age at first treatment episode 27 
Number of previous treatment episodes 5 
Number of periods of abstinence 1 
Date participant entered trial 18/01/2006 
Date of qualitative interview 10/01/2014 
Current treatment status OM 
Treatment preferences at baseline 1.SIH; 2. SIM; 3. OOM 
Treatment preferences at 6 months 1.SIH; 2. SIM; 3. OOM 
Date participant left IOT 
Last data collected at 6 months 
(09/08/2006) 
Dose at baseline 120mg 
Additional OM at baseline 140mg 
Treatment at 3 months SIM 
Dose at 3 months 100mg 
Additional OM at 3 months 50mg 
Treatment at 4 months SIM 
Dose at 4 months 50mg 
Treatment at 5 months SIM 
Dose at 5 months 100mg 
Additional OM at 5 months 50mg 
Treatment at 6 months SIM 
Dose at 6 months 100mg 
Additional OM at 6 months 50mg 
Drug at 24 months OM 
Drug at 36 months OM 
Dose at 36 months 100mg 
IV or IM Both 
Other clinical info 
HIV positive. Was in a residential 
alcohol detox during trial. 
436 
 
Drug use at 1 month 
Heroin=21; crack/cocaine=20; 
cannabis=1; alcohol=8 
Drug use at 2 months 
Heroin=2; crack/cocaine=6; 
cannabis=4; alcohol=12 
Drug use at 3 months 
Heroin=0; crack/cocaine=4; 
cannabis=2; alcohol=8 
Drug use at 4 months 
Heroin=1; crack/cocaine=2; 
cannabis=20; alcohol=20 
Drug use at 5 months 
Heroin=1; crack/cocaine=1; 
cannabis=14; alcohol=30 







Case note review 8 – ID 8, Harry 
File item  
Response 
RIOTT ID 56 
Qualitative ID 8 
Gender Male 
Clinic locality London 
DoB 19/03/1963 
Employment status 
Unemployed/sickness (baseline and at 
qualitative interview) 
Parental status 0 
Accommodation status Hostel 
Treatment allocation condition SIM 
Treatment trajectory SIH: 30 months; SIM: 6 months 
Treatment discharge status Positive: voluntary move to OM 
Responder status (6 months) Non-responder 
Age at interview 50 
Ethnic origin WB 
Drug on trial entry Buprenorphine 
Treatment episode length 2 years 
Dose on trial entry 8mg 
How many days injected in the last month 
(baseline) 16 
Injecting heroin Yes 
Other regular use Alcohol and benzodiazepines 
Age of first use (heroin) 20 
Age regular use 20 
Age first injected 21 
Age at first treatment episode 26 
Number of previous treatment episodes 3 
Number of periods of abstinence 2 (residential rehabs) 
Date participant entered trial 12/11/2007 
Date of qualitative interview 20/12/2013 
Current treatment status Treatment free (abstinent) 
Treatment preferences at baseline 1.SIH; 2. SIM; 3. OOM 
Treatment preferences at 3 years Missing 
Date participant left IOT Last data at 31 months (05/07/2010) 
Treatment at 1 month SIM 
Dose at 1 month 60mg 
Additional OM at 1 month 10mg 
Treatment at 2 months SIM 
Dose at 2 months 50mg 
Additional OM at 2 months 40mg 
Treatment at 5 months SIM 
Dose at 5 months 100mg 
Treatment at 6 months SIM 
Dose at 6 months 100mg 
Treatment at 9 months SIH 
Dose at 9 months 140mg (twice a day) 
Additional OM at 9 months 50mg 
Drug at 18 months SIH 
Dose at 18 months 1.200mg; 2. 170mg 
Additional MXL at 18 months 390mg 
Drug at 31 months SIH 
Dose at 31 months 170mg 
Additional OM at 31 months 50mg 
Illicit use through Treatment Yes 
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Use of other drugs through Treatment Yes 
IV or IM Both 
Other clinical info Hepatitis C 
Drug use at baseline Heroin=20; alcohol=30 
Drug use at 1 month 
Heroin=30; crack/cocaine=4; 
benzodiazepines=2; alcohol=30 
Drug use at 2 months 
Heroin=18; crack/cocaine=5; 
benzodiazepines=2; alcohol=30 
Drug use at 3 months 
Heroin=20; crack/cocaine=4; 
benzodiazepines=2; alcohol=30 
Drug use at 5 months Heroin=15; crack/cocaine=8; alcohol=8 
Drug use at 6 months 
Heroin=20; crack/cocaine=8; 
alcohol=30 
Drug use at 9 months Heroin=0; crack/cocaine=4; alcohol=30 
Drug use at 18 months Alcohol=30 





Case note review 9 – ID 9, Tom 
File item  
Response 
RIOTT ID 334 
Qualitative ID 9 
Gender Male 





Parental status SIH 
Treatment allocation condition SIH:  
Treatment trajectory SIH: 36 months 
Treatment discharge status Positive: voluntary detox 
Responder status (6 months) Responder 
Age at interview 47 
Ethnic origin WB 
Drug on trial entry OM 
Treatment episode length 25 years 
Dose on trial entry 80mg 
How many days injected in the last month 
(baseline) 3 
Injecting heroin Yes 
Other regular use Cannabis, benzodiazepines 
Age of first use (heroin) 14 
Age regular use 15 
Age first injected 14 
Age at first treatment episode 15 
Number of previous treatment episodes 4  
Number of periods of abstinence 3 
Date participant entered trial 07/12/2007 
Date of qualitative interview 19/12/2013 
Current treatment status Buprenorphine 
Treatment preferences at baseline 1.SIM; 2. SIH; 3. OOM 
Treatment preferences at 3 years 1.SIH; 2. SIM; 3. OOM 
Date participant left IOT 
Last data collected at 36 months 
(07/12/2010 - check) 
Treatment at baseline SIH 
Treatment at 3 months SIH 
Dose at 5 months SIH 
Dose at 6 months 225mg 
Dose at 12 months 220mg 
Additional OM at 12 months 130mg 
Dose at 18 months 220mg 
Additional OM at 18 months 100mg 
Dose at 24 months 220mg 
Additional OM at 24 months 100mg 
Drug at 36 months SIH 
Dose at 36 months 150mg 
Additional OM at 36 months 40mg 
IV or IM Both 
Drug use at 3 months Heroin=0; cannabis=30; alcohol=4 
Drug use at 6 months 
Heroin=0; cannabis=30; alcohol=5 (2 
glasses of wine per occasion) 





Drug use at 24 months 
Heroin=0; Cannabis=30; alcohol=10 
(0.5 pint per occasion) 
Drug use at 36 months Heroin=0; cannabis=30; alcohol=10 
 
Case note review 10 – ID 10, participant Fay 
File item  
Response 
RIOTT ID 324 
Qualitative ID 10 
Gender Female 
Clinic locality Brighton 
DoB 21/12/1970 
Employment status White Irish 
Parental status 0 
Treatment allocation condition OOM 
Treatment trajectory 
OOM: 12 months; SIM: 6 months; SIH: 
18 months 
Treatment discharge status Long-term IOT 
Responder status (6 months) Non-responder 
Age at interview 43 
Ethnic origin White Irish 
Drug on trial entry OM 
Treatment episode length 3 years 
Dose on trial entry 70mls 
How many days injected in the last month 
(baseline) 8 
Injecting heroin Yes 
Other regular use None 
Age of first use (heroin) 13 
Age regular use 17 
Age first injected 14 
Age at first treatment episode 20 
Number of previous treatment episodes 18 
Number of periods of abstinence 6 
Date participant entered trial 26/11/2007 
Date of qualitative interview 07/01/2013 
Current treatment status IOT (SIH) 
Treatment preferences at baseline 1.SIM; 2. OOM; 3. SIH 
Treatment preferences at 3 years 1.SIH; 2. SIM; 3. OOM 
Date participant left IOT Still in IOT at time of interview 
Treatment at 3 months OOM 
Treatment at 5 months OOM 
Treatment at 6 months OOM 
Dose at 6 months 160mg 
Drug at 12 months SIM 
Dose at 12 months 100mg 
Additional OM at 12 months 160mg 
Drug at 18 months SIH 
Drug at 24 months SIH 
Dose at 24 months 160mg 
Drug at 36 months SIH 
Dose at 36 months 140mg 
Illicit use through Treatment Yes 
Use of other drugs through Treatment Yes 
IV or IM Missing 
Drug use at baseline Heroin=28; cannabis=15; alcohol=3 
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Drug use at 6 months 
Heroin=7; crack/cocaine=1; 
cannabis=30; benzodiazepines=14 
Drug use at 12 months Heroin=0; cannabis=8 
Drug use at 36 months Heroin=0; cannabis=30 
Case note review 11 – ID 11, participant Sammy 
File item  
Response 
RIOTT ID 309 
Qualitative ID 11 
Gender Male 
Clinic locality Brighton 
DoB 20/10/1974 
Employment status Unemployed/sickness benefit 
Parental status 0 
Treatment allocation condition SIM 
Treatment trajectory 
OOM: 6 months; SIM: 9 months; SIH: 3 
months (then ongoing post trial) 
Treatment discharge status Long-term IOT 
Responder status (6 months) Unknown (planned absence) 
Age at interview 39 
Ethnic origin WB 
Drug on trial entry OM 
Treatment episode length 9 months 
Dose on trial entry 60ml 
How many days injected in the last month 
(baseline) 18 
Injecting heroin Yes 
Other regular use Alcohol 
Age of first use (heroin) 21 
Age regular use 22 
Age first injected 26 
Age at first treatment episode 29 
Number of previous treatment episodes 2 
Number of periods of abstinence 0 
Date participant entered trial 31/08/2007 
Date of qualitative interview 07/10/2013 
Current treatment status Long-term IOT 
Treatment preferences at baseline 1.SIH; 2. SIM; 3. OOM 
Treatment preferences at 3 years 1.SIH; 2. SIM; 3. OOM 
Date participant left IOT Still in IOT at time of interview 
Treatment at 3 months Missing 
Treatment at 6 months OST 
Drug at 24 months SIM 
Dose at 24 months 80 
Drug at 36 months SIH 
Dose at 36 months 130mg 
Additional OM at 36 months 120mg 
Illicit use through Treatment No (in prison during trial) 
Use of other drugs through Treatment Yes 
IV or IM Both 
Other clinical info 
Went to prison during the trial (data 
collected from prison) 
Drug use at baseline 
Heroin=30; cannabis=3; 
benzodiazepines=2; alcohol=30 
Drug use at 3 months NB. In prison. 0 for all. 
Drug use at 6 months NB. In prison. 0 for all. 
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Case note review 12 – ID 12, participant Reg 
File item  
Response 
RIOTT ID 3 
Qualitative ID 12 
Gender Male 
Clinic locality London 
DoB 20/01/1956 
Employment status 
Baseline: Unemployed; Interview: Full-
time employment 
Parental status Parent; 1 child; resides elsewhere 
Treatment allocation condition OOM 
Treatment trajectory 
OOM: 6 months; SIH: 30 months (and 
beyond the trial) 
Treatment discharge status Long-term IOT 
Responder status (6 months) Non-responder 
Age at interview 57 
Ethnic origin White Irish 
Drug on trial entry Oral methadone 
Treatment episode length 7.5 months 
Dose on trial entry 45 mls / 45 mg 
How many days injected in the last month 
(baseline) 20 
Injecting heroin Yes 
Other regular use Cannabis and cocaine 
Age of first use (heroin) 42 
Age regular use 47 
Age first injected 48 
Age at first treatment episode Opiates: 48 / cocaine: 40 
Number of previous treatment episodes 0 
Number of periods of abstinence 0 
Date participant entered trial 03/10/2005 
Date of qualitative interview 31/07/2013 
Current treatment status 
IOT: SIH 100 / MXL 600 (5 days) & 
MXL 800 (2 days) 
Treatment preferences at baseline 1. SIH; 2. SIM; 3. OM 
Treatment preferences at 3 years 1. SIH; 2. SIM; 3. OM 
Date participant left IOT 
Ongoing (as of qualitative interview 
date) 
Treatment at 3 months OM 
Dose at 3 months 140mg 
Treatment at 5 months OM 
Dose at 5 months 140mg 
Treatment at 6 months OM 
Dose at 6 months 60mg 
Drug at 12 months SIH 
Dose at 12 months 330mg 
Additional OM at 12 months 50mg 
Drug at 15 months SIH 
Dose at 15 months 330mg 
Additional OM at 15 months 50mg 
Drug at 18 months SIH 
Dose at 18 months 380mg 
Additional OM at 18 months 50mg 
Drug at 21 months SIH 
Dose at 21 months 380mg 
Additional OM at 21 months 50mg 
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Drug at 24 months SIH 
Dose at 24 months 380mg 
Additional OM at 24 months 50mg 
Drug at 30 months SIH 
Dose at 30 months 410mg 
Additional OM at 30 months 50mg 
Drug at 33 months SIH 
Dose at 33 months 430mg 
Drug at 36 months SIH 
Dose at 36 months 
380mg x 5 days per week; 230mg x1 
day; OM 155mg x 1 day per week. 
Drug at 42 months SIH 
Dose at 42 months 380mg 
Additional MXL at 42 months 240mg 
Illicit use through Treatment Yes 
Use of other drugs through Treatment Yes 
IV or IM 
OM for first year, then IV SIH, then 
moved to IM with encouragement for 
this from staff. 
Other clinical info 
Alcoholic for 30 years - stopped 
drinking 10 years ago (medical notes 
did indicate incidences of drinking over 
the course of RIOTT). 
Drug use at 1 month 
Heroin=28; crack/cocaine=30; 
alcohol=0; benzodiazepines=2/30 
Drug use at 2 months 
Heroin=30; crack/cocaine=10; 
alcohol=2 
Drug use at 3 months 
Heroin=29; benzodiazepines=3; 
crack/cocaine=10; cannabis 12; 
alcohol=2 
Drug use at 4 months 
Heroin=30; crack/cocaine=10; 
alcohol=30; benzodiazepines=4 
Drug use at 5 months 
Heroin=30; crack/cocaine=8; alcohol 
and benzodiazepines=0 
Drug use at 6 months 
Heroin=30; crack/cocaine=10; 
cannabis=4 
Drug use at 12 months Heroin=15; crack/cocaine=20 
Drug use at 15 months 
Heroin=14; crack/cocaine=14; 
alcohol=3 
Drug use at 18 months Heroin=8; crack/cocaine=8 
Drug use at 21 months Heroin=8; crack/cocaine=8; alcohol=1 
Drug use at 24 months Heroin=8; crack/cocaine=8 
Drug use at 30 months Heroin=8; crack/cocaine=8; alcohol=2 
Drug use at 33 months Heroin=4; crack/cocaine=8; alcohol=0 
Drug use at 36 months Heroin=8; crack/cocaine=8; alcohol=0. 





Case note review 13 – ID 13, participant Fran 
File item  
Response 
RIOTT ID 9 
Qualitative ID 13 
Gender Female 
Clinic locality London 
DoB 25/05/1968 
Employment status Unemployed 
Parental status 2 adult children; reside elsewhere 
Treatment allocation condition SIM 
Current treatment status (time of 
interview) IOT 
Treatment trajectory SIM: 6 months; SIH: 30 months 
Treatment discharge status Long-term IOT 
Responder status (6 months) Non-responder 
Age at interview 46 
Ethnic origin WB 
Drug on trial entry Oral methadone 
Treatment episode length 6 months 
Dose on trial entry 90 mls 
How many days injected in the last 
month (baseline) 16 
Injecting heroin (baseline) Y 
Other regular use (baseline) Cannabis, benzodiazepines, crack 
Age of first use (heroin) 14 years old 
Age regular use 14 
Age first injected 16 
Age at first treatment episode 16 
Number of previous treatment 
episodes 9 (5 detox; 3 rehab; 1 stabilised) 
Number of periods of abstinence 1 
Date participant entered trial 14/11/2005 
Date of qualitative interview 22/08/2014 
Current treatment status IOT: SIH 
Treatment preferences at baseline 1. SIH and SIM; 2. OM 
Treatment preferences at 3 years 1. SIH; 2. SIM; 3. OM 
Date participant left IOT Ongoing (as of qualitative interview date) 
Treatment at 3 months IM 
Dose at 3 months 160mg 
Treatment at 6 months IM 
Dose at 6 months 150mg 
Treatment at 12 months IH 
Dose at 12 months 460mg 
Additional OM at 12 months 80mg 
Treatment at 18 months IH 
Dose at 18 months 460mg 
Additional OM at 18 months 100mg 
Treatment at 24 months IH 
Dose at 24 months 460mg 
Additional OM at 24 months 100mg 
Treatment at 33 months IH 
Dose at 33 months 480mg 
Treatment at 36 months IH 
Dose at 36 months 500mg 
Treatment at 60 months IH 
Dose at 60 months 300mg 
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Additional OM at 42 months 50mg 
Illicit use through Treatment Yes 
Use of other drugs through 
Treatment Yes 
IV or IM Both 
Drug use at 1 month 
Heroin=2; alcohol=6; crack/cocaine=10; 
cannabis=2 
Drug use at 2 months 
Heron=0; alcohol=12; benzodiazepines=2; 
crack/cocaine=14; cannabis=3 
Drug use at 3 months 
Heroin=0; alcohol=30; crack/cocaine=25; 
cannabis=12 
Drug use at 4 months 
Heroin=0; alcohol=6; benzodiazepines=2; 
crack/cocaine=10; cannabis=2 
Drug use at 5 months 
Heroin=2; alcohol=6; crack/cocaine=10; 
cannabis=8 
Drug use at 6 months 
Heroin=1 (smoked); crack/cocaine =12; alcohol=6; 
benzodiazepines=1 
Drug use at 15 months Alcohol=3; crack/cocaine=1; cannabis=1 
Drug use at 18 months Cannabis=2 
Drug use at 21 months Alcohol=1; cannabis=1 
Drug use at 24 months Crack=2; cannabis=2 
Drug use at 30 months Alcohol=3; crack/cocaine=1; cannabis=30/30 
Drug use at 33 months Alcohol=7; cannabis=10 
Drug use at 44 months Alcohol=1; cannabis=30 
6 years Crack use 
7 years Heroin, crack and alcohol use 





Case note review 14 – ID 14, participant Nicholas 
File item  
Response 
RIOTT ID 41 
Qualitative ID 14 
Gender Male 
Clinic locality London 
DoB 09/12/1966 
Employment status Unemployed 
Parental status 5 children (live elsewhere) 
Treatment allocation condition SIH 
Treatment trajectory SIH: 24 months; SIM: 12 months 
Treatment discharge status Positive: voluntary move to OM 
Responder status (6 months) Responder 
Age at interview 48 years old 
Ethnic origin WB 
Drug on trial entry Oral methadone 
Treatment episode length (baseline) Missing data 
Dose on trial entry 50 mg / mls 
How many days injected in the last month 
(baseline) 30 
Injecting heroin (baseline) Yes 
Other regular use (baseline) Crack/cocaine 
Age of first use (heroin) 19 
Age regular use 19 
Age first injected 19 
Age at first treatment episode 26 
Number of previous treatment episodes 5 
Number of periods of abstinence 0 
Date participant entered trial 27/11/2006 
Date of qualitative interview 10/10/2013 
Current treatment status OM 
Treatment preferences at baseline 1. SIH; 2. SIM; 3. OM 
Treatment preferences at 3 years 1. SIH or SIM; 2. OM 
Date participant left IOT 2009 
Reason for discharge Voluntary move to OM 
Treatment at 3 months SIH 
Dose at 3 months 840mg 
Treatment at 6 months SIH 
Dose at 6 months 560mg 
Treatment at 12 months SIH 
Dose at 12 months 560mg 
Additional OM at 12 months 60mg 
Treatment at 18 months SIH 
Dose at 18 months 600mg 
Additional OM at 18 months 60mg 
Treatment at 24 months SIH 
Dose at 24 months 400mg 
Additional MXL at 24 months 450mg 
Treatment at 36 months OM 
Dose at 36 months 150mg 
Illicit use through Treatment Yes 
Use of other drugs through Treatment Yes 
IV or IM IV 
Drug use at baseline Heroin=30; crack=10; cannabis=1 
Drug use at 3 months Heroin=0; crack=5; cannabis=20 
Drug use at 6 months Heroin=1; crack=4; cannabis=15 
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Drug use at 9 months 
Heroin=2; crack=10; 
benzodiazepines=4; cannabis=1 
Drug use at 15 months Heroin=0; crack=1; cannabis=10 
Drug use at 21 months Crack=8; cannabis=8 





Case note review 15 – ID 15, participant Ben 
File item  
Response 
RIOTT ID 350 
Qualitative ID 15 
Gender Male 
Clinic locality Brighton 
DoB 30/04/1966 
Employment status Unemployed/sickness benefit 
Parental status 0 
Treatment allocation condition SIH 
Treatment trajectory OOM: 12 months; SIH: 15 months 
Treatment discharge status Long-term IOT 
Responder status (6 months) Unknown (planned absence: prison) 
Age at interview 47 
Ethnic origin WB 
Drug on trial entry OM 
Treatment episode length Notes illegible 
Dose on trial entry 100mg 
How many days injected in the last month 
(baseline) 30 
Injecting heroin Yes 
Other regular use Crack/cocaine 
Age of first use (heroin) 18 
Age first regular use 18 
Age first injected 17 (speed) 
Age first treatment episode 26 
Number of treatment episodes 6 
Number of periods of abstinence 0 
Date participant entered trial 08/08/2008 
Date of qualitative interview 26/09/2013 
Current treatment status Long-term IOT (SIH) 
Treatment preferences at baseline 1.SIH; 2. SIM; 3. OOM 
Treatment preferences at 3 years 1.SIH; 2. OOM; 3. SIM 
Date participant left IOT Still in IOT at time of interview 
Treatment at baseline SIH 
Dose at baseline 140mg 
Additional OM at baseline 50mg 
Treatment at 3 months SIH 
Dose at 3 months 770mg 
Additional OM at 3 months 470mg 
Treatment at 6 months OST 
Drug at 12 months OM 
Dose at 12 months 180 
Drug at 24 months SIH 
Dose at 24 months 260 
Additional OM at 24 months 130 
Drug at 36 months SIH 
Illicit use through Treatment Yes 
Use of other drugs through Treatment Yes 
IV or IM Both 
Other clinical info Went to prison during trial 
Drug use at baseline 
Heroin=30; illicit methadone=2; 
crack/cocaine=30; benzodiazepines=2 
Drug use at 3 months 





Drug use at 6 months 
Heroin=27; crack/cocaine=30; 
benzodiazepines=25; alcohol=5 
Drug use at 24 months 
Heroin=0; illicit methadone=1; 
crack/cocaine=1; cannabis=1; 
alcohol=6 





Case note review 16 – ID 16, participant Oliver 
File item  
Response 
RIOTT ID 341 
Qualitative ID 16 
Gender Male 
Clinic locality Brighton 
DoB 25/12/1954 
Employment status Unemployed/sickness benefit 
Parental status 0 
Treatment allocation condition SIH 
Treatment trajectory SIH: 36 months (and beyond trial) 
Treatment discharge status Long-term IOT 
Responder status (6 months) Responder 
Age at interview 59 
Ethnic origin WB 
Drug on trial entry OM 
Treatment episode length 3 months 
Dose on trial entry 50ml 
How many days injected in the last month 
(baseline) 30 
Injecting heroin Yes 
Other regular use Yes 
Age of first use (heroin) 16 
Age first regular use 31 
Age first injected 16 
Age first treatment episode 31 
Number of treatment episodes 5 
Number of periods of abstinence 0 
Date participant entered trial 02/05/2008 
Date of qualitative interview 28/09/2013 
Current treatment status IOT (SIH) 
Treatment preferences at baseline 1.SIH; 2. SIM; 3. OOM 
Treatment preferences at 3 years 1.SIH; 2. SIM; 3. OOM 
Date participant left IOT Still in IOT at time of interview 
Treatment at baseline SIH 
Treatment at 3 months SIH 
Treatment at 6 months SIH 
Dose at 6 months 150mg 
Additional OM at 6 months 70mg 
Drug at 12 months SIH 
Dose at 12 months 70mg 
Additional OM at 12 months 80mg 
Dose at 18 months 100mg 
Additional OM at 18 months 80mg 
Dose at 24 months 195mg 
Additional OM at 24 months 60mg 
Dose at 36 months 100mg 
Additional OM at 36 months 60mg 
Illicit use through treatment No 
Use of other drugs through treatment Yes (minimal) 
IV or IM Both 
Drug use at baseline Heroin=30; cannabis=2 
Drug use at 3 months Cannabis=15 
Drug use at 6 months All=0 
Drug use at 12 months All=0; alcohol=13 
Drug use at 24 months All=0; cannabis=1 
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Drug use at 36 months All=0 
Case note review 17 – ID 17, participant Matthew 
File item  
Response 
RIOTT ID 4 
Qualitative ID 17 
Gender Male 
Clinic locality London 
DoB 14/05/1961 
Employment status Unemployed/sickness benefit 
Treatment allocation condition SIM 
Treatment trajectory SIM: 24  
Treatment discharge status 
Negative (compulsory discharge; 
behaviour) 
Parental status 0 
Responder status (6 months) Responder 
Age at interview 52 
Ethnic origin WB 
Drug on trial entry OM 
Treatment episode length Missing data 
Dose on trial entry 75ml 
How many days injected in the last month 
(baseline) 25 
Injecting heroin Yes 
Other regular use No 
Age of first use (heroin) 24 
Age first regular use 24 
Age first injected 24 
Age first treatment episode 27 
Number of previous treatment episodes 4 
Number of periods of abstinence 0 
Date participant entered trial 28/09/2005 
Date of qualitative interview 28/08/2013 
Current treatment status Treatment drug free (abstinent) 
Treatment preferences at baseline 1.SIM; 2. SIH; 3. OOM 
Treatment preferences at 3 years 1.SIM;  
Date participant left IOT 
Last data collected at 36 months 
(17/12/2008) 
Treatment at baseline SIM 
Dose at baseline 100mg 
Treatment at 3 months SIM 
Dose at 3 months 100mg 
Additional OM at 3 months 20mg 
Treatment at 6 months SIM 
Dose at 6 months 100mg 
Drug at 12 months SIH 
Dose at 12 months 100mg 
Additional OM at 12 months 20mg 
Drug at 15 months SIM 
Dose at 15 months 100mg 
Additional OM at 15 months 20mg 
Drug at 18 months SIM 
Dose at 18 months 135mg 
Additional OM at 18 months 20mg 
Drug at 21 months SIM 
Dose at 21 months 100mg 
Additional OM at 21 months 20mg 
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Drug at 24 months SIM 
Dose at 24 months 100mg 
Additional OM at 24 months 20mg 
Drug at 36 months SIM 
Dose at 36 months 50mg 
Additional OM at 36 months 20mg 
Illicit use through Treatment Yes 
Use of other drugs through Treatment Yes 
IV or IM Both 
Other clinical info 
Participant had an allergic reaction to 
the diamorphine treatment (suffered 
anaphylactic shock). Participant was on 
an ATR (Alcohol Treatment 
Requirement) at time of interview. 
Diagnosed with hepatitis C. 
Drug use at 1 month Heroin=9; crack/cocaine=9 
Drug use at 2 months Heroin=8; crack/cocaine=4 
Drug use at 3 months 
Heroin=0; crack/cocaine=1; 
alcohol=data illegible 
Drug use at 4 months Heroin=7; crack/cocaine=6 
Drug use at 5 months Heroin=0; crack/cocaine=2; alcohol=1 
Drug use at 6 months Heroin=0; crack/cocaine=4; alcohol=24 
Drug use at 15 months Heroin=0; crack/cocaine=1; alcohol=30 
Drug use at 18 months 
Heroin=0; illicit methadone=1; 
alcohol=14 
Drug use at 21 months Missing 
Drug use at 24 months All=0; alcohol=30 





Case note review 18 – ID 18, participant Luke 
File item  
Response 
RIOTT ID 22 
Qualitative ID 18 
Gender Male 
Treatment locality London 
DoB 14/08/1965 
Employment status Unemployed/sickness benefit 
Parental status 0 
Treatment allocation condition OOM 
Treatment trajectory OOM: 12 months; SIH: SIH 
Treatment discharge status Negative: compulsory discharge 
(sedation; benzodiazepine use) 
Responder status (6 months) Non-responder 
Age at interview 48 
Ethnic origin WB 
Drug on trial entry OM 
Treatment episode length 6 months 
Dose on trial entry 90mg 
How many days injected in the last month 
(baseline) 13 
Injecting heroin Yes 
Other regular use 
Cannabis, crack/cocaine and 
benzodiazepines 
Age of first use (heroin) 19 
Age first regular use 22 
Age first injected 25 
Age first treatment 22 
Number of previous treatment episodes 7 
Number of periods of abstinence 0 
Date participant entered trial 16/07/2008 
Date of qualitative interview 28/08/2013 
Current treatment status OM 
Treatment preferences at baseline 1.SIH; 2. SIM; 3. OOM 
Treatment preferences at 3 years Missing 
Date participant left IOT 
Last data collected at 28 months 
(02/07/2008) 
Treatment at 2 months OOM 
Dose at 2 months 100mg (once per day) 
Additional diazepam at 2 months 40mg (twice per day) 
Treatment at 3 months OOM 
Dose at 3 months 120mg 
Treatment at 4 months OOM 
Dose at 4 months 120mg (once a day) 
Treatment at 5 months OOM 
Dose at 5 months 120mg (once a day) 
Treatment at 6 months OOM 
Dose at 6 months 120mg 
Treatment at 7 months OOM 
Dose at 7 months 120mg 
Treatment at 8 months OOM 
Dose at 8 months 120mg 
Treatment at 9 months OOM 
Dose at 9 months 120mg 
Drug at 12 months SIH 
Dose at 12 months 430mg 
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Additional OM at 12 months 30mg 
Drug at 15 months SIH 
Dose at 15 months 460mg 
Additional OM at 15 months 30mg 
Drug at 18 months SIH 
Dose at 18 months 200mg 
Additional OM at 18 months 30mg 
Drug at 21 months SIH 
Dose at 21 months 230mg 
Additional OM at 21 months 30mg 
Drug at 24 months SIH 
Dose at 24 months 460mg 
Additional OM at 24 months 40mg 
Drug at 27 months OM 
Dose at 27 months 150mg 
Drug at 30 months OM 
Dose at 30 months 150mg 
Illicit use through Treatment Yes 
Use of other drugs through Treatment Yes 
IV or IM Both 
Other clinical info 
Participant cited a sarcastic comment 
to staff at reason why he was ejected 
from IOT, notes state over-sedation. 
Diagnosed with Autistic Spectrum 
Condition (ASC) during the trial. 
Drug use at 1 month 
Heroin=16; illicit methadone=4; 
benzodiazepines=1; crack/cocaine=30; 
cannabis=30; alcohol=1 
Drug use at 2 months 
Heroin=9; illicit methadone=3; 
benzodiazepines=1; crack/cocaine=20; 
cannabis=4; alcohol=1 
Drug use at 3 months 
Heroin=8; illicit methadone=8; 
benzodiazepines=4; crack/cocaine=8; 
cannabis=15; alcohol=2 
Drug use at 4 months 
Heroin=12; illicit methadone=7; 
benzodiazepines=2; crack/cocaine=14; 
cannabis=8; alcohol=12 
Drug use at 5 months 
Heroin=9; illicit methadone=5; 
benzodiazepines=4; crack/cocaine=12; 
cannabis=30; alcohol=12 
Drug use at 6 months 
Heroin=8; illicit methadone=6; 
benzodiazepines=2; crack/cocaine=12; 
cannabis=30; alcohol=12 
Drug use at 7 months 
Heroin=30; illicit methadone=12; 
benzodiazepines=4; crack/cocaine=16; 
cannabis=16; alcohol=18 
Drug use at 8 months 
Heroin=28; illicit methadone=8; 
benzodiazepines=1; crack/cocaine=21 
or 27 (difficult to tell which; 
handwriting); cannabis=8; alcohol=7  
Drug use at 9 months 
Heroin=20; crack/cocaine=16; illicit 
methadone=8; benzodiazepines=4; 
cannabis=16; alcohol=3 
Drug use at 12 months 
Heroin=0; crack/cocaine=12; 
cannabis=12 
Drug use at 15 months Missing 





Drug use at 21 months 
Heroin=0; benzodiazepines=1; 
cannabis=1; crack/cocaine=1 








Drug use at 28 months 
Heroin=22; crack/cocaine=18; 
cannabis=8; benzodiazepines=4 






Case note review 19 – ID 19, participant Pam 
File item  
Response 
RIOTT ID 55 
Qualitative ID 19 
Gender Female 
Clinic locality London 
DoB 19/08/1965 
Employment status Sickness benefit 
Parental status 
Baseline data stated 0 – qualitative 
interview revealed participant had 3 
children (living elsewhere) 
Treatment allocation condition SIH 
Treatment trajectory SIH: 24 months; MXL: 12 months 
Treatment discharge status Positive: voluntary move to MXL 
Responder status (6 months) Responder 
Age at interview 48 
Ethnic origin WB 
Drug on trial entry OM 
Treatment episode length 3 years + 
Dose on trial entry 50mg 
How many days injected in the last month 
(baseline) 16 
Injecting heroin Yes 
Other regular use Benzodiazepines 
Age of first use (heroin) 20 
Age first regular use 21 
Age first injected 21 
Age first treatment episode 33 
Number of previous treatment episodes 1 
Number of periods of abstinence 0 
Date participant entered trial 03/09/2007 
Date of qualitative interview 29/08/2013 
Current treatment status MXL (fortnightly prescription) 
Treatment preferences at baseline 1.SIH; 2. SIM; 3. OOM 
Treatment preferences at 3 years 
1.SIH (MXL as number 1); 2. OOM; 3. 
SIM 
Date participant left IOT Moved to MXL at 24 months  
Treatment at 1 month 310mg 
Treatment at 1 month 100mg 
Additional OM at baseline 20mg 
Additional OM at 1 month 40mg 
Treatment at 3 months SIH 
Dose at 3 months 460mg 
Additional OM at 3 months 55mg 
Treatment at 4 months SIH 
Dose at 4 months 590mg 
Additional OM at 4 months 55mg 
Treatment at 5 months SIH 
Dose at 5 months 520mg 
Additional OM at 5 months 55mg 
Treatment at 6 months SIH 
Dose at 6 months 550mg 
Additional OM at 6 months 55ml 
Drug at 12 months SIH 
Dose at 12 months 580mg 
Additional OM at 12 months 55mg 
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Drug at 18 months SIH 
Dose at 18 months 560mg 
Additional OM at 18 months 40mg 
Drug at 21 months SIH 
Dose at 21 months 580mg  
Drug at 36 months MXL 
Dose at 36 months 1000mg 
Illicit use through Treatment Yes 
Use of other drugs through Treatment Yes 
IV or IM Both 
Other clinical info 
Hepatitis C. Service user 
representative 
Drug use at baseline Heroin=20; crack/cocaine=20 (smoked) 
Drug use at 1 month 
Heroin=4; crack/cocaine=12; illicit 
methadone=1;  
Drug use at 2 months 
Heroin=4; crack/cocaine (smoked)=12 
illicit methadone=1 
Drug use at 3 months Heroin=2; crack/cocaine-10 
Drug use at 4 months Heroin=1; crack/cocaine=7 
Drug use at 5 months 
Heroin=2; benzodiazepines=2; 
crack/cocaine=9; 
Drug use at 6 months 
Heroin=1; benzodiazepines=2; 
crack/cocaine=6 
Drug use at 12 months Crack/cocaine=3 
Drug use at 21 months All=0 
Drug use at 24 months All=0 





Case note review 20 – ID 20 – participant Gerry 
File item  
Response 
RIOTT ID 314 
Qualitative ID 20 
Gender Male 
Clinic locality Brighton 
DoB 07/07/1961 
Employment status Unemployed/sickness benefit 
Parental status 0 
Treatment allocation condition SIH 
Treatment trajectory SIH: 36 months 
Treatment discharge status Long-term IOT 
Responder status (6 months) Responder 
Age at interview 52 
Ethnic origin WB 
Drug on trial entry OM 
Treatment episode length 30 months 
Dose on trial entry 90ml 
How many days injected in the last month 
(baseline) 30 
Injecting heroin Yes 
Other regular use 
Benzodiazepines (alcohol and 
crack/cocaine – sporadic use) 
Age first use (heroin) 18 
Age first regular use 21 
Age first injected  18 
Age first treatment episode 20 
Number of previous treatment episodes 10 
Number of periods of abstinence 2 (methadone) 
Date participant entered trial 15/10/2007 
Date of qualitative interview 23/09/2013 
Current treatment status SIH 
Treatment preferences at baseline 1.SIH; 2. SIM; 3. OOM 
Treatment preferences at 3 years 1.SIH; 2. SIM; 3. OOM 
Date participant left IOT 
Retained in long-term IOT (in SIH at 
interview) 
Treatment at 3 months SIH 
Dose at 3 months Missing 
Treatment at 5 months SIH 
Treatment at 6 months SIH 
Dose at 6 months 175mg 
Additional OM at 6 months 50mg 
Drug at 12 months SIH 
Dose at 12 months 175mg 
Additional OM at 12 months 60mg 
Drug at 18 months SIH 
Dose at 18 months 130mg 
Additional OM at 18 months 70mg 
Dose at 24 months 80mg 
Additional OM at 24 months 80mg 
Drug at 36 months SIH 
Dose at 36 months 200mg 
Additional OM at 36 months 140mg 
Illicit use through Treatment Yes (first few months) 
Use of other drugs through Treatment Yes 
IV or IM IV 
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Drug use at baseline 
Heroin=30; crack/cocaine=10; 
alcohol=12 
Drug use at 3 months 
Heroin=15; crack/cocaine=12; 
cannabis=1; alcohol=12 
Drug use at 6 months Cannabis=30; alcohol=10 
Drug use at 12 months Crack/cocaine=7; alcohol=15 
Drug use at 24 months Cannabis=20; alcohol=5 







Case note review 21 – ID 21, participant Shane 
File item  
Response 
RIOTT ID 25 
Qualitative ID 21 
Gender Male 
Clinic locality London 
DoB 09/11/1962 
Employment status Unemployed/sickness benefit 
Parental status 0 
Treatment allocation condition SIM 
Treatment trajectory SIM: 6 months; SIH: 30 months 
Treatment discharge status Long-term IOT 
Responder status (6 months) Non-responder 
Age at interview 51 
Ethnic origin WB 
Drug on trial entry OM 
Treatment episode length 16 years 
Dose on trial entry 70ml 
How many days injected in the last month 
(baseline) 30 
Injecting heroin Yes 
Other regular use Yes 
Age of first use (heroin) 18 
Age first regular use 19 
Age first injected 20 
Age first treatment episode 23 
Number of previous treatment episodes 1 
Number of periods of abstinence 0 (“rehab.”) 
Date participant entered trial 10/05/2006 
Date of qualitative interview 05/08/2013 
Current treatment status SIH 
Treatment preferences at baseline 1.SIH; 2. SIM; 3. OOM 
Treatment preferences at 3 years Missing 
Date participant left IOT Still in IOT at time of interview 
Treatment at baseline SIM 
Dose at baseline 90mg 
Additional OM at baseline 80mg 
Treatment at 2 months SIM 
Dose at 2 months 30mg 
Additional OM at 2 months 30mg 
Treatment at 3 months SIM 
Dose at 3 months 100mg 
Additional OM at 3 months 30mg 
Treatment at 6 months SIM 
Dose at 6 months 120mg 
Additional OM at 6 months 20mg 
Treatment at 10 months SIH 
Dose at 10 months 470mg 
Additional OM at 10 months 50mg 
Drug at 12 months SIH 
Dose at 12 months 520mg 
Additional OM at 12 months 50mg 
Drug at 15 months SIH 
Dose at 15 months 540mg 
Additional OM at 15 months 50mg 
Drug at 18 months SIH 
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Dose at 18 months 540mg 
Additional OM at 18 months 50mg 
Drug at 21 months SIH 
Dose at 21 months 540mg 
Additional OM at 21 months 50mg 
Drug at 26 months SIH 
Drug at 27 months SIH 
Dose at 27 months 540mg 
Additional OM at 27 months 50mg 
Drug at 36 months SIH 
Dose at 36 months 270mg 
Additional MXL at 36 months 390mg 
Drug at 38 months SIH 
Dose at 38 months 540mg 
Additional MXL at 38 months 390mg 
Illicit use through treatment Yes 
Use of other drugs through Treatment Yes 
IV or IM Both 
Drug use at baseline 
Heroin=29; crack/cocaine=29; 
benzodiazepines=12 
Drug use at 2 months 
Heroin=10; crack/cocaine=30; 
benzodiazepines=15; cannabis=4 
Drug use at 3 months 
Heroin=20; crack/cocaine-20; 
cannabis=2 
Drug use at 4 months Heroin=15; crack/cocaine=20 
Drug use at 5 months 
Heroin=10; crack/cocaine=22; 
benzodiazepines=1 
Drug use at 6 months Heroin=5; crack/cocaine=20 
Drug use at 15 months Crack/cocaine=20 
Drug use at 18 months Crack/cocaine=20 (smoked) 
Drug use at 21 months 
Heroin=1; crack/cocaine=25; 
cannabis=2; benzodiazepines=2 
Drug use at 24 months Heroin=1; crack/cocaine=20 
Drug use at 27 months Crack/cocaine=12; cannabis=1 
Drug use at 28 months Heroin=2; crack/cocaine=20 




Case note review 22 – ID 22, participant Ellie 
File item  
Response 
RIOTT ID 65 
Qualitative ID 22 
Gender Female 
Clinic locality 20/06/1972 
DoB 
Unemployed/sickness benefit 
(baseline) / University course (at time 
of interview) 
Employment status 0 
Parental status SIH 
Treatment allocation condition SIH: 36 months (and post-trial) 
Treatment trajectory Positive: voluntary move to MXL 
Treatment discharge status Responder 
Responder status (6 months) 41 
Age at interview WB 
Ethnic origin OM 
Drug on trial entry 12 months 
Treatment episode length 60ml 
Dose on trial entry 16 
How many days injected in the last month 
(baseline) Yes 
Injecting heroin Alcohol and crack/cocaine 
Other regular use 17 
Age of first use (heroin) 27 
Date participant entered trial 30 
Date of qualitative interview 32 
Current treatment status 8 
Treatment preferences at baseline 3 
Treatment preferences at 3 years 04/06/2008 
Date participant left IOT 03/10/2013 
Treatment at 3 months MXL (fortnightly subscription) 
Dose at 3 months 1.SIH; 2/3: SIM and OM (can’t choose) 
Treatment at 5 months 1.SIH; 2. SIM; 3. OOM 
Dose at 5 months Post-RIOTT 
Treatment at 6 months SIH 
Dose at 6 months 420mg 
Additional OM at 6 months 60mg 
Drug at 12 months SIH 
Dose at 12 months 400mg 
Additional OM at 12 months 450mg 
Drug at 15 months SIH 
Dose at 15 months 400mg 
Additional MXL at 15 months 450mg 
Drug at 18 months SIH 
Dose at 18 months 220mg 
Additional MXL at 18 months 700mg 
Drug at 24 months SIH 
Dose at 24 months 200mg 
Additional MXL at 24 months 600mg 
Drug at 36 months SIH 
Dose at 36 months 160 
Additional MXL at 36 months 700 
Illicit use through Treatment Yes 
Use of other drugs through Treatment Yes 
IV or IM Both 
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Other clinical info 
Partner also on the trial, and 
interviewed 
Drug use at baseline 
Heroin=26; crack/cocaine=26; 
cannabis=1; alcohol=30 
Drug use at 3 months Heroin=2; codeine=3; alcohol=12 
Drug use at 6 months Heroin=1; crack/cocaine=1; alcohol=7 
Drug use at 12 months Alcohol=6 
Drug use at 15 months All=0 
Drug use at 24 months Alcohol=19 





Case note review 23 – ID 23, participant Andy 
File item  
Response 
RIOTT ID 49 
Qualitative ID 23 
Gender Male 
Clinic locality London 
DoB 09/02/1975 
Employment status Unemployed/sickness benefit 
Parental status 0 
Treatment allocation condition OOM 
Treatment trajectory 
OOM: 6 months; SIH: 6 months; MXL: 
12 months (and post-RIOTT – time of 
interviewing) 
Treatment discharge status Positive: voluntary move to MXL 
Responder status (6 months) Non-responder 
Age at interview 38 
Ethnic origin WB 
Drug on trial entry OM 
Treatment episode length 8 months (this episode) 
Dose on trial entry 40ml 
How many days injected in the last month 
(baseline) 22 
Injecting heroin Yes 
Other regular use Crack/cocaine; alcohol and cannabis 
Age of first use (heroin) 15 
Age first regular 23 
Age first injected 25 
Age first treatment episode 27 
Number of previous treatment episodes 6 
Number of periods of abstinence 0 
Date participant entered trial 24/04/2007 
Date of qualitative interview 03/10/2013 
Current treatment status MXL 
Treatment preferences at baseline 1.SIH; 2. SIM; 3. OOM 
Treatment preferences at 3 years Missing 
Date participant left IOT 
Transferred to MXL at 2 years (data 
collection date:  
Treatment at 1 month OM 
 90mg 
Treatment at 2 months OM 
Dose at 2 months 90mg 
Treatment at 3 months OOM 
Dose at 3 months 100mg 
Treatment at 4 months OOM 
Dose at 4 months 50mg 
Treatment at 5 months OOM 
Dose at 5 months 50ml 
Treatment at 6 months OOM 
Dose at 6 months 60mg 
Treatment at 9 months 400mg 
Additional OM at 9 months 55mg 
Drug at 12 months SIH 
Dose at 12 months 300mg 
Additional OM at 12 months 50ml 
Drug at 15 months SIH 
Dose at 15 months 270 
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Additional OM at 15 months 50ml 
Drug at 24 months MXL 
Dose at 24 months 780mg 
Drug at 36 months MXL 
Dose at 36 months 650mg 
Illicit use through Treatment Yes 
Use of other drugs through Treatment Yes 
Other clinical info 
Partner also in RIOTT trial, and was 
interviewed 
Drug use at baseline 
Heroin=20; crack/cocaine=10; 
cannabis=4; alcohol=30 
Drug use at 1 month 
Heroin=25; crack/cocaine=6; 
cannabis=3; alcohol=30 
Drug use at 2 months 
Heroin=20; crack/cocaine=4; 
cannabis=2; alcohol=30 
Drug use at 3 months 
Heroin=16; crack/cocaine=5; 
cannabis=2; alcohol=30 
Drug use at 4 months 
Heroin=12; crack/cocaine=5; 
cannabis=2; alcohol=30 
Drug use at 5 months 
Heroin=20; crack/cocaine=8; 
cannabis=2 
Drug use at 6 months 
Heroin=16; crack/cocaine=4; 
cannabis=8; alcohol=2 
Drug use at 9 months 
Heroin=5; crack/cocaine=2; 
cannabis=3 
Drug use at 12 months All=0 
Drug use at 15 months All=0 
Drug use at 24 months Cannabis=7 





Case note review 24 – ID 24, participant Trevor 
File item  
Response 
RIOTT ID 33 
Qualitative ID 24 
Gender Male 
Clinic locality London 
DoB 07/08/1968 
Employment status Unemployed/sickness benefit 
Parental status 2 (live elsewhere) 
Treatment allocation condition OOM 
Treatment trajectory OOM: 6 months; SIH: 24 months 
Treatment discharge status 
Negative (compulsory discharge; 
benzodiazepine use) 
Responder status (6 months) Non-responder 
Age at interview 45 
Ethnic origin WI 
Drug on trial entry OM 
Treatment episode length 24 months 
Dose on trial entry 125ml 
How many days injected in the last month 
(baseline) 21 
Injecting heroin Yes 
Other regular use 
Crack/cocaine, benzodiazepines and 
alcohol 
Age of first use (heroin) 14 
Age first regular use 15 
Age first injected 14 
Age first treatment 17 
Number of previous treatment episodes 5 
Number of periods of abstinence 0 
Date participant entered trial 04/07/2006 
Date of qualitative interview 08/10/2013 
Current treatment status OM 
Treatment preferences at baseline 1.SIH; 2. OOM; 3. SIM 
Treatment preferences at 5 years 1.SIH; 2. SIM; 3. OOM 
Date participant left IOT 
Last data collected at 21 months 
(08/05/2008) 
Treatment at 1 month OOM 
Dose at 1 month 150mg 
Treatment use at 2 months OOM 
Dose at 2 months 150mg  
Treatment at 3 months OOM 
Dose at 3 months 150mg (once a day) 
Treatment at 4 months OOM 
Dose at 4 months 150mg 
Additional OM at 4 months 160mg 
Treatment at 5 months OM 
Dose at 5 months 170mg (once a day) 
Treatment at 6 months OOM 
Dose at 6 months 130mg 
Additional OM at 6 months 40mg 
Drug at 9 months SIH 
Dose at 9 months 150mg 
Additional OM at 9 months 50mg 
Drug at 10 months SIH 
Dose at 10 months 560mg 
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Additional OM at 10 months 50mg 
Drug at 12 months SIH 
Dose at 12 months 500mg 
Drug at 15 months SIH 
Dose at 15 months 560mg 
Additional OM at 15 months 50mg 
Drug at 18 months SIH 
Dose at 18 months 560mg 
Additional OM at 18 months 50mg 
Drug at 21 months SIH 
Dose at 21 months 580mg 
Additional OM at 21 months 50mg 
Drug at 5 years OM 
Illicit use through Treatment Yes 
Use of other drugs through Treatment Yes 
IV or IM Both 
Other clinical info 
Hep C and DVT. Groin injecting during 
IOT. 
Drug use at baseline 
Heroin=28; illicit methadone=4; 
crack/cocaine=5; benzodiazepines=2; 
alcohol=15 
Drug use at 1 month 
Heroin=30; crack/cocaine=15; 
benzodiazepines=2; alcohol=20 
Drug use at 2 months 
Heroin=30; illicit methadone=5; 
tramadol=2; crack/cocaine=20; 
benzodiazepines=2; alcohol=12 
Drug use at 3 months 
Heroin=28; crack/cocaine=16; 
benzodiazepines=2; alcohol=20 
Drug use at 4 months 
Heroin=30; crack/cocaine=15; 
benzodiazepines=3; alcohol=yes 
(number of days unclear/amounts 
listed) 
Drug use at 5 months 
Heroin=26; illicit methadone= 2; 
crack/cocaine=18; benzodiazepines=2; 
alcohol=20 
Drug use at 6 months 
Heroin=25; crack/cocaine=20; 
alcohol=30 
Drug use at 9 months 
Heroin=3; crack/cocaine=3; 
benzodiazepines=3; alcohol=16 
Drug use at 10 months 
Heroin=3; crack/cocaine=3; 
benzodiazepines=2; alcohol=30 
Drug use at 15 months Crack/cocaine=4 
Drug use at 18 months 
Heroin=1; crack/cocaine=1; 
benzodiazepines=2; alcohol=30 
Drug use at 21 months Crack/cocaine=4; alcohol=30 
Drug use at 35 months Alcohol=30 





Case note review 25 – ID 25, participant Iain 
File item  
Response 
RIOTT ID 32 
Qualitative ID 25 
Gender Male 
Clinic locality London 
DoB 05/07/1964 
Employment status Unemployed/sickness benefit 
Parental status 0 
Treatment allocation condition SIM 
Treatment trajectory SIM: 6 months; OM: 12 months 
Treatment discharge status 
Positive: voluntary move to OM 
(declined SIH) 
Responder status (6 months) Non-responder 
Age at interview 49 
Ethnic origin WB 
Drug on trial entry OM 
Treatment episode length 24 months 
Dose on trial entry 60ml 
How many days injected in the last month 
(baseline) 25 
Injecting heroin Yes 
Other regular use Crack/cocaine 
Age of first use (heroin) 16 
Age first regular use 16 
Age first injected 16 
Age first treatment episode 18 
Number of previous treatment episodes 5 
Number of periods of abstinence 1 (detox) 
Date participant entered trial 02/06/2006 
Date of qualitative interview 10/03/2013 
Current treatment status OM 
Treatment preferences at baseline 1.SIH; 2. OOM; 3. SIM 
Treatment preferences at 6 months 1.OOM (“doesn’t want any injectables”) 
Date participant left IOT 20/12/2006 (transferred to OOM) 
Treatment at baseline SIM 
Dose at baseline 80mg 
Additional OM at baseline 120mg 
Treatment at 1 month 100mg 
Additional OM at 1 month 10mg 
Treatment at 2 months SIM 
Dose at 2 months 100mg 
Additional OM at 2 months 40mg 
Treatment at 3 months SIM 
Dose at 3 months 100mg 
Additional OM at 3 months 30mg 
Treatment at 4 months SIM 
Additional OM at 4 months 30mg 
Treatment at 5 months SIM 
Dose at 5 months 100mg 
Additional OM at 5 months 30mg 
Treatment at 6 months SIM 
Dose at 6 months 100mg 
Additional OM at 6 months 30mg 
Drug at 24 months OM 
Dose at 24 months 115mg 
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Drug at 36 months OM 
Dose at 36 months 115mg 
Illicit use through Treatment Yes 
Use of other drugs through Treatment Yes 
IV or IM Both 
Drug use at 1 month 
Heroin=20; crack/cocaine=20; 
cannabis=4; alcohol=15 
Drug use at 2 months 
Heroin=20; crack/cocaine=20; 
cannabis=2; alcohol=20 
Drug use at 3 months 
Heroin=10; crack/cocaine=10; 
cannabis=3; alcohol=25 
Drug use at 4 months 
Heroin=4; dihydrocodeine tablets=7; 
crack/cocaine=25; alcohol=30 
Drug use at 5 months 
Heroin=2; crack/cocaine=25; 
cannabis=1; alcohol=30 
Drug use at 6 months 
Heroin=3; crack/cocaine=20; 
cannabis=3; alcohol=30 





Case note review 26 – ID 26, participant Jason 
File item  
Response 
RIOTT ID 61 
Qualitative ID 26 
Gender Male 
Clinic locality London 
DoB 02/05/1970 
Employment status Unemployed/sickness benefit 
Parental status 0 
Treatment allocation condition OOM 
Treatment trajectory OOM: 18 months; SIH: 18 months 
Treatment discharge status 
Negative: compulsory; ongoing crack 
use 
Responder status (6 months) Responder 
Age at interview 43 
Ethnic origin Black British, Caribbean 
Drug on trial entry OM 
Treatment episode length 11 months 
Dose on trial entry 35mg 
How many days injected in the last month 
(baseline) Missing 
Injecting heroin Yes 
Other regular use 
Crack/cocaine; alcohol; 
benzodiazepines (prescribed) 
Age of first use (heroin) 21 
Age first regular use 27 
Age first injected 27 
Age first treatment episode 28 
Number of previous treatment episodes 18 
Number of periods of abstinence 0 
Date participant entered trial 27/02/2008 
Date of qualitative interview 17/10/2013 
Current treatment status OM 
Treatment preferences at baseline 1.SIH; 2. SIM; 3. OOM 
Treatment preferences at 3 years Missing 
Date participant left IOT 
Last data collected at 2 years 
(07/03/2010) 
Treatment at baseline OOM 
Dose at baseline 115mg 
Treatment at 2 months OOM 
Dose at 2 months 85mg 
Treatment at 3 months OOM 
Dose at 3 months 85mg 
Treatment at 6 months OOM 
Dose at 6 months 100 
Drug at 12 months SIH 
Dose at 12 months 300mg 
Additional MXL at 12 months 300mg 
Drug at 18 months SIH 
Dose at 18 months 100mg 
Drug at 24 months SIH 
Dose at 24 months 240mg 
Drug at 36 months OM 
Dose at 36 months 85mg 
Illicit use through treatment Yes 
Use of other drugs through treatment Yes 
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Other clinical info Hospitalised during trial. 
Drug use at baseline 
Heroin=30; illicit methadone=2; 
crack/cocaine=30; benzodiazepines=1; 
cannabis=2; alcohol=2 
Drug use at 1 month 
Heroin=12; crack/cocaine=15; 
benzodiazepines=30; MDMA=1 
Drug use at 2 months Missing data - hospitalised 




Drug use at 6 months 
Heroin=3; illicit methadone=2; 
crack/cocaine=1; alcohol=3 
Drug use at 12 months 
Crack/cocaine=20; cannabis=2; 
alcohol=8 
Drug use at 24 months Heroin=0; cannabis=17; alcohol=10 





Case note review 27 – ID 27, participant Ron 
File item  
Response 
RIOTT ID 21 
Qualitative ID 27 
Gender Male 
Clinic locality London 
DoB 30/12/1964 
Employment status Unemployed/sickness benefit 
Parental status 0 
Treatment allocation condition SIM 
Treatment trajectory SIM: 6 months; SIH: 36 months 
Treatment discharge status Long-term IOT 
Responder status (6 months) Non-responder 
Age at interview 49 
Ethnic origin WB 
Drug on trial entry OM 
Treatment episode length 9 months 
Dose on trial entry 35ml 
How many days injected in the last month 
(baseline) 15 
Injecting heroin Yes 
Other regular use Crack/cocaine (2 times in last month) 
Age of first use (heroin) 30 
Age first regular use 36 
Age first injected 36 
Age first treatment Not known 
Number of previous treatment episodes 0 
Number of periods of abstinence 0 
Date participant entered trial 27/02/2006 
Date of qualitative interview 09/08/2013 
Current treatment status SIH 
Treatment preferences at baseline 1.SIH; 2. SIM; 3. OOM 
Treatment preferences at 4 years 1.SIH; 2. SIM; 3. OOM 
Date participant left IOT 
Retained in IOT – in SIH at time of 
interview 
Treatment at 2 months SIM 
Dose at 2 months 100mg 
Additional OM at 2 months 50mg 
Treatment at 3 months SIM 
Dose at 3 months 100mg 
Additional OM at 3 months 50mg 
Treatment at 4 months SIM 
Dose at 4 months 50mg 
Additional OM at 4 months 50mg 
Treatment at 5 months SIM 
Dose at 5 months 50mg 
Additional OM at 5 months 100mg 
Treatment at 6 months SIM 
Dose at 6 months 50mg 
Additional OM at 6 months 100mg 
Treatment at 9 months SIH 
Dose at 9 months 400 
Drug at 12 months SIH 
Dose at 12 months 200mg 
Additional OM at 12 months 50mg 
Drug at 15 months SIH 
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Dose at 15 months 200mg 
Additional OM at 15 months 50mg 
Drug at 18 months SIH 
Dose at 18 months 200mg 
Additional OM at 18 months 50mg 
Drug at 21 months SIH 
Dose at 21 months 235mg 
Additional OM at 21 months 50mg 
Drug at 24 months SIH 
Dose at 24 months 235mg 
Additional OM at 24 months 50ml 
Drug at 27 months SIH 
Additional OM at 27 months 235 
Additional MXL at 27 months Dose missing 
Drug at 28 months SIH 
Drug at 36 months SIH 
Dose at 36 months 210mg (once a day, since 18 months) 
Additional MXL at 36 months 300mg 
Drug at 41 months SIM 
Dose at 41 months 230mg 
Additional MXL at 42 months 300mg 
Drug at 48 months SIH and MXL – doses not recorded 
Illicit use through Treatment Yes 
Use of other drugs through Treatment Yes 
IV or IM Both 
Other clinical info 
Low mood at referral – in counselling 
treatment 
Drug use at 1 month Heroin=28; crack/cocaine=20 
Drug use at 2 months 
Heroin=28; crack/cocaine=20; codeine 
tablet=1 
Drug use at 3 months Heroin=20; crack/cocaine=15 
Drug use at 4 months 
Heroin=28; crack/cocaine=24; 
alcohol=1 
Drug use at 5 months Heroin=28; crack/cocaine=20 
Drug use at 6 months Heroin=25; crack/cocaine=25 
Drug use at 9 months Heroin=2; crack/cocaine=2 
Drug use at 12 months Heroin=2; crack/cocaine=2 
Drug use at 18 months Heroin=2; crack/cocaine=2 
Drug use at 21 months Heroin=2; crack/cocaine=2 
Drug use at 24 months Heroin=2; crack/cocaine=2 
Drug use at 27 months All=0 
Drug use at 28 months All=0 
Drug use at 36 months All=0 
Drug use at 41 months All=0 





Case note review 28 – ID 28, participant Robert 
File item  
Response 
RIOTT ID 227 
Qualitative ID 28 
Gender Male 
Clinic locality Darlington 
DoB 30/03/1978 
Employment status Unemployed/sickness benefit 
Parental status 1 (lives elsewhere) 
Treatment allocation condition SIH 
Treatment trajectory 
SIH: 36 months (with an 8 week period 
on SIM according to notes) 
Treatment discharge status IOT clinic closure 
Responder status (6 months) Responder 
Age at interview 35 
Ethnic origin WB 
Drug on trial entry OM 
Treatment episode length 3.5 years 
Dose on trial entry 40ml 
How many days injected in the last month 
(baseline) 30 (2-5 times per day) 
Injecting heroin Yes 
Other regular use Benzodiazepines 
Age of first use (heroin) 16 
Age first regular use 17 
Age first injected 20 
Age first treatment episode 21 
Number of previous treatment episodes 5 
Number of periods of abstinence 0 
Date participant entered trial 23/11/2006 
Date of qualitative interview 02/12/2013 
Current treatment status OM 
Treatment preferences at baseline 1.SIH; 2. SIM; 3. OOM 
Treatment preferences at 3 years 1.SIM; 2. OOM; 3. SIH 
Date participant left IOT 
Last data collected at 3 years 
(02/06/2010) 
Drug at baseline SIH 
Dose at baseline 120mg 
Additional OM at baseline 20mg 
Treatment at 3 months SIH 
Dose at 3 months 500mg 
Additional OM at 3 months 55mg 
Treatment at 6 months SIH 
Dose at 6 months 230mg 
Additional OM at 6 months 55mg 
Drug at 12 months SIH 
Dose at 12 months 230mg 
Additional OM at 12 months 75mg 
Drug at 18 months SIH 
Dose at 18 months 110mg 
Additional OM at 18 months 55mg 
Drug at 24 months SIH 
Dose at 24 months 220mg 
Additional OM at 24 months 75mg 
Drug at 36 months SIH 
Dose at 36 months Missing 
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Illicit use through Treatment Yes 
Use of other drugs through Treatment Yes 
IV or IM IV 
Other clinical info Diagnosis of depression 
Drug use at baseline 
Heroin=30; crack/cocaine=2; illicit 
methadone=2; cannabis=2 
Drug use at 3 months 
Heroin=2; crack/cocaine=2; 
cannabis=3 
Drug use at 6 months Crack/cocaine=1; cannabis=15 
Drug use at 9 months Crack/cocaine=1; cannabis=4 
Drug use at 12 months Cannabis=15 





Case note review 29 – ID 29, participant Rita 
File item  
Response 
RIOTT ID 220 
Qualitative ID 29 
Gender Female 
Clinic locality Darlington 
DoB 24/09/1959 
Employment status Unemployed/sickness benefit 
Parental status 0 
Treatment allocation condition SIM 
Treatment trajectory SIM: 12 months; OOM: 24 months 
Responder status (6 months) Non-responder 
Treatment discharge status 
Negative; ejected (violations of protocol 
– tried to take some IOT home) 
Age at interview 54 
Ethnic origin WB 
Drug on trial entry OM 
Treatment episode length 2.5 years 
Dose on trial entry 75mg 
How many days injected in the last month 
(baseline) 30 
Injecting heroin Yes 
Other regular use Cannabis 
Age of first use (heroin) 40 
Age first regular use 40 
Age first injected 40 
Age first treatment episode 41 
Number of previous treatment episodes 3 (detox and methadone) 
Number of periods of abstinence 0 
Date participant entered trial 21/09/2006 
Date of qualitative interview 03/12/2013 
Current treatment status OM 
Treatment preferences at baseline 1.OOM; 2. SIH; 3. SIM 
Treatment preferences at 3 years 1.OOM; 2. SIM; 3. SIH 
Date participant left IOT 
Last data collected at 3 years 
(21/04/2010) 
Treatment at baseline SIM 
Dose at baseline 60mg 
Treatment at 3 months SIM 
Dose at 3 months 60mg 
Treatment at 6 months SIM 
Dose at 6 months 50mg 
Drug at 12 months SIM 
Dose at 12 months 90mg 
Drug at 18 months SIM 
Dose at 18 months 90mg 
Drug at 24 months OOM 
Dose at 24 months 90ml 
Drug at 36 months OOM 
Dose at 36 months 90mg 
Illicit use through Treatment Yes 
Use of other drugs through Treatment 
Yes (cannabis – NB. According to clinic 
staff and clinicians there is no crack 
available in Darlington) 
IV or IM IM 
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Other clinical info 
Diagnosis of depression and 
prescribed antidepressants 
Drug use at baseline Heroin=21; cannabis=17 
Drug use at 1 month Heroin=15 
Drug use at 2 months Heroin=19 
Drug use at 3 months Heroin=24 
Drug use at 4 months Heroin=12 
Drug use at 5 months Heroin=6 
Drug use at 6 months Heroin=12 
Drug use at 24 months Heroin=6 





Case note review 30 – ID 30, participant Wayne 
File item  
Response 
RIOTT ID 208 
Qualitative ID 30 
Gender Male 
Clinic locality Darlington 
DoB 06/05/1966 
Employment status Unemployed/sickness benefit 
Parental status 1 (lives elsewhere) 
Treatment allocation condition SIM 
Treatment trajectory SIM: 24 months; SIH: 12 months 
Treatment discharge status IOT clinic closure 
Responder status (6 months) Responder 
Age at interview 47 
Ethnic origin WB 
Drug on trial entry OM 
Treatment episode length 24 months 
Dose on trial entry 40mg 
How many days injected in the last month 
(baseline) 15 
Injecting heroin Yes 
Other regular use Cannabis 
Age of first use (heroin) 18 
Age first regular use 18 
Age first injected  
17 (scored as 17, presume another 
drug was injected prior to heroin use) 
Age first treatment episode 25 
Number of previous treatment episodes 3 
Number of periods of abstinence 0 
Date participant entered trial 08/05/2007 
Date of qualitative interview 03/12/2013 
Current treatment status OM 
Treatment preferences at baseline 1.SIH; 2. SIM; 3. OOM 
Treatment preferences at 2 years 1.SIM; 2. SIH; 3. OOM 
Date participant left IOT Data recorded up to 3 years (2010) 
Treatment at baseline SIM 
Dose at baseline 80 
Treatment at 3 months SIM 
Dose at 3 months 150 
Treatment at 6 months SIM 
Dose at 6 months 120 
Drug at 12 months SIM 
Dose at 12 months 150 
Additional OM at 12 months 40 
Dose at 18 months 150 
Additional OM at 18 months 170 
Drug at 24 months SIM  
Dose at 24 months 90mg 
Drug at 29 months SIM 
Dose at 29 months 90mg 
Illicit use through Treatment Yes 
Use of other drugs through Treatment Yes 
IV or IM IV 
Other clinical info Incarcerated briefly during RIOTT 





Drug use at 2 months Heroin=5; amphetamine=30 
Drug use at 3 months Heroin=3; amphetamines=30 
Drug use at 4 months Amphetamine=10 
Drug use at 5 months 
Incarcerated briefly – stated ‘very little 
use’. 
Drug use at 6 months Cannabis=3 
Drug use at 8 months Amphetamines=10 
Drug use at 10 months All=0 
Drug use at 24 months Cannabis=1 





Case note review 31 – ID 31, participant Wes 
File item  
Response 
RIOTT ID 209 
Qualitative ID 31 
Gender Male 
Clinic locality Darlington 
DoB 09/04/1974 
Employment status Unemployed/sickness benefit 
Parental status 0 
Treatment allocation condition SIH 
Treatment trajectory SIH: 24 months; OOM: 12 months 
Treatment discharge status IOT clinic closure 
Responder status (6 months) Responder 
Age at interview 39 
Ethnic origin WB 
Drug on trial entry OM 
Treatment episode length 6 months 
Dose on trial entry 50mg 
How many days injected in the last month 
(baseline) 30 
Injecting heroin Yes 
Other regular use 
Alcohol; cannabis (NB. Amphetamines 
not included as an option on the 
referral form) 
Age of first use (heroin) 21 
Age first regular use 21 
Age first injected 21 
Age first treatment episode 23 
Number of previous treatment episodes 3 
Number of periods of abstinence 1 
Date participant entered trial 31/05/2007 
Date of qualitative interview 02/12/2013 
Current treatment status OM 
Treatment preferences at baseline 1.SIH; 2. SIM; 3. OOM 
Treatment preferences at 3 years Missing 
Date participant left IOT Data missing 
Treatment at baseline SIH 
Dose at baseline 200mg 
Additional OM at baseline 25mg 
Treatment at 3 months SIH 
Dose at 3 months 400 
Additional OM at 3 months 40 
Treatment at 6 months SIH 
Dose at 6 months 200mg 
Additional OM at 6 months 65mg 
Drug at 12 months SIH 
Dose at 12 months 30mg 
Drug at 18 months SIH 
Dose at 18 months 30mg 
Drug at 24 months OOM 
Dose at 24 months 40mg 
Drug at 36 months OOM 
Dose at 36 months Missing 
Illicit use through Treatment No 
Use of other drugs through Treatment Yes 
IV or IM IV 
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Drug use at 3 months 
Benzodiazepines=12; cannabis=30; 
alcohol=30 





Case note review 32 – ID 32, participant Susie 
File item  
Response 
RIOTT ID 241 
Qualitative ID 32 
Gender Female 
Clinic locality Darlington 
DoB 17/03/1977 
Employment status Unemployed/sickness benefit 
Parental status 0 
Treatment allocation condition OOM 
Treatment trajectory OOM: 6 months; SIH: 18 months 
Treatment discharge status 
Negative: ejected (continued illicit use 
– which the participant claimed were 
false positive UDS results during 
qualitative interview) 
Responder status (6 months) Non-responder 
Age at interview 36 
Ethnic origin WB 
Drug on trial entry OM 
Treatment episode length “Years” 
Dose on trial entry 40mg 
How many days injected in the last month 
(baseline) 28 
Injecting heroin Yes 
Other regular use Benzodiazepines 
Age of first use (heroin) 21 
Age first regular use 21 
Age first injected 25 
Age first treatment episode 25 
Number of previous treatment episodes 3 
Number of previous periods of abstinence 0 
Date participant entered trial 27/03/2008 
Date of qualitative interview 05/12/2013 
Current treatment status OM 
Treatment preferences at baseline 1.SIH; 2. SIM; 3. OOM 
Treatment preferences at 2 years 1.SIH; 2. SIM; 3. OOM 
Date participant left IOT 
Last data collected at 24 months 
(undated) 
Treatment at baseline OOM 
Dose at baseline 80mg 
Treatment at 3 months OOM 
Dose at 3 months 100mg 
Treatment at 6 months OOM 
Dose at 6 months 120mg 
Drug at 12 months SIH 
Dose at 12 months 470 
Additional OM at 12 months 40mg 
Drug at 18 months SIH 
Dose at 18 months 230mg 
Additional OM at 18 months 40mg 
Drug at 24 months SIH 
Dose at 24 months 470mg 
Additional OM at 24 months 40ml 
Illicit use through Treatment Yes 
Use of other drugs through Treatment 




IV or IM Missing 
Drug use at baseline Heroin=29 
Drug use at 3 months Heroin=20; benzodiazepines=1 
Drug use at 6 months Heroin=30 




Case note review 33 – ID 33, participant Kevin 
File item  
Response 
RIOTT ID 242 
Qualitative ID 33 
Gender Male 
Clinic locality Darlington 
DoB 19/04/1973 
Employment status Unemployed/sickness benefit 
Parental status 1 (lives elsewhere) 
Treatment allocation condition SIH 
Treatment trajectory SIH: 24 months 
Treatment discharge status IOT clinic closure 
Responder status (6 months) Responder 
Age at interview 40 
Ethnic origin WB 
Drug on trial entry OM 
Treatment episode length “Years” 
Dose on trial entry 50mg/ml 
How many days injected in the last month 
(baseline) 30 
Injecting heroin Yes 
Other regular use None 
Age of first use (heroin) 15 
Age first regular use 21 
Age first injected 15 
Age first treatment episode 29 
Number of previous treatment episodes 2 
Number of periods of abstinence 0 
Date participant entered trial 01/07/2008 
Date of qualitative interview 05/12/2013 
Current treatment status OM 
Treatment preferences at baseline 1.SIH; 2. SIM; 3. OOM 
Treatment preferences at 2 years 1.SIH; 2. SIM; 3. OOM 
Date participant left IOT 
Last data collected at 2 years 
(13/10/2010) 
Treatment at baseline SIH 
Dose at baseline 80mg 
Additional OM at baseline 80mg 
Treatment at 3 months SIH 
Dose at 3 months 680mg 
Additional OM at 3 months 40mg 
Treatment at 6 months SIH 
Dose at 6 months 340mg 
Additional OM at 6 months 40mg 
Drug at 12 months SIH 
Dose at 12 months 640mg 
Additional OM at 12 months 40ml 
Drug at 18 months SIH 
Dose at 18 months 360mg 
Additional OM at 18 months 35mg 
Drug at 24 months SIH 
Dose at 24 months 360mg 
Additional OM at 24 months 35mg 
Illicit use through Treatment No (only once, at 3 months) 
Use of other drugs through Treatment No 
IV or IM Both 
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Drug use at 3 months Heroin=1;  
Drug use at 6 months All=0 
Drug use at 12 months All=0 
Drug use at 24 months All=0 
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Case note review 34 – ID 34, participant Richard 
File item  
Response 
RIOTT ID 237 
Qualitative ID 34 
Gender Male 
Clinic locality Darlington 
DoB 01/06/1969 
Employment status Unemployed/sickness benefit 
Parental status 1 (lives with participant) 
Treatment allocation condition SIM 
Treatment trajectory 
SIM: 12 months; SIH: 6 months; OOM: 
6 months 
Treatment discharge status Negative; ejected – Valium use 
Responder status (6 months) Responder 
Age at interview 44 
Ethnic origin WB 
Drug on trial entry OM 
Treatment episode length Missing 
Dose on trial entry 110mg 
How many days injected in the last month 
(baseline) 30 
Injecting heroin Yes 
Other regular use Benzodiazepines 
Age of first use (heroin) 25 
Age first regular use 25 
Age first injected 28 
Age first treatment episode 3 
Number of previous treatment episodes 3 
Number of periods of abstinence 0 
Date participant entered trial 07/02/2008 
Date of qualitative interview 05/12/2013 
Current treatment status OM 
Treatment preferences at baseline 1.SIH; 2. SIM; 3. OOM 
Treatment preferences at 2 years 1.SIH; 2. SIM; 3. OOM 
Date participant left IOT 
Last data collected at 2 years 
(24/03/2010) 
Treatment at baseline SIM 
Dose at baseline 100mg 
Treatment at 3 months SIM 
Dose at 3 months 170mg 
Treatment at 6 months SIM 
Dose at 6 months 150mg 
Drug at 12 months SIH 
Dose at 12 months 300mg 
Additional OM at 12 months 40mg 
Drug at 18 months OOM 
Dose at 18 months 95mg 
Drug at 24 months SIM 
Dose at 24 months Missing 
Drug at 36 months Missing 
Dose at 36 months Missing 
Illicit use through Treatment Yes 
Use of other drugs through Treatment Yes 
IV or IM Both 





Drug use at 1 month 
Heroin=15; crack/cocaine=3; 
cannabis=3; amphetamine=2 
Drug use at 2 months 
Heroin=8; benzodiazepines=6; 
crack/cocaine=4; cannabis=24 
Drug use at 3 months Heroin=1; crack/cocaine=2; alcohol=10 
Drug use at 4 months 
Heroin=4; benzodiazepines=5; 
crack/cocaine=1; cannabis=20 
Drug use at 5 months 
Heroin=1; benzodiazepines=2; 
cannabis=10; alcohol=20 
Drug use at 6 months 
Benzodiazepines=2; cannabis=30; 
alcohol=10 
Drug use at 24 months 





Case note review 35 – ID 35, participant Scott 
File item  
Response 
RIOTT ID 54 
Qualitative ID 35 
Gender Male 
Clinic locality London 
DoB 17/07/1970 
Employment status Unemployed/sickness benefits 
Parental status 0 
Treatment allocation condition OOM 
Treatment trajectory OOM: 3 months; SIH: 30 months 
Treatment discharge status Long-term IOT 
Responder status (6 months) Non-responder 
Age at interview 43 
Ethnic origin WB 
Drug on trial entry OM 
Treatment episode length 1 month (previous was 18 months) 
Dose on trial entry 65mg 
How many days injected in the last month 
(baseline) 30 
Injecting heroin Yes 
Other regular use Crack/cocaine 
Age of first use (heroin) 16 
Age first regular use 16 
Age first injected 30 
Age first treatment episode 22 
Number of previous treatment episodes 1 
Number of periods of abstinence 0 
Date participant entered trial 07/01/2007 
Date of qualitative interview 23/09/2013 
Current treatment status SIH 
Treatment preferences at baseline 1.SIH; 2. SIM; 3. OOM 
Treatment preferences at 3 years Missing 
Date participant left IOT 
Retained in IOT – in IOT at time of 
interview 
Treatment at 1 month OOM 
Dose at 1 month 120mg 
Treatment at 3 months OOM 
Dose at 3 months 130mg 
Treatment at 4 months OOM 
Dose at 4 months 130mg 
Treatment at 5 months OOM 
Dose at 5 months 90mg 
Treatment at 6 months OOM 
Dose at 6 months 130mg 
Treatment at 9 months SIH 
Dose at 9 months 460mg 
Additional MXL at 9 months 400mg 
Drug at 12 months SIH 
Dose at 12 months 500mg 
Additional MXL at 12 months 500mg 
Drug at 21 months SIH 
Dose at 21 months 410mg 
Additional OM at 21 months 45mg 
Drug at 24 months SIH 
Dose at 24 months 410mg 
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Additional MXL at 24 months 500mg 
Illicit use through Treatment Yes 
Use of other drugs through Treatment Yes 
Drug use at 1 month Heroin=17; crack/cocaine=10 
Drug use at 3 months Heroin=15; crack/cocaine=10 
Drug use at 4 months Heroin=16; crack/cocaine=8 
Drug use at 5 months 
Heroin=15; crack/cocaine=8; 
benzodiazepines=3 
Drug use at 6 months Heroin=16; crack/cocaine=8 
Drug use at 9 months Heroin=5; crack/cocaine=8 
Drug use at 12 months All=0 
Drug use at 21 months Alcohol=7 
Drug use at 24 months All=0 





Case note review 36 – ID 36, participant Lee 
File item  
Response 
RIOTT ID 19 
Qualitative ID 36 
Gender Male 
Clinic locality London 
DoB 19/03/1963 
Employment status Unemployed/sickness benefit 
Parental status 0 
Treatment allocation condition SIH 
Treatment trajectory SIH: 36 months 
Treatment discharge status Long-term IOT 
Responder status (6 months) Responder 
Age at interview 50 
Ethnic origin WB 
Drug on trial entry OM 
Treatment episode length 5 years 
Dose on trial entry 35ml 
How many days injected in the last month 
(baseline) 20 
Injecting heroin Yes 
Other regular use Yes 
Age of first use (heroin) 16 
Age first regular use 16 
Age first injected 18 
Age first treatment episode 23 
Number of previous treatment episodes 5 (detox) 
Number of periods of abstinence 0 
Date participant entered trial 01/02/2006 
Date of qualitative interview 14/08/2013 
Current treatment status SIH 
Treatment preferences at baseline 1.SIH; 2. SIM; 3. OOM 
Treatment preferences at 3 years Missing 
Date participant left IOT Still in IOT at time of interview 
Treatment at baseline SIH 
Dose at baseline 230mg 
Additional OM at baseline 20mg 
Treatment at 1 month SIH 
Treatment at 2 months SIH 
Dose at 2 months 230mg 
Additional OM at 2 months 20ml 
Treatment at 3 months SIH 
Dose at 3 months 230mg 
Additional OM at 3 months 20mg 
Treatment at 4 months SIH 
Dose at 4 months 280mg 
Additional OM at 4 months 15mg 
Treatment at 5 months SIH 
Dose at 5 months 300mg 
Additional OM at 5 months 15mg 
Treatment at 6 months SIH 
Dose at 6 months 300mg 
Additional OM at 6 months 15mg 
Treatment at 9 months SIH 
Dose at 9 months 240mg 
Additional OM at 9 months 45mg 
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Drug at 12 months SIH 
Dose at 12 months 250mg 
Additional OM at 12 months 45mg 
Drug at 15 months SIH 
Dose at 15 months 250mg 
Additional OM at 15 months 45mg 
Drug at 18 months SIH 
Dose at 18 months 250mg 
Additional OM at 18 months 45mg 
Drug at 21 months SIH 
Dose at 21 months 250mg 
Additional OM at 21 months 45mg 
Drug at 24 months SIH 
Dose at 24 months 250mg 
Additional OM at 24 months 45mg 
Drug at 36 months SIH 
Dose at 36 months 250mg 
Additional MXL at 36 months 360mg 
Drug at 41 months SIH 
Dose at 41 months 250mg 
Additional MXL at 41 months 360mg 
Illicit use through Treatment Yes (minimal use at the beginning) 
Use of other drugs through Treatment Yes 
IV or IM Both 
Drug use at 1 month 
Heroin=4; crack/cocaine=4; 
benzodiazepines=2; alcohol=12 




Drug use at 3 months 
Crack/cocaine=3; benzodiazepines=1; 
cannabis=2; alcohol=8 
Drug use at 4 months 
Crack/cocaine=2; benzodiazepines=1; 
cannabis=5; alcohol=12 
Drug use at 5 months Crack/cocaine=3; alcohol=12 
Drug use at 6 months 
Crack/cocaine=3 cannabis=1; 
alcohol=7 
Drug use at 9 months Crack/cocaine=4; alcohol=8 
Drug use at 12 months Crack/cocaine=3; alcohol=8 
Drug use at 15 months 
Crack/cocaine=2; cannabis=1; 
alcohol=16 
Drug use at 18 months Alcohol=8 
Drug use at 21 months Cocaine=2; alcohol=15 
Drug use at 24 months Alcohol=8 
Drug use at 28 months Alcohol=3 





Case note review 37 – ID 37, participant Elena 
File item  
Response 
RIOTT ID 12 
Qualitative ID 37 
Gender Female 
Clinic locality London 
DoB 14/09/1962 
Employment status Unemployed/sickness benefit 
Parental status 0 
Treatment allocation condition SIM 
Treatment trajectory SIM: 6 months; SIH: 30 months 
Treatment discharge status Positive: progressed to MXL 
Responder status (6 months) Responder 
Age at interview 51 
Ethnic origin White Other 
Drug on trial entry OM 
Treatment episode length 3 years + 
Dose on trial entry 35ml 
How many days injected in the last month 
(baseline) 25 
Injecting heroin Yes 
Other regular use None 
Age of first use (heroin) 19 
Age first regular use 24 
Age first injected 19 
Age first treatment episode 26 
Number of previous treatment episodes 1 
Number of periods of abstinence 0 
Date participant entered trial 26/10/2005 
Date of qualitative interview 16/08/2013 
Current treatment status MXL 
Treatment preferences at baseline 1.SIM; 2. SIH; 3. OOM 
Treatment preferences at 3 years Missing 
Date participant left IOT 
Data collected at 44 months 
(13/01/2009) 
Treatment at 3 months SIM 
Dose at 3 months Missing 
Treatment at 4 months SIM 
Dose at 4 months 60mg 
Treatment at 6 months SIM 
Dose at 6 months 100mg 
Additional OM 75mg 
Treatment at 9 months SIH 
Dose at 9 months 280mg 
Additional OM at 9 months 65mg 
Drug at 12 months SIH 
Dose at 12 months 280mg 
Additional OM at 12 months 55mg 
Drug at 15 months SIH 
Dose at 15 months 310mg 
Additional OM at 15 months 55mg 
Drug at 18 months SIH 
Dose at 18 months 320mg 
Additional OM at 18 months 65ml 
Drug at 21 months SIH 
Dose at 21 months 320mg 
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Additional OM at 21 months 65mg 
Drug at 24 months SIH 
Dose at 24 months 410mg 
Additional OM at 24 months 45ml 
Drug at 30 months SIH 
Dose at 30 months 280mg 
Additional OM at 30 months 85mg 
Drug at 36 months SIH 
Dose at 36 months a.200mg   
Additional MXL at 36 months a.630mg / b. 900mg 
Additional OM at 36 months b. 25mg 
Illicit use through Treatment Yes 
Use of other drugs through Treatment Yes 
IV or IM IM 
Other clinical info Ex-partner also on trial 
Drug use at baseline 
Heroin=24; crack/cocaine=4; 
alcohol=17 
Drug use at 1 month 
Heroin=15; crack/cocaine=9; 
cannabis=2;alcohol=20 
Drug use at 2 months 
Heroin=13; crack/cocaine=8; 
cannabis=1; alcohol=13 
Drug use at 3 months 
Heroin=4; crack/cocaine=6; codeine=1; 
alcohol=20 
Drug use at 4 months 
Crack/cocaine=4; codeine (for flu)=5; 
alcohol=20 
Drug use at 5 months Heroin=1; crack/cocaine=2/ alcohol=24 
Drug use at 6 months Heroin=2; crack/cocaine=4; alcohol=24 
Drug use at 9 months Crack/cocaine=5; alcohol=30 
Drug use at 12 months Alcohol=30 
Drug use at 15 months 
Codeine=1 (“for headache”); 
crack/cocaine=1; alcohol=30 
Drug use at 24 months Alcohol=7 
Drug use at 30 months Cannabis=7; alcohol=5 
Drug use at 36 months Alcohol=30 





Case note review 38 – ID 38, participant Euan 
File item  
Response 
RIOTT ID 40 
Qualitative ID 38 
Gender Male 
Clinic locality London 
DoB 23/03/1966 
Employment status Unemployed/sickness benefit 
Parental status 0 
Responder status (6 months) Non-responder 
Treatment allocation condition SIM 
Treatment trajectory 
OOM: 12 months; SIH: 6 months; SIM: 
6 months 
Treatment discharge status Negative (Other): prison 
Age at interview 47 
Ethnic origin WB 
Drug on trial entry OM 
Treatment episode length 15 months 
Dose on trial entry 80mg 
How many days injected in the last month 
(baseline) 12 
Injecting heroin Yes 
Other regular use None 
Age of first use (heroin) 18 
Age first regular use 20 
Age first injected 19 
Age first treatment episode 19 
Number of previous treatment episodes 3 (methadone) 
Number of periods of abstinence 0 
Date participant entered trial 06/11/2006 
Date of qualitative interview 19/08/2013 
Current treatment status OM 
Treatment preferences at baseline 1.SIH; 2. OOM (would not take up SIM) 
Treatment preferences at 6 months 1.SIH; 2. SIM; 3. OOM 
Date participant left IOT By 18 months (around May 2008) 
Treatment at baseline SIM 
Dose at baseline 80mg 
Treatment at 2 months SIM 
Dose at 2 months 120mg 
Additional OM at 2 months 20mg 
Treatment at 3 months SIM 
Dose at 3 months 150mg 
Additional OM at 3 months 40mg 
Treatment at 4 months 150mg 
Additional OM at 4 months 40mg 
Treatment at 5 months SIM 
Dose at 5 months 150mg 
Additional OM at 5 months 40mg 
Treatment at 6 months SIM 
Dose at 6 months 150mg 
Additional OM at 6 months 40mg 
Drug at 12 months SIH 
Dose at 12 months Missing 
Drug at 18 months In prison 
Dose at 18 months Missing 
Drug at 24 months OM 
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Dose at 24 months Missing 
Drug at 36 months OM 
Dose at 36 months Missing 
Drug at 51 months OM 
Dose at 51 months 100mg 
Illicit use through Treatment Yes 
Use of other drugs through Treatment Yes 
IV or IM Both 
Other clinical info HIV positive 
Drug use at baseline 
Heroin=30; crack/cocaine=30; 
benzodiazepines=1; cannabis=5 
Drug use at 2 months 
Heroin=22; crack/cocaine=22; 
cannabis=5; alcohol=10 
Drug use at 3 months 
Heroin=10; crack/cocaine=10; 
cannabis=4 
Drug use at 4 months Heroin=9; crack/cocaine=9 
Drug use at 5 months 
Heroin=8; crack/cocaine=8; 
cannabis=1; alcohol=16 
Drug use at 6 months Heroin=14; crack/cocaine=14 
Drug use at 51 months 






Case note review 39 – ID 39, participant Patrick 
File item  
Response 
RIOTT ID 45 
Qualitative ID 39 
Gender Male 
Clinic locality London 
DoB 25/09/1974 
Employment status Unemployed/sickness benefit 
Parental status 2 (live elsewhere) 
Treatment allocation condition OOM 
Treatment trajectory OOM: 12 months; SIH: 24 months 
Treatment discharge status Long-term IOT 
Responder status (6 months) Responder 
Age at interview 39 
Ethnic origin WB 
Drug on trial entry OM 
Treatment episode length Missing 
Dose on trial entry 50mg 
How many days injected in the last month 
(baseline) 30 
Injecting heroin Yes 
Other regular use Crack/cocaine 
Age of first use (heroin) 17 
Age first regular use 28 
Age first injected 30 
Age first treatment episode 30 
Number of previous treatment episodes 2 
Number of periods of abstinence 0 
Date participant entered trial 20/02/2007 
Date of qualitative interview 15/08/2013 
Current treatment status SIH 
Treatment preferences at baseline 1.SIH; 2. SIM; 3. OOM 
Treatment preferences at 3 years 1.SIH; 2. SIM; 3. OOM 
Date participant left IOT Still in IOT at time of interview 
Treatment at 1 month OOM 
Dose at 1 month 100mg 
Treatment at 2 months OOM 
Dose at 2 months 120mg 
Treatment at 3 months OOM 
Dose at 3 months 120mg 
Treatment at 4 months OOM 
Dose at 4 months 120mg 
Treatment at 5 months OOM 
Dose at 5 months 130mg 
Treatment at 6 months OOM 
Dose at 6 months 130mg 
Treatment at 9 months SIH 
Dose at 9 months 430mg 
Additional OM at 9 months 60mg 
Drug at 12 months SIH 
Dose at 12 months 250mg 
Additional OM at 12 months 60mg 
Drug at 18 months SIH 
Dose at 18 months 280 
Drug at 21 months SIH 
Dose at 21 months 220mg 
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Additional MXL at 21 months 600mg 
Drug at 24 months SIH 
Dose at 24 months 220mg 
Additional MXL at 24 months 600mg 
Drug at 36 months SIH 
Dose at 36 months Missing 
Illicit use through treatment Yes 
Use of other drugs through treatment Yes 
IV or IM IM 
Other clinical info Diagnosed with bipolar disorder. 
Drug use at baseline 
Heroin=30; crack/cocaine=1; 
cannabis=2 
Drug use at 1 month 
Heroin=30; crack/cocaine=30;  
benzodiazepines=2 
Drug use at 2 months 
Heroin=30; crack/cocaine=30; 
cannabis=4 
Drug use at 3 months 
Heroin=30; crack/cocaine=30; 
cannabis=5 
Drug use at 4 months Heroin=30; crack/cocaine=30 
Drug use at 5 months 
Heroin=30; crack/cocaine=30; 
cannabis=1 
Drug use at 6 months 
Heroin=30; crack/cocaine=30; 
cannabis=2 
Drug use at 9 months Heroin=2; crack/cocaine=12 
Drug use at 21 months Crack/cocaine=2 
Drug use at 24 months Crack/cocaine=3 





Case note review 40 – ID 40, participant Cheryl 
File item  
Response 
RIOTT ID 57 
Qualitative ID 40 
Gender Female 
Clinic locality London 
DoB 23/02/1975 
Employment status Unemployed/sickness benefit 
Parental status 0 
Treatment allocation condition SIM 
Treatment trajectory SIM: 6 months; OM: 12 months 
Treatment discharge status Positive: Voluntary move to OM 
Responder status (6 months) Responder 
Age at interview 38 
Ethnic origin White Other 
Drug on trial entry OM 
Treatment episode length 18 months 
Dose on trial entry 70ml 
How many days injected in the last month 
(baseline) Missing 
Injecting heroin Yes 
Other regular use 
Crack cocaine; occasional cannabis 
and benzodiazepines 
Age of first use (heroin) 14 
Age first regular use 20 
Age first injected 40 
Age first treatment episode 41 
Number of previous treatment episodes 0 
Number of periods of abstinence 0 
Date participant entered trial 11/09/2007 
Date of qualitative interview 21/08/2013 
Current treatment status OM 
Treatment preferences at baseline 1.SIH; 2. SIM; 3. OOM 
Treatment preferences at 6 months Missing 
Date participant left IOT 6 months (17/04/2008) 
Treatment at 2 months 100mg 
Additional OM at 2 months 50mg 
Treatment at 3 months SIM 
Dose at 3 months 100mg 
Additional OM at 3 months 50mg 
Treatment at 4 months SIM 
Dose at 4 months 100mg 
Additional OM at 4 months 50mg 
Treatment at 5 months SIM 
Dose at 5 months 100mg 
Additional OM at 5 months 90mg 
Treatment at 6 months SIM 
Dose at 6 months 100mg 
Drug at 12 months Missing 
Dose at 12 months Missing 
Drug at 18 months Missing 
Dose at 18 months Missing 
Drug at 24 months OM 
Dose at 24 months 175mg 
Drug at 32 months OM 
Illicit use through Treatment Yes (first six months only) 
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Use of other drugs through Treatment Yes 
IV or IM Both 
Other clinical info Diagnosis of depression 
Drug use at baseline 
Heroin=30; crack/cocaine=20; 
cannabis=1;  
Drug use at 2 months 
Heroin=15; crack/cocaine=16; 
benzodiazepines=1 
Drug use at 3 months 
Heroin=15; crack/cocaine=23; 
cannabis=7 
Drug use at 4 months 
Heroin=7; crack/cocaine=10; 
cannabis=2 
Drug use at 5 months 
Crack/cocaine=12; benzodiazepines=1; 
cannabis=4 
Drug use at 6 months Crack/cocaine=9 
Drug use at 24 months Crack/cocaine=16; benzodiazepines=1 





Case note review 41 – ID 41, participant Josh 
File item  
Response 
RIOTT ID 301 
Qualitative ID 41 
Gender Male 
Clinic locality Brighton 
DoB 24/11/1977 
Employment status Unemployed/sickness benefit 
Parental status 0 
Treatment allocation condition SIH 
Treatment trajectory SIH: 36 months 
Treatment discharge status Long-term IOT 
Responder status (6 months) Non-responder 
Age at interview 36 
Ethnic origin WB 
Drug on trial entry OM 
Treatment episode length 5 years (“on and off”) 
Dose on trial entry 50ml 
How many days injected in the last month 
(baseline) 30 
Injecting heroin Yes 
Other regular use None 
Age of first use (heroin) 16 
Age first regular use 21 
Age first injected 16 
Age first treatment episode 24 
Number of previous treatment episodes 6 
Number of periods of abstinence 0 
Date participant entered trial 03/08/2007 
Date of qualitative interview 07/10/2013 
Current treatment status SIH 
Treatment preferences at baseline 1.SIH; 2. SIM; 3. OOM 
Treatment preferences at 3 years 1.SIH; 2. SIM; 3. OOM 
Date participant left IOT Still in SIH at time of interview 
Treatment at 3 months SIH 
Dose at 3 months Missing 
Treatment at 6 months SIH 
Dose at 6 months 190mg 
Additional OM at 6 months 50mg 
Drug at 12 months SIH 
Dose at 12 months 170mg 
Additional OM at 12 months 50mg 
Drug at 18 months SIH 
Dose at 18 months 160mg 
Additional OM at 18 months 60mg 
Dose at 24 months 160mg 
Additional OM at 24 months 50mg 
Drug at 36 months SIH 
Dose at 36 months 160mg 
Additional OM at 36 months 50mg 
Illicit use through Treatment Yes 
Use of other drugs through Treatment Yes 
IV or IM Both 
Drug use at baseline Heroin=30; crack/cocaine=2; alcohol=8 
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Drug use at 6 months 
Heroin=10; crack/cocaine=3; 
benzodiazepines=2; alcohol=16 
Drug use at 12 months Heroin=1; crack/cocaine=1; alcohol=28 
Drug use at 25 months Alcohol=18 
Drug use at 36 months Heroin=1; alcohol=15 
 
 
